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Abstract
In humans, Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is capable of 
establishing latent infection in B-cells. During latency no infectious virions are 
produced, the viral episome is maintained and few viral genes are expressed. Latently 
infected cells, however, retain the capacity to enter the lytic cycle. KSHV ORF50 
encodes the transcription factor RTA whose expression is sufficient to initiate the full 
lytic cycle.
RNA interference (RNAi) involves the sequence specific silencing of gene expression. 
Although extensively validated and widely available at present, lentiviral vector- 
mediated RNAi was unavailable in 2002. This thesis describes the generation and 
characterisation of shRNA expression cassettes that can be delivered using self- 
inactivating lentiviral vectors. Using shRNAs designed to interfere with KSHV ORF50 
expression, the number of cells expressing RTA following chemical induction of the 
lytic cycle was greatly reduced. Analysis of viral lytic antigens and virus production 
suggests that reducing RTA expression prevents latent KSHV from initiating the lytic 
cycle.
Although KSHV infects B-cells in vivo, most B-cell lines are recalcitrant to KSHV 
infection in vitro. This thesis describes the in vitro susceptibility of a panel of B-cell 
lines, representing different stages of B-cell differentiation, and other common cell-lines 
to recombinant KSHV infection. Interestingly, all the adherent cell-lines examined 
were susceptible to recombinant KSHV infection whereas we were unable to identify 
any B-cell lines which were efficient targets for recombinant KSHV infection
KSHV positive primary effusion lymphoma (PEL) cells are phenotypically similar to 
plasmablasts, which represent a late stage in B-cell differentiation, immediately 
preceding terminal differentiation into plasma cells. This thesis examines the stage at 
which B-cell development is arrested in PEL, focussing on the transcription factor X- 
box binding protein-1 (XBP-1) and the unfolded protein response (UPR). Using 
exogenously expressed XBP-1, the role of XBP-1 as the possible molecular switch 
linking terminal differentiation and KSHV lytic reactivation is considered.
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Chapter 1
Introduction
1. Kaposi’s Sarcoma-associated Herpesvirus (KSHV)
1.1.1. The history of KSHV
In 1872 the Hungarian dermatologist Mauritz Kaposi described an idiopathic multiple 
pigmented sarcoma of the skin (Kaposi, 1872). This rare angiomatous neoplasm 
affected elderly men of a Mediterranean, Middle Eastern and African origin and is now 
described as classic Kaposi’s sarcoma (reviewed in Schwartz, 2004). Herpesvirus 
particles were first described in tissue culture explants of classic Kaposi’s sarcoma (KS) 
in 1972 (Giraldo et al., 1972) although these were thought to be human 
cytomegalovirus particles (Giraldo et al., 1980). In 1981, during the early stages of the 
AIDS epidemic, a more aggressive and disseminated form of KS was reported in young 
homosexual men (Hymes et al., 1981). The predominant risk factor for developing KS 
was determined to be homosexual sex between men, suggesting an infectious aetiology 
of AIDS associated KS (Weiss and Biggar, 1986).
Chang and colleagues discovered Kaposi’s sarcoma-associated herpesvirus (KSHV) in 
1994 through representational difference analysis (Lisitsyn et al., 1993) of AIDS 
associated KS and adjacent normal skin (Chang et al., 1994). This identified sequences 
homologous to, but distinct from, capsid and tegument genes of herpesvirus saimiri and 
Epstein Barr virus indicating an eighth human herpesvirus (HHV-8) had been 
discovered. KSHV was later classified as a gamma-2-herpesvirus, genus Rhadinovirus, 
the first member of this genus known to infect humans (Moore et al., 1996b). 
Consistent with the lymphotropic nature of homologous viruses, KSHV sequences were 
rapidly detected in primary effusion lymphoma cells (Cesarman et al., 1995a). This 
allowed the propagation of KSHV positive cell-lines (Cesarman et al., 1995b) and the 
cloning and sequencing of the viral genome (Russo et al., 1996).
KSHV is now widely accepted to be the aetiological agent of Kaposi’s sarcoma, the 
most common malignancy in regions of sub-Saharan Africa (Dedicoat and Newton,
2003). KSHV is also associated with two B-cell neoplasms: primary effusion
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lymphoma (Cesarman et a l, 1995a) and the plasma cell variant of multicentric 
Castleman’s disease (Soulier et a l, 1995).
1.1.2. Human Herpesviruses
KSHV is well adapted to its host and likely coevolved with humans (reviewed in 
Hayward, 1999). Consistent with this ancient relationship between members of the 
Herpesviridae and Homo sapiens the term herpes was used by Hippocrates over 2000 
years ago to describe a rash that appeared to creep along the skin. Derived from 
herpein, meaning to creep, the term herpes was used for centuries to describe a variety 
of skin lesions not necessarily associated with herpesviruses. In 1924 herpesvirology 
was bom when herpes simplex vims (HSV) was isolated and serially transmitted 
between rabbits (Gruter, 1924).
At present, over 100 herpesviruses have been identified and membership is defined by 
virion morphology and nucleic acid content (www.ncbi.nlm.nih.gov/ICTVdb). All 
herpesviruses, by definition, are enveloped viruses that contain an icosahedral particle 
and double stranded DNA. Herpesviruses can be further subdivided into a, (3 and y- 
herpesviruses. Classification was initially based on host range and properties in vitro 
(Roizman et al., 1981), and subsequently according to genomic DNA sequence. The 8 
human herpesviruses are described in table 1.1.2.
Table 1.1.2. Human herpesviruses and their disease associations.
Sub­
family
Human
herpesvirus
Common name Disease associations
a HHV-1 Herpes-sim plex virus (HSV)-1 O ropharangeal herp es (cold so res) 
Genital herp es
a HHV-2 Herpes-sim plex virus (HSV)-2 Genital herpes
a HHV-3 Varicella-Zoster virus (VZV) Varicella (chickenpox) 
Z oster (shingles)
Y HHV-4 Epstein-Barr virus (EBV) Infectious m ononucleosis 
N asopharyngeal carcinom a 
Burkitfs lymphoma 
C lassical Hodgkin’s lymphoma
(3 HHV-5 Human cytomegalovirus 
(HCMV)
CM V-mononucleosis 
CMV d isease
P HHV-6a
HHV-6b
Exanthem  subitum (sixth d isease ) 
R oseola infantum 
Encephalitis
P HHV-7 Exanthem  subitum (sixth d isease ) 
Encephalitis
Y HHV-8 K aposi’s  sarcom a-associated  
herpesvirus (KSHV)
Kaposi’s  sarcom a 
Primary effusion lymphoma 
Multicentric C astlem an’s  d isease
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KSHV is a y-herpesvirus whose closest human homologue is Epstein Barr virus (EBV). 
The Gammaherpesvirinae are defined by their limited host range, lymphocyte tropism 
and frequent latent infection of lymphoid tissue.
1.1.2.1. The Rhadinoviridae
KSHV is a Rhadinovirus (Moore et al., 1996b) and prior to the discovery of KSHV, 
herpesvirus saimiri was the archetypal Rhadinovirus (reviewed in Fickenscher and 
Fleckenstein 2001). Herpesvirus saimiri (HVS) and the closely related herpesvirus 
ateles infect New World squirrel monkeys {Saimiri sciureus) and spider monkeys 
{Ateles geoffryi) respectively. Both are T-lymphotropic viruses capable of causing T- 
cell lymphoma in numerous non-natural primate hosts (reviewed in Ensser and 
Fleckenstein, 2005). Rhadinoviruses have also been identified in African green 
monkeys (Greensill et al., 2000b) and macaques (Desrosiers et al., 1997). In macaques 
the rhadinoviruses retroperitoneal fibromatosis-associated herpesvirus Macacca 
nemestrina (RFHVMn) and retroperitoneal fibromatosis-associated herpesvirus 
Macacca mulatta (RFHVMm) can cause a proliferation of spindle cells reminiscent of 
KS (Rose et al., 1997). Interestingly, similar to the association of KS and AIDS, 
retroperitoneal fibramatosis is associated with simian acquired immunodeficiency 
syndrome (SAIDS). Rhadinoviruses have also been identified in Old World primates 
such as Chimpanzees (Greensill et al., 2000a) and Gorillas (Lacoste et al., 2000) 
although, currently, they are only loosely associated with tumourigenesis.
1.1.3. The KSHV virion
The herpesvirus virion is composed of four morphologically distinct substructures. An 
inner core of toroidal packaged DNA (Furlong et al., 1972) is surrounded by a 
structurally repetitive icosahedral capsid. A dense protein layer termed the tegument 
surrounds the nucleocapsid, which is less structured than the capsid but partially mirrors 
its symmetry (Zhou et al., 1999; Chen et al., 1999). The mature virion is enveloped in a 
cellular membrane, enriched with viral glycoproteins, derived from the trans-Golgi 
network (Skepper et al., 2001).
The KSHV capsid structure has been solved by cryo-electron microscopy. The capsid 
shell is composed of 162 capsomers arranged in a T=16 icosahedral arrangement (Wu et 
al., 2000). Recently the composition of KSHV virions have been analysed identifying 
many host proteins, viral proteins (Bechtel et al., 2005b; Zhu et al., 2005) and mRNAs 
(Bechtel et al., 2005a) present in the virion. The viral components of the KSHV virion
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Table 1.1.3. KSHV virion composition (adapted from Bechtel et al., 2005a; 2005b; Zhu et 
al., 2005).
Gene Protein Protein 
present in 
virions?
mRNA 
present in 
virions?
Function
ORF17.5 VP 17.5 Yes Capsid
ORF25 Major capsid Yes Capsid
protein
ORF26 Minor capsid Yes Capsid
protein
ORF62 TRI-1 Yes Assembly/DNA maturation
ORF65 SCIP Yes Capsom er-interacting protein
ORF8 gB Yes Envelope glycoprotein
ORF K8.1 K 8.1 Yes Yes Envelope glycoprotein
ORF22 gH Yes Envelope glycoprotein
ORF28 Yes Envelope
ORF39 gM Yes Envelope glycoprotein
ORF47 gL Yes Envelope glycoprotein
ORF53 gN Yes Envelope glycoprotein
ORF68 Yes Envelope glycoprotein
ORF21 TK Yes Tegum ent
ORF33 Yes Tegum ent
ORF45 Yes Tegum ent
ORF63 Yes Tegum ent
ORF64 Yes Tegum ent
ORF75 Yes T egum ent
ORF6 SSB Yes ssDNA binding protein
ORF7 Yes
ORF11 Yes
ORF27 Yes
ORF52 Yes
ORF50 RTA Yes Lytic transactivator
ORF K8 K-bZIP Yes Transcription/DNA replication
ORF37 SOX Yes Exonuclease-H ost shut-off
ORFK2 vlL-6 Yes Autocrine IL-6 like activity
ORFK4 vMIP-ll Yes CCR4 agonist
ORFK5 K5 Yes Downregulate MHC c lass I
ORFK6 VMIP-I Yes CCR8 agonist
ORFK7 K7 Yes Protein
degradation/antiapoptotic
ORF17 Pr and AP Yes P ro tease  and assem bly  protein
ORF54 dU T Pase Yes
ORF58 Yes
ORF59 PF-8 Yes DNA replication
ORF K12 Kaposin A Yes O ncogenic/encodes miRNAs
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identified in these studies is summarised in table 1.1.3. This list is not comprehensive 
as most components were identified through mass spectrometry. The regulator of  
transcription activation (RTA), KSHV basic leucine zipper containing protein (K-bZEP) 
and shutoff and exonuclease (SOX) protein were identified using specific antibodies 
(Bechtel et al., 2005b) but their peptides were not detected by mass spectrometry 
(Bechtel et al., 2005b; Zhu et al., 2005). This suggests that many other unidentified 
proteins may be present at lower abundance within the virion.
Many host proteins associated with KSHV virions were identified in the studies. Most 
of these are abundant proteins, such as p-actin and heat shock protein 90, and it is not 
clear whether they are selectively or randomly incorporated into the virion.
Capsid diameter 
100 nm
Envelope
Capsid
DNA genome
Tegument
Glycoproteins
Virion diameter 
170 nm
Figure 1.1.3. The KSHV virion
A diagrammatic representation of the KSHV virion is shown. Capsid and virion diam eters were 
determined by Wu and colleagues (Wu et al., 2000) and Wang and Montalvo (Wang et al., 
1998) respectively.
1.1.4. The KSHV g e n o m e
The KSHV genome exists as a circular dsDNA episome within infected cell nuclei and 
as linear dsDNA within the virion and during lytic replication. Sequencing o f the 
KSHV genome identified a -140.5 kilobase (kb) long unique region (LTJR) flanked by
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multiple 801bp terminal repeat (TR) units (Russo et al., 1996). The repetitive nature of 
the TR region makes sequence data difficult to interpret making accurate measurements 
of genome length difficult. The KSHV linear virion-associated genome is estimated to 
be ~ 165 kb long (Zhong et al., 1996; Renne et al., 1996a)
The KSHV genome shares the 7-block organisation of other characterised herpesviruses 
(reviewed in Chee and Barrell, 1990) with gammaherpesvirus, Rhadinovirus and 
KSHV-specific genes present between blocks (Russo et al., 1996). 81 open reading 
frames (ORFs) of >100 amino acids were initially assigned to the KSHV LUR. Of 
these, 66 have homologues in HVS and the KSHV LUR shares almost complete 
syntenny to HVS. Accordingly, KSHV ORFs were assigned based on HVS 
nomenclature with ORFs not homologous to HVS genes numbered in consecutive order 
and prefixed with a K (K1-K15). Since initial characterisation several additional ORFs 
have been characterised notably K4.1, K4.2, K8.1, K10.1, K10.5, K ll .l ,  K14.1 and 
many spliced isoforms have been reported (Reviewed in Zheng, 2003).
Rhadinoviruses encode a greater number of cellular homologues than other 
herpesviruses. KSHV seems to have evolved to encode cellular proteins rather then 
induce their expression. For example, EBV latent membrane protein 2 is capable of 
inducing cyclin D2 expression in B-cells (Arvanitakis et al., 1995) whereas KSHV 
encodes a cyclin D2 homologue (Cesarman et al., 1996). The reasons for this direct 
molecular piracy are unclear.
Recently herpesviruses have been shown to encode microRNAs (Pfeffer et al., 2004). 
KSHV is thought to encode 10-11 microRNAs (miRNAs) adjacent to other genes 
expressed during latency in vitro (Pfeffer et al., 2005; Cai et al., 2005 and Samols et al., 
2005). The functional targets of these miRNAs have yet to be characterised.
1.1.4.1. KSHV genomic variation
As with all biological entities, KSHV exhibits genomic variation. Analysis of ORF K1 
variation identified 4 KSHV subtypes differing 15-30% in their K1 amino acid 
sequence (Zong et al., 1999). Based on ORF K1 variation, KSHV can be divided into 
subtypes A-D and the presence of ORF K15 M or P alleles further define the KSHV 
subtype (Zong et al., 2002). KSHV subtypes correlate with geographical and/or ethnic 
origin of the infected host and probably arose during geographic isolation of host
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populations (Hayward, 1999; Zong et al., 2002). Although ORF K1 is highly variable 
between subtypes (Zong et al., 1999) this genomic locus seems to be highly 
polymorphic and estimates of overall genomic variation are approximately 1.5% (Zong 
et al., 1997). As well as variation within the LUR the TR region is also subject to 
variation. Similar to EBV, episome circularisation is an unpredictable process resulting 
in a variable number of repeats in each circularisation event (Raab-Traub and Flynn, 
1986). This property has proved useful in analysing the clonality of KSHV-associated 
tumours (Judde et al., 2000).
As well as subtype variations, large-scale variation of the KSHV genome is also 
possible. Both duplications (Russo et al., 1996) and deletions (Deng et al., 2004) have 
been reported in primary effusion lymphoma (PEL) cells in vivo. The role of aberrant 
KSHV genomes in KSHV-associated tumours is unclear, but cells infected with lytic 
replication defective KSHV have been suggested to have enhanced transformation and 
proliferation potential and could be relevant in tumour progression (Deng et al., 2004).
1.1.5. KSHV cellular infection
The KSHV lifecycle can be considered at many different scales. This thesis will first 
describe the molecular events of KSHV infection and replication (Summarised in figure 
1.1.5) before considering infection and transmission within and between human hosts 
(section 1.1.6).
Herpesvirus attachment can be divided into two distinct steps (reviewed in Spear and 
Longnecker 2003; Gamer 2003). Binding initially occurs through adsorption to target 
cells followed by specific receptor engagement and fusion of the viral envelope with the 
plasma membrane. Similarly to HSV, KSHV first adsorbs to cells through an 
interaction between heparin sulphate and glycoprotein K8.1 (Akula et al., 2001) or 
glycoprotein gB (Birkmann et al., 2001). These interactions increase KSHV infectivity 
presumably through increasing the probability of KSHV interacting with cellular 
receptors involved in fusion. However, these interactions are not necessary for KSHV 
entry (Luna et ah, 2004).
Following adsorption, KSHV glycoproteins interact with their cognate receptors. 
KSHV glycoproteins gB, gH, and gL can all mediate membrane fusion in vitro (Pertel, 
2002) but the interaction of gB with integrin a3|31 is the only characterised receptor
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Figure 1.1.5. The replication cycle of hum an h e rp e sv iru se s  (adap ted  from  M ettenleiter, 
2004)
A diagrammatic summary of the herpesvirus lifecycle.
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interaction for KSHV (Akula et al., 2002). Although clearly important in KSHV entry, 
it is not clear whether integrin a3pi is the main cellular receptor (Inoue et al., 2003). 
As well as facilitating viral entry, receptor engagement can also initiate intracellular 
signalling cascades. This is the case for KSHV and integrin a3(31. KSHV engagement 
of integrin a3pl activates focal adhesion kinase (Sharma-Walia et al., 2004) a process 
which could aid penetration of the actin cytoskeleton or even prime cells for the 
establishment of latency (Sharma-Walia et al., 2005).
Following receptor engagement, membrane fusion ensues. This generally occurs at the 
plasma membrane, although virion endocytosis prior to fusion has been reported (Akula 
et al., 2003). After fusion, unenveloped virion particles traffic to the nucleus along 
microtubules utilising dynein motors (Naranatt et al., 2005). The herpesvirus 
nucleocapsid is too large to traverse the nuclear pore complex (NPC). Instead, the 
nucleocapsid is able to dock with the NPC in the presence of importin p and, in an 
energy dependent manner, is able to eject the herpesvirus genome into the nucleus 
(reviewed in Greber and Fassati, 2003). Following nuclear entry, the linear genome 
circularises and the virus enters a lytic or latent replication programme (discussed in 
sections 1.1.6 and 1.1.11).
1.1.6. KSHV lytic gene expression
Like other herpesviruses, KSHV lytic replication involves viral DNA replication by 
virus-encoded machinery, and packaging of viral DNA into infectious virions. This is 
achieved through a tightly regulated gene expression cascade (reviewed in Roizman and 
Knipe, 2001). Genes expressed during lytic replication can be assigned to different 
classes depending on how their expression is affected by the protein synthesis inhibitor 
cycloheximide or viral DNA replication inhibitors such as phosphonoacetic acid. The 
classification of herpesvirus genes is summarised in table 1.1.6. It is important to 
remember when considering KSHV gene expression that this classification is an 
intellectual creation and that designation is not absolute. The complex host-virus 
relationship means that viral genes respond to the changing host-cell environment as 
well as viral replication programmes. An example of this is KSHV latent nuclear 
antigen 2 (LANA2). LANA2 is expressed during latency in B-cells but is exclusively a 
lytic gene in KS lesions (Rivas et al., 2001). The cell-type and context dependence of 
this classification system means that single-gene assays may not be reliable at 
identifying cells harbouring KSHV in the lytic cycle (Krishnan et al., 2004). Rather it
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is likely that multiple layers of evidence, in terms of viral gene expression, are required 
to distinguish latent and lytic KSHV gene expression programmes.
Table 1.1.6. Regulatory classes of herpesvirus genes expressed during lytic replication 
after de novo infection.
Class Symbol Definition
Immediate-early a Expression requires no prior viral protein synthesis 
(transcription insensitive to cycloheximide).
Early P Expression is independent of virus DNA synthesis 
(transcription prevented by cycloheximide but insensitive to 
DNA synthesis inhibitors).
Partial-late yl Expression is increased by viral DNA synthesis (transcription 
prevented by cycloheximide and reduced by DNA synthesis 
inhibitors.
True-late y2 Expression requires viral DNA synthesis (transcription blocked 
by cycloheximide or DNA synthesis inhibitors).
Definitions reproduced from Roizman and Knipe (2001).
KSHV RTA expression is necessary and, in most circumstances, sufficient for KSHV 
lytic replication (Lukac et al., 1998). RTA is an immediate early gene and is a 
transcriptional activator capable of initiating the lytic cycle (reviewed in West and 
Wood, 2003). Although several studies have began categorising lytic gene expression 
(Zhu et al., 1999; Lu et al., 2004) a comprehensive study involving cycloheximide and 
DNA synthesis inhibitors in the same cell-line has yet to emerge. However, by analogy 
to HSV lytic replication, immediate early genes tend to encode transcription factors 
required for early gene expression, early genes tend to be involved in viral DNA 
replication and late genes tend to be structural, required for the formation of new virions 
(reviewed in Roizman and Knipe, 2001; Jenner et al., 2001).
1.1.6.1. Abortive lytic replication
Initiation of the KSHV lytic replication cycle does not always ensure faithful 
completion of that cycle. Partial lytic cycles are termed abortive lytic replication. 
Although the name insinuates that the lytic cycle has gone wrong, gene expression 
profiles classified as ‘abortive lytic’ probably represent tightly regulated but poorly 
characterised stages of the KSHV lifecycle. The best-characterised abortive lytic 
expression programme occurs immediately following cellular infection with KSHV.
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KSHV virions contain RTA, probably as a component of the tegument (Bechtel et al., 
2005b). Following infection this results in initiation of an abortive lytic gene 
expression programme (Krishnan et al., 2004), followed by supervention of a latency 
programme. This is similar to HSV-1 whose virions contain virion protein 16 (VP 16). 
VP 16 enhances a gene expression following infection, initiating lytic replication 
(Campbell et al., 1984; Post et al., 1981). It seems that KSHV has modified this 
conserved herpesvirus mechanism of entering lytic replication immediately following 
infection to prime cells for latency, the default programme of KSHV infection in vitro 
(Bechtel et al., 2003).
Abortive lytic replication is widely regarded to be necessary for sarcomagenesis 
(Reviewed in Hayward, 2003; Boshoff, 1998a). These models centre on the 
involvement of the KSHV viral G-protein coupled receptor (vGPCR) in paracrine 
stimulation of endothelial cell proliferation. The vGPCR is a lytic gene whose 
exogenous expression in murine endothelial cells is sufficient to induce 
angioproliferative tumours similar to KS (Montaner et al., 2003). The important role of 
the vGPCR in sarcomagenesis has led researchers to consider vGPCR expression and 
abortive/spontaneous lytic cycles (Chiou et al., 2002; Ciufo et al., 2001; Cannon et a l, 
2005). How abortive lytic reactivation is induced and regulated is unclear, but has been 
documented in vitro (Nicholas et al., 1998).
1.1.7. KSHV lytic DNA replication
Herpesvirus DNA replication is best characterised for HSV-1 whose DNA replication 
has been reconstituted in vitro (reviewed in Boehmer and Lehman, 1997; Lehman and 
Boehmer, 1999). Much of the machinery involved in DNA replication is conserved in 
all herpesviruses suggesting DNA replication proceeds by a conserved mechanism. 
KSHV ORFs 40/41, 6, 9, 44, 56 and 59 encoding a primase-helicase, single stranded 
DNA (ssDNA) binding protein, helicase, primase and processivity factor 8 (PF-8) 
respectively are capable of forming pseudo-replication compartments, even in the 
absence of viral DNA (Wu et al., 2001). Herpesvirus DNA replication proceeds via a 
rolling circle mechanism generating concatermeric linear DNA.
Two origins of KSHV lytic replication have been defined (AuCoin et al., 2002). K- 
bZIP and RTA are required for efficient replication initiation (AuCoin et al., 2004;
22
Wang et al., 2004c). The sequence of the lytic origin of DNA replication (ori-Lyt) is 
part of a functional KSHV promoter element, and RTA dependent transcription may be 
required for efficient replication initiation (Wang et al., 2004c). Herpesviruses also 
encode a number of genes involved in DNA repair and nucleotide metabolism, such as 
uracil-DNA glycosidase and thymidine kinase. These enzymes are often necessary for 
replication in vivo, but are unnecessary in vitro. For example, murine 
gammaherpesvirus 68 with a disrupted thymidine kinase gene replicates normally in 
vitro but is severely attenuated in vivo (Coleman et al., 2003).
1.1.8. KSHV assembly and morphogenesis
There is a paucity of published data regarding KSHV virion assembly and 
morphogenesis. Instead, the better-characterised events of HSV, HCMV and VZV 
assembly and morphogenesis will be considered here and are summarised in figure
1.1.5.
Herpesvirus capsid proteins synthesised in the cytoplasm are transported into the 
nucleus. Heterodimeric complexes of the scaffold protein and major capsid protein 
assemble into hexons and pentons (Wood et al., 1997) generating a spherical procapsid 
which also contains minor capsid proteins (Newcomb et al., 1999). A series of 
conformational changes induced by viral protease activity results in transformation of 
the procapsid into an icosahedral capsid structure (Trus et al., 1996), a process that can 
be recapitulated in vitro (Newcomb et al., 1994). DNA packaging involves the removal 
of scaffold proteins from the capsid and insertion of a single copy of linear genomic 
DNA. The details of this process are poorly defined but probably involve terminase 
proteins which recognise packaging signals in the viral DNA (Bogner et al., 1998). 
Terminase proteins may also possess ATPase and endonuclease activity required for 
packaging and cleavage of concatameric genomes (Bronstein et al., 1997; Dasgupta and 
Wilson, 1999).
The route of KSHV egress from the nucleus was, until recently, a controversial subject. 
Herpesviruses can be observed budding into different cellular membranes by electron 
microscopy (reviewed in Enquist et al., 1998 and Roizman and Knipe, 2001). Using 
HSV-1 gD mutants with ER retention signals Minson and colleagues provided 
overwhelming evidence for an “Envelopment —* Deenvelopment —► Reenvelopment” 
pathway of herpesvirus egress (Skepper et al., 2001).
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Newly assembled nucleocapsids are able to bud through the inner nuclear membrane 
(Darlington and Moss, 1968). HSV-1 UL31 and UL34 are essential for this process 
(Chang et al., 1997; Roller et al., 2000) which is termed primary envelopment. UL34 is 
incorporated into the primary envelope whereas UL31 is involved in recruiting protein 
kinase C (PKC) which may phosphorylate the nuclear lamina easing primary 
envelopment (Muranyi et al., 2002). Primary envelopment results in the generation of 
primary enveloped virions in the perinuclear space (Darlington and Moss, 1968). 
Consistent with their origin, primary enveloped virions have a different tegument 
structure and envelope consistency to mature virions (Granzow et al., 1997).
Primary enveloped virions fuse with the outer membrane of the nuclear envelope 
releasing the nucleocapsid and primary tegument into the cytosol. The nucleocapsid 
then acquires a secondary envelope by budding into trans-Golgi vesicles (Siminoff and 
Menefee, 1968), a process termed secondary envelopment. Prior to secondary 
envelopment the nucleocapsid must acquire a mature tegument. The tegument is the 
structural component of the herpesvirion that varies the most between a, p, and y- 
herpesviruses and few details of KSHV tegumentation are known. The details of 
tegument assembly will not be considered further here, see Mettenleiter, 2004 for an 
extensive review.
The nucleocapsid surrounded by a mature tegument undergoes secondary envelopment 
generating a mature herpesvirus virion inside a trans-Golgi vesicle. Viral glycoproteins 
are enriched at the site of secondary envelopment through the action of gM (Crump et 
al., 2004). This generates a mature viral envelope rich in viral glycoproteins. Vesicle 
fusion with the plasma membrane liberates the mature virion, which can potentially 
infect new target cells and be transmitted to new hosts.
1.1.9. KSHV Transmission
Current understanding of the KSHV life cycle is at best fragmented. Elucidation of the 
lifecycle has been hampered by the lack of a KSHV animal model, poor in vitro 
infectivity, mild symptomatic infection of the immunocompetent host and large 
variations in the serological and molecular techniques used to monitor infections in 
vivo. In the absence of an accepted coherent model of the KSHV lifecycle, data
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concerning the transmission and tropism of KSHV in vivo are discussed here and in 
section 1.1.10.
Many epidemiological studies of KSHV have focussed on KSHV transmission 
(reviewed in Corey et ah, 2002; Henke-Gendo and Schulz 2004). These studies have 
focussed on maternal, sexual, blood borne and transplant associated transmission and 
these are considered in turn. Maternal transmission of KSHV is supported by several 
epidemiological studies (Plancoulaine et al., 2000; Sitas et al., 1999). In regions where 
KSHV is endemic, the probability of being seropositive increases with age and maternal 
antibody titre for KSHV (Ziegler et al., 2003; Sitas et al., 1999).
Sexual transmission of KSHV continues to be an extremely controversial issue. It is 
clear that among homosexual men in Europe and North America promiscuity, HIV- 
infection and a history of other sexually transmitted diseases are behavioural risk factors 
associated with KSHV seropositivity (Reviewed in Schulz, 2000). However, the risk 
factors associated with heterosexual activities are far less clear. Several studies suggest 
heterosexual sexual transmission is unlikely, finding no increased transmission between 
spouses (Plancoulaine et al., 2000), no association with other sexually transmitted 
diseases (Fernandez et al., 2002) and no increased transmission to sex workers 
(Marcelin et al., 2002). However, studies that directly contradict these observations 
have also been published (Mbulaiteye et al., 2003; Baeten et al., 2002; Eltom et al., 
2002).
KSHV DNA is readily detectable in serum from blood donors (Enbom et al., 2002) 
however there have been no well-documented cases of transfusion-borne KSHV 
infection (Operskalski et al., 1997), although possible cases have been highlighted 
(Dollard et al., 2005).
Many years before the discovery of KSHV, an association between KS and transplant 
recipients was apparent (Harwood et al., 1979). This association is mainly due to 
reactivation of KSHV, which can lead to KS, in immunosuppressed patients (Cattani et 
al., 2001). Transmission of KSHV from donor to recipient patients has also been 
documented (Parravicini et al., 1997a). More recently, transmission of KSHV positive 
donor-derived progenitor cells was demonstrated to initiate sarcomagenesis in 
transplant recipients. These transplanted cells remained in KS lesions of recipient
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patients (Barozzi et al., 2003), suggesting that transmission of other tumours to 
immunocompromised individuals may be possible (Moore, 2003).
Although post transplant KS is important in the clinic, data concerning KSHV 
transmission suggests that saliva is the most common source of transmissible KSHV. 
KSHV DNA is detected at a far higher frequency in oropharyngeal samples (30%) than 
in anal or genital samples (1%) of KSHV-positive men who had sex with men (Pauk et 
al., 2000). As many as lx l06 copies per ml of KSHV DNA have been detected in 
saliva (Koelle et al., 1997) and saliva is the only mucosal secretion in which KSHV 
virions have been identified (Vieira et al., 1997). Salivary transmission has also been 
suggested to explain epidemiological data supporting transmission within homosexual 
male risk groups (Pauk et al., 2000). However, it is difficult to reconcile this 
explanation with the lack of association between KSHV transmission and heterosexual 
risk groups. It is interesting to note that the prevalence of KSHV is far lower than other 
herpesviruses whose transmission is predominantly through salivary contact. EBV, 
CMV, HHV-6 and HHV-7 are nearly ubiquitous in human populations whereas KSHV 
seroprevalence ranges from 1-10% in most of Europe and Asia, rises to approximately 
25% in the Mediterranean and the Middle East, and approaches 70% in regions of sub- 
Saharan Africa (reviewed in Iscovich et al., 2000). The factors accounting for the lower 
seroprevalence of KSHV relative to other herpesviruses and the wide geographic 
variation in prevalence are unclear.
1.1.10. KSHV cellular tropism in vivo
Following transmission of KSHV, the initial cell-target of infection is not clear although 
oral epithelial cells have been suggested as a possible permissive cell-type (Duus et al., 
2004). Initial infection seems to be accompanied by viraemia both in 
immunocompetent children (Kasolo et al., 1997) and immunocompromised adults 
(Wang et al., 2001a; Goudsmit et al., 2000). This initial viraemia is associated with a 
febrile illness and mild lymphadenopathy (Wang et al., 2001a; Kasolo et ah, 1997). 
Although the default outcome of KSHV infection in vitro with PEL-derived and 
recombinant KSHV seems to be latent infection (Bechtel et ah, 2003), virions obtained 
from saliva may favour entry into a lytic cycle (Gasperini et ah, 2005; Duus et ah,
2004), possibly accounting for this initial burst of viraemia.
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Following initial viraemia, latent infection of B-cells can be detected (Harrington et al., 
1996; Mesri et al., 1996; Campbell et al., 2005). The frequency of infected cells is too 
low for the exact B-cell subset supporting latency to be identified. However, B-cells are 
the likely latent reservoir of KSHV in vivo and are the only cell-type that latent KSHV 
has been detected in healthy individuals (Campbell et al., 2005).
KSHV infection can also be detected in malignancies associated with KSHV, discussed 
in sections 1.1.16-1.1.18. Infected B-cells can be detected in PEL (Cesarman et al., 
1995a) and multicentric Castleman’s disease (MCD) (Soulier et al., 1995), whereas 
infected endothelial cells (Boshoff et al., 1995) and to a lesser extent monocytes can be 
detected in KS (Blasig et al., 1997). It is important to note that KSHV infection of 
endothelial cells has not been reported in immunocompetent, healthy individuals and is 
probably not a requirement of the KSHV lifecycle.
1.1.11. Cells supporting KSHV infection in vitro
In accordance with the widespread expression of characterised KSHV receptors 
(reviewed in Page et al., 1997; Kreidberg et al., 2000) the range of cells supporting 
KSHV infection in vitro is wider than the apparent tropism in vivo (table 1.1.11). All 
the known targets of KSHV infection in vivo support KSHV infection in vitro as well as 
a range of adherent mammalian cell-lines.
The most intriguing facet of KSHV infection in vitro is the difficulty in infecting 
cultured lymphoma-derived cell-lines. The EBV negative Burkitt’s lymphoma derived 
cell-line BJAB (Menezes et al., 1975) is the only B-cell line in which KSHV infection 
has been reported in vitro (Naranatt et al., 2004; Gasperini et al., 2005). Only two 
groups have achieved BJAB infection in vitro and several groups have been unable to 
achieve BJAB infection (Chen and Lagunoff, 2005; Bechtel et al., 2003; Blackboum et 
al., 2000b; Renne et al., 1998). There are numerous explanations that could explain this 
apparent discrepancy, most of which concern variation in the source of KSHV, method 
of infection and assays used to monitor infection. Whatever the explanation, it is clear 
that B-cell lines appear to be largely recalcitrant to KSHV infection in vitro a fact 
apparently at odds with the cellular tropism of KSHV in vivo.
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Table 1.1.11. The host range of KSHV in cultured cells
Cell type/line Abbreviation References
Primary CD19+ B-cells Mesri eta!.,  1996
Human Peripheral blood mononuclear cells Human PBMC Blackbourn et  al., 2000b
Baboon Peripheral blood mononuclear cells Human PBMC Blackbourn etal . ,  2000b
Rhesus macaque Peripheral blood Human PBMC Blackbourn et  al., 2000b
mononuclear cells
Human monocyte derived macrophages Blackbourn etal . ,  2000b
Human umbilical cord mononuclear cells UCMC Blackbourn etal . ,  2000b
EBV transformed lymphoblastoid cell-lines LCL Blackbourn etal . ,  2000b
BJAB-derived B-cell line BFF Gasperini et al., 2005
Dermal microvascular endothelial cells DMVEC Flore etal . ,  1998
Immortalised dermal microvascular t-DMVEC Blackbourn et  al., 2000b
endothelial cells
Transformed dermal microvascular DMVEC Moses etal . ,  1999
endothelial cells 
Mesoendothelial cells RMEC-1 Blackbourn et  al., 2000b
Brain-derived endothelial cell-line BB19 Blackbourn et  al., 2000b
Transformed human brain endothelial cells 181GB1-4 Renne etal . ,  1998
Neonatal capillary endothelial cells Renne etal . ,  1998
Chinese hamster ovary cell-line CHO Bechtel etal . ,  2003
Owl monkey kidney cells OMK637 Renne etal . ,  1998
Human epithelial kidney cells 293 Renne etal . ,  1998
Baby hamster kidney cells BHK-21 Renne etal . ,  1998
Prostate cancer derived cell line Ln-Cap Renne etal . ,  1998
Human lung carcinoma cells A549 Renne etal . ,  1998
Chediak-Higachi syndrome cells CHELI Renne etal . ,  1998
Squamous cell carcinoma of the tongue SCC15 Renne etal . ,  1998
Human foreskin fibroblasts HFF Bechtel etal . ,  2003
KS-derived endothelial cell-line (KSHV -ve) SLK Bechtel et  al., 2003
African green monkey kidney cell-line CV-1 Bechtel etal . ,  2003
Human cervical carcinoma cell-line HeLa Bechtel etal . ,  2003
Murine fibroblast cell-line 3T3 Bechtel etal . ,  2003
Quail fibroblast cell-line QT-6 Bechtel etal . ,  2003
Adapted from; R enne et al., 1998; Blackbourn et al., 2000b; Corey et al., 2001; Bechtel et al., 
2003.
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1.1.12. Establishing latency
Latency is a fascinating aspect of herpesvirology. The concept of latency was first 
applied to herpesviruses in the late 1930s. Burnet and Williams stated that, “Herpes 
simplex infections, however, once contracted, seem to persist for life. The virus remains 
for the most part latent; but under the stimulus of trauma, fever, and so forth it may at 
any time be called into activity and provoke a visible herpetic lesion” (Burnet and 
Williams, 1939). The observation that herpesviruses can establish lifelong latent 
infections has stood the test of time and all known human herpesviruses can establish 
such infections. There are many different operational and clinical definitions of 
herpesvirus latency, but all definitions concur that latency is an initially nonproductive 
herpesvirus infection that retains the capacity to reactivate and produce infectious 
virions (Roizman and Knipe, 2001; Kieff and Rickinson, 2001; Mocarski and Courcelle, 
2001).
The study of herpesviral latency began with human alphaherpesviruses. Reactivation of 
alphaherpesviruses from latency frequently, but not necessarily, results in the generation 
of herpetic lesions (reviewed in Efstathiou and Preston, 2005; Kennedy, 2002). This 
has lead to the term ‘reactivation’ being used to describe both clinical recurrence of 
symptoms and the molecular switch from latent to lytic gene expression programmes. 
For clarity, this thesis uses the term ‘reactivation’ to describe, solely, the molecular 
switch from a latent to a lytic gene expression programme.
Following cellular infection herpesviruses either enter a lytic or latent gene expression 
programme. How the virus is directed into either programme is a subject of great 
interest. For alphaherpesvirus, the nature of the host cell seems critical for governing 
which programme the virus enters. For example HSV-1 enters a lytic cycle upon 
infection of oral mucosal epithelium but upon infection of sensory neurons innervating 
the site of infection, HSV-1 enters a latent gene expression programme (Bastian et al., 
1972). It is widely accepted that HSV-1 latency occurs by default if the lytic cycle is 
not initiated following infection (Reviewed in Roizman and Knipe, 2001). This model 
is strongly supported by the observation that impairing alpha gene expression following 
infection can switch HSV-1 from a lytic to a latent gene expression programme in vitro 
(Samaniego et al., 1998; Marshall et al., 2000). Exactly how alpha gene expression is 
prevented in vivo following infection of neurons is unclear, but probably involves the
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host proteins Octamer binding protein (Oct-1) and host cell factor (HCF). Oct-1 and 
HCF bind to VP 16 (Stem et a l , 1989; Gerster and Roeder, 1988) forming a 
heterotrimeric complex capable of promoting immediate early gene expression 
(reviewed in Wysocka and Herr, 2003). It has been suggested that the cytoplasmic 
location of HCF in neurons prevents active complex formation in the nucleus, resulting 
in greatly reduced alpha gene expression and initiation of a latent gene expression 
programme (Kristie et al., 1999; La Boissiere et al., 1999).
The establishment of latency for human betaherpesviruses is not as well characterised as 
human alphaherpesviruses. It is clear that HCMV can establish a latent infection in 
lineage committed myeloid cells including progenitors of granulocytes, macrophages 
and dendritic cells (Hahn et al., 1998). The mechanism determining latent infection of 
these cells is poorly characterised, but similarly to alphaherpesviruses a lack of alpha 
gene expression is implicated in this process. Transcriptional repressors expressed in 
myeloid progenitors are capable of reducing gene expression from the HCMV major 
immediate early promoter (reviewed in Meier and Stinski, 1996), possibly resulting in 
non-productive HCMV latency by default (reviewed in Sinclair, 2000).
Herpesvirus latency is best characterised for human gammaherpesviruses and EBV 
latency is discussed in sections 1.2.7. In contrast to alpha and beta herpesviruses, 
minimal KSHV alpha gene expression is not the decisive factor in determining entry of 
KSHV into a latent gene expression programme. In a fascinating study, Chandran and 
colleagues revealed that entry into an abortive lytic gene expression programme 
precedes the latency programme (Krishnan et al., 2004). KSHV receptor binding 
(Sharma-Walia et al., 2005; Lu et al., 2005b) and constituents of the virion (Bechtel et 
al., 2005a; 2005b) seem to result in the restricted expression of lytic genes following 
infection in vitro (Krishnan et al., 2004). This gene expression is transient and latency 
ensues. The mechanism through which latency interrupts the lytic cycle is uncertain, 
but induction of latency-associated nuclear antigen (LANA) expression by RTA (Lan et 
al, 2005b; Matsumura et a l, 2005) and subsequent repression of RTA expression by 
LANA (Lan et a l, 2004) has been suggested as a potential model (Lan et a l, 2005b).
1.1.13. KSHV latent gene expression
A key feature of latency is the restricted expression of viral genes, which minimises the 
number of viral epitopes presented to the immune system assisting in immune evasion
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(reviewed in Stevenson, 2004). Latent infection by KSHV is predominant in KS, PEL 
and MCD and the contribution of KSHV genes, expressed during latency, to 
tumourigenesis has been the focus of much research (reviewed in Cathomas, 2003).
In all documented latent infections KSHV expresses LANA (Kedes et al., 1997), viral 
Fas-associated death domain (FADD) interleukin-1 P-converting enzyme (FLICE) 
inhibitory protein (vFLIP) (Grundhoff and Ganem, 2001; Low et al., 2001) and viral- 
cyclin (v-cyclin) (Cesarman et al., 1996). These proteins, expressed from the major 
latency locus (Dittmer et al., 1998), are encoded by differentially spliced polycistronic 
mRNAs usually originating from a common promoter (Talbot et al., 1999; Pearce et al., 
2005). This constitutively active promoter is particularly strong in B-cells (Jeong et al.,
2002), upregulated during S-phase (Sarid et al., 1999) and autoactivated by LANA 
(Renne et al., 2001).
Table 1.1.13.1. KSHV genes expressed during latency.
Gene Protein Function References
ORF71 vFLIP Inhibits FAS-mediated apoptosis Djerbi et al., 1999
Activates NFkB Liu et al., 2002
ORF72 v-cyclin Constitutively activates CDK6 Sw anton e ta l., 1997
ORF73 LANA Episome m aintenance B allestas e t al., 1999
Binds p53 and rep resses  transcription Friborg e ta l., 1999
Transcriptional regulation Radkov et al., 2000
ORF K2 vlL-6 Autocrine growth factor Moore et al., 1996a
Induces cellular IL-6 expression An et al., 2002
ORF K10.5 LANA2 Binds p53 and rep resses  transcription Rivas et al., 2001
Inhibits PKR E steban  et al., 2003
ORF K11.1 vlRF2 Inhibits PKR Burysek and Pitha, 2001
Inhibits IRF-1 and IRF-7 m ediated Burysek et al., 1999
transcription
ORF K12 Kaposi n Stabilises cytokine transcripts McCormick and G anem ,
2005
Source of miRNAs Cai et al., 2005
ORF K15 K15 Activates Mitogen activated protein Brinkmann et al., 2003
kinases and nuclear factor kappa B
In addition to genes transcribed from the major latency locus, several other KSHV 
genes are commonly transcribed during latency. These genes and their functions are 
listed in table 1.1.13.1. It is important when considering latent gene expression to 
remember that genes expressed during latency are not exclusive to latency. Indeed,
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viral interleukin 6 (vIL-6) (Katano et al., 2000), K12 (Sadler et al., 1999), LANA, 
vFLIP and v-cyclin (Jenner et al., 2001; Matsumura et al., 2005) all increase their 
expression following lytic induction in vitro.
KSHV latent infections are not uniform and gene expression profiles vary in different 
situations. By analogy to EBV it is possible that KSHV has tightly regulated latent 
gene expression programmes suited to its different cellular lifestyles. Characterisation 
of KSHV latent gene expression has been hampered by the inability of KSHV to form 
lymphoblastoid cell-lines in vitro (Kliche et al., 1998) and the rarity of KSHV infected 
B-cells in healthy individuals. However, KSHV gene expression can be monitored in 
KS biopsies, MCD biopsies, PEL cells and PEL cell-lines. This is summarised in table
1.1.13.2.
Table 1.1.13.2. Characterised latent gene expression.
Gene/
protein
Expressed during 
latency in KS?
Expressed during 
latency in PEL?
Expressed in KSHV 
associated MCD?
ORF71/
vFLIP
Yes
(Sturzl eta l., 1999)
Yes
(Low eta l., 2000)
ORF72/
v-cyclin
Yes
(R eed eta l., 1998)
Yes
(Platt et al., 2000)
ORF73/
LANA
Yes
(Rainbow et al., 1997)
Yes
(Rainbow et al., 1997)
Yes
(Dupin et al., 1999)
ORF K2/ 
vIL-6
Yes
(S taskus e ta l., 1999)
Yes
(S taskus e ta l., 1999)
ORF K10.5/ 
LANA2
Yes (Rivas et al., 2001) Yes (Rivas et al., 2001)
ORF K11.1/ 
VIRF2
Yes
(Burysek and Pitha, 
2001)
ORF K12/ 
Kaposin
Yes
(Zhong e ta l., 1996)
Yes
(Muralidhar eta l., 1998)
ORF K15/ 
K15
Yes
(Glenn eta l., 1999)
Yes
(Sharp et al., 2002)
The characterisation of KSHV genes as latent can be problematic. A small proportion 
of cells in PEL, PEL cell-lines and KS biopsies express lytic genes and are in a lytic or
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abortive lytic gene expression programme (Parravicini et al., 2000). Although only a 
minority of cells express these genes, they can be expressed at such a level that they 
dominate lysates from a population of cells. An example of this is the polyadenylated 
nuclear transcript (PAN) also described as nuclear transcript 1 (nut-1) or transcript 1.1 
(T l.l). PAN was initially described as a latent gene (Zhong et al., 1996), but was 
subsequently recognised as being expressed at high levels in cells supporting lytic 
replication (Staskus et al., 1997; Zhong et al., 1997; Sun et al., 1999). To qualify as 
being expressed during latency, a larger proportion of cells than those expressing lytic 
genes must be identified. This has led to in situ hybridisation (Reed et al., 1998) and 
immunohistochemistry (Dupin et al., 1999) being adopted as the techniques of choice 
for identifying latent gene expression.
Perhaps the most interesting observation from KSHV-associated neoplasms is the 
differential regulation of LANA2 expression. LANA2 is expressed during latency in B- 
cells, but is exclusively a lytic gene in KS biopsies (Rivas et al., 2001). Although the 
mechanism and benefit of this differential expression are unclear, it is proof of principle 
that KSHV can adopt multiple latency programmes. Different latency programmes 
could explain some controversial aspects of latent gene expression. For example vIL-6, 
whose expression is important in the pathogenesis of KSHV-associated MCD 
(Parravicini et al., 1997b), has been classified as both a lytic gene (Katano et al., 2000) 
and a latent gene (Cannon et al., 2000). Although KSHV infected cells in MCD can 
express vIL-6 (Parravicini et al., 1997b; 2000), it is uncertain whether this is latent or 
lytic cycle expression. The inclusion of vIL-6 in table 1.1.13.2 is therefore 
controversial, but it is clear that vIL-6 can be expressed during latency in PEL cell-lines 
(Cannon et al., 2000) and that expression can be modulated in the absence of lytic 
replication (Chatterjee et al., 2002; Deng et al., 2003; Chang et al., 2005a).
There is great potential for the individual regulation of KSHV gene expression during 
latency. KSHV ORF34, a gene of unknown function, is one such gene. Hypoxia 
response elements in the ORF34 promoter facilitate the upregulation of ORF34 in a 
hypoxia inducible factor-1 alpha (HIF-1 alpha) and HIF-2 alpha dependent fashion 
(Haque et al., 2003). It is possible that other KSHV genes are independently controlled 
and expressed during latency in vivo. Indeed, notch signalling has recently been 
demonstrated to induce the expression of multiple viral genes without initiating a lytic 
replication programme (Chang et al., 2005a). In light of the apparent flexibility of
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KSHV gene expression, it is tempting to speculate that KSHV might adopt a variety of 
latent gene expression programmes during its life cycle. A strategy analogous to that 
which is used by EBV (reviewed in Kieff and Rickinson, 2001; Thorley-Lawson, 2001).
1.1.14. KSHV reactivation from latency
Reactivation from latency in B-cells is an important facet of the KSHV lifecycle. A 
better understanding of KSHV reactivation could aid our understanding of disease 
progression and viral transmission. The importance of lytic gene expression in KS and 
MCD (Discussed in section 1.2.7) suggests that the study of reactivation could identify 
new targets of therapeutic interest for the treatment of KS and KSHV-associated MCD.
Waves of virus shedding can be detected in the saliva of KSHV positive individuals 
(Pauk et al., 2000) and reactivation of KSHV from latency in B-cells is probably 
responsible for initiating waves of transient viraemia, a process important in viral 
transmission.
As well as transmission, reactivation from latency is important in KSHV pathogenesis. 
KSHV infection may precede KS development by decades (Cattani et al., 2001) and 
reactivation from latency in B-cells seems critical for progression from asymptomatic 
infection to KS. Treatment of existing KS lesions with ganciclovir, an anti-herpetic 
drug that inhibits lytic replication (Cheng et al., 1983; Cannon et al., 1999), has little 
effect on disease progression (Robles et al., 1999). This is probably because latent and 
early gene expression drives tumourigenesis (reviewed in Hayward, 2003), both of 
which are insensitive to ganciclovir treatment (Lu et al., 2004). Although unable to 
facilitate resolution of KS lesions, ganciclovir is remarkably effective at reducing the 
risk of developing KS. Treatment of HIV-positive individuals, suffering from 
cytomegalovirus retinitis, with oral or intravenous ganciclovir reduced the risk of 
developing KS by 75% or 93% respectively (Martin et al., 1999), presumably through 
preventing reactivation of latent KSHV. These data are consistent with the observation 
that an increased KSHV viral load in PBMC is associated with progression to KS in 
previously asymptomatic carriers (Ambroziak et al., 1995).
Lytic reactivation may also be important in the pathogenesis of KSHV-associated MCD 
(Parravicini et al., 2000). Consistent with this hypothesis, treatment of MCD patients
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with ganciclovir can reduce the frequency of episodic flares (Casper et al., 2004) 
highlighting the importance of reactivation in this disease.
Although no direct role for KSHV lytic replication in the development or pathogenesis 
of PEL has been described, understanding reactivation could be important in the 
treatment of PEL. Inducing lytic replication in PEL cells could make anti-herpetic 
drugs, such as ganciclovir, useful therapeutic agents in treating this neoplasm. For 
example, valproate is a histone deacetylase inhibitor licensed for use in the treatment of 
various neurological disorders. Valproate can reactivate latent KSHV at concentrations 
similar to those observed in the clinic (Shaw et al., 2000). A combination of Valproate 
and ganciclovir has proved effective in blocking KSHV lytic replication and inducing 
apoptosis of PEL cells in vitro (Klass et al., 2005). The clinical utility of this strategy 
has already been observed in a patient suffering from post-transplant 
lymphoproliferative disease, a B-cell neoplasm associated with EBV. EBV lytic 
replication was induced through administration of arginine-butyrate and blocked 
through administration of ganciclovir. This resulted in substantial tumour necrosis 
(Mentzer etal., 1998).
Over 20 situations resulting in the reactivation of KSHV from latency in vitro have been 
described and these are summarised in table 1.1.14.1. All of these stimuli have been 
shown to, or are presumed to, act through inducing RTA expression (reviewed in West 
and Wood, 2003). It is widely accepted that expression of RTA is both necessary (Xu 
et al., 2005) and sufficient (Lukac et al., 1998) to initiate KSHV lytic replication in PEL 
cell-lines. Once expressed, RTA is able to autoactivate the ORF50 promoter (Deng et 
al., 2000) resulting in substantial amplification of any stimulus that induces RTA 
expression.
The proportion of cells harbouring KSHV that reactivate following stimulation varies 
depending on which stimulus is used (Chang et al., 2000). This could be due to cellular 
factors or viral factors. For example, 10-fold more PEL cells synchronised in S-phase 
reactivate following TP A treatment relative to asynchronous controls (McAllister et al., 
2005) and cells harbouring the naturally occurring KSHV deletion mutant KV-1 are 
unable reactivate in vitro (Deng et al., 2004) As well as variation within cell 
populations, different cell types respond differently to each stimulus. For example TPA 
causes maximal induction in most PEL cell-lines, but HBL-6 and HH-B2 PEL cell-lines
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Table 1.1.14.1. Stimuli reported to reactivate latent KSHV.
Stimulus Mechanism Reference
12-0-tetradecanoyl 
phorbol-13-acetate 
(TPA)
Requires activation of protein kinase C6 (Deutsch e t  al., 2004) 
and involves activating protein 1 (Wang etal.,  2004b)
Renne eta l . ,  1996b 
Moore etal. ,  1996b
Sodium butyrate Inhibits histone deacetylases causing chromatin remodelling of 
ORF50 promoter
(Lu etal. ,  2003) and recruitment of stimulating protein 1 (Sp1) 
and Sp3 com plexes (Ye et al., 2005)
Miller e ta l . ,  1996 
Miller eta l .,  1997
lonomycin Mobilises Ca2+ and reactivation is dependent on calcineurin 
(Zoeteweij et al., 2001)
Chang etal. ,  2000
Thapsigargin Mobilises Ca2+ and reactivation is dependent on calcineurin 
(Zoeteweij et al., 2001)
Zoeteweij e t  al., 2001
5-azacytidine Demethylation of ORF50 promoter 
(Chen etal. ,  2001)
Chen e t  al., 2001
Prostratin
Bortezomib
Brown etal.,  2005  
Brown e t  al., 2005
Valproic acid Inhibits histone deacetylases (reviewed in Blaheta eta l .,  2005) Shaw etal.,  2000
Hypoxia Hypoxia inducible factors (HIFs) activate the ORF50 promoter 
(Haque e t  al., 2003)
Davis etal.,  2001
Epithelial
differentiation
Johnson et al., 2005
Adrenalin and 
Noradrenalin
Effect dependent upon protein kinase A Chang etal. ,  2005b
Interferon^ Blackbourn e ta l . ,  2000a  
Chang e t  al., 2000  
Mercader e t  al., 2000  
Monini et al., 1999
Oncostatin M Mercader eta l .,  2000
Hepatocyte growth 
factor/ scatter factor
Mercader e t  al., 2000
lnterleukin-6 Song etal. ,  2002
T richostatin A Inhibits histone deacetylases Lu e t  al., 2003
Hydrocortisone Hudnall eta l .,  1999
HIV-1 tat Harrington eta l . ,  1997
HVS RTA Goodwin et al., 2001
KSHV RTA Auto activates RTA expression (Deng e t  al., 2000) Lukac etal. ,  1998
MHV68 RTA Damania eta l . ,  2004
RRV RTA Damania e t  al., 2004
cFOS-cJUN
heterodimer
Transactivate ORF50 promoter (Wang e t  al., 2004b) Wang e t  al., 2004b
HHV6 coinfection Lu e ta l . ,  2005a
HIV-1 coinfection Possibly HIV-1 tat protein Merat e t  al., 2002
HCMV coinfection Vieira etal. ,  2001
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seem refractory to induction with TPA (Chiou et al., 2002; Ye et al., 2005). With the 
exception of interferon-y, the proportion of cells reactivating in response to cytokines 
and hormones is typically low. Indeed, the ability of hydrocortisone and interleukin-6 
to induce reactivation of KSHV is not consistently reported (Zoeteweij et al., 2002; 
Chang et al., 2000) even using the same cell-line (Song et al., 2002; Chang et al.,
2000). Both oncostatin M and IL-6 are produced by PEL cell-lines (Drexler et al., 
1999) and could be involved in initiating the low level ‘spontaneous reactivation’ 
observed in these cells under standard culture conditions.
The reactivation mechanisms described to date demonstrate that many different 
pathways including; activation of protein kinase C8 (PKC8) (Deutsch et al., 2004), 
mobilisation of intracellular calcium (Zoeteweij et al., 2001), histone acetylation (Lu et 
al., 2003), expression of hypoxia inducible factors (Haque et al., 2003) and 
demethylation of the ORF50 promoter (Chen et al., 2001) can induce ORF50 
expression in vitro. The existence of multiple pathways effecting reactivation in vitro 
suggests that latent KSHV retains the capacity to reactivate in a multitude of different 
scenarios in vivo. However, despite so many reactivation stimuli being described, it is 
unclear which pathways are physiologically relevant and which stimuli activate many 
pathways in vivo. The most convincing study analysing reactivation in vivo observed 
that DNA methylation patterns of the ORF50 promoter vary between asymptomatic 
latent-infections and biopsies from KSHV-associated disease in vivo (Chen et al.,
2001). However, the mechanism(s) resulting in promoter demethylation in vivo and a 
causal connection to reactivation in vivo remain elusive.
1.1.15. RTA and the ORF50 promoter
RTA has a pivotal role in the lifecycle of KSHV. Once expressed, RTA amplifies its 
own expression (Deng et al., 2000) and participates in complexes activating multiple 
viral and cellular genes (reviewed in West and Wood, 2003), initiating a tightly 
regulated gene expression cascade eventually resulting in the production of progeny 
virions. RTA can therefore be considered as a ‘molecular switch’ whose expression 
must be suppressed during latency and activated to initiate lytic replication. The 
decision between latent and lytic gene expression programmes can therefore be 
considered in terms of the transcriptional activation state of the ORF50 promoter.
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Sequence specific transcription factors act as a bridge between regulatory DNA 
sequences and the core transcriptional machinery and chromatin remodelling factors 
(reviewed in Kadonaga, 2004). Because of their decisive role in reactivation, 
transcription factor complexes involving RTA and the ORF50 promoter are an 
important area of KSHV research. Much of the work in this field involves the study of 
complexes associated with RTA. Whilst these complexes are essential for amplifying 
and maintaining initial activation of the ORF50 promoter, they are not informative 
about the complex(es) involved in initiating reactivation in the absence of RTA. In 
addition, RTA is involved in the transcriptional regulation of multiple viral and cellular 
promoters and interacts with a multitude of viral and cellular factors. This makes it 
difficult to generalise about transcription factor complexes involving RTA. Indeed, 
different complexes involving RTA facilitate the differential regulation of multiple 
RTA responsive promoters, an essential feature of the KSHV lytic gene expression 
cascade. The reported interactions directly implicated in the control of ORF50 
expression are summarised in table 1.1.15.1.
Seven transcription factors, in addition to RTA, have been described which initiate 
ORF50 expression when exogenously expressed in vitro (Wang et al., 2003; Haque et 
al., 2003; Wang et al., 2004b; Malik et al., 2004) and are listed in table 1.1.15.1. 
KSHV ORF57 is not expressed during latency (Lukac et al., 1999) and is unlikely to 
play a part in initiating ORF50 expression. Of the remaining transcription factors, only 
HIF-2 has a defined mechanism resulting in its expression in B-cells in vivo. B-cells are 
frequently exposed to hypoxic environments because lymphoid organs have a much 
lower oxygen tension than blood (Kojima et al., 2003). The physiological events 
capable of modulating CCAAT/ Enhancer-binding protein-a (C/EBPa), activating 
protein 1 (AP-1), cAMP response element binding protein (CBP) and specificity protein 
1 (SP-1) activity in vivo and their possible role in KSHV reactivation remain unclear.
Following chemical induction of lytic replication in vitro many factors involved with 
transcriptional regulation of the ORF50 promoter have been identified. Most of these 
factors interact with RTA although Oct-1 is a notable exception (Sakakibara et al,
2001). Although a potent activator of ORF50 expression, RTA is unable to bind the 
ORF50 promoter directly (Sakakibara et al, 2001). Protein-protein interactions
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therefore seem essential to direct RTA to the ORF50 promoter. A particularly 
interesting interaction directing RTA to the ORF50 promoter is with recombination
Table 1.1.15.1. Transcription factors reportedly involved in activating transcription from 
the ORF50 promoter.
Protein Capable of transactivating the Capable of cooperating with RTA
ORF50 promoter in the absence to activate the ORF50 promoter? 
of RTA?
cFOS-cJUN/ 
activating protein 1 
(AP-1)
cJun
CCAAT /
Enhancer-binding
protein-a
(C/EBPa)
ORF57
Hypoxia inducible 
factor-2 (HIF-2)
Specificity protein 
1 (SP-1)
Recombination 
signal-binding 
protein 1 for J- 
kappa (RBP-Jk)
MGC2663/ KSHV- 
RTA binding 
protein (K-RBP)
Octamer-binding 
protein 1 (Oct-1)
cAMP response  
elem ent (CRE)- 
binding protein 
(CBP)
Exogenously expressed  AP-1 can 
induce RTA expression in BCBL- 
1 cells (Wang et al., 2004b)
Can transactivate the ORF50 
prom oter in cotransfection 
experim ents with reporter gene 
constructs (Gwack et al., 2001)
Exogenously expressed  C /EBPa 
can induce RTA expression in 
BCBL-1 cells (Wang et al., 2003)
Can transactivate the ORF50 
prom oter in cotransfection 
experim ents with reporter gene 
constructs (Malik et al., 2004)
Can transactivate the ORF50 
promoter in cotransfection 
experim ents with reporter gene 
constructs (Haque et al., 2003).
Can transactivate the ORF50 
prom oter in cotransfection 
experim ents with reporter gene 
constructs (Ye et al., 2005).
Interacts with RTA enhancing RTA- 
m ediated transactivation (Wang et 
al., 2004b)
C ooperates with RTA in activating 
the ORF50 prom oter (W ang et al.,
2003)
Interacts with RTA enhancing RTA 
m ediated transactivation (Malik et al.,
2004)
Can transactivate the ORF50 
prom oter in cotransfection 
experim ents with reporter gene 
constructs (Lu et al., 2003)
Interacts with RTA helping to target 
RTA transactivation Liang et al.,
2002)
Interacts with RTA weakly enhancing 
RTA-mediated transactivation (Wang 
et al. ,2 0 0 1 b )
Oct-1 binds octam er seq u e n ces  in 
the ORF50 prom oter and en h an ces  
RTA-mediated transactivation 
(Sakakibara et al., 2001)
CBP binds RTA and en h an ces  RTA 
m ediated transcription (Gwack eta l., 
2001)
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signal-binding protein 1 for J-kappa (RBP-Jk) also known as C-promoter binding factor 
(CBF). RBP-Jk is a transcriptional repressor which is the major target of Notch 
signalling (reviewed in Mumm and Kopan, 2000). Notch signalling results in the 
displacement of corepressor complexes from RBP-Jk and the subsequent recruitment of 
coactivator complexes. Similarly, when RTA is recruited to RBP-Jk it results in the 
formation of a transcriptional activating complex in a Notch ligand-independent fashion 
(Liang et al., 2002). RBP-Jk may therefore help maintain latency by repressing ORF50 
transcription whilst remaining essential for reactivation (Liang et al., 2003), by 
directing RTA to the ORF50 promoter and other viral promoters following RTA 
induction (Liang et al., 2002; Chang et al., 2005c).
An important process in transcriptional regulation is chromatin remodelling. Analysis 
of the ORF50 promoter in PEL cell-lines harbouring latent KSHV indicates that the 
ORF50 promoter is in a region of densely packed chromatin associated with histone 
deacetylases (Lu et al., 2003). Following chemical induction of the lytic cycle with 
sodium butyrate or trichostatin A the chromatin conformation is transformed to a more 
relaxed acetylated state (Lu et al., 2003). RTA is able to interact with cAMP response 
element (CRE)-binding protein (CBP) (Gwack et al., 2001), a protein with intrinsic 
histone acetyl transferase (HAT) activity (Bannister and Kouzarides, 1996), potentially 
recruiting HAT activity to the ORF50 promoter. Following induction of KSHV lytic 
replication in vitro, both CBP and p300, another protein with intrinsic HAT activity 
(Ogryzko et al., 1996), can be detected in complexes on the ORF50 promoter (Ye et al.,
2005).
The importance of ORF50 promoter de-repression is further supported by the DNA 
methylation state of the ORF50 promoter in vivo. The ORF50 promoter in 
asymptomatic KSHV-positive individuals is heavily methylated (Chen et al., 2001). 
Methyl CPG binding proteins (MeCPs) bind methylated DNA and are capable of 
recruiting HDACs (Nan et al., 1998), helping to maintain a transcriptionally repressed 
state. Treating PEL cell-lines with 5-azacytidine, a demethylating agent, leads to 
reactivation of KSHV in vitro (Chen et al., 2001), suggesting that demethylation plays 
an important role in activating ORF50 expression in vivo. The chromatin configuration 
at the ORF50 promoter is clearly important in regulating KSHV reactivation in vitro 
and in vivo. Understanding the sequence of events resulting in the recruitment of
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remodelling complexes to the ORF50 promoter probably lies at the heart of a molecular 
understanding of reactivation.
As well as factors cooperating with RTA, interactions that potentially repress 
reactivation have been described and are summarised in table 1.1.15.2. The potentially 
repressive interactions of KSHV LANA are particularly interesting. LANA is able to 
interfere with RTA-mediated transactivation of the ORJF50 promoter (Lan et al., 2004), 
possibly through interactions with CBP, RBP-Jk and RTA (Lim et al., 2001; Lan et al., 
2005a; Lan et al., 2004). It is tempting to speculate that LANA inhibits the interaction 
of RTA with CBP and RBP-Jk. Such negative regulation would prevent undesired 
reactivation from a ‘leaking’ ORF50 promoter and ensure that only significant RTA 
expression would result in autoactivation of the ORF50 promoter and entry into the 
lytic cycle. Indeed, such negative regulation may be common to many rhadinoviruses. 
LANA homologues are capable of suppressing productive infection of rhesus monkey 
rhadinovirus and Herpesvirus saimiri in vitro (DeWire and Damania, 2005; Schafer et 
a l , 2003).
Table 1.1.15.2. Potential negative regulators of RTA.
Protein Capable of repressing RTA activity?
RBP-Jk Interacts with LANA (Lan et al., 2005a)
K-bZIP Interacts with RTA and rep resses  RTA-mediated transactivation of K8 
prom oter (Liao et al., 2003)
Interacts with CBP repressing AP-1 m ediated transactivation (Hwang et 
al., 2001)
LANA Interacts with RTA (Lan et al., 2004) 
Interacts with RBP-Jk (Lan et al., 2005a) 
Interacts with CBP (Lim et al., 2001)
HDAC1 Interacts with RTA (Gwack et al., 2001)
Nuclear factor 
kappa B
Inhibits RTA-mediated transactivation (Brown et al., 2003)
1.1.16. Primary effusion lymphoma
Body cavity based lymphomas (BCBL) presenting in the body cavities of AIDS patients 
were described as early as 1989 (Knowles et al., 1989). Not long after the discovery of 
KSHV, an association between BCBL and KSHV was reported (Cesarman et al., 
1995a). The realisation that not all BCBLs were associated with KSHV led to the
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designation of KSHV-positive BCBLs as primary effusion lymphomas (PELs), a 
distinct clinicopathologic entity (Nador et al., 1996)
PEL accounts for approximately 3% of all HIV-related non-Hodgkin lymphomas 
(Knowles, 2003) and usually presents as a lymphomatous effusion in the pleural, 
pericardial or peritoneal cavities, usually without significant tumour mass (reviewed in 
Ablashi et al., 2002). Although the majority of PEL patients are HIV positive and 
immunosuppressed (Komanduri et al., 1996), PEL has also been observed in HIV- 
negative individuals (Nador et al., 1996). The molecular and clinical features of PEL 
are identical in AIDs-related and non-related PEL. However, AIDS unrelated PEL 
tends to develop later in a life (Nador et al., 1996; Carbone et al., 1996).
The origin of PEL cells was initially difficult to determine because of the intermediate 
immunophenotype of these cells (reviewed in Matolcsy, 1999). The lack of classical B- 
cell associated antigens, most notably cell determinant (CD) 19, expressed by PEL cells 
resulted in the B-cell origin of these tumours being determined by analysis of 
immunoglobulin (Ig) gene rearrangements (Nador et al., 1996; Carbone et al., 1996). 
Most PEL-cells have hypermutated immunoglobulin genes suggesting they have been 
through a germinal centre reaction (Matolcsy et al., 1998; Fais et al., 1999). In 
addition, most PEL cells express CD45, CD30, CD38, CD71, epithelial membrane 
antigen (EMA), the antigen recognised by monoclonal antibody Ki-67 and 
CD138/syndecan-l. This expression profile is reminiscent of cycling plasmablasts. 
The surface antigen CD138 is a marker of pre-B-cells and plasma cells and is not 
expressed by any other lymphomatous effusion (Gaidano et al., 1997), this marker is 
therefore useful for clinical diagnosis and for defining the stage of B-cell development 
PEL represents.
The mature immunophenotype and hypermutated immunoglobulin genes suggest that 
PEL cells represent a preterminal stage of B-cell differentiation, close to that of plasma 
cells (Gaidano et al., 1997). This hypothesis was subsequently confirmed using gene 
expression profiling which determined that PEL cells have a plasmablastic gene 
expression profile (Jenner et al., 2003; Klein et al., 2003). Most PEL cells contain 
somatically hypermutated Ig genes (reviewed in Matolcsy, 1999) suggesting the 
tumours developed from post-germinal centre B-cells. However many cases with 
germline rearranged Ig genes have been described, such as BC-3 (Arvanitakis et al.,
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1996), suggesting passage through a germinal centre reaction is not essential for the 
development of PEL.
The association of KSHV with PEL has been confirmed by multiple studies (Pastore et 
al., 1995; Carbone et al., 1996, Otsuki et al., 1996; Gessain et al., 1997, Karcher and 
Alkan, 1995) and KSHV is present within every PEL cell (Lennette et al., 1996; Kellam 
et al., 1997). Approximately 20-200 copies of the viral episome are present in every 
cell (Gessain et al., 1997; Cesarman et al., 1995a) and KSHV latent gene expression is 
essential for PEL cell survival (Guasparri et al., 2004). Over three quarters of PEL cells 
are coinfected with EBV and it has been suggested that EBV coinfection favours 
tumour development after the germinal centre reaction whereas EBV negative PEL can 
originate from naive B-cells as well as post-germinal centre B-cells (Hamoudi et al., 
2004). Crucially, it is difficult to distinguish the gene expression profile of EBV 
positive and EBV negative PELs (Jenner et al., 2003; Klein et al., 2003) suggesting 
KSHV is the dominant viral factor contributing to PEL (Fan et al., 2005).
The presence of clonal Ig gene rearrangements suggests PEL is a clonal tumour (Nador 
et al., 1996). EBV and KSHV terminal repeat analysis indicates that y-herpesvirus 
episomes are usually clonal in PEL (Judde et al., 2000; Boulanger et al., 2005) 
indicating that latent infection precedes tumour development or provides a selective 
advantage to an infected subset of polyclonal tumour cells. PEL is uncommon, even in 
populations where KSHV is endemic and rare KSHV negative EBV negative tumours 
similar to PEL have been described (Barbey et al., 1990). KSHV infection can 
therefore be considered as a significant risk factor for the development of PEL but other 
transforming events are also required. For example, the B-cell lymphoma-6 (BCL-6) 
promoter is frequently mutated in PEL (Gaidano et al., 1999) and trisomy 7 and trisomy 
12 are common chromosomal abnormalities (Wilson et al., 2002). No cytogenetic 
abnormality common to all cases of PEL has been identified, underlining the 
importance of KSHV infection in the development of PEL.
A feature of PEL is the lack of Ig expression. Despite the similarity of PEL cell-lines to 
plasmablasts, PEL cells do not secrete Ig. Indeed, surface Ig is not expressed by many 
PEL-cells (Nador et al., 1996). PEL cells express B-lymphocyte induced maturation 
protein 1 (BLIMP-1) (described in section 1.2.5.4) and the cleaved 50 kDa form of 
activating transcription factor (ATF)-6 (described in section 1.2.6.2) (Jenner et al.,
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2003), a transcription factor complement usually sufficient for terminal differentiation 
into plasma cells. PEL cells have been reported to lack PU.l, a transcription factor 
involved in Ig light chain expression (Arguello et al., 2003), but it is unclear whether 
this is solely responsible for the reduced Ig expression in PEL. The lack of secreted Ig 
suggests that X-box binding protein 1 (XBP-1) is unspliced in PEL, but the splice status 
is PEL has not been determined.
PEL cells harbour latent KSHV with less than 1% of cells harbouring KSHV in the lytic 
cycle (Parravicini et al., 2000; Katano et al., 2000). KSHV genes expressed in PEL 
cells are summarised in table 1.1.13.2 and unlike KS and MCD, KSHV lytic replication 
seems to be unimportant in the development and pathogenesis of PEL.
1.1.17. Multicentric Castleman’s disease
MCD is an unusual lymphoproliferative disorder that is characterised by episodic 
lymphadenopathy, fever and splenic infiltration (reviewed in Waterston and Bower,
2004). Prior to the discovery of KSHV, an association between KS and MCD had long 
been suspected (Rywlin et al., 1983). Soon after the discovery of KSHV, KSHV DNA 
was detected in samples from patients suffering from MCD (Soulier et al., 1995). In 
addition, KSHV is strongly associated with MCD, is present in nearly all reported 
AIDs-associated MCD cases and around half of HIV-negative cases (Soulier et al., 
1995; Gessain et al., 1996; Luppi et al., 1996; Izuchukwu et al., 2003). 
Immunohistochemical analysis of MCD patient lymph nodes revealed that KSHV was 
present in plasmablasts, mainly in the mantle zone of B-cell follicles (Dupin et al., 
1999). It rapidly became clear that KSHV-associated MCD involves KSHV-positive 
plasmablasts, which have a CD20+ CD5- CD23- CD30- CD38- CD45- 
immunophenotype, and express germ-line immunoglobulin genes which are lambda 
light chain restricted (Dupin et al., 1999; Dupin et al., 2000 Du et al., 2001). KSHV- 
positive MCD plasmablasts only express IgM X whereas surrounding KSHV negative 
cells are polytypic (Dupin et al., 1999; Du et al., 2001). The cause of lambda restriction 
in KSHV-associated MCD plasmablasts is currently unclear.
Despite being lambda light chain restricted, analysis of Ig gene rearrangements (Du et 
al., 2001) and KSHV terminal repeats (Judde et al., 2000) suggests that MCD 
plasmablasts are polyclonal in origin. Unlike PEL-cells, coinfection with EBV has not 
been detected and KSHV positive MCD plasmablasts probably result from KSHV
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infection of naive B-cells (Dupin et al., 1999; Du et al., 2001). MCD disease severity is 
closely associated with KSHV viral load (Oksenhendler et al., 2000) and it is likely that 
MCD pathogenesis may reflect active KSHV replication in lymphoid tissue (reviewed 
in Schulz, 2006). Consistent with this hypothesis, KSHV lytic antigens are readily 
detectable in a minority of KSHV-positive MCD plasmablasts (Parravicini et al., 2000; 
Katano et al., 2000).
1.1.18. Kaposi’s sarcoma
There are four epidemiologically distinct forms of KS: classic, endemic, post-transplant 
or iatrogenic and AIDS-associated. Classic KS (reviewed in Iscovich et al., 2000) is the 
form originally described by Moritz Kaposi (Kaposi, 1872) and occurs predominantly in 
elderly men of Southern European, Arabic or Jewish ancestry. In areas of sub-Saharan 
Africa a more aggressive form of KS has been characterised which affects lymph nodes, 
in addition to the extremities, and sometimes occurs in children. This form is described 
as endemic KS (Ziegler et al., 1996). There is a long-standing association between 
transplant recipients and KS (Harwood et al., 1979), and these cases are described as 
post-transplant KS (reviewed in Gotti and Remuzzi, 1997). KS is the most common 
neoplasm in patients suffering from AIDS and this aggressive disease is described as 
AIDS-associated KS (Beral et al., 1990).
It is now widely accepted that KSHV causes KS and there are multiple lines of evidence 
that this is the case: (i) the KSHV genome is invariably detected in each of the four 
forms of KS (reviewed in Schulz, 1998; 1999). (ii) KSHV DNA, RNA and antigens are 
readily detectable in KS spindle cells, and endothelial cells, but not in surrounding 
healthy cells (Boshoff et al., 1995; Dupin et al., 1999; Parravicini et al., 2000). (iii) 
KSHV viral load is predictive of the progression to KS (Whitby et al., 1995). (iv) 
KSHV seroconversion in HIV-positive men, who have sex with men, is predictive of 
KS development, (v) the prophylactic administration of antiherpetic drugs prevents KS 
development (Robles et al., 1999). (vi) KSHV is monoclonal in advanced lesions 
suggesting that infection precedes sarcomagenesis (Judde et al., 2000). (vii) Exogenous 
expression of the viral G-protein coupled receptor in murine endothelial cells, in vivo, 
induces angioproliferative tumours similar to KS (Montaner et al., 2003).
Early stage KS lesions are composed of small irregular endothelial-lined spaces 
surrounding normal blood vessels. These lesions described as ‘patch stage’ are
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accompanied by an infiltrate of inflammatory cells. As the disease progresses, ‘plaque 
stage’ lesions develop. These lesions involve slit-like vascular channels, containing 
erythrocytes, lined by spindle cells, which penetrate the dermis. Late stage lesions, 
described as the ‘nodular stage’, consist of sheets of spindle cells and slit-like vascular 
spaces. Spindle cells are a defining feature of Kaposi’s sarcoma (reviewed in Gessain 
and Duprez, 2005) and have a variable immunophenotype expressing endothelial, 
monocyte, fibroblast and smooth muscle markers. This had led to much controversy 
surrounding the identity of the precursor cells from which spindle cells are derived. 
Recently, three molecular studies have illuminated this area. Gene expression profiling 
of KS-lesions identified spindle cells as having a gene expression profile similar to 
lymphatic endothelial cells (LECs) (Wang et al., 2004a). Infection of blood vessel 
endothelial cells (BECs) with KSHV in vitro led to the reprogramming of BECs to a 
more LEC-like state (Wang et al., 2004a; Hong et al., 2004b; Carroll et al., 2004). This 
suggests that KSHV is able to infect LECs and BECs, and that these reprogrammed 
cells are the precursors of spindle cells.
In early KS lesions, only around 10% of spindle cells are KSHV positive (Dupin et al., 
1999). Although KSHV is associated with all KS lesions, it is clear that paracrine 
events are essential for sarcomagenesis (reviewed in Ensoli et al., 2001) and many 
inflammatory cytokines, angiogenic factors and chemokines have been detected in KS- 
lesions (reviewed in Ensoli, 2001). Interestingly, proteins involved in lytic replication 
and the inflammatory environment resulting from viral replication may be required for 
this process (reviewed in Hayward, 2003) suggesting that the minority of cells in KS- 
lesions expressing lytic antigens may drive sarcomagenesis.
Clonality is an important aspect of all malignancies. Studies examining both the 
clonality of host cells (Gill et al., 1998) and the clonality of viral TRs in spindle cells 
(Judde et al., 2000) have yielded conflicting results. This is most likely due to 
contaminating healthy cells affecting the analysis of host-cell clonality. Crucially, 
monoclonal or oligoclonal patterns of KSHV TRs are more frequently detected in late- 
stage, nodular KS-lesions (Judde et al., 2000) suggesting that KSHV infection precedes 
sarcomagenesis and that a predominantly latent KSHV infection drives spindle-cell 
proliferation.
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1.2. B-cell differentiation and gammaherpesviruses
The developmental process which generates plasma cells and memory B-cells can be 
divided into three stages: (i) the generation of mature immunocompetent B-cells. (ii) 
The activation of mature B-cells after encountering antigen, (iii) The differentiation of 
activated B-cells into plasma cells or memory B-cells. Each stage of B-cell 
development is summarised here in turn. Particular attention is paid to stage iii as the 
impact of plasma cell differentiation on KSHV reactivation is considered in chapter 6. 
The multiple pathways of B-cell development are summarised in figure 1.2.1.1
1.2.1. B-cell maturation
An important aspect of the adaptive immune response is the ability to respond to a 
varied array of different pathogens. B-cells have a central role in this process, having 
the potential to produce billions of different immunoglobulins.
B-cells are formed in the bone marrow, or foetal liver, from pluripotent haematopoietic 
stem cells. Commitment to the B-cell lineage is signified by CD45 expression (Allman 
et al., 1999) and these cells are described as progenitor (pro)-B cells. Pro-B cells 
proliferate and differentiate within the bone marrow stimulated by factors such as 
stromal cell-derived factor-1 (SDF-1) (Nagasawa et al., 1996), stem-cell factor (SCF) 
(McNiece et al., 1991) and interleukin (IL)-7 (reviewed in Lee et al., 1988), which are 
produced by the surrounding stromal cells. During pro-B cell development CD 19, the 
major cell determinant of B-cells, is expressed. CD 19 expression is upregulated by the 
B-cell-specific activating protein (BSAP) (Kozmik et al., 1992) encoded by the PAX-5 
locus (Adams et al., 1992). Once expressed, BSAP maintains commitment to the B-cell 
lineage, suppressing alternative lineage choices (Nutt et al., 1999). Interestingly, 
microRNAs (described in section 1.3) have recently been implicated in B-cell lineage 
commitment (Chen et al., 2004).
During the pro-B cell stage, rearrangement of the immunoglobulin heavy chain locus 
occurs (reviewed in Collins et al., 2003; Hozumi and Tonegwa, 1976; Brack et al., 
1978). First to occur is the joining of the diverse (D) and joining (J) gene segments of 
the immunoglobulin (Ig) heavy chain (IgH) (Hardy et al., 1991). This is followed by 
the recombination of the variable (V) region with the DJ segment to form a complete
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IgH gene. The process of immunoglobulin gene rearrangement is catalysed by 
recombinase-activating genes (RAG) 1 and 2 (Oettinger et al., 1990) and terminal 
deoxynucleotide transferase (TdT) (Komori et al., 1993). Successful rearrangement of 
the IgH locus is a major checkpoint in B-cell maturation and successful IgH 
rearrangements are positively selected based on their ability to associate with the 
proteins >-5 and VpreB. These two proteins interact and form a structure similar to an 
immunoglobulin light chain (Karasuyama et al., 1990), described as the surrogate light 
chain (SLC) (Cherayil et al., 1991). Cells that fail to generate an IgH which complexes 
with the SLC, described as the pre-B cell receptor, are unable to complete B-cell 
maturation (Kitamura et al., 1992). Conversely, cells expressing a functional pre-B-cell 
receptor undergo a proliferative burst (Hardy et al., 1991) and RAG gene expression is 
transiently downregulated to prevent further gene rearrangements (Grawunder et al., 
1995).
The subsequent pre-B-cell stage is characterised by rearrangement of the genes 
encoding the Ig light chain (IgL) (reviewed in Ehlich and Kuppers, 1995). There are 
two loci encoding light chain gene segments, k  and X. The k  loci are rearranged first, 
and if this fails, the A, loci are rearranged (Mehr et al., 1999). Successful light chain 
rearrangement results in the expression of IgL. If the expressed IgL is able to complex 
with the jlx heavy chain, forming IgM, an immature BCR complex is then formed 
through association with Iga and Igp (CD79a and b). If the immature BCR signals 
above a critical threshold, RAG gene expression is, again, downregulated (Grawunder 
et al., 1995; Lang et al., 1996). If signalling through the BCR is activated by self­
antigen in the bone marrow, there are three possible outcomes: (i) high affinity 
interactions result in apoptosis (clonal deletion) (Nemazee and Burki, 1989) whereas 
low affinity interactions result in (ii) the maintenance of RAG expression whilst the 
light chains are replaced (receptor editing) (Tiegs et al., 1993) or (iii) anergy, a state 
where antigen binding does not trigger intracellular signalling (Goodnow et al., 1989). 
Mature B-cells, which do not recognise self-antigen, exit the bone marrow and enter 
circulation.
1.2.2. Minority B-cell subsets
B-cells can be divided into many subsets based on their location, developmental stage 
and immunophenotype. However, all B-cells, at one stage of differentiation, can be 
divided into 3 subsets. These are described as mature recirculating/follicular/B-2 B-
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cells, marginal zone B-cells and B-l B-cells. B-2 B-cells are the most common B-cell 
subset, and most of the details described in sections 1.2 apply to these cells. Marginal 
zone and B-l B-cells make ‘natural antibodies’, antibodies that arise without any known 
antigenic stimulation (reviewed in Martin and Kearney, 2000) and have the capacity to 
rapidly generate effector-plasmablasts in early stages of an immune response (reviewed 
in Martin et al., 2001).
Marginal zone (MZ) B-cells (reviewed in Pillai et al., 2005b) are named after 
noncirculating B-cells which reside in the splenic marginal zone of rodents (Gray et al., 
1982). In humans however, MZ B-cells circulate in a manner similar to circulating 
memory cells (reviewed in Spencer et al., 1998). Indeed, the splenic marginal zone, in 
humans, is populated with both MZ B-cells and memory B-cells. Circulating IgM+ 
memory cells and MZ B-cells carry similar somatic mutations in their IgM genes 
(Weller et al., 2004) and are indistinguishable by gene expression profiling (Weller et 
al., 2004) and probably represent the same B-cell subset. The somatic mutations 
characteristic of MZ B-cells also occur in individuals suffering from HyperlgM-l who, 
due to a mutated CD40 ligand, cannot form germinal centres (Weller et al., 2001). In 
addition, these mutations occur in response to T-independent antigens in mice (de 
Vinuesa et al., 2000). These observations suggest that MZ B-cell somatic mutations 
arise via an extra-follicular route but the details of this process are unclear.
B-cell entry into the marginal zone subset is favoured by low affinity BCR signalling 
(Cariappa et al., 2001) and requires notch signalling. This is clearly apparent in mice, 
with an engineered defect in RBP-Jk, who are unable to generate MZ B-cells (Tanigaki 
et al., 2002). MZ B-cells have elevated levels of BLIMP-1 (Martin et al., 2001). This 
allows MZ B-cells to rapidly differentiate into plasmablasts within hours of 
encountering antigen. This provides the host with a rapid and substantial IgM response, 
an essential defence against blood-borne pathogens (Zandvoort et al., 2002).
The B-l subset of B-cells was originally identified based on the presence of CD5 
(Caligaris-Cappio et al., 1982). However it is now clear that CD5- B-l B-cells also 
exist (Kantor et al., 1992). Indeed, CD5 is a poor marker of B-l B-cells because CD5 
expression can also be induced on follicular B-cells (Cong et al., 1991). B-l B-cells are 
the main population of B-cells in foetal life (Bhat et al., 1992) but are the minority B- 
cell subset in adult life (Dono et al., 1996). B-l B-cells are extremely long-lived cells
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and were originally thought to exist throughout an individual’s life, without a 
requirement for renewal. Although the details of B-l B-cell self-renewal have yet to be 
unravelled, it is clear that adult bone marrow can produce B-l B-cells (Waddick and 
Uckun, 1993). BCR activation, through encounter with self-antigen, seems important in 
B-l B-cell development (reviewed in Hayakawa et al., 2000), providing a possible 
explanation for the increased proportion of autoantibodies produced by this subset (Qin 
etal., 1999).
Similarly to MZ B-cells, B-l B-cells are involved in the production of ‘natural 
antibody’ and isolated B-l B-cells secrete IgM in vitro (Casali et al., 1987). The IgM 
expressed by B-l B-cells are not mutated (Kuppers et al., 1993). Interestingly, the 
transcriptional programme resulting in the production of ‘natural antibodies’ by B-l B- 
cells is different to follicular B-cells, with no apparent requirement for BLIMP-1 or the 
spliced form of XBP-1 (Tumang et al., 2005).
1.2.3. B-cell activation
Heightened reactivity to antigen recall is the central defining characteristic of the 
adaptive immune response (Burnet and Fenner, 1949). The follicular B-cell subset can 
give rise to antigen specific memory B-cells, an essential feature of immunological 
memory. Follicular B-cells are attracted into follicles of secondary lymphoid organs by 
B-lymphocyte chemokine (Gunn et al., 1998). In the follicle, B-cells differentiate into 
IgM+, IgD+ mature B-cells. Only a fraction of immature B-cells differentiate into 
mature B-cells, with self-reactive B-cells suffering clonal deletion (Russell et al., 1991), 
or failing to compete for entry into the follicular niche (Cyster et al., 1994). Once in the 
follicles, B-cells receive pro-survival signals such as the tumour necrosis factor (TNF) 
family B-cell activating factor (BAFF), also described as BLyS (Harless et al., 2001). 
Mature antigen naive B-cell survival also requires low-level signalling through the BCR 
(Turner et al., 1997).
1.2.3.1. Development of effector T-helper cells: Immune synapse I
The T and B-cells in secondary lymphoid organs are dependent on antigen being
presented to them by dendritic cells (DCs). DCs can detect conserved motifs on many 
different pathogens through Toll-like receptors (TLRs) (reviewed in Kawai and Akira,
2005) and receptors which recognise carbohydrates (Reviewed in Figdor et al., 2002). 
Pattern recognition stimulates DCs to endocytose and process antigen. This leads to
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DCs presenting antigen-derived peptides complexed with class II major 
histocompatibility complex (MHC) molecules (pMHCII) (reviewed in Quah and 
O’Neil, 2005). In addition, DC activation through pattern recognition also causes the 
upregulation of receptors, such as the CC chemokine receptor 7 (CCR-7) (Dieu et al.,
1998) or osteopontin receptors (Weiss et al., 2001), which cause DCs to migrate from 
the site of antigen-encounter to the secondary lymphoid organs.
Once in the secondary lymphoid organ, antigen is presented by dendritic cells in the T- 
cell zones of lymph nodes or periarteriolar lymphoid sheath (PALS) of the spleen. 
Antigen specific CD4-positive T-cells interact with DCs forming an immunological 
synapse (Monks et al., 1998; Grakoui et al., 1999). The main interaction at this 
immunological synapse is between pMHCII and antigen specific T-cell receptors 
(TCRs) with prolonged interaction sufficient to drive T-helper ( T h)  cell proliferation 
(Lee et al., 2002b). The coupling of DCs, activated by pattern recognition in peripheral 
sites, with antigen specific T-cells provides a bridge between the innate and adaptive 
arms of the immune response.
1.2.3.2. Activation of naive antigen specific B-cells: Immune synapse II
To activate resting, naive, antigen-specific B-cells, at least two sets of signals are
required (Lanzavecchia, 1985). The naive B-cell first encounters antigen, usually 
presented by antigen presenting cells, which activates signalling through the BCR 
(signal 1). BCR activation also stimulates internalisation of antigen (Batista et al., 
2001) which is then processed and presented as pMHCII (Lanzavecchia, 1985). This 
complex is recognised by the TCRs of clonally expanded Th cells generated by immune 
synapse I (signal 2). Although these two signalling events are the main protagonists in 
B-cell activation, it is clear that a number of costimulatory signals modulate B-cell 
activation (reviewed in Bishop and Hostager, 2001). CD40 and CD40 ligand have an 
essential role in class switch recombination (CSR) and germinal centre (GC) formation 
(reviewed in Banchereau et al., 1994). 0X40 (CD 134) and OX40-ligand also seem 
essential for CSR (Murata et al., 2000) and CD27-CD70 interactions may promote 
plasma cell development (Jacquot et al., 1997). Once activated, B-cells are described as 
lymphoblasts and proliferate to form a primary focus (Jacob et al., 1991a). At this 
stage, lymphoblasts can either form a secondary follicle or can differentiate into short­
lived plasma cells (Ho et al., 1986) which secrete germline encoded antigen-specific
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antibodies (Jacob and Kelsoe, 1992). Exactly how the signals at the T-B-cell synapse 
interact to specify different cell fates following B-cell activation remains unclear.
Class switch recombination (CSR) (reviewed in Stavnezer and Schrader, 2006) allows 
the immunoglobulin isotype expressed by a B-cell to be changed. The different IgH 
constant regions are arranged sequentially in the human genome and CSR involves 
recombination between switch-region sequences located upstream of each of the IgH 
constant regions (except s) resulting in intrachromasomal deletion of the intervening 
sequence. This results in a different IgH gene being expressed with the variable region. 
The molecular machinery involved had not been fully defined but involves activation 
induced cytidine deaminase (AID) (Okazaki et al., 2002; Ta et al., 2003) and uracil-N- 
glycosidase (Rada et al., 2002).
Although the majority of CSR occurs within the germinal centre, the outcome of CSR 
may be determined early during immune synapse II. CD40-CD40L interactions are 
important for CSR (reviewed in Banchereau et al., 1994), a function which may be 
substituted by BAFF expression (Litinskiy et al., 2002). Despite the importance of 
these interactions, the extent of CSR seems to be determined by Tn-cell cytokine release 
with IL-4 (Kuhn et al., 1994), IL-21 (Ozaki et al., 2002), IFN-y (Snapper and Paul, 
1987), transforming growth factor p (Coffman et al., 1989) and BSAP (Qiu et al., 1998) 
all implicated in this process. Additionally, there may be a role for IL-2, IL-5 and IL-6 
(Kopf et al., 1994) in supporting the survival of B-cells expressing different classes of 
immunoglobulin.
1.2.3.3. The germinal centre reaction
Lymphoblasts can migrate into a primary follicle, forming a secondary follicle. 
Lymphoblasts expressing BCRs with high affinity for antigen are preferentially 
recruited at this stage (Shih et al., 2002). The proliferating lymphoblasts displace 
resting follicular B-cells generating a germinal centre (reviewed in Wolniak et al., 2004; 
McHeyzer-Williams, 2003; Guzman-Rojas, 2002). A GC reaction is defined 
anatomically by the formation of a zone of proliferating centroblasts, described as the 
dark zone, and a zone of noncycling centrocytes, described as the light zone. The 
germinal centre is a cyclical reaction in which B-cell clonal expansion is followed by 
BCR diversification and affinity-selection of BCRs. This results in affinity maturation, 
a process which generates BCRs with increased affinity for antigen.
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Once in the germinal centre, clonal expansion is coupled to somatic hypermutation 
(Jacob et al., 1991b; Berek et al., 1991). Somatic hypermutation results in the 
introduction of substitutions, and rare insertions and deletions, within the variable 
regions of Ig genes. AID is an essential enzyme involved in SHM (Revy et a\., 2000; 
Muramatsu et al., 2000) although its exact mode of action is unclear (reviewed in 
Franklin and Blanden, 2004; Honjo et al., 2005), it is clear that dsDNA breaks (Bross et 
al., 2000) and error prone DNA polymerases are involved (Zan et al., 2001). 
Approximately one mutation is inserted per cell division (McKean et al., 1984) and the 
near-random mutation of variable regions creates BCRs with increased or decreased 
affinity for antigen. GC B-cells with high affinity antigen receptors out-compete those 
with lower affinity receptors, in the light zone, through receiving survival signals 
through their BCR (Liu et al., 1989). Cells expressing BCRs with lowered affinity for 
antigen are deleted through apoptosis (Takahashi et al., 1999). The exact method of 
antigen presentation and selection in the germinal centre is unclear, but must involve 
antigen free of immune complexes (Hannum et al., 2000) and probably involves 
follicular DCs (FDCs) (reviewed in Kosco-Vilbois, 2003) and antigen specific T-cell 
help (Kim et al., 2001).
Following positive selection in the light zone, centrocytes can return to the dark zone 
and undergo another round of clonal expansion and SHM. In this way higher affinity 
mutants of the original BCR are generated through cyclical rounds of mutation and 
selection. A process described as affinity maturation. Eventually, B-cells which 
survive the GC reaction leave the germinal centre and differentiate into memory or 
plasma cells. The cues which cause B-cells to exit the germinal centre are unknown. 
Interestingly, B-cells deficient for AID (Muramatsu et al., 2000) and BLIMP-1 
(Shapiro-Shelef et al., 2003) accumulate in the GC suggesting that intrinsic B-cell 
mechanisms may be involved. In addition, CD40 signalling is able to downregulate B- 
cell lymphoma (BCL)-6 (described in section 1.2.5) expression (Panagopoulos et al.,
2004), which de-represses BLIMP-1 expression, suggesting a role for T-cell help in this 
process.
1.2.4. Memory B-cells
Exit from the germinal centre results in at least two different B-cell fates, memory cells 
and plasma cells. Memory B-cells are, CD27 positive (Klein et al 1998), long-lived
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nondividing cells (Maruyama et al., 2000) which circulate in the blood (Benner et al., 
1977) or colonise the MZ of the spleen (Liu et al., 1988). Upon secondary challenge 
with antigen, memory cells rapidly differentiate into antibody-secreting plasma cells, 
(Burnet and Fenner, 1949; Mitchell et ah, 1972; Arpin et al., 1997) providing a rapid 
and specific immune response. Interestingly, in addition to antigen, memory B-cells 
seem poised to respond to polyclonal activation through pattern recognition and T-cell 
help (Bemasconi et a l, 2002; 2003), whereas naive B-cells are not responsive to 
polyclonal signals (Bemasconi et al., 2003). This facilitates the persistent production of 
antigen specific antibodies, and maintenance of the memory pool, in the absence of 
specific antigen.
The memory compartment includes post-GC, B-cell-CD45 positive (Bleesing et al.,
2003), memory cells, the best characterised B-cell memory compartment (Mitchell et 
al., 1972). More recently, a second B-cell-CD45 negative memory compartment, 
described as the pre-plasma memory compartment, has been defined (McHeyzer- 
Williams et a l, 2000; Driver et a l, 2001). The specific functions of this subset are 
currently unclear (Blink et al., 2005). In addition, other minority post-GC memory 
subsets may exist (Cascalho et a l, 2000).
The observation that B-cells unable to express BLIMP-1 can develop post-GC memory 
cells but not pre-plasma memory cells (Shapiro-Shelef et a l, 2003) led McHeyzer 
Williams and colleagues to suggest a linear model of memory B-cell development 
(depicted in figure 1.2.1.1) in which post-GC memory B-cells lie upstream of pre­
plasma memory cells (Shapiro-Shelef et a l, 2003; reviewed in McHeyzer-Williams and 
McHeyzer-Williams, 2005). However, this model has yet to be verified and the cues 
which determine the post-GC cell fate are largely unknown.
1.2.5. Plasma cells
Plasma cells are the effector cells of the B-cell lineage (reviewed in Calame et al., 2003; 
Lin et a l, 2003b; Shapiro-Shelef and Calame, 2004; Shapiro-Shelef and Calame, 2005). 
Plasma cells are terminally differentiated B-cells which are able to synthesise and 
secrete large amounts of immunoglobulins, an integral feature of the innate and 
adaptive immune responses.
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The signals resulting in commitment to plasma cell differentiation are not yet 
understood. However, many signals have been implicated in this process. Yet again, 
signals from the BCR seem important in this process. BCR signalling can result in 
phosphorylation of B-cell lymphoma-6 (BCL-6) resulting in degradation via the 
ubiquitin/proteasome pathway in vitro (Niu et al., 1998). Crucially, the activation of 
BCR signalling and subsequent degradation of BCL-6 is not sufficient to cause BLIMP- 
1 expression or plasma cell differentiation (Schliephake and Schimpl, 1996). As well as 
the BCR-antigen interaction, other signals are required. Indeed, activation of B-cell 
signalling in the presence of IL-2 and IL-5 does result in BLIMP-1 expression and 
differentiation into plasma cells (Schliephake and Schimpl, 1996). In addition, IL-6 
(Piskurich et al., 2000), IL-10 (Choe and Choi, 1998) and IL-21 (Ozaki et al., 2004) 
have also been implicated in plasma cell development. Although these cytokines 
activate many different signalling pathways, the signal transducer and activator of 
transcription (STAT) family of transcription factors, particularly STAT-3 are thought to 
be involved in the upregulation of BLIMP-1 expression (Reljic et al., 2000). 
Interestingly, at each cell division during clonal expansion in the GC reaction there is a 
predictable probability of commitment to the plasma cell fate (reviewed in Tangye and 
Hodgkin, 2004). This probability is further increased in the presence of IL-4 or IL-5 
(Hasbold et al., 2004) which suggests that intrinsic and extrinsic mechanisms influence 
the commitment to plasma cell differentiation.
Ultimately, any signals which promote plasma cell differentiation manifest themselves 
in changes in the transcription factor repertoire. In order for plasma cell differentiation 
to occur, the transcription factors required for the maintenance of the pre-plasma B-cell 
phenotype must be repressed and transcription factors inducing differentiation must be 
activated. Many of the transcription factors involved in defining the B-cell/GC state 
and those governing plasma cell differentiation are well defined and summarised in 
figure 1.2.5. And the impact of each transcription factor is considered in turn.
1.2.5.1. PAX-5IBSAP
The BSAP protein encoded by the pax-5 locus is a helix-tum-helix DNA binding 
protein that is required for commitment and maintenance of the B-cell fate (Nutt et al.,
1999). BSAP expression is restricted to B-cells, in cells of a haematopoietic lineage, 
and is involved in isotype switching (Qiu et al., 1998). BSAP acts as a transcriptional 
repressor, blocking differentiation into plasma cells. This is achieved through multiple
57
activities which converge on the transcription factor XBP-1. BSAP is able to directly 
repress XBP-1 transcription (Reimold et al., 1996). In addition, BSAP is able to repress 
immunoglobulin expression through repressing J-chain (Rinkenberger et al., 1996), IgH 
expression (Singh et al., 1993; 1996) and kappa light chain expression (Shaffer et al., 
1997). Immunoglobulin expression is thought to be the driving force behind the 
expression of the spliced form of XBP-1 (described in section 1.2.6.2) and BSAP 
therefore reduces XBP-1 expression and XBP-1 splicing.
1.2.5.2. BCL-6 and metastasis-associated 1 family member 3 (MTA3)
BCL-6 is a sequence specific transcriptional repressor belonging to the poxvirus and
zinc finger (POZ)/Zinc-finger protein family (Chang et al., 1996) and is expressed at 
high levels in GC B-cells (Cattoretti et al., 1995). Crucially, BCL-6 is required for GC 
formation and BCL-6 knockout mice are unable to form germinal centres (Dent et al.,
1997). BCL-6 expression prevents B-cell exit from the GC and subsequent 
differentiation into plasma cells. This is achieved through downregulating BLIMP-1 
expression (Shaffer et al., 2000; Tunyaplin et al., 2004). Consistent with this, plasma 
cell differentiation is accelerated in vitro and serum antibody levels are increased in 
BCL-6 knockout mice (Tunyaplin et al., 2004). BCL-6 is able to suppress BLIMP-1 
expression through at least two different mechanisms. BCL-6 binds to intronic 
sequences within the positive-regulatory domain containing 1 (prdml) gene, which 
encodes BLIMP-1, repressing BLIMP-1 expression (Tunyaplin et al., 2004). In 
addition, BCL-6 is able to interfere with STAT-3 signal transduction, preventing the 
action of cytokines favouring plasma cell differentiation (Reljic et al., 2000).
Interestingly, metastasis-associated 1 family member 3 (MTA3) is required for BCL-6- 
mediated repression of BLIMP-1 expression. Ablation of MTA3 expression using 
RNAi has little affect on BCL-6 expression, but results in the de-repression of BLIMP-1 
expression and subsequent plasma cell differentiation. Astonishingly, exogenous 
expression of BCL-6 in the plasma cell-like multiple myeloma cell line NCI-H929, 
results in MTA3 dependent de-differentiation. These cells lose BLIMP-1 expression 
and resume expression of genes characteristic of GC B-cells, such as CD 19 (Fujita et 
al., 2004). MAP kinase signalling (Niu et al., 1998) and BCL-6 acetylation by CBP 
(Bereshchenko et al., 2002) have both been implicated in the negative regulation of 
BCL-6. The sequence of events resulting in BCL-6 inactivation and degradation in vivo
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are currently unclear but probably involve BCR signalling (Niu et al., 1998), T-cell help 
(Panagopoulos et al., 2004) and cytokine signalling (Schliephake and Schimpl, 1996).
1.2.5.3. Micropthalmia-associated transcription factor (MITF) and Interferon-regulatory 
factor-4 (IRF4)
Micropthalmia-associated transcription factor (MITF) and interferon-regulatory factor-4 
(IRF4) are both important regulators of plasma cell differentiation. Exactly how their 
action is integrated with the other major transcription factors effecting plasma cell 
differentiation has yet to be determined. MITF is a basic helix-loop-helix leucine zipper 
containing transcription factor (Hemesath et al., 1994) which is expressed at high levels 
in resting B-cells. Defective MITF activity results in spontaneous B-cell activation and 
antibody secretion (Lin et al., 2004). Furthermore, exogenous MITF expression is 
sufficient to repress IRF-4 expression and antibody secretion in vitro (Lin et al., 2004).
The function of IRF4 is less clear because IRF4 knockout mice have multiple defects in 
their immune system (Mittrucker et al., 1997). However, these mice are unable to 
mount detectable antibody responses. Although the details of the involvement of IRF4 
in plasma cell differentiation is unclear, IRF4 heterodimerises with PU. 1 and binds to 
enhancers of the kappa and lambda light chains (Eisenbeis et al., 1995), potentially 
enhancing IgL expression.
1.2.5.4. B-lymphocyte induced maturation protein 1 (BLIMP-1)
BLIMP-1 was first identified as a novel repressor of beta-interferon gene expression 
(Keller and Maniatis, 1991) and is a five zinc-finger motif containing protein (Keller 
and Maniatis, 1992) which acts as a transcriptional repressor by recruiting HDACs (Yu 
et al., 2000) and histone methyltransferases (Gyory et al., 2004). BLIMP-1 expression 
in mature B-cells is sufficient to induce terminal differentiation into immunoglobulin 
secreting plasma cells (Turner et al., 1994; Schliephake and Schimpl, 1996; Shaffer et 
al., 2002). However, it was not until relatively recently that BLIMP-1 was identified as 
being necessary for plasma cell differentiation (Shapiro-Shelef et al., 2003).
Staudt and colleagues identified 228 transcripts that were downregulated and 32 that 
were induced following exogenous expression of BLIMP-1 in mature B-cells (Shaffer 
et al., 2002). The repressed genes fell into two main categories, those specifying B-cell 
function and those involved in regulating proliferation. This suggests that BLIMP-1 
mediates plasma cell differentiation through extinguishing the GC B-cell gene
60
expression programme and de-repressing genes required for plasma cell differentiation. 
Crucially, BLIMP-1 represses both BCL-6 expression (Shaffer et al., 2002) and Pax-5 
expression (Lin et al., 2002). BCL-6 repression de-represses BLIMP-1 expression 
(Tunyaplin et al., 2004) amplifying the induction of BLIMP-1 expression. PAX-5 
repression de-represses XBP-1 (Reimold et al., 1996), J-chain (Rinkenberger et al.,
1996), IgH (Singh et al., 1993; 1996) and kappa light chain expression (Shaffer et al.,
1997) which promotes plasma cell differentiation.
1.2.6. Plasma cell differentiation, XBP-1 and the unfolded protein 
response
The transcription factor X-box binding protein 1 (XBP-1) is a bZIP transcription factor 
first identified by its ability to bind to the x-box, a conserved transcriptional element, in 
the human leukocyte antigen (HLA) DR alpha promoter (Liou et al., 1990). XBP-1 is 
essential for plasma cell differentiation (Reimold et al., 2001). Furthermore, 
differentiation requires not only the expression of XBP-1 but the expression of the 
spliced isoform of XBP-1 s. The de-repression of XBP-1 and the splicing of XBP-1 
under conditions of ER-stress are described here in turn.
1.2.6.1. De-repression of XBP-1 expression
XBP-1 is ubiquitously expressed in mammalian cells. However, XBP-1 expression is 
substantially repressed by BSAP in B-cells (Reimold et al., 1996). BLIMP-1 
expression decreases the abundance of BSAP, which de-represses XBP-1 expression 
(Reimold et al., 1996; Shaffer et al., 2002). In addition, XBP-1 expression is 
upregulated by IL-4 (Iwakoshi et al., 2003) and the processed 50 kDa form of ATF-6 
(Yoshida et al., 2000).
1.2.6.2. XBP-1 s and the unfolded protein response (UPR)
The unfolded protein response (UPR) (reviewed in Schroder and Kaufman, 2005) was 
first characterised as a stress response resulting in the induction of glucose-regulated 
proteins (Kozutsumi et al., 1988). In the presence of unfolded and misfolded proteins 
the UPR regulates the expression of chaperones and foldases, the expansion of the 
secretory apparatus, the inhibition of protein synthesis, inhibition of cell cycle 
progression and promotes apoptosis. Using these mechanisms, the UPR is able to 
minimise the impact of unfolded/misfolded proteins by increasing a cell’s capacity to 
correctly fold proteins and ensuring the removal of cells, unable to achieve this, through 
apoptosis.
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The sensing of unfolded proteins in the ER is mediated through the IgH-binding protein 
BiP (Haas and Wabl, 1983). BiP is able to bind, with low affinity, to short hydrophobic 
motifs which usually reside in the interior of soluble proteins (Flynn et al., 1991; Blond- 
Elguindi et al., 1993). Unfolded proteins are therefore able to recruit BiP, which 
removes BiP from its ‘normal’ cellular binding partners. Removal of BiP from PKR- 
like ER kinase (PERK), inositol requiring 1 (IRE1) or activating transcription factor 6 
(ATF-6) allows the unfolded protein signal to be transduced across the ER-membrane 
and these three pathways are summarised in figure 1.2.5.2.
Following the titration of BiP from PERK, PERK undergoes oligomerisation and 
phosphorylates its substrates. The major substrates of PERK are eukaryotic initiation 
factor-2alpha (eIF2a) (Harding et al., 1999) and the bZIP transcription factor nuclear 
factor erythroid 2 (NF-E2)-related factor 2 (NRF2) (Cullinan et al., 2003). 
Phosphorylation of eIF2a results in a near global inhibition of translation (Harding et 
al., 1999), which results in decreased levels of high-tumover proteins such as cyclin Dl. 
The removal of cyclin Dl causes cells experiencing ER-stress to arrest in Gi of the cell 
cycle (Tomida et al., 1996). Phosphorylated NRF2 migrates from inactive cytosolic 
complexes to the nucleus, where it upregulates the expression of genes containing 
antioxidant response elements (Venugopal and Jaiswal, 1998).
The arrest in translation caused by phosphorylated eIF2a is incomplete and the 
translation of ATF-4 is actually enhanced following the phosphorylation of eIF2a 
(Harding et al., 2000). The increased abundance of ATF-4 results in increased 
transcription of ATF-4 target genes. One such gene is GADD34, a protein that is able 
to accelerate the dephosphorylation of eIF2a, mediated by protein phosphatase 1 
(Novoa et al., 2003). GADD34 therefore participates in a negative feedback loop which 
minimises the inhibition of translation caused by PERK activation. Interestingly, no 
role for PERK signalling has been reported in plasma cell differentiation. Indeed, the 
selective activation of different UPR pathways lies at the heart of the ‘physiological 
UPR’. Exactly how IRE1 and ATF-6 are specifically activated without activating 
PERK during plasma cell differentiation remains unclear.
Following the titration of BiP from ATF-6, two Golgi localisation motifs are exposed 
on ATF-6 (Shen et al., 2002) causing it to migrate to the Golgi. In the Golgi, two 
rounds of proteolysis result in the liberation and nuclear translocation of the 50 kDa,
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transcriptionally active, N-terminal portion of ATF-6 (Ye et al., 2000). ATF-6 is a bZIP 
transcription factor able to homodimerise or heterodimerise with other bZIP proteins 
including XBP-1 (Newman and Keating, 2003). ATF-6 is able to upregulate the 
expression of many foldases and chaperones and also represses the BiP promoter 
(Thuerauf et al., 2004). Interestingly, ATF-6 is also involved in negative feedback 
regulation of the PERK response. ATF-6 upregulates the expression of p58 inhibitor of 
PKR (IPK) (Yan et al., 2002; van Huizen et al., 2003), another factor capable of 
promoting the dephosphorylation of eIF2a.
Interestingly, ATF-6 is able to sense ER-stress through an alternative mechanism. ATF- 
6 has three glycosylation sites, which when glycosylated promote interaction with 
calreticulin (Hong et al., 2004a). This interaction anchors ATF-6 in the ER and 
underglycosylated ATF-6 traffics to the Golgi (Hong et al., 2004a). The selective 
activation of ATF-6 in response to glycosylation provides a link between the 
calnexin/calreticulin quality control cycle of the ER (reviewed in Kleizen and 
Braakman, 2004) and the UPR. The selective activation of ATF-6 by this pathway may 
allow the UPR to be tailored to particular stresses.
Following the removal of BiP from IRE1, IRE1 is activated in manner analogous to 
PERK. Indeed, the oligomerisation domains of PERK and IRE1 are functionally 
interchangeable in S. cerevisiae (Bertolotti et al., 2000; Liu et al., 2000). Following the 
dissociation of BiP, IRE1 oligomerises and activates its ribonuclease domain through 
autophosphorylation (Shamu and Walter, 1996; Welihinda and Kaufman, 1996). 
Because the lumen of the ER is continuous with the perinuclear space, the activated 
ribonuclease domains can penetrate the inner leaflet of the nuclear envelope (Lee et al., 
2002a). Within the nucleus, activated IRE1 catalyses the excision of a 26 nucleotide 
unconventional intron (Calfon et al., 2002), from XBP-1 mRNA, in a manner 
mechanistically similar to pre-tRNA splicing (Gonzalez et al., 1999). Removal of this 
intron causes a frame shift in the XBP-1 coding sequence resulting in the translation of 
a 371 amino acid, 54 kDa, XBP-ls isoform rather than the 261 amino acid, 33 kDa, 
XBP-lu isoform (Calfon et al., 2002).
XBP-1 is a bZIP transcription factor whose isoforms are both capable of binding at least 
two well-defined sequence elements (Clauss et al., 1996). The extended C-terminal 
domain can act as a transcriptional activation domain and it has been proposed that
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XBP-1 u may act as a dominant negative inhibitor of XBP-ls, by occupying target 
sequences without promoting transcription (Lee et al., 2003a). Consistent with this, 
proteosomal degradation of XBP-1 u seems to be required for full XBP-ls activity (Lee 
et al., 2003a).
For a bZIP transcription factor, XBP-1 has surprisingly few binding partners (Newman 
and Keating, 2003). Indeed, XBP-lu is only known to heterodimerise with ATF-6. 
However, most studies concerning XBP-1 binding-partners were performed using the 
XBP-lu isoform and it is possible that XBP-ls has an extended repertoire of binding 
partners.
XBP-ls upregulates a number of target genes associated with the UPR (Lee et al., 
2003b) most of which seem to act within the ER. There is a considerable overlap 
between the target genes of ATF-6 and XBP-ls suggesting that XBP-1 and ATF-6 may 
serve partially redundant functions (Lee et al., 2003b). Interestingly, one such 
redundant target is p53 IPK, representing another negative feedback mechanism for the 
regulation of PERK.
1.2.6.3. The affect of XBP-1 s on plasma cell differentiation
XBP-1 is required to make functional plasma cells (Reimold et al., 2001) and the 
requirement for XBP-1 is downstream of BLIMP-1 expression. Crucially, exogenous 
expression of XBP-ls in prdm-1 knockout B-cells does not restore CD 138 expression 
and IgM secretion whereas exogenous expression of BLIMP-1 does (Shapiro-Shelef et 
al., 2003). In addition, microarray analysis of plasma cell differentiation in vitro 
indicated that 34 of the 36 genes upregulated by XBP-ls were also upregulated by 
BLIMP-1 expression (Shaffer et al., 2004). Despite this, XBP-ls expression expanded 
the endoplasmic reticulum, increased cell size, lysosome content, mitochondrial mass, 
ribosome content and total protein synthesis (Shaffer et al., 2004). This suggests that 
the role of XBP-1 in plasma cell development is to facilitate development of the 
professional secretory phenotype, which is required to synthesise and secrete large 
quantities of immunoglobulin. This model proposes that the de-repression of 
immunoglobulin expression, caused by BLIMP-1 expression, causes ER-stress which 
activates IRE1. The subsequent expression of XBP-ls facilitates the final expansion of 
the secretory apparatus required for the substantial synthesis and secretion of 
immunoglobulin required in an immune response (Tirosh et al., 2005a).
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In an interesting twist, van Anken and colleagues have reported that expansion of the 
secretory apparatus precedes upregulation of IgM expression (van Anken et al., 2003). 
This suggests that additional, as yet unidentified, mechanisms may exist to prepare 
plasma cells for the secretory phenotype.
1.2.7. EBV and B-cell activation and differentiation
The relationship between EBV and human B-cells has been extensively characterised 
and how EBV manipulates B-cell development is increasingly well understood 
(Reviewed in Kieff and Rickinson, 2001; Thorley-Lawson, 2001; Thorley-Lawson and 
Gross, 2004; Thorley-Lawson, 2005). In the absence of a model for KSHV infection of 
human B-cells, it is useful to consider the interaction between EBV and B-cells to 
identify possible similarities between the viral lifecycles.
EBV achieves lifelong persistence by establishing a lifelong latent infection in memory 
B-cells (Babcock et al., 1998; Babcock et al., 1999; Souza et al., 2005). Memory B- 
cells are not the in vivo target for EBV infection. Instead, EBV mimics many aspects of 
physiological B-cell differentiation and infects naive B-cells and drives them towards 
the memory compartment (Thorley-Lawson and Babcock, 1999). This model is 
summarised in figure 1.2.7.
1.2.7.1. EBV and B-cell activation
During the EBV lifecycle, EBV is able to adopt multiple, latent, gene expression 
programmes to manipulate differentiation (summarised in table 1.2.7.). Following 
salivary transmission, EBV is able to infect IgD-positive antigen naive B-cells present 
in the nasopharyngeal lymphoid tissue (Joseph et al., 2000). Subsequently, BSAP 
expressed by the naive cells activates the expression of Epstein-Barr nuclear antigen 
(EBNA)-2 (Tierney et al., 2000).
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Table 1.2.7. EBV expression programmes (adapted from Thorley-Lawson, 2001).
Expression programme Proteins
expressed
Expression 
observed in
Function
Latency III Growth
programme
EBNA1-6
LMP1
LMP2A-B
Activated B-cell 
LCLs
Activates resting B- 
cells to form 
lymphoblasts
Latency II 
Latency 1
Default
programme
EBNA1
LMP1
LMP2A
EBNA-1
LMP2A transcript
GC-B-cell
Classical Hodgkin’s 
lymphoma
Burkitt’s lymphoma
Episome 
maintenance, 
survival and 
proliferation 
Allows persistence
Latency 0 Latency
Programme
None Memory B-cells Allows persistence
Lytic
replication
Ordered lytic 
cascade
Plasma cells Produces infectious 
virions
EBNA-2 acts as a controlling transcription factor in the growth programme/latency III. 
EBNA-2 is able to activate expression of viral genes (Abbot et al., 1990) necessary to 
activate signalling pathways and ‘trick’ the naive B-cell into becoming activated (Wang 
et al., 1987).
1.2.7.2. EBV and the germinal centre reaction
Following activation, EBV-positive lymphoblasts migrate to lymphoid follicles where 
they can take part in the germinal centre reaction. At this point the EBV gene 
expression programme changes from latency Ill/the growth programme to latency II/the 
default programme. This change requires that EBNA-2 transcriptional activation is 
downregulated. Exactly how this is achieved is unclear, but EBNA-2 
hyperphosphorylation (Yue et al., 2004) has been implicated at this stage. Entering 
latency II allows the EBV-positive B-cell to adopt a germinal centre like phenotype. 
Indeed, the latent membrane protein (LMP)-2A is capable of driving antigen 
independent GC formation in transgenic mice (Casola et al., 2004). LMP-2A is able to 
mimic BCR signalling through association with the tyrosine kinase lyn (Burkhardt et 
al., 1992). The signalling induced by LMP-2A is pro-survival and LMP-2A can rescue 
B-cell development in immunoglobulin knockout mice (Caldwell et al., 1998).
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LMP-1 is able to mimic signalling through CD40 providing a signal similar to T-cell 
help (Zimber-Strobl et al., 1996; Kilger et al., 1998). LMP-1 achieves this through 
ligand-independent recruitment of tumour necrosis factor (TNF) receptor-associated 
factors (TRAFs). Interestingly, LMP-1 can also upregulate BAFF expression (He et al.,
2003), which can partially substitute for CD40 activation (Litinskiy et al., 2002), 
causing ligand-independent CSR (He et al., 2003).
The concerted action of LMP-2A and LMP-1 mimic the signals caused by encounter 
with antigen and T-cell help. To survive the germinal centre reaction, B-cells must 
receive these pro-survival signals to escape negative selection. Although LMP-2A and 
LMP-1 favour the survival of EBV-positive B-cells within the germinal centre, it is 
clear that there is a role for the BCR in the development of EBV-positive memory cells. 
EBV-positive memory cells all express a functional BCR (Souza et al., 2005). This 
suggests that the pro-survival signals of LMP-1 and LMP-2A are not sufficient to 
replace BCR signalling in the generation and maintenance of memory cells.
1.2.7.3. EBV reactivation and plasma ceil differentiation
Eventually, EBV-positive GC B-cells exit the germinal centre reaction. LMP-1 may be 
involved in this process and is capable of repressing BCL-6 expression in transgenic 
mice (Panagopoulos et al., 2004). Exit from the germinal centre is associated with 
differentiation into memory cells or plasma cells, and each is considered in turn.
Memory cell differentiation of EBV-positive cells is the mechanism through which 
EBV achieves lifelong persistence. EBV-positive memory cells re-enter circulation and 
preferentially home to the tonsils and adenoids (Laichalk et al., 2002). Persistence 
within the memory cell compartment is associated with the latency/latency 0/1 viral 
gene expression programmes. Minimal viral protein expression, within memory cells, 
allows immune evasion and, in most cases, non-pathogenic persistence.
Plasma cell differentiation is the cue for EBV reactivation (Crawford and Ando, 1986; 
Laichalk et al., 2005). Exactly how reactivation is triggered in these cells is unclear, but 
reactivation may be largely abortive (Laichalk et al., 2005). All EBV carriers shed 
EBV in their saliva (Yao et al., 1989) but the number of plasma cells supporting 
reactivation cannot account for the magnitude of virus production. This suggests that 
virus production from plasma cells is subsequently amplified in the oral mucosa
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(Laichalk et al., 2005). Persistence within the memory pool coupled to reactivation in 
plasma cells allows EBV to maintain lifelong infection, yet continually produce 
infectious virus through antigen-independent memory cell activation (Bemasconi et al.,
2002). The plasma cell also represents an ideal environment for herpesvirion 
production and the ability of plasma cells to synthesise, fold and secrete large quantities 
of protein may inadvertently have adapted plasma cells for vims production.
1.2.8. The aims of this thesis
The difficulty of isolating KSHV-positive B-cells from healthy individuals coupled to 
the inability of KSHV to form LCLs in vitro (Kliche et al., 1998) has largely restricted 
the understanding of KSHV latency in B-cells to PEL-derived cell lines. We 
hypothesize that, similarly to EBV, KSHV has a lifecycle which is intertwined with B- 
cell differentiation. The observation that KSHV is latent in PEL cells, which resemble 
plasmablasts (Jenner et al., 2003), but is lytic in a minority of cells within MCD lesions 
(Parravicini et al., 2000; Katano et al., 2000) led us to consider that, similarly to EBV, 
plasma cell differentiation is a cue for KSHV reactivation.
The low susceptibility of B-cell lines to infection with KSHV in vitro is an enigmatic 
feature of KSHV biology. We hypothesize that in vitro susceptibility is related to the B- 
cell developmental stage and activation state of the target B-cell. It is possible that the 
recalcitrant nature of some B-cell lines, to KSHV infection, may be a consequence of 
those cell lines representing a stage or subset of B-cells not targeted by KSHV in vivo.
Finally, the difficulty in isolating and generating KSHV positive B-cells has led us to 
explore alternative approaches for investigating KSHV-B-cell relationships. This led us 
to consider the utility of RNA interference at specifically attenuating viral or host cell 
gene expression within PEL-derived cell lines and RNA interference is considered in 
section 1.3.
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1.3. RNA interference (RNAi)
1.3.1. The history of RNAi
The term RNA interference (RNAi) was first used to describe an interference with gene 
expression caused by introducing sense or antisense RNA into C. elegans embryos (Fire 
et al., 1991 and Guo and Kemphues, 1995). The key breakthrough in understanding this 
phenomenon was the realisation that double stranded RNA (dsRNA) was the most 
effective mediator of RNAi. Introducing dsRNA into C. elegans resulted in mRNA 
degradation with the sequence of the dsRNA specifying which transcripts were 
degraded (Fire et al., 1998). It rapidly became clear that RNAi pathways were 
conserved across a wide variety of eukaryotes and the same phenomenon, termed 
“cosuppression” or “post transcriptional gene silencing” was already the subject of 
intensive research in plants (Napoli et al., 1990, van der Krol et al., 1990).
A significant barrier existed before this technology could be exploited experimentally in 
mammalian cells. Double stranded RNA was well known to shut-off translation in 
mammalian cells (Ehrenfeld and Hunt, 1971). This phenomenon is caused in part by 
protein kinase R (PKR), which when activated through binding dsRNA greater than 30 
base pairs (bp) in length (Manche et al., 1992) homodimerises and undergoes 
autophosphorylation (Zhang et al., 2001). This creates an active PKR homodimeric 
complex capable of phosphorylating eukaryotic initiation factor 2 (eIF2) preventing 
translation initiation (Farrell et al., 1977). It was unclear, however, if long dsRNA- 
mediated RNAi could be used specifically without activating innate pathways sensitive 
to dsRNA (described in section 1.3.5.2).
Conservation of the RNAi machinery in mammalian cells was demonstrated using long 
RNA hairpins, greater than 500 bp in length, in mouse preimplantation embryos to 
achieve silencing (Svoboda et al., 2001). However, it was not until further 
characterisation of the mechanism of RNAi that the importance of mammalian RNAi 
became more widely appreciated and experimentally applicable. In 2000 it was realised 
that long dsRNAs were processed to 20-25 bp small/short interfering RNAs (siRNAs) 
and that these were incorporated into a RNAi-effector complex capable of degrading 
target mRNAs (Zamore et al., 2000; Hammond et al., 2000). By transfecting 
chemically synthesized 21 bp siRNAs, thought to be too short to activate dsRNA
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sensitive pathways, Tuschl and colleagues were able to suppress endogenous and 
exogenous gene expression in human cell lines (Elbashir et al., 2001a). The discovery 
of RNAi as a novel control mechanism of gene expression and the utility of this 
mechanism in experimental systems has resulted in an explosion of interest in RNAi 
and its rapid adoption as a standard technique in molecular biology (figure 1.3.1.1).
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Figure 1.3.1.1. Rapid increase in publications related to RNAi.
Number of publications returned using the integrated, text-based search and retrieval system 
Entrez returned from the PubMed database using the query “RNAi”. A 2006 estimate is 
included based upon publications prior to April 1st, 2006.
Since its discovery, the RNAi machinery and pathways have become increasingly well 
characterised (reviewed in Meister and Tuschl, 2004; Zamore and Haley 2005; 
Filipowicz, 2005) and a wide variety of naturally expressed microRNAs have been 
identified and their activity characterised (reviewed in Ambros, 2004; Sontheimer and 
Carthew 2005; Pasquinelli et al., 2005). Features affecting siRNA potency have 
become increasingly well defined (reviewed in Silva et al., 2003) and RNAi as a 
therapy has entered clinical trials. A summary of some of the ‘landmarks’ in RNAi is 
illustrated in figure 1.3.2.1.
1.3.2. The mechanisms of RNAi
Depending on their origin, small RNAs can be divided into three categories short/small 
interfering RNAs (siRNAs), microRNAs (miRNAs) and repeat-associated small 
interfering RNAs (rasiRNAs). All 3 classes tend to operate in different pathways, using 
complexes which may be identical but effect different methods of gene silencing 
(Figure 1.3.2.2).
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Figure 1.3.2.1. A tim eline of sign ifican t d isco v eries  related  to  RNAi.
Aadapted from Zamore and Haley, 2005 and Godfrey e t  al., 2003.
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dicers (Lee et al., 2004) and dicers from different species can produce siRNAs of 
different lengths (Bernstein et al., 2001; Ketting et al., 2001) and have differing ATP 
requirements. Human cells express a single dicer, whose enzymatic activity is ATP 
independent, which starts 'dicing' at the ends of long dsRNA (Zhang et al., 2002).
As well as a requirement in generating siRNAs, dicer seems to have a pivotal role in 
incorporating siRNAs into the RISC. RNAi-mediated knockdown of dicer in HeLa 
cells inhibits siRNA mediated silencing of the reporter gene luciferase (Doi et al., 2003) 
and introduction of siRNAs into dcr-2 null embryos fails to achieve silencing at levels 
similar to wild-type embryos (Lee et al., 2004). This suggests that dicer’s involvement 
in RNAi stretches beyond generating siRNAs. Indeed, short 27 bp dsRNA dicer 
substrates seem more potent effectors of silencing than their 21 nt siRNA counterparts 
(Kim et al., 2005)
A breakthrough in siRNA design was facilitated by determining dicer’s role in silencing 
downstream of generating siRNAs. It is generally accepted that dicers are capable of 
interacting with Argonaute (Ago) proteins a key component of the RISC (Hammond et 
al., 2001; Tabara et al., 2002; Tahbaz et al., 2004). Simultaneous biochemical 
(Schwarz et al., 2003) and bioinformatics (Khvorova et al., 2003) approaches identified 
an asymmetry in the siRNA strand incorporated into the RISC. This asymmetry 
involves the preferential loading of the siRNA strand whose 5’ end resides at the RNA 
duplex terminus with the lowest free energy (reviewed in Silva et al., 2003). D. 
melanogaster dicer-2 binds siRNAs as a heterodimer with the protein R2D2 (Liu et al.,
2003) forming a ternary complex termed the RISC-loading complex (RLC). 
Photocrosslinking of siRNAs within this complex identified preferential binding of 
dicer to the less stable siRNA terminus and preferential binding of R2D2 to the more 
stable siRNA terminus (Tomari et al., 2004) the structural determinants of this 
selectivity have yet to be determined. The asymmetric formation of the RLC probably 
represents the step at which the siRNA guide strand is selected (reviewed in Filipowicz, 
2005). The asymmetry rule seems applicable to all organisms investigated and R2D2 
homologues and the human immunodeficiency virus transactivating response RNA- 
binding protein (TRBP) seems functionally analogous to R2D2 in humans 
(Chendrimada et al., 2005). Overexpressed TRBP has been shown to inhibit PKR 
activity (Park et al., 1994) but any functional relevance of this interaction in RNAi has 
yet to be identified.
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Figure 1.3.2.2. The m ech a n ism s  of RNAi
A diagrammatic representation of RNAi is shown. Repeat associated RNA, pri-miRNAs and 
shRNAs are transcribed in the nucleus. Complementary repeat associated RNA is synthesised 
by RDRPs. Pri-miRNAs are Drosha-processed, generating pre-miRNAs. Pre-miRNAs, shRNAs 
and ssRNA are exported from the nucleus where they become dicer substrates resulting in the 
generation and asymmetric presentation of siRNAs, rasiRNAs and miRNAs to the RISC. The 4 
possible modes of RISC action are indicated; Cleavage of mRNA by the RISC, inhibition of 
translation by the miRISC, mRNA sequestration in the P-body and transcriptional silencing by 
the RITS. pri-miRNA, primary miRNA; shRNA, short hairpin RNA; RDRPs, RNA dependent 
RNA polymerases; ssRNA, single stranded RNA; siRNA, small interfering RNA; rasiRNAs, 
repeat associated small interfering RNA; miRNA, microRNA; RISC, RNA-induced silencing 
complex; miRISC, miRNA induced silencing complex; P-body, processing body; RITS, RNA 
induced transcriptional silencing complex.
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If the RLC determines the siRNA strand which is loaded as a guide, the observations 
that dicer directs binding to long dsRNA at the RNA termini (Zhang et al., 2002) but 
bind siRNAs in an orientation determined by RNA duplex stability (Tomari et al., 2004) 
are difficult to reconcile. These apparently conflicting observations could mean that the 
asymmetry rule should be broken approximately 50% of the time when dicer processes 
long dsRNA and is unable to select the less stable duplex terminus, binding the exposed 
terminus. Alternatively, dicer could release processed siRNAs before selectively re­
binding them for presentation to the RISC. A mechanistic consensus has yet to arise but 
it is clear that dicer-processed miRNAs are incorporated asymmetrically into the RISC 
in vivo (Khvorova et al., 2003) supporting the notion that dicer processed RNAs are 
presented asymmetrically by the RLC.
The protein composition of the RISC has been the subject of intensive research, and 
many complexes have been isolated, their catalytic activity analysed and their protein 
components characterised. Most of this analysis has been done using Drosophila S2 cell 
extracts. RISC complexes can be isolated associated with polysomes at 80S (Pham et 
al., 2004), as large holoRISC complexes at ~500 kDa (Nykanen et al., 2001; Hammond 
et al., 2001) or minimal complexes isolated under high salt conditions (Martinez et al., 
2002; Martinez et al., 2004). The only protein components present in all isolated RISC 
complexes are the Argonaute (Ago) family members. Ago proteins contain 2 RNA 
binding domains, the piwi domain and the piwi/Argonaute/zwille (PAZ) domain 
(reviewed in Cerutti et al., 2000). The Ago 2 protein complexed with an ssRNA guide 
mediates the catalytic activity of the RISC (Rand et al., 2004; Rivas et al., 2005). The 
catalytic activity resides in the piwi domain which is structurally homologous to RNase 
H and is dependent on the triad motif DDH which is absent in other Argonaute family 
members (Liu et al 2004; Rivas et al., 2005). Although the mechanism of RNA transfer 
from the RLC to the RISC remains obscure, structural studies indicate that the 5’ end of 
the siRNA is anchored in the piwi domain (Parker et al., 2004) and the 3’ end in the 
PAZ domain (Lingel et al., 2004). The Ago-2 guide RNA complex is able to scan 
mRNA, and in the presence of sufficient complementary base pairing, catalyse 
endonucleolytic cleavage of the mRNA between bases 10-11 of the RNA guide 
(Elbashir et al., 2001b). Human Ago 2 complexed with RNA is competent to undergo a 
single round of cleavage in the absence of ATP (Rivas et al., 2005), but in the presence
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of additional protein factors and ATP, Ago-2 forms the catalytic heart of a multiple- 
tumover enzyme complex capable of directing multiple rounds of mRNA cleavage 
(Hutvagner and Zamore 2002). Once cleaved the mRNA is rapidly degraded by 
exonucleases (Orban and Izaurralde, 2005), reducing mRNA abundance of a targeted 
transcript resulting in reduced protein expression from a targeted mRNA.
1.3.2.2. MicroRNAs and repression of translation
The C. elegans miRNA lin-4 was the first microRNA (miRNA) to be identified (Lee et 
al., 1993). However it was not until a role for dicer in miRNA processing was 
identified that miRNAs were linked to other RNAi phenomena (Grishok et al., 2001). It 
is important when considering miRNAs to remember that the term miRNA refers to its 
origin and not the mode of action (Table 1.3.2.1.). Indeed plant miRNAs tend to 
mediate RNAi in a canonical RISC complex, cleaving target mRNAs (Llave et al., 
2002; Rhoades et al., 2002) and transfected siRNAs can act in a miRNA-induced 
silencing complex (Doench et al., 2003). The miRISC is therefore defined by its action 
in repression of target mRNA translation, not by the origin of its small RNA 
component.
The database miRBase (http://microma.sanger.ac.uk), formerly the microRNA registry 
(Griffiths-Jones, 2004) catalogues over 3000 miRNAs. MicroRNAs have been 
identified in plants, metazoans and herpesviruses. The control of gene expression by 
miRNAs seems to be an essential process in most organisms and miRNA regulation has 
been documented in many cellular processes (reviewed in Ambros, 2004). MicroRNAs 
are important in stem-cell division (Hatfield et al., 2005), haematopoiesis (Chen et al.,
2004), oncogenesis (He et al., 2005), cancer-classification (Lu et al., 2005c) and 
regulate large numbers of mRNAs helping to define the global gene expression profile 
(Lim et al., 2005).
MicroRNAs are ~22 nt RNAs derived from long, largely unstructured, usually 
noncoding RNA genes called primary miRNAs (pri-miRNAs). These transcripts are 
capped, polyadenylated and transcribed by RNA polymerase II (Cai et al., 2004). 
Hairpin structures ~70 nt in length present in the pri-miRNA are excised from pri- 
mRNAs by a Microprocessor complex consisting of the enzyme Drosha and the 
DiGeorge syndrome critical region gene 8 (DGCR8) protein (Gregory et al., 2004). 
These hairpins, termed pre-miRNAs, are exported from the nucleus by exportin 5 (Yi et
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al., 2003) where they are processed by dicer enzymes (Grishok et al., 2001). It is clear 
that similar asymmetry rules to siRNAs apply to miRNAs (Khvorova et al., 2003) 
implying similar asymmetric dicer-TRBP binding of miRNAs and presentation to the 
miRISC.
Characterisation of protein components of the miRISC has failed to identify any specific 
protein components conferring inhibition of translation to the miRISC. Many if not all 
the protein components are shared between the RISC and miRISC complexes and it is 
possible that the only difference between a RISC mediating mRNA cleavage and a 
miRISC mediating inhibition of translation lies in the ability of a guide RNA to form a 
helix with the target mRNA (reviewed in Filipowicz, 2005). Indeed, inhibition of 
translation might represent the default pathway of RNAi as tethering of Argonaute 
proteins to mRNAs results in inhibition of translation (Pillai et al., 2004). The 
mechanism by which the miRISC prevents target mRNA translation has yet to be 
determined. However, it is known that inhibition occurs at or just after translation 
initiation (Olsen and Ambrose 1999; Pillai et al., 2005a). In addition to translation 
inhibition, the miRISC is capable of sequestering target mRNAs by moving them to 
cytoplasmic P-bodies (Liu et al., 2005; Sen and Blau, 2005). In P-bodies Argonaute 
proteins associate with enzymes involved in mRNA degradation (Liu et al., 2005; Sen 
and Blau, 2005) accounting for the accelerated target mRNA turnover observed in the 
presence of miRNAs (Lim et al., 2005). The combination of inhibition of target mRNA 
translation and accelerated target mRNA degradation is responsible for the reduction of 
target protein expression caused by RNAi through the miRISC pathway.
1.3.2.3. The RNA induced transcriptional silencing (RITS) complex
RNA induced transcriptional silencing involves the suppression of mRNA transcription 
through DNA methylation and histone modification (reviewed in Bernstein and Allis,
2005). This process is most characterised in lower eukaryotes where the RITS complex 
has been purified (Verdel et al., 2004) and RITS complexes can be found bound to 
regions of heterochromatin such as centromeres and telomeres (Volpe et al., 2002). 
RITS complexes usually contain repeat associated siRNAs (rasiRNAs) generated from 
long mRNAs transcribed from regions of repetitive sequence usually amplified by 
RNA-dependent RNA polymerases to generate dsRNA (Sugiyama et al., 2005) and 
processed by dicers. The absence of RNA-dependent RNA polymerases and lower 
levels of repeat associated RNA have hampered characterisation of this pathway in
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mammalian cells. However it is clear that siRNAs can direct DNA methylation in 
mammalian cells (Kawasaki and Taira, 2004; Morris et al., 2004) and the RNAi 
machinery may be involved in regulating mammalian centromeres (Fukagowa et al.,
2004) But the importance and generality of RITS remains unclear.
1.3.3. The technology of RNAi
After demonstration of transfected siRNA efficacy in cultured mammalian cells 
(Elbashir et al., 2001a), siRNA transfection was rapidly adopted as an experimental tool 
in mammalian cell culture (Garrus et al., 2001, Cortez et al., 2001; Harborth et al., 
2001). The transfection of siRNAs usually involves chemically synthesised RNAs 
protected at their 3’ termini with deoxythymidine dinucleotides. Lipid-based 
transfection reagents are then used to deliver these artificial siRNAs to the cytoplasm. 
Although transfected siRNAs are the most common experimental mediator of RNAi, 
they were not used in experiments detailed in this thesis and are not discussed further.
The realisation that hairpin pre-miRNAs expressed in vivo are processed by dicer 
(Grishok et al., 2001) led to the development of DNA vectors capable of expressing 
short hairpin RNAs (shRNAs), which analogous to pre-miRNAs could be processed by 
dicer generating siRNAs. Two initial reports detailed use of the human HI-promoter 
(Brummelkamp et al., 2002) and the murine U6-promoter (Sui et al., 2002) to achieve 
gene silencing. Both promoters are RNA polymerase III (pol III) type-3 promoters 
requiring no intragenic enhancers, a common feature of other RNA pol III promoters 
(reviewed in Willis, 1993). Although many different promoters have been used to 
deliver shRNAs, The HI and U6-promoters remain the most popular promoters and no 
consensus has emerged regarding the most effective shRNA design and delivery system.
Chapter 3 of this thesis details the generation of an shRNA expression cassette. The 
anatomy of an shRNA is detailed in figure 1.3.3.1. For an shRNA to be functional in 
gene silencing it must contain sufficient helical dsRNA to act as a substrate for dicer. 
This can be achieved with duplexes as short as 19 bp (Brummelkamp et al., 2002) 
although longer stems seem to be more favourable substrates for dicer, resulting in more 
potent gene silencing (Siolas et al., 2005). The primary function of the loop region is to 
structurally permit helical interaction of the two strands of the duplex stem. Dicer 
processing of shRNAs is a cytoplasmic process (Lee et al., 2002c) and shRNAs must be 
exported from the nucleus, probably using exportin 5 (Yi et al., 2003) to be processed
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into siRNAs. Making shRNA loops similar to miRNA loops has been reported to 
increase the efficiency o f silencing, possibly due to enhanced shRNA export (Miyagishi 
et al., 2004). The molecular basis of any increased silencing, in shRNAs engineered to 
contain miRNA loops, is unclear because exportin 5 and dicer seem unable to recognise 
shRNA loops (Zeng and Cullen, 2004; Vermeulen et al., 2005). Many shRNAs are 
designed to contain GU basepairs within the duplex stem. The presence of GU 
basepairs reduces DNA secondary structures easing shRNA cloning and sequencing. 
Introducing GU basepairs is usually achieved by mutating only the sense strand of an 
shRNA, relative to the target mRNA. This retains Watson-Crick basepairing between
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A. A diagrammatic representation of an shRNA expression cassette. The DNA template is 
displayed 5 ’-3 ’ and loop and transcription terminator sequences are indicated. The sense and 
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representation of the predicted shRNA expressed from the template in A. The loop, stem and 
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the guide RNA and the target mRNA. Transcription termination of shRNAs is achieved 
by a run of 5 or more consecutive thymidines, as is the case for the HI (Baer et al., 
1990) and U6 (Kunkel and Pederson, 1988) small RNA genes.
The shRNA expression cassette detailed in this thesis utilises the human U6-promoter. 
The expressed U6 small nuclear RNA exists in a small nuclear ribonucleoprotein 
complex which is involved in spliceosome assembly and catalysis of pre-mRNA 
splicing (reviewed in Butcher and Brow, 2005). The U6-promoter is suitable for 
shRNA mediated RNAi because the promoter is capable of expressing small RNAs to a 
very high level, approximately 4xl05 per cell (Weinberg and Penman, 1968), and 
requires no intragenic transcription enhancers. Exogenously expressed small RNA 
transcripts, initiating with guanine, driven by the U6-promoter are easily detectable 
(Good et al., 1997). Because the sequences required for capping of U6 snRNAs are 
intragenic (Singh et al., 1990; Good et al., 1997) the U6-promoter is capable of 
expressing large amounts of uncapped shRNAs, an RNA species similar to pre- 
miRNAs, which can mediate potent RNAi (Sui et al., 2002).
With regard to siRNA and shRNA design, it is not yet possible to predict the potency of 
a siRNA from its sequence. However, it is clear that the stability of duplex RNA ends 
determines which strand is preferentially incorporated into the RISC and this constraint 
should be considered when designing siRNAs (Reynolds et al., 2004; Khvorova et al., 
2003; Schwarz et al., 2003). Many programmes are currently available to assist in 
siRNA/shRNA design. Most of these programmes are based upon energetic constraints 
related to the asymmetry rule as well as constraints related to shRNA cloning and 
processing (Vermeulen et al., 2005; Siolas et al., 2005). A consensus has yet to emerge 
regarding which method designs the most potent siRNAs.
1.3.4. Lentiviral vectors
This thesis describes the use of lentiviral vectors both to deliver shRNA expression 
cassettes to a variety of cells (chapter 3) and to deliver the transcription factor XBP-1 to 
PEL cell lines (chapter 5). Lentiviral vectors are one of the most flexible gene delivery 
systems available, capable of transducing a wide variety of cells and delivering
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sustained heritable expression of transgenes (reviewed in Buchschacher and Wong- 
Staal, 2000; Quinonez and Sutton, 2002; Wiznerowicz and Trono 2005).
1.3.4.1. The HIV life cycle
Human immunodeficiency virus 1 (HIV-1) is the aetiological agent of AIDS and is the 
most characterised lentivirus. Most lentiviral vectors are derived from HIV-1 and to 
understand their utility and biosafety, the natural lifecycle of HIV-1 must first be 
considered. This is summarised in figure 1.3.4.1. Lentiviral vector genomes do not 
contain the genetic information required to make new infectious particles and therefore 
only undergo a single round of transduction also summarised in figure 1.3.4.1.
HIV-1 particles consist of a diploid ssRNA genome 9.3 kb in length (Schwartz et al., 
1990), packaged inside a retroviral core which in turn is surrounded by a lipid envelope 
containing host proteins and viral glycoproteins. The main cellular receptor for HIV-1 
is CD4 (Dalgleish et al., 1984). In addition, HIV-1 entry also requires the coreceptor 
CCR5 (Dragic et al., 1996) or CXCR4 (Feng et al., 1996). After fusion, the viral core is 
delivered into the cytosol where the genomic RNA is reverse transcribed by the HIV-1 
encoded reverse transcriptase which is packaged within the viral core. During reverse 
transcription the HIV-1 core undergoes an uncoating process, involving the progressive 
disassembly of the viral core, the details of which are poorly understood.
The uncoating process leaves the reverse transcription complex (RTC) free to interact 
with the host-cell cytosol. The RTC contains multiple host and viral proteins, most 
notably HIV-1 integrase and matrix which may contain functional nuclear localisation 
signals (Dubrovsky et al., 1995; Bouyac-Bertoia et al., 2001). The reverse transcription 
complex is capable of traversing the nuclear envelope. This process is poorly 
understood, but is active (Bukrinsky et al., 1992) involves nuclear pores (Popov et ah,
1998) and may even require structural DNA-RNA hybrids within the central polypurine 
tract region (cPPT) of the HIV-1 genome (Zennou et al., 2000). The ability of HIV-1 to 
cross the nuclear pore allows HIV-1 to infect quiescent nondividing cells, such as 
macrophages (Weinberg et al., 1991).
Once inside the nucleus, integration of HIV-1 double stranded DNA into the host 
genome ensues. Integration is catalysed by HIV-1 integrase and is not sequence 
specific. However, HIV-1 integration is more frequent in transcriptionally active
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regions of the chromosome (Schroder et al., 2002). Once integrated, the virus is referred 
to as a provirus.
HIV-1 genes transcribed from the integrated provirus, are expressed from a single 
promoter region within the 5’ long terminal repeat (LTR). The HIV-1 LTR can be 
divided into 3 regions; the 450 bp unique 3’ (U3) region, a 100 bp repeat (R) region and 
a 180 bp unique 5’ (U5) region. Transcription from the LTR results in a single 9.3 kb 
transcript which can be spliced into over 30 mRNA species (Schwartz et al., 1990). 
Most elements required to drive transcription reside within the U3 region of the LTR, 
and transcription initiates within the R region of the 5’ LTR. Transcription from the 
LTR is activated 100 to 500-fold by the HIV-1 Tat protein (Jones and Peterlin, 1994). 
Tat does not bind the proviral DNA LTR directly. Instead Tat activates transcription 
via an interaction with a stem-loop structure at the 5’ end of the nascent RNA transcript 
termed the transactivating response (TAR) RNA. TAR-RNA is an approximately 60 bp 
stem loop similar in structure to pre-miRNAs and is also bound by TRBP (Gatignol et 
al, 1991).
In the absence of viral proteins, the nascent transcript is extensively spliced. To 
produce the full-length genomic transcript, capable of nuclear export and packaging into 
new lentiviral particles, the HIV-1 regulator of expression of virion (Rev) protein is 
required. Rev binds to a 351 nucleotide (nt) region of secondary structured RNA within 
the envelope coding region (<env) referred to as the Rev response element (RRE) (Daly 
et al., 1989) and is able to mediate nuclear export of unspliced and partially spliced 
RNAs (Fischer et al., 1994). The full-length ssRNA genome is then complexed with 
HIV-1 structural gag-derived proteins and buds through cellular membranes (reviewed 
in Kaplan et al., 2002), forming an immature viral core. Following budding, these 
immature particles undergo HIV-1 protease mediated maturation to generate enveloped 
infectious virions.
Although HIV-1 derived lentiviral vectors had existed for some time (Page et al., 1990), 
the utility of HIV-1 as a gene-delivery vector was only demonstrated in 1996 when 
Didier Trono and colleagues demonstrated the ability of lentiviral vectors to transduce 
nondividing neurons (Naldini et al., 1996). These first generation lentiviral vectors 
were generated by transient transfection of HEK 293-T cells with 3 plasmids: a plasmid 
encoding the minimal ssRNA genome, a plasmid encoding all HIV-1 proteins excluding
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the envelope and a plasmid encoding envelope glycoproteins. This 3-plasmid 
transfection system provides the first facet o f lentiviral vector biosafety. By separating 
the nucleic acids encoding the protein constituents o f a virion from the viral vector-
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genome, multiple recombination events would be required between the plasmids to 
generate a replication competent virus. The HIV-1 envelope severely limits the range of 
cells that could be transduced by HIV-1 vectors. This has lead to the use of plasmids 
expressing vesicular stomatitis G (VSV-G) envelope protein in the place of plasmids 
expressing the HIV-1 envelope protein (Naldini et al., 1996). This generates pantropic, 
pseudotyped lentiviral vectors. The potential use of lentiviral vectors in gene therapy 
spurred rapid improvements in the biosafety of lentiviral vectors. The second 
generation of lentiviral vectors (Zufferey et al., 1997) involved the generation of p8.91, 
a gag-pol expression construct that does not include the accessory genes vif, vpr, vpu 
and nef. Third generation systems now exist with packaging plasmids including only 
gag-pol and rev genes (Dull et al., 1998). Further removal of HIV-1 genes would result 
in the loss of functions essential in producing infectious particles. Both gag and pol 
genes are required to form the virion and to facilitate reverse transcription and 
integration of the vector. Rev is required to allow nuclear export of the full-length 
vector genome in the transfected packaging cells. The genomic organisation of HIV-1 
and the organisation of open reading frames within the plasmids required to generate 
second generation lentiviral vectors are displayed in figure 1.3.4.2.
Similar to the plasmids involved in lentiviral vector packaging, the lentiviral vector 
genome has been modified to improve biosafety and utility. The most significant 
development has been the introduction of self-inactivating (SIN) vectors. First 
developed for Moloney murine leukaemia virus vectors (Yu et al., 1986) SIN vectors 
involve deletion of the U3 region of the 3’ LTR. After reverse transcription and 
integration, the deletion is present in both proviral LTRs. This has 3 effects on the 
vector. Firstly, transcription from the LTR is attenuated by deletion of the major 
promoter elements; this prevents transcription of the full length SIN vector genome 
within transduced cells, ensuring a single round of infection. Secondly the reduction of 
transcription from the LTR increases the potential for transcriptional control using 
internal promoters because full-length LTRs are capable of interfering with internal 
promoters (Miyoshi et al., 1998). Finally, LTR deletion reduces the possibility of 
transcriptionally activating cellular genes after proviral integration. Many SIN lentiviral 
vectors have been developed based on HIV-1 (Zufferey et al., 1998; Miyoshi et al.,
1998) and efficient mobilisation of SIN vectors does not occur even in the presence of 
replication competent HIV (Bukovsky et al., 1999). Although SIN vectors greatly 
reduce the chance of mobilisation, it remains possible if integration occurs in certain
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contexts (Logan et al., 2004). A schematic representation of reverse transcription 
displaying how deleting the U3 region of the 3’ LTR generates 5’ LTRs lacking a U3 
region is displayed in figure 1.3.4.3
Much of the HIV-1 genome can be deleted to allow insertion of transgenes and 
promoters required for lentiviral vector-function. However, some cis-acting sequences 
are required to allow reverse transcription and packaging into retroviral particles. As 
well as partial LTRs, the lentiviral genome must contain a tRNA binding site (Barat et 
al., 1989), packaging signal (T) (Lever et al., 1989), RRE (Daly et al., 1989) and a 3’ 
polypurine tract (PPT) (Wohrl and Moelling 1990). In addition to essential sequences, 
the cPPT is often retained to increase transduction efficiency (Zennou et al., 2000; 
Sirven et al., 2000). Another element often included in lentiviral vectors is the 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). The WPRE 
increases transgene expression in a cell-type independent fashion (Zufferey et al., 1999) 
and may increase vector transcript abundance increasing the titre of a given vector 
(Ramezani et al., 2000).
The ability to generate high titre lentiviral vectors capable of transducing nondividing 
cells makes lentiviral vectors a promising vector choice for gene therapy, indeed 
lentiviral vectors expressing antisense env are currently being used in clinical trials for 
the treatment of HIV (www.virxsys.com). After the demonstration of shRNA-mediated 
gene silencing, shRNA cassettes were rapidly demonstrated to be functional in lentiviral 
vectors (Abbas-Terki et al., 2002; Rubinson et al., 2003) a technology which may in the 
future be transferred to the clinic.
1.3.5. Limitations of lentiviral vectors and RNAi
Although initially thought to exhibit perfect target selectivity and go unnoticed by a 
cell’s innate immune sensors, the non-specific effects of siRNAs and their precursors 
are becoming increasingly clear (reviewed in Sledz and Williams, 2004; Jackson and 
Linsley, 2004). Lentiviral vectors do not escape immune pathways and this can affect 
in vitro permissivity and transduction. Lentiviral vectors can also cause insertional 
mutagenesis.
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1.3.5.1. Off-target silencing
Small interfering RNAs were demonstrated to have exquisite target selectivity when 
Tuschl and colleagues showed that single nucleotide mismatches between a siRNA 
guide and a target mRNA severely attenuated silencing (Elbashir et al., 2001b). 
However, as similarities between the RISC and miRISC mediated pathways became 
clearer, several groups systematically tested this assumption of specificity (Chi et al., 
2003; Semizarov et al., 2004; Jackson et al., 2003; Scacheri et al., 2004; Persengiev et 
al., 2004). Some studies analysed global gene expression profiles or specific indicators 
of cellular stress and identified changes in gene expression of multiple genes the 
siRNAs were not designed to target (Jackson et al., 2003: Scacheri et a l , 2004; 
Persengiev et al., 2004). This effect was independent of siRNA potency and occurred 
with endogenous and exogenous targets (Jackson et al., 2003; Persengiev et al., 2004). 
The silencing of genes not intended to be a siRNA target is termed off-target silencing. 
Off-target silencing may (Persengiev et al., 2004) or may not be (Jackson et al., 2003: 
Scacheri et al., 2004) dependent on the concentration of transfected siRNAs and 
requires as few as 7 nucleotides of complementary sequence between the guide RNA 
and mRNA targets (Lin et al., 2005). The lack of complementarity suggests that off- 
target silencing occurs through a miRISC-mediated pathway. If this is the case, the 
multitude of targets for each siRNA is unsurprising as miRNAs have been described 
which affect the expression of ~100 mRNAs (Lim et al., 2005). It is important to 
consider that studies monitoring transcript abundance (Jackson et al., 2003; Persengiev 
et al., 2004 and Lim et al., 2005) in miRISC mediated silencing will only detect 
changes caused by accelerated mRNA degradation in the P-body (Sen and Blau, 2005). 
These studies likely represent an underestimation of silencing because they did not 
quantify inhibition of translation, the primary role of the miRISC.
Not all studies have identified a role for siRNAs in off-target silencing. Two studies did 
not report off-target silencing (Chi et al., 2003; Semizarov et al., 2004) mediated by 
transfected siRNAs although relatively low concentrations were used. The results of 
these studies of off-target silencing are conflicting and difficult to reconcile. In the 
absence of a coherent model of off-target silencing is important to design siRNA 
experiments using the minimal effective dose of siRNAs and to consider off-target 
explanations for any phenotypes observed.
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1.3.5.2. The ce llu lar re s p o n se  to  dsRNAs
The first reports o f mammalian RNAi (Elbashir et al., 2001a) suggested that siRNAs are 
too short to elicit an antiviral response in mammalian cells. Mammalian cells have 
many intrinsic dsRNA sensors. These sensors are integrated into the interferon 
response, an innate response to viral pathogens. Double stranded RNA is sensed in cells 
by at least 4 proteins; toll like receptor 3 (reviewed in Sen and Sarkar, 2005), the RNA
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Figure 1.3.5.1. The ce llu la r re sp o n se  to  dsRNA s (adap ted  from  de V eer et al., 2005).
A diagrammatic representation of dsRNA activated pathways of the interferon response. The 
dsRNA activated protein OAS polymerises ATP 2 ’-5 ’ generating oligoadenylates which activates 
RNase L resulting in indiscriminate RNA degradation. The dsRNA-activated kinase PKR 
phosphorylates elF2a resulting in translation inhibition. PKR also initiates signal cascades 
resulting in interferon expression. RIG-1 and TLR-3 recognise dsRNA resulting in interferon 
expression. Secreted interferon leads to autocrine and paracrine activation of interferon 
receptors resulting in expression of interferon-stimulated genes (ISGs). IFN; interferon TLR3; 
Toll-like receptor 3, OAS: 2 ’-5 ’ oligoadenylate synthetase, PKR; protein kinase R, elF2a; 
eukaryotic initiation factor 2a, RIG-I; retinoic acid inducible gene 1, MAPK; mitogen-activated 
protein kinase, IRF; interferon regulatory factor, NFkB; nuclear factor kappa B; IKKp; inhibitor of 
kappa B kinase beta.
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helicase retinoic acid-inducible gene 1 (RIG-I) (Yoneyama et al., 2004), the RNA 
helicase helicard (Kang et al., 2002) Protein kinase R (PKR) (reviewed in Williams,
2001) and 2 \  5’-oligoadenylate synthetase (OAS) whose activities are summarised in 
figure 1.3.5.1. PKR and OAS are the best-characterised dsRNA sensors requiring >30 
bp or >65 bp of dsRNA to become activated respectively (Manche et al., 1992; Minks et 
al., 1979) comfortably above the 19 bp dsRNA in siRNAs.
Although the molecular details remain obscure there have been reports of siRNAs 
(Sledz et al., 2003; Semizarov et al., 2004; Kim et al., 2004; Kariko et al., 2004a; 
2004b) and shRNAs (Bridge et al., 2003; Fish and Kruithof 2004; Pebemard and Iggo, 
2004; Cao et al., 2005) activating a robust interferon response in mammalian cells. 
PKR (Sledz et al., 2003) and Toll-like receptor 3 (TLR3) have been implicated in 
initiating such a response (Kariko et al., 2004a; 2004b). Other studies have 
concentrated on the role of 5’ dsRNA end(s) in activating an interferon response. 
Transfected siRNAs and dicer products typically end in a 5’ monophosphate (Zhang et 
al., 2002) whereas siRNAs generated by T7 RNA polymerase end in a 5’ triphosphate 
group. Rossi and colleagues demonstrated that this triphosphate group is a potent 
inducer of an interferon response (Kim et al., 2004). This has implications for most 
shRNA expression systems because in the absence of capping signals, most of which 
are intragenic, RNA pol III transcripts will contain a 5’ triphosphate group. This seems 
to be the case for U6 promoter driven shRNA cassettes which express uncapped 
transcripts if the capping signal is not present in the transcript (Good et al., 2004). 
Indeed, the context of U6 transcription initiation could be important in inducing an 
interferon response (Pebemard and Iggo, 2004) although this conflicts with another 
study where the authentic transcription initiation context did not prevent an interferon 
response (Fish and Kruithof, 2004).
No study has linked the activation of an interferon response to the potency of gene 
silencing. Transducing cells with lentiviral vectors differing only in shRNA sequence is 
capable of eliciting a robust interferon response or not eliciting a detectable response at 
all (Bridge et al, 2003). The magnitude of the interferon response also seems to be 
dependent on the MOI used to deliver the shRNAs (Bridge et al, 2003). Studies using 
transfected siRNAs have found that siRNA concentration also affects the interferon 
response (Semizarov et al., 2004). Despite the importance of long dsRNA in triggering
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an interferon response, no simple relationship between the shRNA length and the 
magnitude of an interferon response has been identified (Fish and Kruithof, 2004).
A consensus has yet to emerge on how frequently siRNAs and shRNAs induce 
interferon responses, and identification of common themes is confounded by the many 
varied techniques of introducing and generating siRNA species. Despite this, it seems 
clear that small dsRNAs can elicit an interferon response and poorly defined sequence 
and structural elements determine the extent and magnitude of a cell’s response.
1.3.5.3. The cellular response to lentiviral vectors
There is a paucity of published data concerning the intrinsic cellular response to 
transduction with lentiviral vectors. However it is clear that vector-transduction is a less 
potent activator of the interferon response than shRNA expression (Bridge et al., 2003). 
Although escaping intrinsic sensors, vector transduction can cause insertional 
mutagenesis (reviewed in Ferguson et al., 2005). This is a particular problem with 
HIV-1 based vectors as integration favours transcriptionally active sites (Schroder et al.,
2002) and >80% of lentiviral vector insertions have been reported to occur within genes 
(Imren et al., 2004). This represents a significant obstacle for gene therapy. Insertional 
mutagenesis caused by retroviral vectors (reviewed in Yi et al., 2005) halted the 
treatment of children with severe combined immunodeficiency disease type XI 
(Cavazzana-Calvo et al., 2000) when three out of 11 patients developed leukaemia. To 
improve biosafety, many groups are trying to achieve targeted integration of lentiviral 
vectors (reviewed in Bushman, 2002). Although undesirable, insertional mutagenesis is 
not a problem in most experimental systems, but is a consideration when working with 
clonal transduced cell lines.
Although lentiviral vectors do not seem to be potent inducers of an interferon response, 
protein factors with specific antiretroviral activity are becoming increasingly well 
characterised (reviewed in Towers et al., 2005). The recent discovery that the tripartite 
motif containing protein (Trim) 5a from rhesus macaque (Macaca mulatto) is able to 
attenuate HIV-1 infection (Stremlau et al., 2004) exemplifies the potential 
complications of lentiviral transduction. Although human trim5a does not affect HIV-1, 
it represents a significant barrier to HIV-derived lentiviral vector transduction of non­
human primate cells. It is difficult to predict the efficiency of lentiviral transduction of 
different cells and empirical testing is usually required. For example, lentiviral vector
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stocks of a vector commonly used in our laboratory efficiently transduced EBV- 
transformed lymphoblastoid cell lines (LCLs), but were unable to transduce resting B- 
cells from which the LCLs were derived (Rosemary Tierney, personal communication). 
The reason for this lowered permissivity is unclear and could represent a block at any 
stage of transduction from viral entry to transgene expression.
1.3.6. The subjects of this thesis
An understanding of how KSHV interacts with the host cell is vital to our understanding 
of the viral lifecycle and of KSHV-associated transformation. We hypothesize that, 
similarly to EBV, KSHV has a lifecycle which is intertwined with B-cell differentiation. 
This thesis describes the generation of tools aimed at dissecting this relationship, 
revisits recombinant KSHV permissivity and identifies a possible link between B-cell 
terminal differentiation and KSHV reactivation.
Although extensively validated and widely available at present, lentiviral vector- 
mediated RNAi was unavailable when this project commenced. Chapter 3 of this thesis 
describes the generation and characterisation of shRNA expression cassettes that can be 
delivered using self-inactivating lentiviral vectors.
As proof of principle that lentiviral vector-mediated RNAi can be used to interfere with 
KSHV gene expression, chapter 4 of this thesis describes lentiviral vector-mediated 
RNA interference with KSHV ORF50 expression. Characterisation of the ORF50 
‘knockdown’ phenotype suggests that RNAi with ORF50 expression prevents initiation 
of KSHV lytic replication.
The low susceptibility of B-cell lines to infection with KSHV in vitro is an enigmatic 
feature of KSHV biology. We hypothesize that in vitro susceptibility is related to the B- 
cell developmental stage and activation state of the target B-cell. Chapter 5 of this 
thesis describes the in vitro susceptibility of a panel of B-cell lines and other common 
cell lines to recombinant KSHV infection. Interestingly, all the adherent cell lines 
examined were susceptible to recombinant KSHV infection whereas we were unable to 
identify any B-cell lines which are efficient targets for recombinant KSHV infection.
Finally, KSHV-positive primary effusion lymphoma (PEL) cells are phenotypically 
similar to plasmablasts; which represent a late stage in B-cell differentiation
94
immediately preceding terminal differentiation into plasma cells. Chapter 6 of this 
thesis examines the role of XBP-1 in KSHV reactivation. Overexpressed XBP-ls is a 
potent activator of KSHV reactivation, driving ORF50 expression in PEL cell lines and 
activating the ORF50 promoter in transient-transfection reporter gene assays. This 
suggests that terminal differentiation, of KSHV-positive B-cells into plasma cells may 
be a cue for KSHV lytic reactivation.
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Chapter 2 
Materials and Methods
2.1. General Molecular biology Techniques
2.1.1. Preparation of competent bacteria
XL-1 Blue Escherichia coli (Stratagene, UK) were streaked onto Luria-Bertani (LB)- 
agar plates containing tetracycline (10 pg/ml) and incubated at 37°C for 16 hours. A 
single colony was used to inoculate 5 ml of LB-broth, supplemented with 50pg/ml 
tetracycline, and shaken at 37°C for 16 hours. This was added to 500 ml LB-broth and 
shaken at 37°C until the absorbance at 600 nm was 0.6 (around 3 hours). The culture 
was then put on ice to cool for 10 minutes. The bacteria were pelleted at 3000g for 10 
minutes at 4°C and resuspended in 15 ml of 100 mM calcium chloride (4°C). After 
incubation on ice for 30 minutes, the bacteria were centrifuged again and then 
resuspended in 2.5 ml of 100 mM calcium chloride containing 15% glycerol by volume 
(4°C). The bacterial suspension was frozen on dry ice in 400 pi aliquots.
2.1.2. Introduction of plasmid DNA into E. coli
1-200 ng of plasmid was mixed with 200 pi of competent XL-1 Blue Escherichia coli 
(Stratagene, UK) and incubated on Ice for 15-30 min. The cells were then heat shocked 
for 45 s at 42 °C and cooled on ice. 300 pi of LB broth was added to the reaction and 
incubated at 37 °C for 30 min. The cells were then plated on LB-agar plates containing 
50 pg/ml ampicillin or kanamycin.
2.1.3. Plasmid DNA midi-preps
Midi preps of plasmid DNA were produced from 50ml overnight cultures of 
transformed XL-1 Blue Escherichia coli using the Plasmid Midi Kit (Qiagen) according 
to the manufacturer’s instructions.
2.1.4. Plasmid DNA mini-preps
Mini preps of plasmid DNA were produced from 3ml overnight cultures of XL-1 Blue 
Escherichia coli using the QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer’s instructions.
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2.1.5. Molecular Cloning
Taq polymerase, restriction endonucleases, mung bean nuclease, T4 polynucleotide 
kinase, Calf intestinal alkaline phosphatase and T4 DNA ligase were purchased from 
Promega, UK and were used in accordance with the manufacturer’s specifications. Gel 
purification kits were purchased from Qiagen, UK, and were used in accordance with 
the manufacturer’s specifications.
2.1.6. PCR cloning using the pGEM-T-Easy vector system (Promega)
The desired region was PCR-amplified using 5 units of Taq polymerase (Promega) in a 
50 pi reaction volume buffered with Taq polymerase buffer A (Promega). PCR 
conditions involved 20-100 ng of template DNA and 30 picomoles of each 
oligonucleotide primer. In addition, the reaction was supplemented with a final 
concentration of 0.2 mM dNTPs (Promega) and between 0.5 and 2 mM MgCE 
(Promega). The correct molecular weight product was separated and visualised using, 
Ethidium Bromide (Invitrogen) stained, agarose gel electrophoresis. The desired 
product was subsequently excised and extracted using the MinElute gel extraction 
system (Qiagen) in accordance with the manufacturer’s instructions. The following 
ligation reaction was used. Negative controls with PCR-amplified DNA substituted 
with H2O were ligated in parallel.
5 pi 2X ligation buffer 
1 pi T4 DNA ligase
1 pi pGEM-T-Easy linear DNA
2 pi MinElute extracted PCR product 
1 pi H20
Ligation reactions were transformed as described in section 2.1.2 and positive colonies 
were identified by blue-white-screening, PCR-screening or restriction enzyme digest as 
desired
2.1.7. DNA sequencing
1.5 pi of plasmid DNA was mixed with 3.5 pi of H2O and heated to 94 °C for 5 minutes. 
Following incubation, 4 pi of Beckman QuickStart mix and 5 picomoles of the relevant
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primer was added. The solution was placed in a thermal cycler and subjected to the 
following conditions:
1. 94°C 3 minutes
2. 96°C 20 seconds
3. 50°C 20 seconds
4. 60°C 4 minutes
5. Steps 1-3 an additional 29 times
DNA was precipitated from the sequencing reaction by adding 2 pi sodium acetate (1.5 
M), 2 pi EDTA (50 mM, Sigma, UK) and 1 pi glycogen (20 mg/ml, Beckman Coulter, 
UK) in a final volume of 20 pi, the mixture was then vortexed prior to the addition of 60 
pi 95% (v/v) ethanol/water (-20°C) and incubated on ice for 10 minutes. DNA was 
pelleted by centrifugation at 14000g for 15 minutes at room temperature. The 
supernatant was removed and the pellet was washed with 200 pi 70% ethanol/water (- 
20°C), and the tube left open at room temperature until dry. DNA was resuspended in 
40 pi deionised formamide (JT Baker, USA) for 15 minutes and transferred to a 96-well 
plate. The sequences were determined using an automated capillary DNA sequencer 
(Beckman Coulter, UK) as per the manufacturer’s instructions.
2.1.8. DNA oligonucleotides 
Table 2.1.8. DNA primers.
Oligo
Number
Primer Name Primer Sequence
1 SJWU61-F GGGGCTGCAGAAGGTCGGGCAGGAAGAGGGCCTATTTCCC
2 SJWU61-RC GTT CCAATAT GCATAAAAAATCTAGAGAAGCGT CGACGGTGTTTCGT CCTTT CCACAAG
3 T7 T AATACG ACT CACTAT AGGG
4 SP6 TATTTAGGTGACACTATAG
5 U6fillerU T CGAATT CAGGAT CCT GAGCT CGTGCA
6 U6fillerL CGAGCTCAGGATCCTGAATTCGATGCA
7 U6 Distal CCCATGATTCCTTCATATTTGC
8 PGEM227-207 GTT GT GT GGAATT GT G AGCGG
9 ORF73F TT GCCACCCACGCAGTCT
10 ORF73RC GGACGCATAGGT GTT GAAGAGT CT
11 XBP-1F GGAAGAT CTT CGGATCCCGCAATT GGTCT GGAGCTAT GGTGGTGGCAGCCG
12 XBP-1RC ATAGTTTAGCGGCCGCAACT CGAGT CAGT GGTGGT GGTGATGGT GGACACTAAT CAGCTGGGGAAAGAGTT C
13 XBP-1shortF CCTT GTAGTT GAGAACCAGG
14 XBP-1shortRC CAGAAT GCCCAACAGGATAT C
15 50REDEXF CGCTCCATTAATTGGAAGCATTCTCTCTTCATCGTGTGTGC
16 50REDEXRC AAGCTTGCTAGCGCGGACCGCCGAAGCTTCTTACCCTAAGGAG
17 ORF50star CACAAAAATGGCGCAAGATGACAAG
18 RedexscreenRC ACCTT GGAGCCGTACT GGAACTGGG
19 Siw50PROMMUTU GCTTTT CAGGAGAGTTAGGTCGACACT GAGGAT GT GGACAAGCTT CTGC
20 Sjw50PROM MUTL GCAGAAGCTT GT CCACAT CCTCAGT GTCGACCTAACT CT CCT GAAAAGC
21 SJWPrimer2076F CGACAGATTAATCCAGGGTTTCCTGGTGGGGCGCGGC
22 SJWPrimer2276F TCAAGCATTAATCCCGCCGGAACTCCACATCCACAAAG
23 SJW Primer2476F TGGGTGATTAATTCTACCACGGTCATACATTGGTGGC
24 SJWPrimer2676F CCCCCCATTAATAGCCAGCGTATGCTTCAGGACCACC
25 SJWPrimer2876F TCAGT CATTAATACGCTAGGGT CT CCCCACCCAACCC
26 SJWPrimer2960F ACCGGCATTAATTTAAGCCCCGCCCAGAAACCAGTAG
27 SJWPrimer3076F GCAGCCATTAATATGGCGCAAGATGACAAGGTAAAGATC
28 ORF50-5' ACCGGTT CT GCT GAGAAACG
29 ORF50-3’ ACACCGT CT GT GAACTACCG
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2.2. Plasmids
2.2.1. pGemll61
The human U6-promoter was PCR amplified using primers 1 and 2 using genomic 
DNA extracted from HBL-6 cells as a template. The PCR product was digested with 
Pst I and Nsi I, gel purified and ligated to Pst I, Nsi I digested self-ligated pGEM-T- 
Easy. The promoter was sequenced using T7 and SP6 primers.
Apa 1 
Aat II
Sph I 
Bst ZI
AMPr
Nco IFI on
Bst ZI
Not I
Sac n
Not I
pGemU61 
3255 bp
Bst ZI
Pst I
U6 promoter
S a il
X b a l
Nsi I
Figure 2.2.1. pGemU61
A restriction m ap of pGemU61 indicating the  p -lac tam ase g en e  (AMPr), bacteriophage F1 origin 
of replication (F1 ori) and  th e  hum an U6-promoter.
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2.2.2. pGemU61-LINKER
Oligonucleotides 5 and 6 were annealed together, phosphorylated by treatment with T4 
polynucleotide kinase and ligated to Nsi I digested pGEMU61. The promoter was 
sequenced using T7 and SP6 primers.
Apa 1 
Aat II
Sph I 
Bst ZI
Nco I
AMPr Bst ZI
fl ori
Not I
Sac n
Not I
Bst ZI
Pst I
pGemU61-LINKER 
3278bp U6 promoter
Sal I
Xba I
Nsi I
Eco RI
Bam HI
Sac I
Figure 2.2.2. pGemU61 -LINKER
A restriction m ap of pGemU61-LINKER indicating the  p-lactam ase g en e  (AMPr), bacteriophage 
F1 origin of replication (F1 ori) and  the hum an U6-prom oter.
2.2.3. ShRNA expressing plasmids
pGemU61-LINKER was linearised by digestion to completion with Sal I, blunt ended 
using Mung bean nuclease (Promega, UK), digested with Xba I and treated with Calf 
intestinal alkaline phosphatase (Promega, UK). The pGemU61-LINKER DNA was 
then ligated with complementary oligonucleotides (table 2.2.3) that had been annealed 
and phosphorylated through treatment with T4 polynucleotide kinase. The resulting 
plasmids were sequenced using oligonucleotides 7 and 8.
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Table 2.2.3. Oligonucleotides used to construct shRNA expression constructs
ShRNA Primer Name Olleonucleotfde Sequence Plasmid Lentiviral vector
GFP REALSJWHPeGFPU TT CATCTGCACCACCGGCAAGCTTCGGCTT GCC GGTGGTGCAGATGAACTTTTT pGemU6-LINKER-RG
GFP-PAC
GR1
GR2GFP REALSJWHpeGFPL CTAGAAAAAGTTCATCTGCACCACCGGCAAGCC GAAGCTTGCCGGTGGT GCAGAT GAA
SJ ORF50sjU ATAAGGGTAGGAAGCTTT GGTGTT CGCGCCGAA GCTTCTTACCCTTGTCI 1T1 T pGemU6-LINKER- 50 SJ SJ-PACSJ ORF50sjL CTAGAAAAAGACAAGGGTAAGAAGCTTCGGCGCGAACACCAAAGCTTCCTACCCTTAT
ORF50M ORF50mU AAGTTCT GC AACACGTAT GATATTCGTATCGTAC GTGTTGTAGAGCTTC11M1 pGemU6-LINKER-50M ORF50M-PACORF50M ORF50mL CTAGAAAAAGAAGCTCTACAACACGT ACGAT ACG AATAT CATACGT GTT GCAGAACTT
ORF50E ORF50ell AATGT GGT GT GCAACACGTT CATTCGT GGAT GT G TTGTACACCATATTCn II I pGemU6-LINKER-50E ORF50E-PACORF50E ORF50eL CTAGAAAAAGAATATGGTGTACAACACATCCACG AAT GAACGT GTT GCACACCACATT
TSG101 AFRtsg101F AATCT CTAGTCTT CTTT CGTT CTT CTT CGGGACGA GAGAAGACT GGAGGTT CTTTTT pGemU6-LINKER-Tsg101 Tsg101-PACTsg101-GFPTSG101 AFRtsg101R CTAGAAAAAGAACCT CCAGTCTT CTCTCGTCCCG AAGAACGAAAGAAGACTAGAGATT
p2 AFR p2F AGGATTAAGT GCAT GGTAGGCATT CGTGCCTGC CATGCGCTTGATCTTCTTTTT pGemU6-LINKER-M2 p2-PACp2-GFPp2 AFRp2R CTAGAAAAAGAAGAT CAAGCGCAT GGCAGGCAC GAATGCCTACCATGCACTTAATCCT
Trim 5 a Trim5a1U CTTAGGGAGGTCAGGTTGAGTCTTCGGGCTCAA CTT GACCTCCCT GAGCTTTTT pGemU6-LINKER-5a1 Trim5a1-PACTrim5a1-GFPTrim 5 a Trim5alL CTAGAAAAAGCT CAGGGAGGT CAAGTT GAGCCC GAAGACT CAACCTGACCT CCCTAAG
Blimpl P BLIMP1PU AGGAGAGGTGTACATATATTGTTTCGACAATGTA TGTACACTTCTCTTC11 II 1 pGemU6-LINKER-BLIMPP blim pp-pacBlimp 1 P BLIMP1PL CTAG AAAAAGAAGAGAAGT GT ACAT ACATT GT CG AAAC AATATATGT ACACCT CT CCT
Blimpl M BLIMP1MU GAT CTCGGT GACTTTAGGAGACTTCGGT CTT CTA AAGTCATCGAGGTCC Mi l l pGemU6-LINKER-BLIMPM BLIMPM-PACBlimpl M BLIMP1MU CTAGAAAAAGGACCTCGATGACTTTAGAAGACCG AAGT CT CCT AAAGTCACCGAGAT C
Blimpl D BLIMP1DU AAGGT CT GACTCGAATTAAT GATT CGT CATTGATT CGGGTCAGATCTTC1 M il pGemU6-LINKER- BLIMPD-PACBlimpl D BLIMPDL CTAGAAAAAGAAGAT CT G ACCCGAAT CAAT GACG AATCATTAATTCGAGTCAGACCTT
PSN1 PSN1U GT CTACTT CGTGT GTT GGTT GATTCGT CAACCAG CATACGAAGT GGACCTTTTT pGemU6-LINKER-PSN PSN-PACPSN1 PSN1L CTAG AAAAAGGT CCACTTCGTAT GCT GGTT GACG AATCAACCAACACACGAAGTAGAC
NCN1 NSNU AAGGGCGAGTTTCCCGTGTAGTTTCGACTGCAC GGGAAACTTGCCCTTC1 M il pGemU6-LINKER- NSN-PACNCN1 NSNL CTAGAAAAAGAAGGGCAAGTTTCCCGT GCAGT C G AAACT AC ACGGG AAACT CGCCCTT
LacZ SJWLacZF CT GT GATT GCGTCT GGGTTT GCTTCGGCAAGCC CGGGCGTAAT CATAGCTTTTT pGemU6-LINKER- LacZ-PAC
LacZ-GFPLacZ SJWLacZR CTAGAAAAAGCTATGATTACGCCCGGGCTTGCC GAAGCAAACCCAGACGCAAT CACAG
2.2.4. Generation of lentiviral vectors encoding shRNAs
pGemU61-LINKER plasmid derivatives encoding shRNAs (table 2.2.3) were digested 
with iscoRI, gel purified and ligated to EcoRl linearised lentiviral vector genome 
plasmids (CSGW, CSRW or CSPW). The orientation of insertion was determined by 
Not I digestion, and shRNAs were sequenced using oligonucleotide 7 in their lentiviral 
vector context prior to use. The names of individual shRNA-expressing lentiviral 
vectors are listed in table 2.2.3.
2.2.5. pXBPIG
The plasmid pXBPIG was a generous gift from C. Tsantoulas who generated pXBPIG 
under the supervision of S. Wilson during an MSc project in the Kellam laboratory. 
The pXBPIG construct encodes XBP-ls tagged with a c-terminal His-tag.
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2.2.6. pXBPUIG
pXBPUIG was generated through PCR amplification of XBP-1 using oligonucleotides 
11 and 12. The PCR-product was cloned into pGEM-T-Easy and sequenced as 
described in section 2.1.7. The XBP-lu cDNA was subsequently sequenced and 
digested with Bam HI and Xho I  and ligated to Bam HI and Xho I digested pIE, also 
described as CSBX, a generous gift from Y. Ikeda.
2.2.7. p50Redi
A 4099 bp region of the ORF50 promoter, first exon, intron and the first 7 codons of the 
second exon was PCR amplified using 100 ng of KSHV BAC36 DNA as a template. 
The PCR-product was cloned into pGEM-T-Easy (described in section 2.1.6). This 
4099 bp fragment was then digested with Ase I and Nhe I and ligated with Ase I and Nhe 
I digested pCMV-DsRed-Express (Bevis and Glick, 2002) (Clontech). The construction 
of p50Redi is summarised in figure 2.2.6.
2.2.8. pA1760
To generate pA1760, p50Redi was digested with Ase I and Nde I. The resulting 6374 bp 
fragment was gel purified and self-ligated to generate pA1760.
2.2.9. pNoRedi
To generate pNoRedi p50Redi was digested with Ase I and Nde I and Nhe I. Following 
digestion, the 4054 bp fragment was gel purified and the sticky ends removed through 
treatment with mung bean nuclease. The p50Redi plasmid was sequenced across the 
ligation site to confirm faithful blunt-ending and ligation had occurred.
2.2.10. pA2078-pA3076
To generate the deletion mutants of p50Redi pA2078 to pA3076, regions of the ORF50 
promoter were PCR-amplified using 100 ng of KSHV BAC36 DNA as a template. 
Primers 21-27 were used in concert with primer 16 to PCR amplify the promoter 
fragments required for pA2078 to pA3076. The correct length PCR products were gel 
purified and cloned into pGEM-T-Easy (as described in section 2.1.6). The PCR 
products in pGEM-T-Easy were then digested with Ase I and Nhe I and ligated to Ase I 
and Nhe I digested pCMV-DsRed-Express (Clontech).
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A
Ase I 
J  ►
Ase I
B
Nhe I 
I_
KSTV ORF50 promoter
PCR-amplification using 
oligonucleotides 15 and 16 ofthe 
ORF50 promoter, intron and 
fragment of second exon
PCR profuct was cloned using pGem-T- 
Easy and digested with Asd and Nhe I 
and ligated with pCMV-DsRed-Express 
(Clontech).
KSTV ORF50 promoter
ORF50 Exon II
Intron
ORF50 
Exon I
50redexpre8s
Nhe I
J ± .
12aa linker 
from CMV- DsRed-ex press
DsRedexpress
M A Q D D K G K K L R R S A L A L
ATG GCG CAA GAT GAC AAG GGT AAG AAG CTT CGG CGG TCC GCG CTA GCG CTA
Nhe I
P D S D P P V A T M A S S
CCG GAC TCA GAT CCA CCG GTC GCC ACC GCC TCC TCC
c
> R T A - E x p r e s s
MAQDDKGKKLRRSALALPDSDPPVATMASSDEVIKEFMRFKVRMEGSVNG 
HEFEIEGEGEGRPY EGTQTAKLKVTKGGPLPFAWDILS PQFQY GSKVYVK 
H PAD IP D  Y KKLS F PEGFKWERVMNFE DGGWTVTQDS S LQDGS F IY  KVKF 
IGVNFPSDGPVMQKKTMGWEASTERLY PRDGVLKGEIHKALKLKDGGHY L 
VE FKSIYMAKKPVQLPGY Y Y VDS K LDITS HNEDYTIVEQY ERAEGRHHLF 
L
2.2.7. The co n s tru c tio n  of p50R edi
A. a diagrammatic representation of PCR-amplification, and insertion of the ORF50 promoter, 
first exon, intron and a 7-codon fragment of the second exon into pCMV-DsRed-Express 
(Clontech). B. The DNA sequence and amino acid sequence ofthe N-terminal region of RTA- 
Express (the fusion protein containing the N-terminus of RTA fused to DsRed-Express). The 
start codon of RTA is highlighted in red and the original start codon of DsRed-Express is 
highlighted in grey. The Nhe I restriction site is highlighted in blue and the coding sequence 
originating from the pCMV-DsRed-Express multiple cloning site is indicated with a dashed line. 
C. The predicted amino acid sequence of RTA-Express.
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2.2.11. pMut50Redi
To generate pMut50Redi, oligonucleotides 19 and 20 were used to facilitate site 
directed mutagenesis using the QuickChange™ mutagenesis system (Stratagene). This 
was executed according to the manufacturer’s instructions. Colonies were rapidly 
screened for successful mutants using an engineered Sal I restriction site. The sequence 
of the mutated region was confirmed prior to use.
2.3. Cell culture
Table 2.3.1. B-Cell lines used in this study.
Cell line B -c e ll tum ou r Viruses R eference
BC-3 Primary effusion lymphoma KSHV (Arvanitakis eta l., 1996)
BCBL-1 Prim ary effusion lymphoma KSHV (R enne e ta l., 1996b)
BCP-1 Prim ary effusion lymphoma KSHV (Boshoff e ta l., 1998b)
BONNA-12 Hairy cell leukaem ia EBV (Kluin-Nelemans eta l., 1992)
DEL Anaplastic-DLBCL (Barbey e ta l., 1990)
HBL-6 Primary effusion lymphoma KSHV and 
EBV
(G aidano e ta l., 1996)
JSC-1 Prim ary effusion lymphoma KSHV and 
EBV
(Cannon et al., 2000)
K arpas-422 Diffuse large B-cell lym phoma EBV (Dyer e ta l., 1990)
L-428 C lassical Hodgkin’s (S chaad t et al., 1979)
NCI-H929 Multiple m yelom a (G azdar e ta l., 1986)
Raji Burkitt’s  lym phoma EBV (Pulvertaft, 1964)
SK-MM-2 P lasm a cell leukaem ia (Eton eta l., 1989)
SU-DHL-5 Diffuse large B-cell lym phoma (Epstein e ta l., 1978)
TOM-1 Pre-B  (acute) lymphoblastic 
leukaem ia
(O kabe e ta l., 1987)
All cell lines are derived from B-cell tumours. Some contain the herpesviruses KSHV 
and/or EBV. All cell lines were grown in RPMI-1640 medium (Invitrogen, UK) with
10% foetal calf serum (FCS) with the exception of BCP-1 cells which were propagated 
in 20% FCS (Biowest, France). In addition, the medium was supplemented with 100 
units/ml penicillin and 100 pg/ml streptomycin (Invitrogen, UK). Cells were incubated 
in 5% C 02 at 37°C.
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Table 2.3.2. Cell lines, not of B-cell origin, used in this study
Cell line D escrip tion R eference
HeLa epitheloid cervix carcinom a S cherer ef a/., 1953
HEK 293-T 293 cells containing the  tem perature 
sensitive g en e  encoding SV40 T-antigen
DuBridge eta l., 1987
SLK M ucosal K aposi’s  sarcom a lesion. From a  
HIV negative patient
Herndier e ta l., 1994
MUTZ-3 Acute myeloid leukem ia Hu e ta l., 1996
TE 671 Hum an m edulloblastom a cell line McAllister et al., 1977
CRFK R enal cell line estab lished  from Felis catus Crandell e ta l., 1973
FRHK Foetal R h esu s  m onkey kidney cell line Form an e ta l., 1969
CV-1 African g reen  m onkey kidney cell line Jen se n  e ta l., 1964
All cell lines, except MUTZ-3, were grown in DMEM medium (Invitrogen, UK) with 
10% foetal calf serum (Biowest, France) 100 units/ml penicillin and 100 pg/ml 
streptomycin (Invitrogen, UK) in 5% or 10% CO2 at 37°C. SLKs were grown in 
medium further supplemented withl% non-essential amino acids (Invitrogen). MUTZ- 
3 were cultured as described by Hu and colleagues (Hu et al, 1996)
2.3.1. Thawing cells
Cells were removed from liquid nitrogen and thawed rapidly at 37°C. B-cell lines were 
added to 10 ml of Roswell Park Memorial Institute (RPMI)-1640 medium (Invitrogen, 
UK) with 10% foetal calf serum (FCS, Biowest, France), 100 units (U)/ml penicillin 
and 100 pg/ml streptomycin (P/S, Invitrogen, UK). The cells were then pelleted at 325 x 
g for 5 minutes, resuspended in 10 ml media and counted with a neubauer-improved 
haemocytometer. The cells were centrifuged for a further 5 minutes and resuspended at 
5xl06 cells/ml or at the density recommended by the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ). HeLa, TE 671, CRFK, FRHK, CV-1, 
SLK and HEK 293-T cells were added to 10 ml of Dulbecco’s Modified Eagle Medium 
(DMEM, Invitrogen, UK) with 10% foetal calf serum (FCS, Biowest, France), 100 units 
(U)/ml penicillin and 100 pg/ml streptomycin (P/S, Invitrogen, UK). The cells were 
then pelleted at 325 x g for 5 minutes, resuspended in 10 ml media and counted with a 
neubauer-improved haemocytometer. The cells were plated drop-wise at the density 
recommended by the American Type Culture Collection (ATCC).
2.3.2. Passaging cells
Cells were cultured in RPMI-1640 with 10% FCS and P/S in 5% CO2 at 37 C or in 
DMEM with 10% FCS and P/S in 5% or 10% C 02 at 37°C.Cells were split 1:2 to 1:8, 
depending on cell density and rate of growth, two or three times per week.
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2.3.3. Freezing cells
Cells were centrifuged at 325 x g for 5 minutes and resuspended at 5xl06 cells/ml in 
cold FCS (FCS, Biowest, France) containing 10% dimethyl sulphoxide (DMSO, Sigma, 
UK). Cells were aliquoted into cryovials (Nunc, USA) and gradually cooled to -80°C in 
an isopropanol-containing cryo-container (Nalgene, USA) before being transferred to 
liquid nitrogen.
2.3.4. Deriving clonal cell populations by limiting dilution
Cell density was determined using a neubauer-improved haemocytometer. Cultures 
were diluted to 50, 5 and 0.5 cells/ml and cultured in 96-well plates containing 200 
lil/well of normal culture medium and filtered conditioned medium (1:1 ratio). The 
plate derived from the lowest concentration of cells that yielded viable cultures in some 
of the wells was selected as the source of clonal cell cultures.
HeLa Cl and JSC-1 Cl cells were generated by transduction with pHR’SINcSDW 
derived lentiviral vector (CSDW) using an input equivalent to a MOI 5 on HEK 293-T 
cells. 48-hours postinfection clonal cell populations were derived as described above. 
Clonal cell lines expressing dEGFP were screened by UV-microscopy and analysed by 
flow cytometry for a single fluorescent population, as an indication of true clonality.
JSC-1 50P and SJP lines were generated by transduction with EP and SJP lentiviral 
vectors with an input equivalent to a MOI 10 on HEK 293-T cells. 48-hours 
postinfection puromycin was added to cultures at a final concentration of 2pg/ml. 120 
hours postinfection clonal cell populations were derived as described above in the 
continued presence of puromycin.
2.3.5. Puromycin selection following lentiviral vector transduction
48-hours postinfection the medium was removed and replaced with medium 
supplemented with 2 pg/ml puromycin dihydrochloride from S. alboniger (Sigma). The 
medium was removed and replaced with fresh medium supplemented with 2 pg/ml 
puromycin every 2-3 days until non-transduced cells, in parallel cult6ures, were no 
longer viable. The puromycin-selected cells were then cultured normally in medium 
supplemented with puromycin.
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2.3.6. Induction of KSHV lytic replication by TPA treatment of PEL cell 
lines.
PEL cells were pelleted by centrifugation, and 0.5x106 cells/ml were resuspended in 
normal culture medium supplemented with 20 ng/ml TPA (Sigma). PEL cells were 
incubated at 37 °C and 5% CO2 for the duration of the experiment unless otherwise 
stated. Where a brief treatment of TPA was required, PEL cells were pelleted and 
resuspended in fresh medium and incubated at 37°C and 5% CO2 .
2.4. Lentiviral vectors
2.4.1. Transient transfection of HEK 293-T cells to make lentiviral vectors.
Lentiviral vectors were produced as described in Besnier et al., 2002. HEK 293-T cells 
were seeded so that 10 cm dishes were confluent on the day of transfection. 18 pi of 
FuGENE-6 (Roche) was added to 200 pi of Opti-MEM (Invitrogen, UK). 1 pg of 
p8.91, 1 pg of pMDG (both generous gifts from Didier Trono) and 1.5 pg of vector- 
genome encoding plasmid DNA were made up to 15 pi in H2O and added to the 
FuGENE-6 and Opti-MEM mixture. The transfection mixture was incubated at room 
temperature for 30 min before being added dropwise to the confluent HEK 293-T cells 
in 8 ml DMEM medium (Invitrogen, UK) with 10% foetal calf serum (Biowest, France) 
100 units/ml penicillin and 100 pg/ml streptomycin (Invitrogen, UK).
The HEK 293-T cells and the transfection reaction were incubated overnight at 37°C 
and 10% CO2 . The lentiviral vector containing supernatants were harvested at 48, 72 
and 96-hours post transfection, passed through a 0.45 pm filter and stored at -80 °C in 1 
ml aliquots.
2.4.2. Lentiviral vector titration of infectious units by GFP expression
1x10s HEK 293-T cells were seeded per well of a 24-well plate and cultured overnight 
at 37°C and 10% C 0 2 in 500 pi of HEK 293-T medium (DMEM containing 10% FCS, 
100 units (U)/ml penicillin and 100 pg/ml streptomycin). 80 pi, 60 pi, 40 pi, 20 pi and 
1 pi of lentiviral-vector containing supernatant were mixed with HEK 293-T medium to 
a total volume of 100 pi. The diluted lentiviral-vector containing supernatants and 100 
pi of undiluted supernatant were added to HEK 293-T cells and incubated overnight at
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37°C and 10% CO2 . The cells were washed once with HEK 293-T medium and 
incubated for a further 36 hours.
After incubation the HEK 293-T cells were trypsinised and the percentage of GFP 
expressing cells determined by flow cytometry relative to non-infected cells. The 
percentage of GFP expressing cells was converted to infectious units by assuming a 
total of 2xl05 cells at the time of infection. Infectious units were plotted against pi of 
supernatant. The absolute titre of the lentiviral vector was determined by extrapolating 
the infectious units per ml (IU/ml) using the straight-line equation of the above plot.
2.4.3. Lentiviral vector titration of infectious units by puromycin selection 
and colony counting
2x105 HEK 293-T cells were seeded per well of a 24-well plate and cultured overnight 
at 37°C and 10% CO2 in 500 pi of HEK 293-T medium (DMEM containing 10% FCS, 
100 units (U)/ml penicillin and 100 pg/ml streptomycin). 10 pi, 1 pi, 0.1 pi, 0.01 pi 
and 0.001 pi of lentiviral-vector containing supernatant were mixed with HEK 293-T 
medium to a total volume of 100 pi. The diluted lentiviral-vector containing 
supernatants were added to HEK 293-T cells and incubated overnight at 37°C and 10% 
CO2. The cells were then trypsinised and cultured in 5 cm dishes containing 5 ml of 
HEK 293-T medium containing 2 pg/ml puromycin (Sigma). 3 days after infection the 
plates were washed and placed in fresh HEK 293-T medium containing 2 pg/ml 
puromycin. 14 days after infection visible puromycin resistant colonies were counted 
and the infectious units extrapolated from the dilution containing approximately 10 
colonies.
2.4.4. Lentiviral infection of suspension cells
1 xlO5 cells were pelleted and resuspended in 1 ml of the required amount of, lentiviral 
vector containing, HEK 293-T supernatant and culture medium. The cells were then 
incubated for 6 hours or overnight at 37°C and 5% CO2 . The cells were then pelleted 
and resuspended in fresh medium.
2.4.5. Lentiviral infection of adherent cells
1 xlO5 cells were plated per well of a 24 well plate. The following day the medium was 
removed and replaced with 1 ml of the required amount of, lentiviral vector containing,
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HEK 293-T supernatant and culture medium. The cells were incubated for 6 hours or 
overnight at 37°C. The lentiviral vector containing, HEK 293-T supernatant and culture 
medium was then removed and replaced with fresh medium.
2.4.6. Spinoculation of PEL cell lines using XBPIG, IE and XBPUIG 
lentiviral vectors
XBPIG, XBPUIG and IE were titrated on HEK 293-T cells as described in section
2.4.2. An input equivalent to a MOI 5 on HEK 293-T cells was then used to spinoculate 
the required amount of PEL cells in a 24-well plate, containing lx l0 5 cells per well, for 
1 hour at 500 x g in medium supplemented with 15 pg/ml polybrene (Sigma). The cells 
were then incubated overnight before being pelleted and resuspended in fresh medium 
and passaged normally.
2.5. Flow cytometry
2.5.1. Flow cytometry
Ten thousand events were collected using a FACScan or LSR flow-cytometers with 
Cellquest software (Becton Dickinson, UK). Data were analysed using Windows 
Multiple Document Interface Flow Cytometry Application (WinMDI, J. Trotter, 
http://facs.scripps.edu).
In experiments analysing EmGFP and DsRed-Express expression simultaneously, data 
were taken using the LSR flow-cytometer. To ensure accurate quantification of EmGFP 
and DsRed-Express positive cells, EmGFP single expressing or DsRed-Express single­
expressing controls were used in each experiment to facilitate accurate compensation. 
In addition, compensation between events greater than lx l04 times brighter than non­
transfected cells is not possible, and these cells have been removed from the analysis in 
chapter 6. For completeness, representative plots are included here.
In experiments simultaneously measuring intracellular RTA-staining and EmGFP 
expression, the LSR flow-cytometer was used. To obviate the requirement for 
compensation, the fluorophore allophycocyanin was always used to visualise RTA 
staining in EmGFP-positive cells. APC and EmGFP were excited by independent 633 
nm and 488 nm light sources respectively and have non-overlaping emission absorption 
spectra. Compensation is therefore not required between APC and EmGFP.
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2.5.2. Preparation of live cells for flow cytometry
48-hours postinfection cells were washed once with PBS, and incubated for 1 minute 
with trypsin-EDTA (Invitrogen) at room temperature. The trypsin was then quenched 
with DMEM supplemented with 10% FCS and P/S and transferred to sealed FACS 
tubes (Falcon). The cells were pelleted, resuspended in PBS and kept on ice prior to 
analysis.
2.5.3. Preparation of BAC36 infected cells for flow cytometry
See section 2.7.3.
2.5.2. Transient transfection of HEK 293-T cells with shRNA expressing 
plasmids
2x105 HEK 293-T cells were seeded per well of a six well plate. The following day the 
culture medium was removed and replaced with fresh medium. The transfection was 
carried out using FuGENE-6 transfection reagent (Roche) as per the manufacturer’s 
instructions. Briefly, transfection mixes included 6 pi of FuGENE-6, 100 pi of Opti- 
MEM (Invitrogen) and 2.5 pg of DNA. The medium containing the transfection 
mixture was removed the day after transfection and replaced with fresh medium. 48- 
hours posttransfection live cells were analysed by flow cytometry.
2.3.3. Transient transfection of HEK 293-T cells with p50Redi and 
derivatives
4xl05 HEK 293-T cells were seeded per well of a six well plate. The following day the 
culture medium was removed and replaced with fresh medium. The transfection was 
carried out using FuGENE-6 transfection reagent (Roche). Transfection mixes included 
6 pi of FuGENE-6, 100 pi of Opti-MEM (Invitrogen) and the DNA masses listed in 
tables 2.3.3.1 and 2.3.3.2.
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Table 2.3.3.1. DNA amounts used to transfect HEK 293-T cells in figure 6.4.1
Sam ple pC M V -R TA  
6.8  kb
pXB PIG  
11.4 kb
pXB PU IG  
11.4 kb
p lE
10.3 kb
pB luescrip t 
I IK S  +
50Redi . 2.8 pg
50Redi + RTA 1-7 99 - - - 1.1 pg
50Redi + IE - - - 2-5 |jg 0.3 pg
50 Red i + XBPIG - 2.8 pg - -
50Redi + 
XBPUIG
2.8 (jg - -
50Redi+IE+RTA 0.85 pg - - 1.25 pg 0.7 pg
50Redi+XBPUIG
+RTA
0.85 |jg - 1.4 pg - 0.55 pg
50Redi+XBPIG+
RTA
0.85 |jg 1.4 (jg ” ■ 0.55 pg
IE - - 2.5 1.3 pg
XBPIG - 2.8 - - 1 MO
XBPUIG - - 2.8 - 1 M0_
DNA concentrations listed in addition to 1 (ig of p50Redi. Last 3 samples omitted from 
figure 6.4.1 for clarity
Table 2.3.3.2. DNA amounts used to transfect HEK 293-T cells in figure 6.4.3
Sam ple p P 50R ed i o r pXB PIG PlE pB luescrip t
derivative 11.4 kb 10.3 kb II KS  +
P50Redi+plE 1 Mg - 2.5 pg 0.3 pg
P50Redi+XBPIG 1 Mg 2.8 pg - -
pA1760+ plE 1 Mg - 2.5 pg 0.3 pg
pA1760+ pXBPIG 1 Mg 2.8 pg - -
pA2078-pNoredi + plE 1 Mg - 2.5 pg 0.3 pg
pA2078-pNoredi + 
pXBPIG
1 Mg 2.8 pg
P50Redi 1 Mg - - 2.8 pg
plE - - 2.5 pg 1.3 pg
pXBPIG - 2.8 pg - 1 M0
Last 3 samples omitted from figure 6.4.3 for clarity
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Figure 2.3.3. Em GFP co n tro ls  in p50Redi rep o rte r g en e  experim en ts
A. Typical fluorescent control of pXBPIG transfected in the absence of RTA-Express encoding 
plasmids. B. Typical fluorescent control of plE transfected in the absence of RTA-Express 
encoding plasmids. C. The density plot in B is shown prior to the removal of extremely bright 
events. The data in figures 6.4.1 and 6.4.3 also has the brightest events removed.
2.5.3. Intracellular antigen staining
5x l05 cells were fixed with 4% paraformaldehyde (Sigma) for 10 minutes on ice before 
quenching with a 10-fold excess o f PBS supplemented with 5% glycine (Sigma). Cells 
were washed once in wash buffer (PBS supplemented with 2% FCS and 0.01% sodium 
azide) before being resuspended in permeabilisation buffer (PBS supplemented with 2% 
FCS, 0.1% Triton-X-100 and 0.01% sodium azide). Antibody incubations were 
performed in either 10 jal or 50 \i\ volumes o f permeabilisation buffer further 
supplemented with 10% FCS. The cells were then washed 3 times with 
permeabilisation buffer subsequent to either antibody incubations or a final wash with 
wash buffer prior to data collection.
2.5.4. Nuclear staining for KSHV ORF50 in cells not expressing Emerald
The anti-RTA antibody (supernatant mouse mAb, IgG a generous gift from Keiji Ueda) 
was used diluted 1:2000 with control mouse IgG (a generous gift from Stuart Neil) used 
at an equivalent concentration as an isotype control The secondary antibody for 
indirect immunofluorescence was tetramethylrhodamine isothiocyanate (TRITC)- 
conjugated polyclonal rabbit anti-mouse IgG (DAKO R0270) used diluted 1:400.
112
2.5.5. Nuclear staining for KSHV ORF50 in cells expressing Emerald
The anti-RTA antibody was used diluted 1:500000 with control mouse IgG used at an 
equivalent concentration as an isotype control. The secondary antibody for indirect 
immunofluorescence was polyclonal goat anti-mouse IgG conjugated to 
allophycocyanin (BioLegend) used diluted 1:400.
2.5.6. Intracellular staining for ORF K8
The anti-K8 antibody (supernatant mouse mAb IgG a generous gift from Keiji Ueda) 
was used diluted 1:2000 with control mouse IgG (a generous gift from Stuart Neil) used 
at an equivalent concentration as an isotype control. The secondary antibody for 
indirect immunofluorescence was tetramethylrhodamine isothiocyanate (TRITC)- 
conjugated polyclonal rabbit anti-mouse IgG (DAKO R0270) used diluted 1:400.
2.5.7. Intracellular staining for ORF59
The anti-ORF59 antibody (purified mouse mAb IgG2b, Advanced Biotechnologies inc.) 
was diluted 1:100 with control mouse IgG2b (a generous gift from Stuart Neil) used at 
an equivalent concentration as an isotype control. The secondary antibody for indirect 
immunofluorescence was tetramethylrhodamine isothiocyanate (TRITC)-conjugated 
polyclonal rabbit anti-mouse IgG (DAKO R0270) used diluted 1:400.
2.6. Detecting virion-associated genome copies using quantitative PCR
2.6.1. Induction of lytic replication
JSC-1 cells and JSC-1 cells transduced with lentiviral vectors RP and EP were pelleted 
and resuspended at a density of 1x10s cells/ml or 5xl04 cells/ml in 10 ml in 15 ml 
falcon tubes. For time courses 300 pi was removed and used as the t=0 sample. TPA 
was added directly to the medium and cell mixture at a final concentration of 20 ng/ml 
(Sigma, dissolved in DMSO at 0.2 mg/ml). The TPA containing cell suspension was 
mixed thoroughly and then incubated for 1 hour at 37°C and 5% CO2 . The cells were 
then pelleted and resuspended in fresh medium and incubated at 37°C and 5% C02.
2.6.2. DNA extraction
300 pi of cells and culture medium was harvested. Cells were removed by 
centrifugation at 500 x g for 5 minutes and 200 pi of cell free supernatant was removed.
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To remove contaminating episomal DNA 1 pi of a 1M MgCl2 solution (Sigma) and 1 pi 
(10 units) of DNase 1 (Roche) was added to the cell free supernatant and incubated at 
37 °C for 1 hr. DNA was subsequently extracted using a QIAamp DNA mini kit 
(Qiagen) according to the manufacturer’s instructions.
2.6.3. Quantitative PCR ORF73 standards
A linearised DNA fragment, encoding KSHV ORF73 and H. sapiens Glyseraldehyde-3- 
phosphate dehydrogenase (a generous gift from Dimitra Bourboulia), at lx l08 copies/pl 
was serially diluted to form plasmid standards of lx l0 5, lxlO4, lx l03 and lx l02 
copies/pl. 10 pi was used of each of these standards giving a range of lx l06, lx l03 
copies to form the standard curves.
2.6.4. Quantitative PCR
Based on a protocol developed by Dimitra Bourboulia (Bourboulia et al., 2004) DNA 
oligonucleotides 9 and 10 were used to amplify KSHV ORF73 using the probe 5’-6- 
FAM-TCTTCTCAAAGGCCACCGCTTTCAAGTC-TAMRA-3 ’. A master mix was 
prepared in a plasmid/cDNA free environment using ABsolute™ QPCR ROX mix 
(ABgene). The master mix was prepared in the volumes listed below per well.
25 pi ABsolute™ QPCR ROX mix
3.5 pi primer 9(10 pM)
3.5 pi primer 10 (10 pM)
1.5 pi probe (5 pM)
6.5 pi H20
The master mix was vortexed for 10 s and transferred to ABgene Thermo-Fast® 96- 
well PCR plates (40 pl/well). The plate was then covered and moved out of the 
plasmid/cDNA free environment and 10 pl/well of plasmid standard, H20  control or 
extracted DNA was added. The plate was covered with an optical adhesive cover 
(ABgene). The PCR was executed using an ABI Prism 7000 (Applied Biosystems) 
using the standard hot start cycling parameters.
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1. 10 min 95 °C
2. 1 min 95 °C
3. 1 min 60 °C
4. Steps 2-3 an additional 39 times
2.6.5. Quantitative PCR data analysis
The data were analysed using ABI prism 7000 SDS software CTS 1.0 (Applied 
Biosystems). Using the standard curves in figures 2.6.5.1 and 2.6.5.2 absolute copies of 
ORF73 present in the PCR reaction could be generated. These values were then 
multiplied by 6 (elution volume from DNA extraction was 60 pi), and then multiplied 
by 5 (DNA was extracted from 200 pi of tissue culture supernatant) to give a value of 
copies/ml. All PCR reactions were carried out using triplicate repeat amplifications and 
the data were only accepted if no copies were detected in H2O controls or in DNA 
extractions from medium prior to contact with cells containing lx l06 copies of the 
ORF73 standard (indicating successful DNase treatment). In figure 4.2.4 A the copy 
number was then divided by the number of cells/ml determined using triplicate counts 
on a Neubauer improved haemocytometer to give a value of copies/cell
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Figure 2.6.5.1. Standard curve for figure 4.2.4 A.
Standard Curve for the  d a ta  p resen ted  in figure 4.2.4 A. R2 : 0.996981. G enerated  by ABI prism 
7000 SD S CTS 1.0.
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Figure 2.6.5.2. Standard curve for figure 4.2.4 B.
Standard Curve for th e  d a ta  p resen ted  in figure 4.2.4 B. R : 0.994255
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2.7. KSHV BAC36
2.7.1. BAC DNA extraction
KSHV BAC36 was a generous gift from S. J. Gao. Isolation of BAC DNA was 
achieved using a Plasmid Midi Kit (Qiagen) using the-user developed protocol 
(http://www 1 .qiagen.com/literature/protocols/pdf7QP01 .pdf). Bacteria were propagated 
using LB-agar plates or LB-broth containing 5 pg/ml chloramphenicol.
2.7.2. Establishing BAC36 producer HEK 293-T cell lines
2xl05 HEK 293-T cells were transfected as described above (2.5.2) using 1 pg of 
BAC36 DNA, 6 pi of FuGENE 6 (Roche) and 100 pi of Opti-MEM (Invitrogen). 48- 
hours posttransfection cells were trypsinised and transferred to 10 cm plates (Techno 
Plastic Products AG) and expanded in DMEM with 10% FCS and P/S supplemented 
with 200 pg/ml Hygromycin B changing the medium once every week. 4 weeks 
posttransfection, the medium was changed and replenished with fresh medium 
containing TPA at a final concentration of 20 ng/ml and incubated for 1 hour at 37°C 
and 10% CO2 . The medium was then removed and replaced with fresh, hygromycin 
free, medium and incubated at 37°C and 10% CO2 for 6 days. The KSHV BAC36 
containing supernatant was harvested, passed through a 0.45 pm filter and stored at -80 
°C in 1 ml aliquots.
KSHV BAC36 containing supernatant was thawed on ice and 15 pg of hexadimetrine 
bromide (polybrene, Sigma) was added and mixed thoroughly. 1 well of a 24-well plate 
(TPP) containing lx l0 5 HEK 293-T cells/well was infected through spinoculation at 
500 x g for 1 h at room temperature, using a Legend RT centrifuge (Sorvall), with 1ml 
of undiluted KSHV BAC36 containing supernatant containing 15 pg polybrene. 48- 
hours postinfection cells were trypsinised and transferred to 10 cm plates (TPP) and 
expanded in DMEM with 10% FCS and P/S supplemented with 200 pg/ml Hygromycin 
B changing the medium once every week. Two weeks postinfection 11 hygromycin 
resistant colonies were removed using a 2 ml pipette and propagated independently
2.7.3. Production and harvesting of infectious KSHV BAC36
lx l07 KSHV BAC36 infected HEK 293-T cells were seeded in 10 cm plates (TPP) and 
expanded in DMEM with 10% FCS and P/S supplemented with 200 pg/ml Hygromycin
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B. The following day, the medium was removed and replaced with medium containing 
TPA at a final concentration of 20 ng/ml and incubated for 1 hour at 37°C and 10% 
CO2 . The medium was then removed and replaced with fresh, hygromycin free, 
medium and incubated at 37°C and 10% CO2 . The KSHV BAC36 containing 
supernatant was harvested, passed through a 0.45 pm filter and stored at -80 °C in 1 or 
10 ml aliquots.
2.7.4. Titration of infectious KSHV BAC36
KSHV BAC36 containing supernatant was thawed on ice and 15 pg of hexadimetrine 
bromide (polybrene, Sigma) was added per ml of supernatant and mixed thoroughly. 
DMEM supplemented with 10% FCS and P/S was also mixed with polybrene and used 
as diluent. Several dilutions of each supernatant were prepared and 1 well of a 24-well 
plate (TPP) containing lxlO5 HEK 293-T cells/well was infected for each dilution 
through spinoculation at 500 x g for 1 h at room temperature, using a Legend RT 
centrifuge (Sorvall). 48-hours postinfection cells were trypsinised and transferred to 
sealed FACS tubes (Falcon). The cells were washed once in PBS, fixed in 3.3% 
formaldehyde (TAAB) for 10 minutes on ice before quenching with a 10-fold excess of 
PBS supplemented with 5% glycine (Sigma). The cells were pelleted and resuspended 
in PBS and the proportion of EGFP-positive cells was determined by flow cytometry. 
The percentage of GFP expressing cells was converted to infectious units by assuming a 
total of 2xl05 cells at the time of infection. Infectious units were plotted against pi of 
supernatant. The absolute titre of recombinant KSHV was determined by extrapolating 
the infectious units per ml (IU/ml) using the straight-line equation of the above plot.
2.8. Confocal microscopy
Images of GFP fluorescence were gathered using an Axiovert 100 TE microscope 
(Zeiss) and Lasersharp 2000 (Bio-Rad).
Imaging of HeLa Cl cells following transduction with GP was achieved by trypsinising 
puromycin resistant cells 144 hours post-transduction and re-seeding them on 
coverslips. 168 hours post-transduction, the medium was removed, cells fixed in 4% 
paraformaldehyde (Sigma) and quenched in PBS supplemented with 5% glycine 
(Sigma). Coverslips were washed twice in PBS and once in water before mounting on 
slides using mowiol (Sigma). Destabilised GFP expression was visualised through
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excitation with 488 nm light of the equivalent intensity for each sample. No image 
enhancement was used. HeLa cell images in figure 3.2.3 are magnified 20 times.
Imaging of live chondrocytes was achieved through replacing the growth medium with 
PBS. EGFP expression was visualised through excitation with 488 nm light of the 
equivalent intensity for each sample. No image enhancement was used. The 
chondrocyte images in figure 5.2.3 are magnified 40 times.
2.9. Determination of XBP1 splice status by RT-PCR
2.9.1. RNA extraction and DNase treatment
RNA was extracted using the TRIzol reagent (Invitrogen). In accordance with the 
manufacturer’s instructions. Briefly, 5xl06-lx l0 7 cells were lysed per ml of TRIzol 
reagent. The cell lysate was then incubated at 70 °C for 10 min prior to repeated 
chloroform extraction. The RNA was precipitated using isopropanol followed by 
washing of the pellet with 75% Ethanol. The pellet was air dried and resuspended in 
RNase free water prior to DNase treatment.
DNase treatment was executed using RQ1 RNase-free DNase (Promega) in accordance 
with the manufacturer’s instructions. Following treatment, the reaction was extracted 
twice using phenol:choloroform:isoamylalcohol (25:24:1) (Sigma). The RNA was then 
precipitated using 0.2 volumes of 8M Ammonium acetate (Sigma) and 2.5 volumes of 
95% ethanol. The pellet was then washed in 75% ethanol prior to air-drying and 
resuspension in RNase-free H2O.
2.9.2. cDNA synthesis
Reverse transcription reactions were carried out using Moloney murine leukaemia virus 
reverse transcriptase (M-MLV RT) Promega, in accordance with the manufacturer’s 
instructions.
2.9.3. XBP1 PCR, P st I digestion and resolution
PCR amplification across the XBP-1 atypical splice junction was achieved using 
oligonucleotides 13 and 14. The desired region was PCR-amplified using 5 units of Taq 
polymerase (Promega) in a 50 pi reaction volume buffered with Taq polymerase buffer
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A (Promega). PCR conditions involved 20-100 ng of template plasmid DNA or 2 pi of 
cDNA and 30 picomoles of each oligonucleotide primer. In addition, the reaction was 
supplemented with a final concentration of 0.2 mM dNTPs (Promega) and 1 mM MgCl2 
(Promega). The PCR was executed using the following cycle:
1. 30 Seconds at 95 °C
2. 30 seconds at 55 °C
3. 1 min at 72 °C
4. Steps 1-3 an additional 39 times
5. 2min at 72 °C
Following PCR amplification, 2 pi of H20  or 20 units of Pst I was added to each 
reaction, which was incubated overnight at 37 °C. 2 pi of 6X loading buffer
(Fermentas) was then added to 10 pi of each reaction and resolved using agarose gel 
electrophoresis. The best separation was achieved using pre-cooled 3 % TBE buffered 
agarose gels, pre-cooled to 4 °C. The gels were resolved at 5 volts/cm in room 
temperature TBE buffer diluted 1:1 with H20 .
2.9.4. DTT treatment of PEL cells
To induce an UPR, 5xl07 JSC-1 and BC-3 PEL cell lines were cultured in normal 
medium or medium containing 2 M DTT. Following treatment, RNA was extracted as 
described in section 2.9.1.
2.10. PCR-amplification and sequencing of the shRNA-50E target 
sequence
DNA was isolated from PEL cell lines using a QIAamp DNA mini kit (Qiagen) 
according to the manufacturer’s instructions. 20ng of DNA was used to PCR-amplify 
the target region of shRNA-50E using oligonucleotides 28 and 29 and the following 
PCR cycle.
120
1. 30 Seconds at 95 °C
2. 30 seconds at 55 °C
3. lm ina t72°C
6. Steps 1-3 an additional 29 times
7. 2min at 72 °C
The PCR-product was cloned using the pGEM-T-Easy kit (Promega) as described in 
section 2.1.6 and 6 positive clones from each cell line were sequenced as described in 
section 2.1.6.
2.11. Microarray analysis
2.11.1. RNA extraction
RNA was extracted as in section 2.9.1.
2.11.2. Labelling (performed by Dr Catherine Gale)
A direct incorporation method (CyScribe First-Strand cDNA Labelling Kit) was used 
(Amersham Biosciences, GE Healthcare). Specifically, 1 pi oligo(dT) and 3 pi KSHV- 
specific primers were added to 25 pg total RNA (TRNA) in a 0.5 ml PCR tube on ice. 
The reaction mixture was incubated at 70°C for 5 minutes followed by incubation at 
room temperature for 10 minutes. Subsequently, 4 pi of CyScript buffer, 2 pi 0.1M 
DTT, 1 pi dCTP nucleotide mix, 1 pi dCTP CyDye-labelled nucleotide and 1 pi 
CyScript reverse transcriptase were added to the reaction mixtures. These were then 
incubated at 42°C for 1.5 h. On all occasions, reference RNA (batched mixture of TPA- 
induced JSC-1 and HeLa TRNA) was labelled with Cy3 labelled nucleotide and 
experimental sample with Cy5. The RNA was then denatured by addition of 2.5 pi 0.5 
M EDTA (pH 8.0) and 10 pi 0.1 M NaOH and incubated at 70°C for 10 minutes, the 
reaction neutralised by addition of 10 pi 0.1 M HC1, 3 pi CoT-1 DNA (Gibco), and 450 
pi TE (pH 8.0). Labelled RNA was purified using a Microcon-100 filter and reduced to 
12 pi. The labelled RNA was immediately prepared for hybridisation.
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2.11.3. Hybridisation (performed by Dr Catherine Gale)
The Cy3 and Cy5 labelled probes were made up to 14 pi with TE (pH 8.0) and the 
hybridisation mixtures prepared as follows: 12 pi 20x SSPE (Sigma), 1.1 pi 0.5 M 
EDTA, 2 pi poly (IA40-60 (Pharmacia), 2 pi yeast tRNA (Sigma), 14 pi Cy3 probe, 14 pi 
Cy5 probe, and finally 1 pi 10% SDS. The mixture was vortexed and incubated at 98°C 
for 2 minutes followed by 37°C for 20 minutes. Subsequently lp l lOOx Denhardt’s 
solution (Sigma) was added to the probe mixture and centrifuged at 13,000 rpm for 15 
minutes at RT. Arrays previously printed in-house (a generous gift from C. Li) and 
baked at 70°C for 3+ hours to immobilise probes were blocked prior to hybridisation. 
Blocking solution consisted of an aqueous solution of 5x SSC, 0.1 % SDS, 0.05 % BSA 
and 0.05 % Milk. This was warmed to 50°C and passed through a 0.45 pm filter prior 
to blocking, which was achieved by first immersing the arrays in blocking solution for 
45 min at 50°C. Arrays were then rinsed twice thoroughly with purified water, 
incubated in water (95°C) for 2 min, and the first blocking procedure repeated. Arrays 
were rinsed a second time, soaked in isopropanol for 30 sec, then immediately dried by 
centrifugation at 350 x g for 2 minutes at room temperature. Arrays were then either 
stored in moisture-free environment for use within 4 hours, or were transferred directly 
to hybridisation chambers, preheated to 65 °C, and allowed to warm for 30 minutes. 
Glass cover slips were cleaned by immersion in 95% ethanol for 2 minutes and 
centrifugation at 350 x g for 2 minutes to dry. 46 pi of the probe was applied to the 
array by adding it to the glass coverslip, this was then applied to the pre-warmed array 
by gently lowering the array over the coverslip until capillary action adhered the two 
together and distributed the probe, with no need for application of pressure. The array 
was placed back into the hybridisation chamber and 150 pi 4x SSPE (65°C) added, the 
chamber lid was firmly secured and the assembly transferred to a 65°C water bath and 
incubated for 16 h.
After incubation the hybridisation chamber was dismantled at 65°C and the array 
carefully removed and immersed in 2x SSPE heated to 50°C. Once the coverslip had 
dissociated the array was immersed in fresh 2x SSPE for 2 minutes at RT (rolling), 
followed by lx  SSPE for 2 minutes and O.lx SSPE for 3 minutes. Subsequently, the 
array was transferred to a clean 50 ml Falcon tube and centrifuged at 350 x g for 2 
minutes to dry.
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2.11.4. Array scanning (performed by Dr Catherine Gale)
Arrays were scanned at 10 jam resolution using the GenePix 4000B array scanner (Axon 
instruments, Molecular Dynamics) and the images analysed using GenePix Pro 3.0 
software. Cy3 and Cy5 fluorophores were simultaneously excited at 532 nm and 635 
nm. A template was fitted over the array image using GenePix Pro 3.0. All the elements 
on each array were checked by eye and manually corrected where necessary. Data were 
extracted from the image by using the adjusted template and the normalisation factor 
(average ratio between signals in the Cy3 and Cy5 channels) calculated automatically 
by the GenePix software. Expression ratios were calculated as the median of the ratios 
between the local background-subtracted Cy3 and Cy5 signals on a pixel-by-pixel basis. 
The data were exported to a spreadsheet created in Excel. The median of ratios were 
filtered to remove flagged array elements and elements for which the signal to 
background ratio was below a stringent threshold in both Cy5 and Cy3 channels.
2.11.5. Array analysis
2.11.5.1. Cluster and treeview (performed by Dr Catherine Gale)
The final array data were analysed using Cluster software (Eisen et al., 1998). The 
program Cluster assembles a set of elements (genes or arrays) into a tree, where 
elements are joined by tree branches whose length is proportional to the distance 
(correlation coefficient) between the elements. Array elements for which expression 
measurements failed, the signal to noise ratio filter were removed and the data 
converted to log base 2. The arrays and genes were then median centred (the median 
expression ratio within each array or of each array element across all arrays was set to 
0). A self-organising map algorithm was then applied, in order to direct the orientation 
of nodes generated by hierarchical clustering. Genes and/or arrays were clustered by 
average-linkage hierarchical clustering and the results were visualised with the software 
Treeview.
2.11.5.2. Significance analysis of microarrays (performed by Dr Catherine Gale)
SAM (Significance Analysis of Microarrays) is a statistical technique for finding
significantly differently expressed genes in a set of microarray experiments (Tusher et 
al, 2001) and functions as a software package (written by B. Narasimhan) for Excel. 
The input to SAM is a gene expression matrix from a set of microarray experiments, as 
well as a response variable from each experiment. In the case of these experiments, the 
response variable is uninduced JCS-1 vs. TPA-treated JSC-1, IE-transduced, XBPUIG- 
transduced or XBPIG-transduced. By inputting normalised log2 ratios (>4 replicates
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for each array/response variable) SAM identifies genes with statistically significant 
changes in expression by assimilating a set of gene-specific T-tests. Each gene is 
assigned a score on the basis of its change in gene expression relative to the standard 
deviation of repeated measurements for that gene. Genes with scores greater than a 
threshold are deemed differentially expressed. The percentage of such genes identified 
by chance is calculated by a false discovery rate (FDR). To estimate the FDR, genes are 
randomly permuted in a form of bootstrapping. The FDR threshold can be adjusted to 
identify smaller or larger sets of genes. The FDR for these experiments was selected as 
5%.
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Chapter 3 
Results: Lentiviral vector-mediated RNAi
3.1. Generating a functional shRNA cassette
Although the use of lentiviral vectors to deliver shRNAs is now commonplace, when 
the work described in this chapter commenced such an approach had not been reported 
and no vectors were available. We wanted to use RNAi in PEL cell lines to study host- 
virus interactions. Because PEL cell lines are difficult to transfect, we wanted to 
modify lentiviral vectors to deliver shRNA expression cassettes capable of mediating 
RNAi.
3.1.1. pGemU61
To generate an shRNA vector-system capable of gene silencing in human cell lines we 
generated pGemU61 (Figure 2.2.1). This plasmid contains the human U6-promoter 
which was previously shown to express shRNAs and achieve gene silencing (Paul et 
al., 2002; Paddison et al., 2002). The U6-promoter was cloned from the human cell line 
HBL-6 and shares 100% sequence identity to nucleotides 1-267 of the human 116- 
promoter (accession number: X07425).
PGemU61 was designed to facilitate the insertion of shRNA coding sequences, whilst 
preserving the authentic sequence of the U6-promoter. To achieve this the restriction 
endonuclease recognition sites Sal I and Xba I were introduced downstream of the 116- 
promoter during PCR amplification (detailed in materials and methods). These sites 
allow insertion of synthetic oligonucleotide-derived sequences encoding shRNAs 
(Figure 3.1.1). The Sal I restriction site is downstream of the U6 transcription start site, 
potentially encoding transcribed nucleotides. We wished to generate a vector that did 
not encode superfluous sequence proximal to the shRNA duplex. To prevent undesired 
sequence, originating from the Sal I restriction site, from being expressed the 5’ 
overhang resulting from Sal I digestion can be removed by mung bean nuclease 
treatment, generating a blunt DNA end. Subsequent Xba I digestion generates an Xba I 
‘sticky end’ facilitating directional cloning of annealed oligonucleotides encoding 
shRNAs. The 5’ G is retained after mung bean nuclease treatment allowing DNA 
sequences to be inserted into pGemU61 encoding any desired RNA gene initiating with 
guanine.
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To avoid undesired sequence at the 3’ end of RNA transcribed from pGemU61, an RNA 
polymerase III termination sequence is inserted 5’ of the Xba I site in the shRNA 
oligonucleotides. This results in transcription termination prior to sequences encoded 
by the Xba I site. A second termination sequence (TTTTTT) is present in pGemU61 
downstream of the Xba I site to facilitate insertion of genes lacking a termination 
sequence.
A Transcription initiation  ►
5 ' -  GAAAGG ACGAAACAC CGT CGACGCTTCTCT AGATTTTTTATGCAT -  3 '
U6-promoter Sal I Xba I pGemU61
terminator
B
Transcription initiation 
 ►
5 ' -GAAAGGACGAAACACC GN NNNNNT TTTT C T AGATTTTTTATG CAT -  3
U6-promoter t t Xba
Expressed
sequence
RNA Pol III 
term inator
pGemU61
terminator
Figure 3.1.1. The context of transcription initiation in pGemU61
Diagrammatic represen ta tion  of pGemU61 before (A) and after (B) mung bean nuclease 
treatm ent and  addition of shRNA coding seq u en ce . Blue seq u e n ces  represent restriction 
endonuclease recognition sites  (or b a se s  derived from recognition sequences). S eq u en ces in 
bold-type rep resen t RNA polym erase III term ination seq u en ces .
3.1.2. Transient transfection of shRNA-GFP
To evaluate the activity pGemU61 we constructed pGemU61-RG. This plasmid 
encodes an shRNA targeting enhanced green fluorescent protein mRNA (Figure 3.1.2 
panel B). The target sequence was based upon a siRNA sequence known to silence 
hygromycin/EGFP fusion protein expression (Miyagishi and Taira, 2002). 
Cotransfection of the green fluorescent protein (GFP) expression vector 
pcDNA3. lEmerald (CMV-EmGFP) and pGemU61-RG in HEK 293-T cells resulted in 
a -60% reduction in Emerald GFP (EmGFP) positive cells relative to cells transfected
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Figure 3.1.2. RNAi with GFP expression in HEK 293-T cells.
A. Schem atic of th e  shRNA expression  ca sse tte . B. P robable structure and sequence of 
shRNA-GFP. C. HEK 293-T  cells w ere transiently transfected  with 0.5 pg of an EmGFP 
expression plasm id (i), 0 .5  pg of an  Em G FP expression plasmid and 2 pg of a plasmid 
containing th e  hum an U 6-prom oter (ii) or 0 .5 pg of an  Em GFP expression plasmid and 2 pg of a 
plasmid expressing  shRN A -G FP (pG em U 61-RG ) (iv). 48-hours post-transfection GFP 
expression w as a s s e s s e d ,  by flow cytom etry, and  H istogram s of FL1-H are  shown. D. 
Graphical rep resen ta tion  of the  h istogram s in C indicating the percen tage of GFP-positive cells 
48-hours post transfection.
127
with PCDNA3.1 Emerald and ‘empty’ pGemU61 (Figure 3.1.2). EmGFP is a GFP 
variant with humanised codon usage and 3 amino acid substitutions increasing the 
intensity of green fluorescence. Crucially, the target sequence of shRNA-GFP is 
present in both EGFP and EmGFP and the reduction of EmGFP fluorescence in the 
presence of shRNA-GFP should therefore represent a ‘knock down’ due to RNAi.
3.2. Lentiviral vector-mediated RNAi 
3.2.1. pGemU61 -LINKER
HEK 293-T cells can be efficiently transfected. To facilitate the introduction of 
shRNAs into a greater variety of cells, we generated pGemU61-LINKER (appendix I). 
Sequences encoding shRNAs can be inserted into pGEMU61-LINKER in an identical 
fashion to pGemU61. Multiple cloning sites flanking the U6-promoter and inserted 
gene potentially allow an shRNA expression cassette to be inserted into a variety of 
viral vectors. Viral vectors should facilitate the introduction of an shRNA cassette into 
cell lines infected with KSHV.
3.2.2. RNAi in HEK 293-T cells stably expressing dEGFP
To deliver the shRNA cassette we used a lentiviral vector-genome commonly used in 
our laboratory. This vector genome is encoded by the plasmid pHR’SINcSGW 
(Demaison et al., 2001), a generous gift from Adrian Thrasher. This SIN lentiviral 
vector encodes EmGFP driven by an internal spleen focus-forming virus (SFFV) LTR- 
promoter. To simplify measurements of the ‘knock down’ in GFP expression, a 
derivative of pHR’SINcSGW (from here on described as CSGW) expressing DsRed2 
was used to deliver the shRNA cassette. This vector encoded by pHR’SINcSRW (from 
here on described as CSRW) was a gift from Andrew Godfrey. The sequences 
encoding shRNA-GFP (figure 3.1.2) were inserted into pGemU61-LINKER and the 
resulting shRNA-GFP cassette was subsequently inserted into CSRW using Eco RI. 
This insertion can occur in 2 possible orientations generating two vector genomes GR1 
and GR2 (figure 3.2.1).
To evaluate the potential use of these vectors for gene silencing, we examined the 
ability of GR1 and GR2 to interfere with GFP expression in the cell line 293-T Cl. 
293-T Cl cells are a clonal cell line transduced with a lentiviral vector encoding
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ALTR/AU3cPPT SFFVRRE EmGFP WPRE
ii)CSRW LTR LTR/AU3cPPT SFFVRRE DsRed2 WPRE
iii) Bidirectional cloning
U6-promoter
shRNA-CFP shRNA coding sequence 
first inserted in pGemU61- 
LINKER
Insertion in CSRW can 
occur in two orientations
CSRW
LTR LTR/AU.3cPPT DsRed2SFFV WPRERRE
iv)GRl
LTR LTR/AU3cPPT DsRed2SFFV WPRERRE
v)GR2
shRNA
U6LTR LTR/AU3DsRed2 WPRESFFVcPPTRRE
shRNA
Figure 3.2.1. Lentiviral vector-mediated RNAi with GFP expression is both potent and 
independent of shRNA expression cassette orientation (continued overleaf).
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Figure 3.2.1. Lentiviral v ec to r-m ed ia ted  RNAi with GFP ex p re ss io n  is both poten t and 
independen t of shRNA e x p re s s io n  c a s s e t te  o rien ta tion .
A. Schematic representations of lentiviral vector-genomes of C SG W  (i), CSRW  (ii), GR1 (iv) 
and GR2 (v). The insertion of shRNA-GFP into C SR W  in two orientations is also summarised 
(III). The vector genomes contain a Long terminal repeat (LTR), retroviral packaging signal OP), 
Rev response element (RRE), central poly pyrimidine tract (cPPT), U6-promoter (U6) driven 
shRNA expression cassette (shRNA), internal spleen focus forming virus LTR (SFFV), coding 
sequence for DsRed2 (DsRed), coding sequence for Emerald GFP (EmGFP) Woodchuck 
hepatitis virus polypyrimidine rich element (W PRE) and a self inactivating LTR (LTR/A3) B. 
HEK 293-T C1 cells (ii) were infected with a MOI 10 of CSRW  (iii), GR1 (iv) or GR2 (v). 7 days 
post-infection GFP expression was assessed, by flow cytometry, and Histograms of FL1-H are 
shown using HEK 293-T  cells (i) as an indication of autofluorescence. C. A single histogram 
plot including all the traces from B. D. GFP expression was quantified for the different samples 
using the mean fluorescence intensities of the histograms in B.
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destabilised GFP (dEGFP), a generous gift from Andrew Godfrey. Destabilised GFP 
contains the degradation domain of mouse ornithine decarboxylase creating a GFP- 
variant with a half-life of approximately 2-hours in HEK 293 cells (Li et a l , 1998). 
Transduction of 293-T Cl cells with a MOI 10 of GR1 or GR2 vectors resulted in a 
~90% reduction in dEGFP expression whereas cells transduced with CSRW expressed 
normal levels of dEGFP (Figure 3.2.1). This reduction suggests that ‘knockdown’ of 
dEGFP expression and was efficient and independent of shRNA-cassette orientation. It 
is impossible to completely separate the emission spectra of EmGFP and DsRed2 using 
our flow cytometers (FACScan and LSR by Becton Dickinson). This could mean the 
data presented in figure 3.2.1 underestimates the level of ‘knock down’ mediated by 
shRNA-GFP.
3.2.3. RNAi using lentiviral vectors conferring resistance to puromycin
The ability of retroviral vectors to integrate into the host-cell genome makes lentiviral 
vectors potentially suitable for achieving sustained shRNA expression and silencing. 
To permit selection of cells transduced with shRNA expressing lentiviral vectors, we 
utilised pHR’SINcSPW (Besnier et al., 2002) a generous gift from Greg Towers. This 
plasmid encodes a lentiviral vector genome which expresses puromycin acetyl 
transferase (PAC), an enzyme conferring resistance to the antibiotic puromycin (Vara et 
al, 1986). We inserted the shRNA-GFP expression cassette into pHR’SINcSPW (from 
here on described as CSPW) generating the viral vector GP. This vector allows 
puromycin-selection of transduced cells and the lack of fluorescent transgenes in CSPW 
vectors makes them particularly amenable to subsequent fluorescent manipulation, of 
transduced cells, uncomplicated by the emission/absorption spectra of EmGFP/DsRed2.
The benefit of selecting transduced cells is illustrated in figure 3.2.1. To evaluate 
shRNA expression vectors derived from CSPW, we investigated their efficacy in 
silencing dEGFP expression in HeLa Cl cells. HeLa Cl cells are a clonal cell line 
expressing dEGFP generated through transduction of HeLa cells with a lentiviral vector 
encoding dEGFP (pHR’SINcSDW, a generous gift from A. Godfrey) and subsequent 
single cell cloning by limiting dilution.
Transduction of HeLa Cl cells with a lentiviral vector input equivalent to a MOI 10 on 
HEK 293-T cells resulted in a significant reduction in dEGFP expression (figure 3.2.2 
panel B). However histogram analysis of dEGFP expression of cells transduced with
GP (figure 3.2.2 panel A) reveals two populations o f cells, those similar to normal HeLa 
cells and those similar to HeLa Cl cells. It seems likely that silencing was effective in 
transduced cells but that lower infectivity of HeLa cells relative to HEK 293-T cells 
results in a non-transduced non-silenced population o f HeLa Cl cells. If this is correct, 
selecting transduced cells using puromycin should yield a single silenced population of 
cells.
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Figure 3.2.2. T ran sd u c tio n  of HeLa C1 ce lls w ith GP in th e  a b se n c e  of purom ycin 
selection.
A HeLa C1 cells (ii) were transduced with a viral vector input equivalent to a MOI 10 on HEK 
293-T cells of the lentiviral vector GP. 48-hours post-infection dEGFP expression was 
assessed, by flow cytometry. Overlaid histograms of HeLa cells (black), HeLa C1 cells (blue) 
and HeLa C1 cells transduced with GP (Red) are shown. B dEGFP expression was quantified 
for triplicate samples using the mean fluorescence intensities of the histograms in A. Error bars 
represent the standard error between triplicate samples.
3.2.4. RNAi in HeLa cells stably expressing dEGFP under puromycin 
selection
To assess the possibility that non-specific interference with gene expression caused by 
lentiviral vectors expressing shRNAs might result in the observed decrease in GFP 
expression, we generated shRNA LacZ (figure 3.2.3 panel A) This shRNA has no 
complementary target in human cells allowing any difference in silencing between 
shRNA-GFP and shRNA-LacZ to be attributed to shRNA sequence. In addition, in
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Figure 3.2.3. Lentiviral v ec to r-m ed ia ted  RNAi with GFP ex p ressio n  in HeLa cells is 
potent and shRNA s e q u e n c e  specific .
A. Sequence and proposed structure of shRNA-GFP and shRNA-LacZ. B HeLa C1 cells (ii) 
were transduced with a viral vector input equivalent to a MOI 10 on HEK 293-T cells of LP (iii) or 
GP (iv) viruses. 48-hours post-infection puromycin selection was applied. 7 days post-infection 
dEGFP expression was examined using confocal microscopy. Images displaying typical fields 
of transmission and green fluorescent channels are shown using HeLa cells (i) as an indication 
of autofluorescence. C As B except 7 days post-infection dEGFP expression was assessed, by 
flow cytometry. Histograms of HeLa cells (i) and HeLa transduced with GP (iv). The 
percentage of cells in the M1 population is indicated. D As C, histograms of FL1-H are shown 
using HeLa cells (i) as an indication of autofluorescence. E. dEGFP expression was quantified 
for the different samples using the mean fluorescence intensities of the histograms in D. Mock 
infection, of HeLa C1 cells, with lentiviral vector-free HEK 293-T supernatant is also shown. 
Error bars represent the standard error between triplicate samples.
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light of the dual populations present in HeLa Cl cells transduced with GP virus (figure 
3.2.2 A) we assessed the efficacy of GP and LP viral vectors at silencing dEGFP 
expression in HeLa Cl cells under puromycin selection. 48-hours post transduction 
puromycin was added to the culture medium. Cells were passaged normally in the 
presence of puromycin and analysed 7 days postinfection by which time non-transduced 
HeLa cells in the presence of puromycin were 0% viable (data not shown) indicating 
that all viable cells passaged in the presence of puromycin had been successfully 
transduced. Transduction of HeLa Cl cells with a lentiviral vector input equivalent to a 
MOI 10 on HEK 293-T cells and subsequent puromycin selection resulted in >80% 
‘knock down’ of dEGFP expression (figure 3.2.3). The effect of shRNA-GFP is potent 
enough that -35% of GP-transduced HeLa Cl cells fluoresce no brighter than normal 
HeLa cells (figure 3.2.3 panel C). Mock infections with viral vector-free HEK 293-T 
supernatant or transduction with shRNA-LacZ expressing vector (LP) resulted in small, 
similar decreases in dEGFP expression. As predicted, nearly all puromycin-selected 
shRNA-GFP expressing HeLa Cl cells form a single silenced population suggesting 
nearly all transduced cells exhibit a silenced phenotype. These data indicate that the 
‘knockdown’ is potent and specific in transduced cells. However, care must be taken to 
ensure efficient transduction or transduced cells must be selected to achieve silencing in 
a population of cells.
3.2.5. Successive Transduction and RNAi
To investigate whether shRNA expression was limiting in our system, we repeatedly 
transduced dEGFP-expressing cells, with different lentiviral vectors, to deliver multiple 
shRNA expression cassettes per cell. To analyse the affect of serial transduction of 
shRNA expressing lentiviral vectors on dEGFP expression, HEK 293-T Cl cells were 
transduced with a MOI 10 of LP or GP viral vectors on 3 occasions at 4-day intervals. 
The results of this investigation are shown in figure 3.2.4. The majority of dEGFP 
expression (-90%) is removed following initial transduction with the lentiviral vector 
GP. Subsequent transduction causes minimal further reduction in dEGFP expression. 
Interestingly, successive transduction with LP also reduces dEGFP expression. 
Histogram analysis of dEGFP expression suggests the decreased mean fluorescence 
intensities result from a reduction in dEGFP expression in the majority of cells, rather 
than transduction of cells not transduced in previous infections (data not shown). The 
observation that successive transduction by GP and LP lentiviral vectors decreases
135
dG
FP
 
ex
pr
es
sio
n 
(A
rbi
tra
ry 
un
its
)
dEGFP expression independent of shRNA sequence, suggests this reduction is not due 
to RNAi but some other non-specific process.
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Figure 3.2.4. S u c c e ss iv e  ro u n d s  o f lentiviral vec to r infection do not greatly enhance 
gene silencing.
293-T C1 cells (ii) were infected with a MOI 10 of GP (iii) or LP (iv) viruses on days 1, 5 and 9. 
On days 0, 4, 8 and 12 days post-infection GFP expression was assessed , by flow cytometry 
using HEK 293-T cells (i) a s  an indication of autofluorescence. GFP expression was quantified 
for the different sam ples using mean fluorescence intensities and these are displayed plotted 
against the time in days (x-axis).
3.2.5. Lentiviral vector-mediated RNAi in PEL cells
We wanted to develop an RNAi vector system that could be used to ‘knock down’ 
KSHV open reading frames (ORFs) to allow investigation of host-virus relationships. 
To evaluate the potential of this system in effecting RNAi in cells latently infected with 
KSHV we examined the activity of GP and LP vectors in the PEL cell line JSC-1 Cl.
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This dEGFP expressing clonal cell line was generated using pHR’SINcSDW-derived 
lentiviral vector in identical fashion to HeLa Cl cells. Surprisingly, shRNA-LacZ is 
extremely toxic in PEL-derived JSC-1 cells. Transduction of JSC-1, JSC-1 Cl or PEL 
derived BC-3 cells with an input equivalent to a MOI 5 on HEK 293-T cells results in 
>80% cell mortality 48-hours postinfection (adjudged by trypan blue exclusion, data not 
shown). Despite repeated attempts, we were unable to derive puromycin resistant JSC-1 
or JSC-1 Cl cultures using LP. BLAST searches of the human, KSHV or EBV 
genomes were unable to identify a complementary target for either strand of shRNA 
LacZ (data not shown). To circumvent the toxicity caused by shRNA LacZ we 
developed shRNA-DsRed (figure 3.2.5 panel A). This shRNA is targeted to the 
fluorescent protein DsRed2 and has no complementary target in human cells. This 
shRNA was developed in collaboration with Andrew Godfrey and inserted into CSPW 
generating the lentiviral vector RP. Transduction of JSC-1 and BC-3 cells with RP 
using an input equivalent to a MOI 10 on HEK 293-T cells showed no obvious signs of 
toxicity (data not shown). Although RP is used solely as a control in this thesis, 
shRNA-DsRed is an active shRNA effecting efficient knockdown of DsRed (Andrew 
Godfrey personal communication).
To evaluate the silencing activity of GP and RP vectors, JSC-1 Cl cells were transduced 
with an input equivalent to a MOI 10 on HEK 293-T cells. 48-hours postinfection JSC- 
1 cells were fixed and dEGFP expression analysed by flow cytometry. Transduction 
with the shRNA-GFP expressing vector GP resulted in >80% decrease in dEGFP 
expression (figure 3.2.5 panel C) relative to mock and RP transduced cells. The 
interference with dEGFP expression was specific to GP transduced cells suggesting the 
‘knock down’ was due to RNAi with gene expression.
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Figure 3.2.5. Lentiviral vector-mediated RNAi with GFP expression in KSHV positive 
JSC-1 cells.
A. A diagram m atic rep resen ta tion  of shRN A-D sRed. B. JSC-1 C1 cells (ii) w ere infected with a 
viral vector input equivalen t to a  MOI 10 on HEK 293-T cells of LP (iv) or GP (v) viruses. 48 h 
post-infection G FP ex p ressio n  w as  a s s e s s e d ,  by flow cytometry, and Histograms of FL1-H are 
shown using JSC-1 cells (i) a s  an  indication of autofluorescence. C. GFP expression was 
quantified for th e  different sam p les  using the  m ean fluorescence intensities of the histograms in 
A. A mock infection using HEK-293-T su p ern a tan t is also  included (histogram not shown). 
Error bars rep resen t th e  s tan d ard  error betw een  triplicate sam ples.
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Discussion I
3.3. Lentiviral vector-mediated RNAi
The aim of this work was to produce an, RNA polymerase III promoter driven, shRNA 
expression system capable of being delivered using lentiviral vectors and mediating 
RNAi. In all cell lines tested (HEK 293-T, HeLa and JSC-1) we were able to 
demonstrate the reduction of GFP expression mediated by shRNA-GFP. This reduction 
is specific to shRNA-GFP and is largely unaffected by shRNA-LacZ, shRNA-DsRed, or 
lentiviral vector transduction. The shRNA expression cassette is functional in either 
orientation within the lentiviral vector backbone. This suggests the proximity of the 
U6-promoter to the internal SFFV LTR promoter does not result in significant promoter 
interference and also facilitates simple cloning of the shRNA expression cassettes. 
These modified lentiviral vectors are capable of reducing their target gene expression by 
-80-90% in multiple cell lines. These vectors are also able to ‘knock down’ dEGFP 
expression in KSHV infected PEL cell lines indicating their potential utility in the 
‘knock down’ of KSHV open reading frames.
The magnitude of ‘knock down’ and the shRNA specificity of this response suggest that 
RNAi is the mechanism by which shRNA-GFP reduces EmGFP/dEGFP expression. 
However, some non-specific effects were observed. The shRNA-LacZ hairpin exhibits 
significant toxicity in PEL cell lines. We were unable to identify a complementary 
target for either strand of shRNA-LacZ and it is likely that shRNA-LacZ is either 
engaged in off-target interference with essential gene expression or is a potent activator 
of the interferon response. We believe it is the former because HeLa cells are capable 
of mounting an interferon response following transduction with lentiviral vectors 
expressing shRNAs (Bridge et al., 2003). However, shRNA LacZ showed no obvious 
signs of toxicity in HeLa cells. Alternatively, the increased toxicity in PEL cell lines 
could represent the differential downstream response of PEL cell lines and HeLa cells to 
dsRNA. The authentic context of U6 transcription initiation from pGemU61-LINKER, 
should however, make these shRNAs minimal inducers of an interferon response 
(Pebemard and Iggo, 2004). No other shRNA used in our laboratory has shown similar 
toxicity in JSC-1 cells.
Using lentiviral vectors to express shRNAs potentially allows sustained gene silencing. 
Puromycin selection of shRNA-GFP transduced HeLa Cl cells generates a single
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population of cells with respect to green fluorescence intensity (Figure 3.2.3 D), 
whereas non-selected cells have two distinct populations (figure 3.2.2 A). Assuming a 
single vector genome integration confers puromycin resistance, this suggests that a 
single vector genome integration is sufficient to mediate potent RNAi with dEGFP 
expression. The concentration dependence of off-target silencing and interferon 
induction suggest that minimising the viral-vector input should minimise non-specific 
effects whilst maintaining effective silencing.
There are currently many commercially available shRNA expression systems. 
However, when this work commenced lentiviral vector-mediated RNAi was an 
unpublished strategy, leading us to develop our own system. Fortuitously the authentic 
context of transcription initiation and >19 bp shRNA duplexes may enhance the 
specificity and magnitude of silencing achieved by our vectors (Pebemard and Iggo, 
2004; Siolas et al., 2005). Despite the multitude of alternative vector systems, the 
SFFV promoter is highly active in cells of a haematopoietic lineage (Demaison et al., 
2002) and CSGW derivatives can be produced to relatively high titres, making this 
system useful in cells such as stem cells and peripheral blood mononucleocytes which 
are otherwise difficult to manipulate. In the absence of a consensus concerning the best 
strategy for shRNA expression, these vectors continue to provide a useful tool for 
achieving sustained gene silencing (Ylinen et al., 2005).
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Chapter 4 
Results: RNAi with KSHV QRF50 Expression
4.1. Screening shRNAs
4.1.1. Screening shRNAs targeting KSHV ORF50
The previous chapter described potent interference with exogenous dEGFP expression 
in JSC-1 cells harbouring latent KSHV. To evaluate the utility of our lentiviral shRNA 
expression system, in interfering with viral gene expression, we targeted KSHV ORF50. 
KSHV ORF50 is necessary and sufficient to initiate the KSHV lytic replication cycle 
(Lukac et al., 1998) allowing the affect of shRNAs targeting ORF50 to be assessed in 
terms of their potency in reducing ORF50 expression and their affect on KSHV lytic 
replication. Reducing the expression of a well-characterised viral protein provides 
proof of principle that viral gene expression can be reduced and the phenotypic 
consequences observed using our lentiviral shRNA expression system.
No siRNAs or shRNAs targeting KSHV ORF50 have been described so 3 shRNAs were 
tested empirically for their activity in reducing KSHV RTA protein expression. The 
three shRNAs were targeted to different regions of ORF50 mRNA (indicated in figure
4.1.1 A/B) including the splice junction (shRNA-50SJ), the middle of the transcript 
(shRNA-50M) and one nearer the 3’ end of the transcript (shRNA-50E). These 
shRNAs are expressed from a CSPW background (section 3.2.3) and are encoded by the 
lentiviral vectors SJP, MP and EP respectively. JSC-1 cells were transduced with an 
input equivalent to a MOI 10 on HEK 293-T cells of SJP, MP, EP, RP and CSPW. 
Transduced cells were puromycin selected and 8-days postinfection the lytic cycle was 
induced through TPA treatment. 24-hours later cells were fixed, permeabilised and 
stained for KSHV RTA expression using a monoclonal antibody specific for KSHV 
RTA (Okuno et al., 2002), a generous gift from Keiji Ueda. Analysis of RTA 
expression by flow cytometry indicated that shRNA-DsRed (encoded by RP) and 
shRNA-50SJ (encoded by SJP) had little affect on KSHV RTA expression whereas 
shRNA-50M (encoded by MP) and shRNA-50E (encoded by EP) prevented RTA 
expression in approximately 70% or 80% of TPA induced JSC-1 cells respectively 
(figure 4.1.1 .C).
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Figure 4.1.1. Screening shRNAs targeting KSHV ORF50 (RTA).
A. Diagram show ing th e  position of s e q u e n c e s  targe ted  by shRNAs in ORF50 mRNA. The 
numbering co rresp o n d s to KSHV genom ic se q u e n c e  (gi: 18845965). B. Probable structure 
and seq u en ce  of shR N A s targeting  KSHV O R F50 (50SJ, 50M and  50E) and DsRed. C. JSC-1 
ceils w ere infected with lentiviral vec to rs  C SPW  (P), RP, S JP , MP and EP with an input 
equivalent to a  MOI 10 on HEK 293-T  cells. 2 d ay s  post-infection a  pure population of 
transduced  cells w as g e n e ra ted  through purom ycin selection. 8-days post-infection transduced 
and not transduced  JSC -1 cells w ere  trea ted  with TPA for 24 hours before being fixed and 
stained for RTA expression . Using flow cytom etry the  p ercen tag e  of RTA positive cells was 
calculated then  norm alised to the  p e rcen tag e  of RTA positive TPA induced JSC-1 cells 
(30.29%). N on-induced JSC -1 cells w ere  a lso  fixed and  stained  to give an indication of 
spon taneous lytic replication.
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4.2. Characterising shRNA-50E
4.2.1. shRNA-50E in distinct cell lines
Only 1 complete KSHV genome sequence exists (Accession: NC 003409) generated 
from KSHV DNA cloned from the PEL cell line BC-1 (Russo et al., 1996). The 
sequence variation of KSHV ORF50 has not been the subject of direct investigation. To 
confirm the presence of the most potent shRNA target sequence (shRNA-50E) in 
distinct cell lines harbouring KSHV of different subtypes, the target region was PCR- 
amplified, using oligonucleotides 28 and 29, from different cell lines and sequenced. 
The cell lines JSC-1, BC-3, BCP-1 and BCBL-1 were used for this analysis and are 
infected with KSHV subtypes C3/P, C3/P, Al/P and A3/P respectively (Zong et al., 
2002). An alignment of the shRNA-50E target region is displayed in figure 4.1.2 B 
indicating the invariant nature of the target sequence in all cell lines tested. To date we 
have no information regarding the target sequence in KSHV from the less common 
clades B and D.
Although fewer KSHV positive BC-3 cells enter the lytic cycle following TPA- 
treatment, analysis of shRNA-50E in JSC-1 and BC-3 cell lines indicates that 
approximately 80% of cells which would normally express RTA do not express 
detectable levels 24-hours postinduction (Figure 4.1.2). Rather than reducing the RTA 
protein levels in all RTA-positive cells, shRNA-50E blocks RTA expression in the 
majority of cells. The minority of cells expressing RTA, in the presence of shRNA- 
50E, do so at levels comparable to untreated cells (adjudged by the mean fluorescence 
intensity of RTA positive cells). The ability of KSHV RTA to auto-activate the KSHV 
ORF50 promoter (Deng et al., 2000) led us to consider the possibility that shRNA-50E 
delayed the positive-feedback effect of RTA, thereby delaying RTA expression. To 
examine this possibility, RTA expression was analysed over a 72-hour period.
4.2.2. Analysis of shRNA-50E over 72-hours in JSC-1 cells
JSC-1 cells were transduced with an input equivalent to a MOI 10 on HEK 293-T cells 
of SJP and EP. Transduced cells were puromycin selected and 8 days postinfection the 
lytic cycle was induced by TPA treatment for 1-hour, after which the cells were washed 
3 times in culture medium, and incubated for 3, 6, 12, 24, 48 and 72-hours. At each 
time point 3xl06 cells were fixed and stored at 4°C for subsequent analysis. After 72-
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Figure 4.1.2. R ep ro d u c ib le  lentiviral v ec to r-m ed ia ted  RNAi w ith RTA ex p ressio n  in 
d istinc t PEL cell lin es (co n tin u ed  overleaf).
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Figure 4.1.2. R ep ro d u c ib le  lentiviral v ec to r-m ed ia ted
R T A  e x p r e s s io n  
RNAi with RTA expression  in 
d istinc t PEL cell lines.
A. The region of KSHV DNA encoding shRNA-50E was PCR amplified from 4 PEL cell lines 
and the PCR product visualised by ethidium bromide stained agarose gel electrophoresis. B. A 
schematic representation of cloned and sequenced PCR products from A. * Indicates identical 
bases in all the PEL cell lines sampled. The shRNA target region is highlighted in red with the 
complementary region of shRNA-50E adjacent to it. C. A graphical representation of RTA 
expression in JSC-1 and BC-3 cells. Transduced and not transduced PEL cells were induced 
with TPA for 24-hours before being fixed and stained for RTA expression. The percentage of 
RTA positive cells was generated as in figure 4.1.1 and normalised to the percentage of RTA 
positive TPA treated PEL cells (JSC-1 32.67% , BC-3 10.28%). Transduced JSC-1 and BC-3 
cells were generated by the same method outlined in figure 4.1.1. Error bars represent the 
standard error between triplicate experiments. D. Typical histograms of RTA expression using 
JSC-1 cells and transduced JSC-1 cells generated in figure 4.1.1. E. Typical histograms of 
RTA expression in transduced and not transduced BC-3 cells.
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Figure 4.2.2. A na lysis  o f RTA e x p re s s io n  in shRNA ORF50 ex p re ss in g  cells.
A. JSC-1 cells transduced with the control lentiviral vector expressing shRNA-50SJ were 
treated with TPA to induce KSHV lytic replication. Cells were harvested at various time points, 
fixed and stained for RTA expression and histograms of RTA expression are shown. B. JSC-1 
cells transduced with a lentiviral vector expressing shRNA-50E were treated as in A and 
histograms of RTA expression are shown. C. The percentage of RTA positive cells analysed 
by flow cytometry was calculated at different time points for not transduced JSC-1 cells and 
cells transduced with shRNA expressing lentiviral vectors and is represented graphically. All 
JSC-1 cells were transduced and puromycin selected as described in figure 4.1.1.
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hours fixed cells were permeabilised and stained for RTA expression, the results of 
which are shown in figure 4.2.2.
The shRNA-50SJ expressing JSC-1 cells display a profile of TPA-induced RTA 
expression similar to normal JSC-1 cells, with a peak of RTA expression 24-hours post­
induction that decreased over time. It is clear that RNAi with RTA expression, 
mediated by shRNA-50E, does not result in a delay in maximal RTA expression. 
Indeed, the profile of RTA expression is similar to normal TPA-induced JSC-1 cells 
except that far fewer cells express RTA. Interestingly, maximal RTA expression is 
detected earlier in cells expressing shRNA-50E than in normal or control shRNA 
expressing cells. The apparent block in lytic induction is closer to 50% at these earlier 
time points.
4.2.3. Analysis of early lytic proteins
To confirm that prevention of RTA expression results in a block to the KSHV lytic 
cycle we analysed the expression of KSHV ORFK8 and ORF59. KSHV ORFK8 is a 
multiply spliced early gene encoding K-bZIP/RAP/K8a and potentially encoding K8p, 
and K8y proteins (Lin et al., 1999). The K-bZIP protein acts as a transcriptional 
repressor (Izumiya et al., 2003) and is also involved in KSHV DNA replication (Lin et 
ah, 2003a). Although K8 exons are included in immediate early transcripts KIE1, 2 and 
3, K-bZIP is only expressed from transcripts driven by the K8 promoter. Lytic cycle 
transcription from the K8 promoter is sensitive to cycloheximide but insensitive to PAA 
treatment (Lin et ah, 1999), designating K8 as a true early gene. KSHV ORF59 is an 
early-late gene encoding processivity factor 8 (PF-8), which is involved in KSHV DNA 
replication (Chan et ah, 1998; 2000). Lytic cycle transcription of ORF59 is sensitive to 
cycloheximide and partially sensitive to PAA treatment (Chan et ah, 1998), designating 
ORF59 as a partial-late (yl) gene.
Preventing RTA expression should prevent all early and late gene expression (Xu et ah, 
2005). The analysis of, the early genes, K-bZIP and PF-8 expression should indicate 
whether the KSHV lytic cycle has been faithfully blocked by shRNA-50E. To 
investigate this hypothesis we examined K-bZIP and PF-8 expression in JSC-1 cells.
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Figure 4.2.3. Expression of lytic proteins downstream of RTA is reduced by shRNA 50E 
(continued overleaf).
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Figure 4.2.3. Expression of lytic proteins downstream of RTA is reduced by shRNA 50E
JSC-1 cells transduced  or not transduced  with shRNA expressing  lentiviral vectors w ere treated 
with TPA to induce lytic replication. 48-hours post induction cells w ere fixed and stained for K- 
bZIP expression. A. H istogram s of K-bZIP expression. B. Graphical representation of K-bZIP 
expression norm alised using not transduced  TPA induced JSC-1 cells (20.6%). JSC-1 cells 
transduced  or not transduced  with shRNA expressing lentiviral vectors w ere treated  with TPA to 
induce lytic replication. 43-hours post induction cells w ere fixed and stained for PF-8 
expression. Error b a rs  rep resen t the standard  error betw een triplicate experim ents. C. 
H istogram s of PF-8 expression . D. Graphical representation  of PF-8 expression normalised 
using not transduced  TPA induced JSC-1 cells (20.3%). Error b ars  rep resen t the standard error 
betw een triplicate experim ents
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JSC-1 cells were transduced with an input equivalent to a MOI 10 on HEK 293-T cells 
of SJP and EP. Transduced cells were puromycin selected and 8 days postinfection the 
lytic cycle was induced by TPA treatment for 1-hour, after which the cells were washed 
3 times in culture medium, and incubated for either 48 or 42 hours. The time of 
maximal expression of K-bZIP and PF-8 expression has not been reported and these 
time points were chosen based on KSHV transcript abundance in JSC-1 cells (Jenner et 
al., 2001). Following incubation, cells were fixed, permeabilised and stained for K- 
bZIP or PF-8 and analysed by flow-cytometry. In accordance with figures 4.1.2 and
4.2.2 the number of TPA-induced cells expressing KSHV early gene products was 
reduced by approximately 75% in the presence of shRNA-50E. This reduction is 
similar to the reduction in cells expressing RTA in the presence of shRNA-50E and 
suggests that cells that are able to overcome the RNAi with ORF50 expression faithfully 
progress through the lytic cycle, whereas cells where RTA expression is blocked fail to 
enter the lytic cycle and do not express early lytic antigens. It is interesting to note that 
whilst the number of cells expressing PF-8 is reduced by shRNA-50E expression, the 
quantity of PF-8 per cell is increased by shRNA-50E expression. The average mean 
fluorescence intensity (MFI) of PF-8 positive shRNA-50E transduced cells is 32.49 
units, more than twice the average MFI of control shRNA transduced and non­
transduced cells, 15.04 and 15.51 units respectively. The reasons for this dysregulated 
PF-8 expression are not clear.
4.2.4. Analysis of virus production
To confirm that shRNA-50E blocks the entire KSHV lytic cycle, we investigated the 
affect of shRNA-50E on KSHV virus production. To achieve this we utilised a KSHV 
qPCR assay developed by Dimitra Bourboulia (Bourboulia et al., 2004). This assay 
utilises a FAM-TAMRA Taq Man probe to quantify the copy number of ORF73 DNA. 
To adapt this protocol to detect virion-associated DNA in tissue culture supernatants, 
viral DNA released from dead cells had to be removed prior to extraction of virion- 
associated DNA. This was achieved by DNase treatment of tissue culture supernatants 
as previously described (McKnight et al., 2001). Following DNase treatment, virion 
associated, DNase resistant DNA could be quantified by qPCR. To validate the DNase 
treatment, culture medium spiked with 5xl06 copies of ORF73 DNA was DNase treated 
and extracted in parallel with experimental samples to ensure efficient DNase treatment.
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F igure  4.2.4. shR N A  ORF50 re d u c e s  v iru s  p ro d u c tio n  from  TPA in d u ced  ce lls .
A. JSC-1 cells transduced with lentiviral vectors expressing shRNAs ORF50 E (EP) or DsRed 
(RP) and untreated JSC-1 s were seeded at 1x105 cells/ml and treated with TPA. At 0, 24, 48, 
72 and 96-hours postinduction DNA was extracted from samples of cell free DNase treated 
culture supernatants. The mean copy number of O RF73 was determined using real-time 
quantitative PCR and plotted as the number of copies per cell. Non-induced JSC-1 s were also 
analysed as a control. B. 5x104 JSC-1 cells transduced with lentiviral vectors expressing 
shRNAs O R F50 E (EP) or DsRed (RP) and untreated JSC-1 s were seeded in triplicate. The 
mean copy number of O R F73 was determined as in A for each replicate and plotted as ORF73  
copies/ml. Error bars represent the standard error between triplicate experiments. C. 1x107 
HEK 293-T  BAC36 clone 6 cells not infected, infected with a MOI 5 of EP or infected with a MOI 
5 of RP were treated with TPA to induce lytic replication. Supernatants were harvested, after 
72-hours, and used to spinoculate HEK 293-T  cells. 48-hours later the number of GFP-positive, 
BAC36 infected cells was assessed by flow-cytometry. The percentage of virus production is 
normalised to TPA-induced clone 6 cells (-1x103 infectious units per ml). Error bars represent 
the standard error between triplicate experiments. D representative dot plots of the data plotted 
in C.
JSC-1 cells were transduced with an input equivalent to a MOI 10 on HEK 293-T cells 
of RP and EP. Transduced cells were puromycin selected and 8 days postinfection the 
lytic cycle was induced by TPA treatment. Immediately following the addition of TPA, 
time zero samples were taken. 1-hour following the TPA-induction, cells were washed 
3 times in culture medium and incubated for 24, 48, 72 and 96-hours. Following 
incubation, cell free tissue culture supernatants were stored at -80°C for subsequent 
analysis. All supernatants were DNase treated and their DNA extracted in parallel. The 
number of viral DNA copies per ml was determined in triplicate for each time point and 
an average copy number was determined. Due to the affect of lentiviral vector 
transduction and TPA treatment on cell doubling times, this figure was adjusted for cell 
density and plotted as the number of ORF73 copies per cell (figure 4.2.4 A). To 
examine the reproducibility of this assay, the experiment was repeated in triplicate and 
ORF73 copy numbers were determined in triplicate for each experimental replicate 72- 
hours post TPA induction (figure 4.2.4 B).
The results of this investigation suggest that shRNA-50E does block TPA-induced 
KSHV production from JSC-1 cells. These data suggest that preventing KSHV ORF50 
expression with shRNA-50E prevents TPA-induced entry into the lytic cycle, 
preventing virus production. Those cells which overcome RNAi with ORF50 
expression and express RTA seem competent to complete the lytic cycle and produce 
KSHV virions. This accounts for the reduced levels of virion associated DNA 
generated by TPA-induced, EP transduced JSC-1 cells.
To confirm the qPCR data we investigated the affect of shRNA-50E on infectious 
recombinant KSHV production using clone 6 producer cells (described in chapter 5). 
Clone 6 producer cells are a clonal HEK-293-T derived cell line harbouring infectious 
recombinant KSHV BAC36 (Zhou et al., 2002). BAC36-infected cells express EGFP 
driven by the CMV IE promoter. Clone 6 producer cells were transduced with a MOI 5 
of RP and EP. Transduced cells were puromycin selected and 14 days postinfection, 
1x10 transduced and non-transduced cells were seeded in triplicate. 24-hours later the 
lytic cycle was induced by TPA treatment and 72-hours postinduction supernatants were 
harvested and spinoculated onto HEK 293-T cells to quantify BAC36 infection. 48- 
hours postinfection, HEK 293-T cells were fixed and EGFP-positive cells were 
quantified by flow cytometry. RNAi with ORF50 expression mediated by shRNA-50E
153
A B
o\
=313o<u
>
O
9*<
<y>
SJ1
SJ3
10“ 101
10° IO1 IO2 1 0 3 10 “
L  »
1 0 3 1 0 “ 10° IO1 IO2 1 0 3 10 4
RTA
c
35 i
<V- n >  &  »2> ^  O  ^  ^  ^  <S>
*§> <£ <£'<£' <$' & <§>' <$' & & <§?' <& ® <$ <§?' <$' <$' <9 <$' <§?'
Figure 4.2.5. Cionai analysis of shRNA ORF50.
A. Clonal lines of JSC-1 cells tran sd u ced  with the lentiviral vector S JP  w ere generated  by 
limiting dilution. 6 w eek s later th e  p e rcen tag e  of RTA-positive cells following treatm ent with 
TPA w as determ ined by flow cytom etry. B. H istogram s of RTA expression depicted in A. C. 
Clonal lines of JSC-1 cells tran sd u ced  with th e  lentiviral vector EP w ere generated  by limiting 
dilution. 6 w eeks later th e  p ercen tag e  of RTA-positive cells following treatm ent with TPA w as 
determ ined by flow cytom etry.
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reduced infectious recombinant KSHV production by approximately 90% (figure 4.2.4 
C). This effect is specific to shRNA-50E and suggests that shRNA-50E prevents RTA 
expression, preventing initiation of the lytic cycle resulting in decreased recombinant 
KSHV production.
4.2.5. Generation of stable knock down cell lines
To investigate the potential of our shRNA expression system to achieve sustained 
shRNA expression we generated clonal transduced cell lines by limiting dilution. JSC-1 
cells were transduced with an input equivalent to a MOI 10 on HEK 293-T cells of SJP 
and EP. Transduced cells were puromycin selected and 5 days postinfection single cell 
cultures were seeded. 4 weeks later, 4 SJP and 20 EP clonal populations were expanded 
and 7 weeks postinfection lytic induction was examined. The KSHV lytic cycle was 
induced through TPA treatment and 24-hours later cells were fixed, permeabilised and 
stained for KSHV RTA expression. RTA expression was analysed by flow cytometry 
and the results are displayed in figure 4.2.5. SJP transduced cell lines were no less 
responsive to TPA-induction of the KSHV lytic cycle than parental JSC-1 cells. 
Surprisingly, SJP transduced clonal lines tended to be more responsive to TPA- 
induction than parental JSC-1 cells, although it is difficult to generalise with so few 
clonal lines. Interestingly all 20 clonal lines transduced with EP were less responsive to 
TPA-induction of the lytic cycle than parental JSC-1 cells and some clonal lines such as 
50P-17 were barely responsive to TPA-induction. These data suggest that shRNA 
expression can be maintained for several weeks in vitro.
We are unsure whether the smaller number of SJP transduced clonal lines relative to EP 
transduced clonal lines is a biological phenomenon related to the different shRNAs or is 
a result of minor differences in the cell densities used to seed the cloning plates.
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Discussion II
4.3. shRNA ORF50 prevents entry into the KSHV lytic replication cycle
The aim of this work was to demonstrate the utility of lentiviral vector-mediated RNAi 
with KSHV gene expression. With this in mind, we targeted the well-characterised 
ORF50 mRNA and investigated the affect of RTA ‘knock down’ on KSHV lytic 
replication.
No rational shRNA design constraints existed when shRNAs 50SJ, 50M and 50E were 
designed. In the absence of clear constraints, shRNA target sequences, with 5’ guanine 
bases, were selected by eye. The potency of shRNAs targeting these regions was then 
tested empirically. Both shRNA 50M and shRNA 50 E were able to prevent RTA 
expression in approximately 80% of cells (figure 4.1.1). Crucially, this reduction was 
not seen with the control shRNA-DsRed suggesting this is a specific ‘knock down’ of 
KSHV RTA. The target sequence of shRNA 50 E was found to be invariant in all cell 
lines tested and accordingly shRNA 50E was active in both JSC-1 and BC-3 cell lines 
(figure 4.2.1). Interestingly, despite fewer BC-3 cells supporting KSHV lytic 
replication following TPA treatment, the proportion of cells prevented from entering the 
lytic cycle was strikingly similar (approximately 80%).
It is important when considering these data to remember that the reduced size of the 
population expressing RTA following TPA-treatment is not directly proportional to the 
level of ‘knock down’ mediated by shRNA-50E. To directly measure the ‘knock down’ 
in ORF50 expression, ORF50 transcript abundance would have to be analysed in the 
absence of RTA autoactivation. For example, quantitative RT-PCR of KSHV ORF50, 
following TPA treatment, in the presence of cycloheximide would indicate the level of 
‘knock down’ achieved by shRNA-50E. We have not determined the potency of 
shRNA-50E and have instead concentrated on the phenotypic effects of shRNA-50E 
treatment.
The possibility that shRNA-50E merely delayed rather than prevented the majority of 
cells entering the lytic cycle led us to examine RTA expression over time. RTA 
expression in JSC-1 cells expressing shRNA-50E has a similar expression profile to 
normal JSC-1 cells following TPA treatment (figure 4.2.2). These data indicate that 
shRNA-50E expression prevents the majority of cells from expressing RTA and
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entering the lytic cycle. It is likely that the ‘knock down’ in ORF50 expression prevents 
the expression of RTA and subsequent autoactivation of the ORF50 promoter. It is 
tempting to speculate that those cells in which RTA is expressed, at sufficient levels, 
following TPA treatment are able to overcome the reduction in expression mediated by 
shRNA-50E and increase ORF50 expression. This in turn could explain the slightly 
earlier peak in ORF50 expression (figure 4.2.2) in the minority of cells expressing RTA 
in the presence of shRNA-50E.
To confirm that prevention of ORF50 expression prevents entry into the lytic replication 
cycle, we analysed KSHV early protein expression (figure 4.2.3). The population of 
cells expressing K-bZIP and PF-8 was reduced by approximately 75%, very similar to 
the reduction observed in RTA expression in shRNA-50E expressing cells. Consistent 
with the accepted role of RTA, this suggests that gene expression downstream of RTA 
expression is blocked when RTA expression is prevented by shRNA-50E. Interestingly, 
the expression level of PF-8 seems to be increased in shRNA-50E expressing PF-8- 
positive cells (figure 4.2.3 panel C). This could represent a dysregulated KSHV gene 
expression programme in the presence of shRNA-50E, where RTA has escaped RNAi 
mediated by shRNA50E.
As expected, shRNA-50E reduces the number of DNase resistant genome copies of 
KSHV Produced by JSC-1 cells and the number of infectious units of BAC36 
(described in chapter 5) following TPA treatment (figure 4.2.4).
The generation of multiple clonal lines expressing shRNA-50E that exhibit a silenced 
phenotype (figure 4.2.5) indicates that shRNA expression can be sustained at effective 
concentrations for several weeks. Some latently infected JSC-1 cells expressing shRNA 
50E express RTA following TPA treatment. Similarly, a varying degree of cells 
respond to TPA induction in each clonal line.
The increased population of cells expressing RTA in SJP transduced clonal lines was 
unexpected. It would be interesting to investigate if this phenotype is common in clonal 
lines generated from non-transduced JSC-1 cells and is stable over multiple passages. 
Our lentiviral vector-mediated shRNA expression system has subsequently been used to 
generate stable clonal cell lines with reduced tripartite motif containing protein 5a 
(TRIM5a) (Ylinen et al., 2005).
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The hairpins shRNA-50SJ and shRNA-DsRed have been used interchangeably in this 
chapter. However, in light of experiments defining the asymmetric loading of the RISC 
(Schwarz et al., 2003; Khvorova et al., 2003), shRNA DsRed probably represents a 
more appropriate control, because it is appropriately incorporated into the RISC.
In summary, lentiviral vector-mediated RNAi with ORF50 expression can prevent the 
majority of cells in a population from expressing RTA. Consistent with the accepted 
role of KSHV RTA, the block is complete, preventing subsequent gene expression and 
virion production. Those cells able to overcome the shRNA-50E mediated silencing 
express RTA, initiate the lytic gene expression cascade and produce new virions. 
Prevention of lytic replication is the expected phenotype from shRNA-ORF50 
indicating our lentiviral vector-mediated shRNA expression system can be effective at 
interfering with viral gene expression.
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Chapter 5 
Results: KSHV BAC36 permissivitv in vitro
5.1. Generating BAC36 producer cells
5.1.1. BAC36
KSHV is a difficult virus to propagate in vitro and it was not until 1996 that the first cell 
culture system for KSHV propagation was reported (Renne et al., 1996b). These 
systems, involving KSHV from chemically induced PEL cell line culture supernatants, 
often require greater than 100-fold concentration to achieve substantial infection. More 
recently recombinant KSHV systems have been developed which can be produced at 
much higher titres (Zhou et al., 2002) and contain EGFP expression cassettes providing 
a surrogate marker of infection (Vieira et al., 2001; 2004; Zhou et al., 2002). KSHV 
BAC36, a generous gift from S. J. Gao, can be used to generate sufficient infectious 
virions that non-concentrated tissue culture supernatants can be used for infection 
assays (Zhou et al., 2002). This chapter describes the generation of our BAC36 
‘producer’ cell lines and an investigation into B-cell line permissivity in vitro. 
Although the term permissivity can be used to describe cells supporting lytic viral 
replication, because KSHV preferentially establishes a latent infection, this chapter uses 
the term permissivity solely to describe initial cellular infection.
5.1.2. Generating and screening BAC36 ‘producer’ cell lines
The generation of producer cell lines is described in chapter 2. The method used is 
briefly summarised below and in figure 5.1.2.1. BAC36 DNA was used to transfect 
HEK 293-T cells. Transfected cells were selected using Hygromycin B. Four weeks 
posttransfection the cells were treated with TPA to induce lytic replication. Six days 
later the tissue culture supernatant was harvested, supplemented with polybrene and 
used to spinoculate lxlO5 HEK-293-T cells. 48-hours later the infected cells were 
selected using Hygromycin B and two weeks postinfection 11 hygromycin resistant 
colonies were isolated and cultured independently.
To assess KSHV production, 5xl06 cells from each clonal line was seeded in a 10cm 
plate and treated with 20 ng/ml TPA for 1 hour. Six days later the medium was 
supplemented with 15 pg/ml polybrene and 1 ml was used to spinoculate 1x10s HEK-
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293-T cells. Spinoculation involves an inoculation of test supernatants under 
centrifugation (Forestell et al., 1996). The percentage of EGFP expressing cells was 
determined by flow cytometry and a graphical representation of the results is show in 
figure 5.1.2.2 A. Of the 11 clonal lines generated 4 produced substantial amounts of 
recombinant KSHV (clones 2,5,6 and 9). Clone 6 produced the most infectious virus 
and was selected as our recombinant KSHV producer cell line.
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Figure 5.1.2.1. Summary of the method used to generate BAC36 ‘producer’ ceil lines
Adapted from Zhou et al., 2002.
To optimise recombinant virus production the amount of infectious virus produced from 
clone 6 cells, plated at various densities, was assessed over time (figure 5.1.2.2 B). The 
greatest virus production occurred 72-hours postinduction with TPA at the highest 
tissue culture density tested (lxlO7 cells per 10cm plate). When spinoculated onto 
2xl05 HEK 293-T cells, supernatant from these conditions resulted in approximately 
4.5% infection. This is equivalent to approximately lxlO4 infectious units per ml.
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treatment with 20ng/ml TPA for 1 hour. 6-days postinduction supernatants were harvested, 
filtered, supplemented with 15 pg/ml polybrene and used to spinoculate 1x105 HEK 293-T cells. 
48-hours postinfection the HEK 293-T cells were fixed and the percentage of EGFP-positive 
cells was quantified by flow cytometry and is plotted in A. B. Clone 6 cells were seeded at 
various cell densities, induced as in A and the quantity of infectious recombinant KSHV 
assessed as in A for various time points postinduction. Clone 6 supernatant was used to infect 
1x105 HEK 293-T cells using various concentrations of polybrene in the presence or absence of 
spinoculation. 48-hours postinfection the HEK 293-T cells were fixed and the percentage of 
EGFP-positive cells was quantified by flow cytometry and is plotted in C.
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Using tissue culture supernatants from clone 6 cells plated at densities above lxlO7 did 
not further increase virus yield (data not shown).
To verify that 15 pg/ml polybrene and spinoculation at 500 x g for 1 hour increased 
recombinant KSHV infection, supernatant derived from clone 6 cells using the 
optimised conditions generated in figure 5.1.2.2 B was used to infect HEK 293-T cells 
using various concentrations of polybrene, with or without spinoculation (figure 5.1.2.2 
C). To investigate whether the recombinant KSHV-containing supernatant was stable 
over a single freeze-thaw cycle, supernatants were frozen and kept at -80°C overnight 
and subjected to identical analysis.
Recombinant KSHV infection is enhanced approximately 7-fold by spinoculation both 
in the presence and absence of polybrene. Polybrene also clearly enhances recombinant 
KSHV infection without spinoculation. Most of this enhancement occurs through 
addition of 2 (ig/ml polybrene and higher concentrations only marginally increase 
infection. The most infection (approximately 7% EGFP-positive cells) was achieved 
through combining spinoculation with polybrene suggesting our initial infection 
conditions were reasonably efficient. Reassuringly, recombinant KSHV seems stable 
over a single freeze thaw cycle, with frozen supernatants resulting in similar levels of 
infection to fresh supernatants.
5.2. KSHV BAC36 permissivity
5.2.1. BAC36 permissivity in B-cell lines
An apparently contradictory feature of KSHV-biology is that the latent reservoir of 
KSHV infection is most likely to be B-cells but B-cell lines are notoriously difficult to 
infect in vitro (Chen and Lagunoff, 2005; Bechtel et al., 2003; Blackboum et al., 2000b; 
Renne et al., 1998). The EBV negative Burkitt’s lymphoma derived cell line BJAB 
(Menezes et al., 1975) is the only B-cell line in which KSHV infection has been 
reported in vitro (Naranatt et a l, 2004; Gasperini et al., 2005). Since the only B-cell 
lines reported to be recalcitrant to KSHV infection were Burkitt’s lymphoma cell lines 
(Chen and Lagunoff, 2005; Bechtel et al., 2003; Blackboum et ah, 2000b; Renne et al., 
1998), we reasoned that B-cell lines derived from malignancies corresponding to 
different stages of B-cell development might resemble the in vivo target of KSHV 
infection more closely and may therefore be more efficiently infected in vitro.
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Figure 5.2.1.1. Recombinant KSHV permissivity in vitro.
A. A diagram m atic rep resen ta tion  of the B-cell lines u sed  in B indicating the  d isease  the cell line 
w as derived from an d  th e  developm ental s tag e  the  cell line rep resen ts  (Jenner et al., 2003). B 
the permissivity of B-cell lines to recom binant KSHV infection. 1x105 cells of each  cell line were 
spinoculated with an  input equivalent to a  MOI 0.1 on HEK 293-T cells. The susceptibility to 
infection is indicated (- no infection; + <1% EGFP positive cells; ++ >1% EGFP-positive cells ND 
not determ ined d u e  to su p ern a tan t toxicity). C As in B only a  panel of cell lines of non B-cell 
origin w as used . D rep resen ta tive  flow cytom etry dot plots of the positive cell lines from A. E. 
Graphical rep resen ta tion  of triplicate infections of the  cell lines susceptib le to infection in A. 
Error b ars  re p resen t th e  s tan d ard  error betw een  triplicate infections. F. Flow cytometry dot 
plots indicating efficient infection of primary hum an nasal chondrocytes spinoculated with an 
input equivalent to a  MOI 0.1 on HEK 293-T cells 48-hours postinfection. G. R epresentative 
confocal m icroscopy fields of chondrocyte infection. B-ALL - precursor B (acute) lymphoblastic 
leukaem ia; DLBCL -  diffuse large B-cell lym phoma (GC-like); BL -  Burkitt’s  lymphoma; HCL -  
hairy cell leukaem ia; HL -  classical Hodgkin’s  lymphoma (L-428); A-DLBCL-anaplastic diffuse 
large B-cell lym phom a; PEL - primary effusion lymphoma; MM -  multiple myeloma
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To investigate this possibility we assessed the permissivity of a panel of B-cell lines 
with gene expression profiles similar to different stages of B-cell development (Jenner 
et al., 2003), which are listed in figure 5.1.1.1 A. lxlO5 cells of each cell line were 
spinoculated with an input of KSHV equivalent to a MOI 0.1 on HEK 293-T cells. The 
inoculum was removed 6-hours postinfection and the cells were cultured normally. The 
cell lines were monitored daily for EGFP expression by UV-microscopy. Cell lines we 
considered to be infected, through UV-microscopic analysis, were analysed by flow- 
cytometry. Ten days postinfection all cell lines were analysed by flow-cytometry. The 
results of this analysis are summarised in figure 5.1.1.1 B.
Consistent with previous reports we found B-cell lines largely resistant to KSHV 
infection. However we did identify two cell lines that could be infected by recombinant 
KSHV. Both NCI H929 and DEL cell lines were infected at low levels with only 0.3% 
and 0.03% of cells respectively becoming EGFP-positive 48-hours postinfection. This 
makes NCI H929 and DEL cell lines approximately 15-fold and 150-fold less 
susceptible to recombinant KSHV infection than HEK 293-T cells respectively. We 
were unable to generate latently infected cultures using hygromycin selection (data not 
shown).
Interestingly, all PEL cell lines tested could be superinfected with recombinant KSHV. 
The BCP-1 cell line was more than 20-fold more susceptible to recombinant KSHV 
infection than JSC-1 and BC-3 cell lines.
5.2.2. BAC36 permissivity in a panel of cell lines
To further characterise recombinant KSHV infection in vitro, we assessed the ability of 
KSHV to infect a panel of cell lines commonly used in our laboratory. The results of 
this analysis are summarised in figure 5.1.1.1 C. Interestingly all adherent cell lines 
tested were susceptible to recombinant KSHV at levels similar to HEK 293-Ts. The 
only cell line less susceptible to recombinant KSHV infection was the non-adherent 
myeloid leukaemia cell line MUTZ-3 (Hu et al., 1996). Consistent with these data 
primary human nasal chondrocytes, a cell type commonly used in our laboratory 
(Hidvegi et al., 2005), were also susceptible to recombinant KSHV infection (figure
5.1.1.1 F and G).
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Discussion III
5.3. Recombinant KSHV permissivity in vitro
The aim of this work was to generate recombinant KSHV ‘producer’ cell lines for use in 
assays involving infectious virus. We successfully generated clone 6 ‘producer’ cells 
and these cells can produce enough infectious recombinant KSHV that unconcentrated 
supernatants can be used in infection assays.
The magnitude of infection with recombinant KSHV was greatly enhanced through 
spinoculation and the addition of polybrene. Spinoculation (Forestell et al., 1996) 
probably increases the rate of virion adsorption without removing the requirement of 
essential glycoproteins for fusion (Scanlan et al., 2005). This is probably achieved by 
depositing virions on the surface of target cells thus removing diffusion as a rate- 
limiting step in virus infection (O’Doherty et al., 2000). Polybrene also increases the 
rate of virion adsorption (Davis et al., 2002). Polybrene is a polycation and probably 
increases the rate of adsorption through ‘charge shielding’ virions from the polyanionic 
glycosaminoglycans at the cell surface (Davis et al., 2004).
Our investigation of permissivity identified two B-cell lines (NCI-H929 and DEL) 
which became EGFP-positive following infection with recombinant KSHV. It is 
important to consider that EGFP expression only indicates that the EGFP expression 
cassette has reached the nucleus of EGFP expressing cells. In this investigation no 
analysis of viral gene expression was undertaken and we cannot exclude the possibility 
that EGFP expression is not a faithful surrogate marker of infection. Indeed, even if the 
EGFP-positive cells represent genuine infectious events, the level of infection is low 
enough to suggest that these cells might be no more representative of the favoured B- 
cell target of KSHV infection than other B-cell lines. However, the level of B-cell line 
infection does seem to be biased towards later stages of B-cell development. It would 
be interesting to expand the panel of cells used to see if this relationship holds true.
Every adherent cell line tested was susceptible to recombinant KSHV infection. This 
was not an unexpected result in light of the ubiquitous expression of heparin sulphate 
and a3pl integrins. However the variation in species and lineage of these cell lines 
makes the recalcitrant nature of B-cell lines to recombinant KSHV even more
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intriguing. It is interesting to note that all the adherent cell lines examined where 
similarly susceptible to recombinant KSHV infection.
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Chapter 6
Results: XBP-1 and KSHV reactivation
6.1. XBP-1 in PEL cell lines
6.1.1. Identifying XBP-1 s by RT-PCR
PEL cell lines have a plasmablastic immunophenotype and gene expression profile 
(Jenner et al., 2003; Klein et al., 2003). Because the transcription factor XBP-1 is 
required for plasma cell differentiation we wanted to determine the splice status of 
XBP-1 mRNA. XBP-1 u is a ubiquitously expressed mRNA which is spliced under 
conditions of ER-stress. This splicing reaction, catalysed by IRE-1, results in the 
excision of a 26-nucleotide intron which generates XBP-ls mRNA (Calfon et al., 
2002). We adapted a murine XBP-1 PCR assay developed by Heather Harding (Calfon 
et al., 2002) and assessed the ability of our PCR assay to distinguish between XBP-ls 
andXBP-lu cDNA.
Oligonucleotides 13 and 14 were used as primers to amplify a region of cDNA spanning 
the cryptic XBP-1 intron. Using XBP-1 u as a template, this generates a 249 bp product 
that can be cleaved by Pst I digestion. Using XBP-ls as a template, PCR amplification 
generates a 223 bp product that is resistant to Pst I digestion (Figure 6.1.1 A). When 
both templates are used together, a third, Pst I resistant, product is apparent when 
visualised by agarose gel electrophoresis. This third band is resistant to Pst I digestion 
and migrates just below the 300 bp marker. To confirm that this third band was a 
hybrid between XBPlu and XBPls PCR products, the Pst I resistant band was excised, 
gel purified and sequenced. Analysis of sequence chromatograms indicate that the 
sequence of this band is XBP-1 until the 5’ splice site is reached. Five nucleotides into 
the intron it is clear that multiple templates are present in the sequencing reaction 
(Figure 6.1.1 C). The divergence is not apparent until 5 nucleotides into the intron 
because the first 5 nucleotides downstream of the intron are identical to the first 5 
nucleotides of the intron. Analysis of the 3’ sequence identifies dual Taq-derived A- 
overhangs, 26 nucleotides apart, the same length as the cryptic XBP-1 intron (Figure
6.1.1 D). These data confirm that the third band is a PCR-hybrid and that both Pst I 
resistant bands require the presence of XBP-ls for a template.
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Figure 6.1.1. XBP-1 RT-PCR
A. A diagrammatic representation of human XBP-1 mRNA. Nucleotides are numbered relative 
to translation initiation. The naturally occurring Pst I recognition sequence is indicated. B. PCR 
using cDNA tem plates of XBP-1 s  (pXBPIG) and XBP-1 u (pXBPUIG) as  templates. PCR 
products were incubated in the presence or absence of the restriction endonuclease Pst I prior 
to agarose gel-electrophoresis. Numbers indicate the length in base pairs of DNA standards. C 
Sequencing chrom atogram  of the gel-purified highest molecular weight band of PsM  digested 
PCR product using a mixture of pXBPIG and pXBPUIG as a template. The 5’ splice junction 
(497) and the beginning of divergent sequence  is indicated (*). D. As in C with the Taq-derived 
A-overhang from both PCR products highlighted (f) spaced by exactly 26 nucleotides.
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6.1.2. The XBP-1 splice status of PEL cell lines
To determine the XBP-1 spice status of a panel of PEL cell lines we used the PCR assay 
described in figure 6.1.1. RT-PCR amplification of RNA extracted from PEL cell lines 
indicated that XBP-ls was barely detectable in the PEL cell lines BC-3, BCBL-1, JSC-1 
and HBL-6 (Figure 6.1.2). However, we were easily able to detect XBP-ls in the 
Burkitt’s lymphoma-derived cell line Raji (Pulvertaft, 1964) and substantial amounts of 
XBP-ls in the plasma cell leukaemia cell line SK-MM-2 (Eton et al., 1989).
6.1.3. PEL cell lines are capable of generating XBP-1 s under conditions of 
ER-stress
The lack of XBP-ls in PEL cell lines, even relative to Raji cells which have a gene 
expression profile similar to germinal centre B-cells (Jenner et al., 2003), led us to 
investigate whether PEL cell lines were capable of splicing XBP-1 mRNA in response 
to ER-stress.
To this end, we artificially introduced ER-stress into JSC-1 and BC-3 cell lines by 
culturing them in the presence of Dithiothreitol (DTT). DTT is a potent inducer of the 
UPR which acts as a reducing agent inhibiting disulphide bond formation and correct 
protein folding. JSC-1 and BC-3 cells were cultured normally or in the presence of 2 M 
DTT for 1-hour prior to RNA extraction and cDNA synthesis. PCR amplification of 
XBP-1 using oligonucleotides 13 and 14 as primers led to the amplification of DNA 
resistant to Pst I digestion only from cDNA derived from cells treated with DTT. The 
Pst I resistant bands are more apparent than the XBP-1 u, Pst I sensitive, PCR product 
suggesting that the stress-induced splicing of XBP-1 u mRNA is efficient in PEL cell 
lines. The ability of PEL cell lines to splice XBP-lu mRNA in the presence of DTT 
indicates that the machinery required to sense ER-stress and the, IRE-1-mediated, XBP- 
1 splicing machinery are intact in these cell lines.
6.2. Exogenous expression of XBP-1 in PEL cell lines
6.2.1. IE, XBPIG and XBPUIG
To investigate the affect of XBP-ls expression on KSHV reactivation, we exogenously 
expressed XBP-ls in PEL cell lines. Because of the difficulty of transfecting PEL cell 
lines this was achieved using lentiviral vectors. All the vectors used in this chapter 
contain an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES)
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Figure 6.1.2. The XBP-1 sp lice s ta tu s  of PEL cell lines
A. RNA was extracted from a panel of PEL cell lines, Raji cells and SK-MM-2 cells. The RNA was used to synthesize cDNA using an oligo dT primer and used as a 
template in the XBP-1 PCR assay used in figure 5.1.2. PCR products were incubated in the presence or absence of the restriction endonuclease P st I prior to 
agarose gel-electrophoresis. XBP-1 u and XBP-1 s standards were also amplified. Numbers indicate the length in base pairs of DNA standards. B. XBP-1 PCR  
amplification using cDNA synthesis reactions with and without the addition of reverse transcriptase as templates.
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Figure 6.1.3. PEL cell lines are capable of generating  XBP-1 s  in re sp o n se  to  E R -stress
A. JSC-1 and BC-3 cells were cultured in the presence or absence of 2 M DTT. RNA was extracted and used to synthesize cDNA using an oligo dT primer. This 
cDNA was used as a template in the XBP-1 PCR assay used in figure 5.1.2. PCR products were incubated in the presence or absence of the restriction 
endonuclease P s t I prior to agarose gel-electrophoresis. XBP-1 u and XBP-1 s standards were also amplified. Numbers indicate the length in base pairs of DNA 
standards. B. XBP-1 PCR amplification using cDNA synthesis reactions without the addition of reverse transcriptase as templates.
which mediates translation o f an EmGFP cistron. The lentiviral vector genome plasmid 
pIE was a generous gift from Y. Ikeda and the lentiviral vector genome plasmids 
pXBPIG and pXBPUIG were produced by C. Tsantoulas, an MSc student under my 
supervision. IE is an ‘empty vector’ encoding only the IRES-EmGFP transcript. 
XBPIG and XBPUIG encode X BP-ls and XBP-lu cDNA cistrons upstream of the 
IRES respectively, and express XBP-1 and EmGFP following transduction. The IE, 
XBPIG and XBPUIG vector-genomes are summarised diagrammatically in figure 6.2.1.
A IE
LTR
B
C
IRES
RRE cPPT SFFV / EmGFP WPRE LTR/AU3
XBPIG
LTR 4* RRE cPPT S^ f V XBP-ls
IRES
EmGFP WPRE LTR/AU3
XBPUIG IRES
¥  RRE cPPT ^ XBP-lu EmGFP WPRE LTR/AU3
Figure 6.2.1. XBP-1 RT-PCR
A diagrammatic representation of IE (A), XBPIG (B) and XBPUIG (C) lentiviral vector-genomes. 
Long terminal repeat (LTR), retroviral packaging signal (4*), Rev response element (RRE), 
central poly pyrimidine tract (cPPT), internal spleen focus forming virus LTR (SFFV), coding 
sequence for XBP-1 (XBP-1 u/XBP-1s), internal ribosome entry site (IRES), coding sequence for 
Emerald GFP (Em GFP) Woodchuck hepatitis virus polypyrimidine rich element (WPRE) and a 
self inactivating LTR (LTR/AU3).
To confirm the expression and activity o f exogenously expressed XBP-1, JSC-1 cells 
were transduced with an input equivalent to a MOI 5 on HEK 293-T cells o f IE, XBPIG 
and XBPUIG vectors. X B P-ls expression results in the expansion o f the secretory 
apparatus, which can be quantified by flow cytometry using side scatter as a measure of 
cellular granularity (Shaffer et al., 2004). Although lentiviral vector transduction 
increases cellular granularity, transduction with XBPIG results in a greater than 60% 
increase in cell granularity. This substantial increase in side scatter suggests that XBP- 
ls  expression is leading to expansion o f the secretory apparatus.
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Figure 6.2.2. XBPIG tra n sd u c tio n  of JSC-1 cells re su lts  in ex p an sio n  of the  secre to ry  
ap p a ra tu s  an d  XBP-1 s  mRNA ex p re ss io n  (con tinued  overleaf).
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Figure 6.2.2. XBPIG transduction  of JSC-1 cells resu lts  in expansion  of th e  sec re to ry  ap p a ra tu s  and XBP-1 s  mRNA expression .
A. Side scatter histograms of JSC-1 cells, 48-hours post infection, transduced with an input equivalent to a MOI 5 of IE, XBPIG and XBPUIG lentiviral vectors or not 
transduced. B A graphical representation of the mean side scatter of the histograms in A. C. Dot-plots from the same samples depicted in A indicating EmGFP 
fluorescence and side scatter. D. RNA was extracted from the samples in A and used to synthesize cDNA using an oligo dT primer which was used as a template 
in the XBP-1 PCR assay used in figure 5.1.2. PCR amplification using cDNA synthesis reactions with and without the addition of reverse transcriptase as templates 
is shown. E. The PCR products shown in D were incubated in the presence or absence of the restriction endonuclease P s t  I prior to agarose gel-electrophoresis. 
XBP-1u and XBP-1 s standards were also amplified in D and E. Numbers indicate the length in base pairs of DNA standards.
RT-PCR analysis of transduced cells indicates that Pst-\ resistant DNA can be 
amplified from XBPIG transduced cells, confirming XBP-ls mRNA expression (figure
6.2.2.E). No amplification was seen using cDNA synthesis reactions without reverse 
transcriptase indicating the Pst I resistant bands result from cDNA amplification and not 
amplification from contaminating plasmid or lentiviral vector DNA (figure 6.2.2 E).
6.2.2. XBPIG transduction results in RTA expression
To investigate the affect of exogenous XBP-ls expression on KSHV reactivation, we 
transduced PEL cell lines with an input equivalent to a MOI 5 on HEK 293-T cells. 48- 
hours post-transduction cells were fixed, permeabilised and stained for KSHV RTA 
expression using a monoclonal antibody specific for KSHV RTA (Okuno et al., 2002), 
a generous gift from Keiji Ueda. TPA treated cells were also stained as a positive 
control for lytic replication. To allow time for vector penetration, reverse transcription 
integration and transgene expression, PEL cell lines were treated with TPA 24-hours 
post-transduction. Because of the wide emission spectrum of EmGFP we used an 
allophycocyanin (APC) conjugated secondary antibody to detect RTA expression. The 
excitation and emission spectra of APC and EmGFP are entirely separate (Craig and 
Carr, 1968) which facilitates the simultaneous measurement of RTA and EmGFP 
expression without a requirement for fluorescent compensation. Analysis of RTA 
expression by flow cytometry indicates that XBPIG transduction results in RTA 
expression (figure 6.2.3). This induction of RTA expression is not observed using the 
‘empty vector’ IE. Crucially, in XBPIG infected cultures only EmGFP expressing cells, 
transduced with XBPIG, express RTA indicating that induction of RTA expression only 
occurs in transduced cells. The level of RTA expression, as judged by the mean 
fluorescence intensity of RTA staining, is reduced in XBPIG transduced cells relative to 
TPA treated cells. The reasons for and the relevance of this difference are unclear.
6.2.3. XBP-1s expression in clone 6 cells increases recombinant virus 
production
To investigate whether RTA expression resulting from XBPIG transduction could 
initiate KSHV lytic replication, we assessed the ability of transfected pXBPIG to 
increase recombinant KSHV production.
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Figure 6.2.3. XBPIG tra n sd u c tio n  in d u ces  KSHV-RTA ex p ress io n  (continued  overleaf)
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Figure 6.2.3. XBPIG tra n sd u c tio n  in d u ces  KSHV-RTA ex p ressio n
A. 8x105 JSC-1 cells were transduced with an input equivalent to a MOI 5 of IE and XBPIG 
lentiviral vectors. 48-hours post-transduction, cells were fixed permeabilised and stained for 
RTA expression. Non-transduced cells and non-transduced cells treated with TPA for 24-hours 
were also stained as negative and positive controls respectively. B. As in A using BCP-1 cells. 
C. As in A using BC-3 cells. D a graphical representation of the dot plots in A, B and C. Error 
bars represent the standard error between triplicate experiments.
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Figure 6.2.4. pXBPIG tran sfec tio n  of c lone 6 cells in c re a se s  recom binan t KSHV 
production  (co n tin u ed  overleaf)
A. 1x107 clone 6 cells were seeded and transfected in triplicate with molar equivalents of plE 
(2.5 pg), pXBPIG (2.8 pg) and pCMV-RTA (1.7 pg). All transfections were made up to 2.8 pg 
using pBluescript II KS +. 24-hours posttransfection the medium was removed and replaced 
with fresh medium. 72-hours posttransfection the medium was removed, filtered, supplemented 
with 15 pg/ml polybrene and used to spinoculate 2x105HEK 293-T cells. 48-hours postinfection 
cells were fixed and the number of EGFP-positive cells quantified by flow cytometry. 
Representative dot-plots are shown. B. Graphical representation of the dot plots in A 
expressed as a percentage relative to pCMV-RTA (100%). Error bars represent the standard 
error between triplicate experiments. C. 2-fold serial dilution of recombinant KSHV containing 
supernatants from a single sample of the experiment in A repeated in triplicate. Error bars 
represent the standard error between triplicate repeats.
lxlO7 clone 6 cells were transfected in triplicate with molar equivalents of plE, 
pXBPIG and pCMV-RTA (a generous gift from A. Whitehouse). 24-hours later the 
media was replenished and the cells were incubated for a further 48-hours. Following 
incubation recombinant KSHV containing supernatants were filtered, supplemented 
with 15 pg/ml polybrene and used to spinoculate 2xl05 HEK 293-T cells. 48-hours 
postinfection the number of EGFP-positive cells was determined by flow cytometry. 
Transfection of clone 6 cells with pXBPIG resulted in a greater than 6-fold increase in 
recombinant KSHV production relative to nontransfected and pEE transfected controls
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(figure 6.2.4 A and B). This analysis was done using undiluted supernatants and a 2- 
fold dilution series of recombinant KSHV-containing supernatants is also shown 
indicating the same trend is observed at lower dilutions. The 6-fold increase using 
pXBPIG was less than approximately 10-fold increase observed for pCMV-RTA, but 
still represents a substantial increase in virus production (figure 6.2.4).
6.3. Gene expression profiling
6.3.1. Microarray analysis of KSHV transcripts
To investigate whether pXBPIG transduction causes lytic reactivation in JSC-1 cells, 
we used microarray analysis to assess global KSHV gene expression and a subset of 
host gene expression simultaneously on the same chip.
2.5x106 JSC-1 cells were transduced in triplicate with an input equivalent to a MOI 5 on 
HEK 293-T cells of IE, XBPUIG and XBPIG vectors. 6-hours post-transduction the 
cells were washed once and resuspended in fresh medium. 72-hours post-transduction, 
the cells were pelleted and resuspended in TRIzol reagent. Contemporary samples of 
non-transduced JSC-1 cells and JSC-1 cells treated with 20 ng TPA for 48-hours were 
also resuspended in TRIzol reagent. Total RNA was purified from all samples and the 
quality and quantity assessed using an Agilent bioanalyzer. From this, mRNA was 
labelled with Cy5 by RT-PCR using a custom primer set containing primers specific to 
every KSHV ORF (Jenner et al., 2001) in addition to oligo dT primer. Labelled cDNA 
was mixed with Cy3-labelled reference RNA and hybridised to the KSHV-human 
microarray. A common reference RNA mixture was used to enable comparison across 
the whole sample set. The cDNA labelling, array-hybridisation and scanning was 
performed by Dr Catherine Gale.
The data were examined by cluster analysis to identify patterns in the gene expression 
data and identify relationships between the samples. Both the genes and samples were 
ordered using a self-organising map algorithm, which acts to minimise the differences 
between adjacent nodes. This ordering was then used to control the orientation of the 
dendrogram nodes subsequently generated by hierarchical clustering (figure 6.3.1). 
This process distinguishes between the experimental conditions used, separating TPA 
treatment and XBPIG transduction, which induce KSHV lytic gene expression, from IE 
transduction and untreated cells which do not express substantial levels of lytic
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Figure 6.3.1. H ierarchical c lu ste rin g  of 15 sam p le s  and  a filtered s e t  of 108 genes.
Each column represents one sample and each row one gene. The dendrogram on the left 
represents the relationship between genes in terms of their expression pattern. Gene 
expression is shown as a pseudo-coloured representation of log(2) expression ratio with red 
being above and green below the row/column median level of expression (set to 0) as shown by 
the scale. The cDNA labelling, array hybridisation and scanning was performed by Dr 
Catherine Gale.
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transcripts. Interestingly, this analysis was unable to distinguish the gene expression 
profiles following IE transduction from the gene expression profiles of untreated JSC-1 
cells. This suggests that the affect of lentiviral vector-transduction has minimal 
influence on JSC-1 gene expression. In addition, XBPUIG transduced cells seem to 
have an intermediate phenotype with repeats 1 and 3 clustering with IE transduced and 
untreated cells but repeat 2 clustering with XBPIG-transduced and TP A-treated cells. 
Figure 6.3.1 shows the cluster of lytic viral genes most strongly upregulated in response 
to TPA-treatment and XBPIG-transduction.
6.3.2. Fold-regulation of KSHV transcripts
To assess the lytic cycle initiated by XBPIG, XBPUIG and TPA, we determined the 
fold-change in gene expression for each of the viral transcripts from the cluster in figure
6.3.1 relative to untreated JSC-1 cells and this data is shown in figure 6.3.2. With few 
exceptions, XBPIG transduced cells expressed the highest level of KSHV transcripts 
followed by TPA treated cells, followed by XBPUIG transduced cells followed by IE 
transduced cells. The fold-change trend of XBPUIG and XBPIG transduced cells are 
extremely similar, and both broadly follow the trend of TPA-induced JSC-1 cells.
A notable exception to this trend are ORFs 61-69, with the exception of ORF66, whose 
expression in TPA treated cells is more upregulated than in XBPIG transduced cells. It 
is unclear whether this represents differing gene expression programmes induced by 
TPA treatment and XBPIG transduction or whether it represents asynchrony between 
samples induced with TPA and samples induced by XBP-1 expression.
Reassuringly, with the exception of ORF74 (vGPCR), no KSHV transcripts were 
greater than 1-fold up or downregulated following IE transduction relative to untreated 
JSC-1 cells. This highlights the minimal affect of lentiviral vector-transduction on JSC- 
1 gene expression.
6.3.3. Significance analysis of microarray (SAM) analysis
To further quantify the affect of XBP-1 on JSC-1 gene expression, significance analysis 
of microarray (SAM) analysis was used on this data set. Because the author did not 
conduct SAM analysis, this data is not considered here. However, for
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Figure 6.3.2. Fold-change in KSHV tran sc rip t abu n d an ce
The fold change in KSHV gene expression from the data displayed in figure 6.3.1. Log(2) expression ratios for each gene are plotted relative to untreated JSC-1 
cells as a fold-change in transcript abundance. The genes are ordered with respect to increasing fold-change of TPA-treated JSC-1 cells. Error bars represent the 
standard error between triplicate repeats.
completeness, the method of SAM analysis is described in chapter 2 and the results of 
this analysis are included in appendix 1.
6.4. p50Redi reporter gene assays
6.4.1. p50Redi
To investigate whether transfected XBP-1 can result in transcriptional activation of the 
ORF50 promoter, we generated the p50Redi reporter gene assay. Although many 
reporter gene assays have already been described which involve the ORF50 promoter, 
none have been adapted for use by flow-cytometry and not all contain the ORF50 
intron.
Sequence analysis of the ORF50 promoter identified a putative XBP-1 binding site 
(Clauss et al., 1996) within the ORF50 promoter between nucleotides 71826 and 71840 
of the KSHV genome (Accession: NC 003409) depicted in figure 6.4.2. We therefore 
wanted to develop a reporter gene assay which maintained the intronic sequence and 
investigate whether the above sequence was an intronic enhancer element. Because our 
XBP-1 expression vectors also encode EmGFP we wanted to develop a flow-cytometry 
assay through which transfection efficiency could be monitored and ‘double positive’- 
cells quantified.
The ORF50 promoter, first exon, intron and the first 7 codons of the second exon were 
PCR amplified and inserted into pCMV-DsRed-Express (Clontech) in place of the 
HCMV immediate early promoter generating p50Redi. The DsRed-Express protein is a 
human codon optimised version of DsRed with increased solubility and reduced green 
fluorescence (Bevis and Glick, 2002). The reduced green fluorescence means that 
DsRed-Express fluorescence can easily be separated from EmGFP fluorescence by flow 
cytometry. A diagrammatic representation of the p50Redi reporter-cassette is shown in 
figure 6.4.1 A. The fusion protein between the N-terminus of RTA and DsRed-Express 
is from hereon referred to as RTA-Express.
To assess whether p50Redi (detailed in section 2.2.7) was transcriptionally activated by 
XBP-1 expression, HEK 293-T cells were cotransfected with p50Redi and twice the 
molar equivalent of plE, pXBPIG, pXBPUIG and pCMV-RTA (figure 6.4.1 C and D).
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Figure 6.4.1. A ctivation of p50Redi
A. A diagrammatic representation of the RTA-Express reporter-cassette. Oligos 15 and 16 are 
highlighted a s  well a s  a 12 amino acid linker between RTA and DsRed-Express encoded by the 
pCMV-DsRed-Express polylinker. Numbers correspond to the KSHV genomic sequence 
(Accession: NC_003409). B. PCR amplification across the splice junction of RTA-Express 
using cDNA synthesis reactions from 4x106 HEK 293-T cells, transfected with 1 pg of p50Redi 
and double the molar equivalent of pCMV-RTA or pXBPIG, with or without the addition of 
reverse transcriptase. C. 4x105 HEK 293-T cells were seeded  in triplicate and transfected with 
1 pg of p50Redi and double the molar equivalent of plE, pXBPUIG, pXBPIG, pCMV-RTA or a 
mixture of the above and m ade up to 3.8 pg with pBluescript II KS+ (Stratagene). DNA 
concentrations are listed in table 2.3.3.1. Density plots of EmGFP and RTA-Express expression 
48-hours post transfection are shown. D A graphical representation of the density plots in C, 
Error bars represent the standard error between triplicate experiments.
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Cotransfection with pXBPIG and p50Redi resulted in an approximately 4-fold increase 
in the percentage of cells expressing RTA-Express. This increase is similar to the 
approximately 6-fold increase in the percentage of cells expressing RTA-Express 
following cotransfection with pCMV-RTA. Crucially, cotransfection with plE or 
pXBPUIG does not result in increased RTA-express expression. Interestingly, only the 
cells expressing the most EmGFP following pXBPIG and p50Redi cotransfection 
express RTA-Express (figure 6.4.1 C). Because EmGFP expression is IRES-mediated, 
cells expressing more EmGFP, following pXBPIG transfection, probably express more 
XBP-ls suggesting that a threshold level of XBP-ls expression has to be attained before 
RTA-Express expression can be activated.
To confirm that stimulation of the p50Redi ORF50 promoter, following pXBPIG 
transfection and pCMV-RTA transfection, results in faithful transcription initiation and 
splicing we carried out RT-PCR amplification across the splice junction of RTA- 
Express (figure 6.4.1 B). A 297 bp amplicon specifically amplified from cDNA is 
readily amplified from HEK 293-T cells cotransfected with p50Redi and pCMV-RTA 
or pXBPIG indicating faithful transcription initiation and splicing of RTA-Express 
transcription from p50Redi.
Cotransfection of p50Redi, pCMV-RTA and either plE, pXBPUIG or pXBPIG in 1:1:1 
molar ratios indicates a possible synergy between XBP-1 and RTA in activating RTA- 
Express expression (figure 6.4.1 C and D). Both pXBPUIG and pXBPIG cotransfection 
with pCMV-RTA and p50Redi results in a greater percentage of RTA-Express 
expressing cells than the molar equivalent of pXBPIG, pXBPUIG or pCMV-RTA 
alone.
6.4.2. Mutation of a putative XBP-1 binding site
To investigate whether the putative XBP-1 binding site between nucleotides 71826 and 
71840 of the KSHV genome (Accession: NC 003409) is involved in pXBPIG
activation of RTA-Express expression we mutated the sequence, in the context of 
p50Redi, generating pMut50Redi (figure 6.4.2 B). Transfection of pXBPIG, using the 
conditions described in section 6.4.1, activated RTA-Express expression by 
approximately 5-fold from pMut50Redi suggesting this sequence is unimportant in 
activating RTA-Express expression from p50Redi.
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Figure 6.4.2. M utation of a  pu tative XBP-1 binding site  d o e s  not affect pXBPIG activation 
of R TA -Express e x p re ss io n  (con tinued  overleaf).
A. 4x105 HEK 293-T cells were seeded in triplicate and transfected with 1 pg of p50Redi or 
pMut50Redi and double the molar equivalent of plE, pXBPUIG, pXBPIG or pCMV-RTA, made 
up to 3.8 pg with pBluescript II KS+ (Stratagene). Density plots of EmGFP and RTA-Express 
expression 48-hours post transfection are shown. B. A diagrammatic representation of the 
putative XBP-1 binding site in the ORF50 intron. Nucleotides highlighted in red are identical to 
the XBP-1 consensus sequence defined in (Clauss e t  al., 1996); nucleotides highlighted in blue 
are mutated in pMut50Redi. The highlighted S a l I restriction site was used for screening. C. A 
graphical representation of the density plots in A. Error bars represent the standard error 
between triplicate repeats.
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6.4.3. Deletion analysis of the ORF50 promoter
To investigate the mechanism of pXBPIG activation of RTA-Express expression from 
p50Redi, we .made a series of deletion mutants to define the region of the ORF50 
promoter which is responsive to XBP-ls expression. These 9 plasmids, displayed 
diagrammatically in figure 6.4.3, are referred to as pA1760-pA3078 and contain 5’ 
deletions of the ORF50 promoter. Another plasmid pNoRedi is a ‘promoterless’ 
construct containing DsRed-Express and no KSHV-derived sequence.
Cotransfection of plasmids containing ORF50 promoter deletions with plE or pXBPIG 
indicates that pA2878 retains maximal promoter activity. This suggests that the 
sequences responding to pXBPIG transfection reside in the 200 bp preceding the 
initiation codon (71396-71596 of the KSHV genome, accession: NC 003409).
Reassuringly, minimal responsivity of pA3078 to cotransfection with pXBPIG was 
observed (Figure 6.4.3 C and D). This plasmid contains no ORF50 promoter sequence, 
but contains KSHV-derived sequence downstream of the initiation codon (nucleotide 
71596 of the KSHV genome, accession: NC-003409). Similarly, no response was 
observed using the ‘promoterless’ construct pNoRedi, supporting the hypothesis that the 
ORF50 promoter responsivity, to pXBPIG cotransfection, resides in the 200 bp 
preceding the initiation codon. The deletion-construct pA2962, deleted 3’ of the AP1- 
binding sequence, deletes nearly half of this region. A sharp decline in responsivity to 
pXBPIG cotransfection is observed with this deletion (Figure 6.4.3 C and D). However, 
as so many factors bind in this region it is difficult to determine the cause of this 
reduced responsivity. As some responsivity is maintained the reduction could be due to 
less activation in response to pXBPIG transfection or due to reduced coactivation from 
basal transcripion factors binding in this region.
193
Figure 
6.4.3. 
D
eletion 
analysis 
of the 
ORF50 
prom
oter (continued 
overleaf)
I
The percentage of EmGFP-positive 
cells which express RTA-Express
O
T 3 "a T 3 _a  'O 'a  "o  T3> > » » > >  £  
w rororo roro ro ->■ o0 ©000)^N)OS 73 
G) ■vl'vj "v l'v j —J CJ5 CD
oo ro oooo oooo c o o a
cd ai
>
D i
p50Redi
pA 1760
PA2078
PA2278
PA2478
plE pXBPIG
01%  33%
6 76%
10*
31.7*
10*824*
43.7%
Figure 6.4.3. D eletion a n a ly s is  of th e  ORF50 p rom oter (con tinued  overleaf)
plE
Dn
pXBPIG
p A2678
PA2878
■ 1% 63 5%
PA2962
pA3078
if - 1
pNoRedi
EmGFP
Figure 6.4.3. D eletion a n a ly s is  of the  ORF50 prom oter.
A. A diagrammatic representation of the ORF50 promoter. The RBP-Jk binding sites (Liang et 
al., 2003), Oct-1 binding sequence  (Sakakibara etal., 2001), C/EBPa binding sites (Wang etal., 
2003), SP1 binding site (Ye et al., 2005) and AP-1 binding site (Wang etal., 2004b) are shown. 
The two reported TATA boxes and transcription initiation sites at 71560 (Lukac etal., 1999) and 
71490 (Deng et al., 2000) are also highlighted. B. A diagrammatic representation of deleted 
ORF50 promoter used in pA1760-pA3078. C. 4x105 HEK 293-T cells were seeded  in triplicate 
and cotransfected with 1 pg of p50Redi, pNoRedi or a plasmid containing a 5’ deleted ORF50 
promoter (displayed in B) in addition to 2.8 pg of pXBPIG or 2.5 pg of plE and 0.3 pg of 
pBluescript II KS+ (Stratagene). DNA concentrations are listed in table2.3.3.2. D.
Representative density plots of the data in C.
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Discussion IV
6.5.1. The splice-status of XBP-1 in PEL cell lines
The aim of these experiments was to further characterise the stage of B-cell 
development that PEL represents and how this relates to the control of the viral lytic 
cycle. PEL-cells are most similar to plasmablasts (Jenner et al., 2003; Klein et al., 
2003) but the particular stage of terminal differentiation has not been fully 
characterised. PEL cells show a partial upregulation of genes expressed in the UPR 
(Jenner et al., 2003) and consistent with this express the cleaved 50 kDa form of ATF-6 
(Jenner et al., 2003). Despite the partial upregulation of the UPR, PEL cells do not 
secrete immunoglobulin. Indeed, many PEL cells do not express surface 
immunoglobulin (Nador et al., 1996). To further characterise the phenotype of PEL 
cells, we examined the splice status of XBP-1 in PEL.
Interestingly, PEL express XBP-lu but levels of XBP-ls are barely detectable by our 
RT-PCR assay (figure 6.1.2). In addition, it is clear that the machinery required to 
sense ER-stress and splice XBP-1 is functional in PEL cells. This is highlighted by the 
efficient generation of XBP-ls following DTT treatment and induction of an artificial 
ER-stress (figure 6.1.3). Taken together, these data suggest that PEL cells are capable 
of responding to ER-stress, but do not express a protein load required to generate a BiP 
dependent ER-stress. It would be interesting to corroborate these data with similar RT- 
PCR analysis of primary PEL cells.
The lack of XBP-ls expression is difficult to reconcile with the efficient cleavage of 
ATF-6 in these cells (Jenner et al., 2003). The processing of ATF-6 in the absence of 
IRE1 activation suggests that PEL cells represent a stage of plasma cell differentiation 
where expansion of the secretory apparatus has begun, but the increased protein load 
required to induce ER-stress has yet to arrive. Although apparently at odds with our 
current understanding of the UPR, this sequence of events has been described by Heck 
and colleagues (van Anken et al., 2003). In addition, ATF-6 is capable of being 
activated in a BiP independent fashion (Hong et al., 2004a) suggesting that selective 
activation of the UPR may be normal cellular process.
In light of these observations, it is tempting to speculate that an inability to upregulate 
immunoglobulin expression may be the ‘missing signal’ preventing terminal
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differentiation of PEL cells; ‘trapping’ them in a proliferating, plasmablastic state. 
Indeed, immunoglobulin secretion is never reported in PEL cells and many PELs do not 
express detectable levels of immunoglobulin (Nador et al., 1996; Matolcsy et al., 1998). 
In addition, PU.l expression is not detectable in PEL cell lines (Arguello et al., 2003). 
IRF4 heterodimerises with PU.l and binds to enhancers of the kappa and lambda light 
chains (Eisenbeis et al., 1995). The absence of PU.l potentially reduces IgL expression 
in PEL cells.
6.5.2. Overexpression of XBP-1 in PEL
The paucity of XBP-ls expression in PEL cell lines led us to consider that plasma cell 
differentiation and XBP-ls expression might initiate KSHV reactivation from latency. 
With this in mind, we examined the affect of the XBP-lu expression vector XBPUIG 
and the XBP-ls expression vector XBPIG on KSHV reactivation. Unfortunately, the 
data in section 6.3 is not presented in chronological order. Because of time constraints, 
generating a sequence validated XBPUIG clone took substantially longer than 
generating an XBPIG clone. XBPUIG was therefore not included in the experiments 
described in figures 6.2.3 and 6.2.4. In addition, a 52 kDa protein is detected 
exclusively in XBPIG-transduced PEL cells (B. Webb, personal communication).
We are confident that XBP-ls is expressed following transduction of XBPIG. 48-hours 
post-transduction, XBPIG transduced cells have increased granularity. This increase is 
attributed to an expansion of the secretory apparatus and is similar to the phenotype 
described Staudt and colleagues (Shaffer et al., 2004). Furthermore, XBP-ls transcript 
is readily detectable in XBPIG-transduced cells, but is largely absent from XBPUIG and 
IE-transduced controls (figure 6.2.2).
Interestingly, XBP-ls expression in PEL cells activates the KSHV lytic cycle. XBPIG- 
transduction of JSC-1, BCP-1 and BC-3 cell lines results in potent activation of RTA 
expression, an affect specific to transduced cells (as visualised by EmGFP expression). 
These three cell lines were chosen because they represent a broad spectrum of PEL cell 
lines encompassing EBV and KSHV dually infected JSC-1 cells (Cannon et al., 2000), 
EBV negative BCP-1 and BC-3 cells (Boshoff et al., 1998b; Arvanitakis et al., 1996) 
and BC-3 cells, which lack the point mutations indicative of SHM suggesting an extra- 
GC pathway of maturation (Matolcsy et al., 1998). Overexpressed XBP-ls is a potent 
activator of RTA-Expression in all three cell lines.
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To investigate whether XBP-ls expression activates the entire lytic cycle, we examined 
the ability of transfected pXBPIG to influence recombinant KSHV production from 
clone 6 cells (described in chapter 5). Transfection of clone 6 cells with pXBPIG 
resulted in a greater than 6-fold increase is virus production (figure 6.2.4). This 
observation suggests that XBP-ls can activate the entire KSHV lytic cycle, presumably 
through upregulating RTA expression. Similarly, gene expression profiling 
demonstrates that many lytic genes are turned on following transduction with XBPIG 
(6.3.1 and 6.3.2). Taken together these data indicate that overexpressed XBP-ls is a 
potent inducer of KSHV lytic replication.
Somewhat surprisingly, microarray analysis suggested that XBPUIG also activates the 
KSHV lytic cycle. In the absence of endogenous XBP-lu protein expression data in 
PEL cell lines, it is difficult to interpret this observation. Although it is clear that 
overexpressed XBP-lu activates the KSHV lytic cycle, whether endogenous XBP-lu 
protein is expressed in PEL cell lines is an open question. However, rapid turnover of 
XBP-lu has been proposed as a major regulatory mechanism of XBP-1 target gene 
expression (Tirosh et al., 2005b), and exogenous expression of XBP-lu may perturb 
this delicate balance. It is likely that the different gene expression profiles indicated in 
figures 6.3.1 and 6.3.2 represent different levels of lytic cycle induction. Comparing 
figures 6.3.2 and 6.2.3 suggests that fewer than 10% of cells express RTA following 
XBPUIG-transduction. In light of the microarray analysis described in figures 6.3.1 and
6.3.2 it would be interesting to repeat the experiments illustrated in figures 6.2.3 and 
6.2.4, to quantify the relative ability of XBPIG and XBPUIG to activate KSHV RTA 
expression and recombinant virus production.
However, despite the unexpected activity of overexpressed XBP-lu, it is clear that 
XBPUIG-transduction does not result in the same magnitude of KSHV lytic gene 
expression as TPA-treatment or XBPIG-transduction of JSC-1 cells. To further 
characterise the roles of XBP-lu and XBP-ls it would be interesting to investigate the 
ability of endogenous XBP-ls to activate KSHV RTA expression in response to ER- 
stress.
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6.5.3. p50Redi reporter gene assays
The aim of developing the p50Redi ORF50 reporter gene assay was to characterise how 
XBP-1 expression upregulates RTA expression. The ORF50 promoter in p50Redi is 
responsive to RTA expression and XBP-ls expression (figure 6.4.1). Interestingly, in 
cells transfected with pXBPIG, only cells expressing substantial levels of EmGFP are 
more likely to coexpress RTA-Express. Because EmGFP and XBP-ls are expressed 
from the same transcript, in pXBPIG-transfected cells, this suggests that a threshold of 
XBP-ls expression has to be attained before RTA-Express expression is activated. We 
are unable to directly compare the activation of RTA-Express expression by RTA and 
XBP-ls because they are expressed from different promoters in unrelated plasmid 
backgrounds.
Mutation of the putative XBP-1 binding site between nucleotides 71826 and 71840 of 
the KSHV genome (Accession: NC 003409) did not decrease the activation of RTA- 
Express expression mediated by XBP-ls (figure 6.4.2). In addition, XBP-ls is unable 
to activate RTA-Express expression from the pA3078 deletion of p50Redi. Taken 
together these data indicate that direct transactivation of RTA-Express expression, 
through XBP-1 binding to intronic sequences, in p50Redi, does not occur. To address 
which region of the RTA promoter responds to XBP-ls expression, we carried out 
deletion analysis of the p50Redi reporter plasmid. Interestingly, the 200 bp fragment of 
the ORF50 promoter, contained in pA2878, retained full responsivity to XBP-ls 
expression. It would be interesting to investigate whether XBP-ls and XBP-lu are 
capable of binding this DNA sequence directly. Understanding whether XBP-1 directly 
transactivates the ORF50 promoter or whether activation results from indirect 
interactions or downstream effects of XBP-1 over expression is central to understanding 
the role of XBP-1 in KSHV reactivation.
The synergistic activation of RTA-Express expression following cotransfection of 
pCMV-RTA with either pXBPUIG or pXBPIG is an interesting observation. Crucially, 
pXBPUIG transfection does not activate RTA-Express expression in the absence of 
pCMV-RTA (figure 6.4.1). However, cotransfection of pXBPUIG and pCMV-RTA 
resulted in greater activation of RTA-Express expression than the molar equivalents of 
pCMV-RTA or pXBPIG. In addition, this synergy is enhanced by cotransfection with 
pXBPIG in place of pXBPUIG. It would be interesting to investigate whether XBP-1
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and RTA interact with each other and whether such an interaction is involved in their 
synergistic activation of RTA-Express expression.
It is tempting to speculate that the ability of over expressed XBP-lu to synergise with 
RTA in activating the ORF5 0-promoter partially explains the observation that XBPUIG 
transduction weakly activates KSHV lytic gene expression. Although over expressed 
XBP-lu, alone, seems unable to activate the ORF50 promoter in transient transfection 
assays, in the context of the latently infected PEL cell XBP-lu overexpression activates 
viral lytic gene expression. The ability of XBP-lu to synergise with RTA may account 
for the increased viral lytic gene expression in these cells. However, it is difficult to 
reconcile this explanation with the supposed presence of endogenous XBP-lu in PEL.
In summary, PEL cell lines seem to be arrested at a stage of B-cell development where 
the UPR is partially activated, containing processed ATF-6 (Jenner et al., 2003) but 
lacking substantial levels of XBP-ls. This is analogous to an intermediate stage of 
plasma cell differentiation identified by Heck and colleagues (van Anken et al., 2003). 
We have shown that although PEL cells lack substantial amounts of XBP-ls, they retain 
the ability to splice XBP-1 in response to ER-stress.
Using reporter gene assays we have demonstrated that over expressed XBP-ls is 
capable of activating the ORF50 promoter. Furthermore, we have shown that 
overexpression of XBP-ls, in PEL cells, results in RTA expression and induction of 
multiple viral lytic genes. Although the experiments discussed in this chapter provide a 
tantalizing glimpse into the possible role of plasma cell differentiation, ER-stress and 
XBP-1 in KSHV reactivation; we are currently unsure how XBP-1 activates RTA 
expression. In addition, we are unable to resolve the respective roles of XBP-lu and 
XBP-ls in modulating RTA expression.
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Summary
This thesis describes the generation of an RNA polymerase III promoter driven, shRNA 
expression system capable of being delivered using lentiviral vectors and mediating 
RNAi. This strategy proved to be effective at attenuating GFP expression in a variety of 
cell lines. The ‘knock down’ of GFP expression was shRNA specific and these 
modified lentiviral vectors are capable of reducing their target gene expression by 
approximately 80-90% in multiple cell lines. These vectors are also capable of 
attenuating dEGFP expression in KSHV infected PEL cell lines indicating their 
potential utility in the ‘knock down’ of KSHV open reading frames.
As proof of principle that these vectors could be used to specifically interfere with 
KSHV gene expression, we targeted the well-characterised ORF50 mRNA and 
investigated the affect of RTA ‘knock down’ on KSHV lytic replication. We were able 
to prevent RTA expression in approximately 80% of cells. Crucially, this reduction was 
not seen with the control shRNA-DsRed suggesting this is a specific ‘knock down’ of 
KSHV RTA. Consistent with our current understanding of KSHV lytic replication, we 
observed a reduction in subsequent viral gene expression and virion production in cells 
expressing shRNA-50E. The potent specific interference with KSHV ORF50 
expression described in chapter 4 suggests that these vectors could be used to target less 
defined KSHV genes, and assist in their characterisation.
Because RTA expression is necessary and sufficient for induction of KSHV lytic 
replication, we wished to examine host-cell triggers for its initial expression. With this 
in mind, we examined the XBP-1 splice-status of PEL cell lines and investigated the 
affect of XBP-1 overexpression on KSHV lytic reactivation. Interestingly PEL cells 
have a partially activated UPR. ATF6 is processed in PEL cell lines (Jenner et al., 
2003), but XBP-ls expression is largely absent in PEL cell lines. Despite the paucity of 
XBP-ls in PEL cell lines, PEL cells retain the ability to splice XBP-1 in response to a 
chemically induced UPR, suggesting that PEL cells are lacking sufficient ER-stress to 
generate XBP-ls. In a developmental context this suggests that PEL cells represent 
plasmablasts arrested close to the plasma cell fate, lacking the physiological protein 
load required to splice XBP-1.
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Overexpressed XBP-1 is capable of activating the ORF50 promoter in transient 
transfection, reporter gene assays. When overexpressed in the context of latently 
infected PEL cells, XBP-ls efficiently induces RTA expression and subsequent 
initiation of the KSHV lytic cycle. Both overexpressed XBP-ls and XBP-1 u are 
capable of synergising with RTA in the activation of the ORF50 promoter in transient 
reporter gene assays. This could partially explain the KSHV lytic gene expression 
observed in PEL cells overexpressing XBP-lu. The experiments described highlight a 
possible role for XBP-1 and plasma cell differentiation in initiating KSHV reactivation. 
F'uture experiments must examine the ability of endogenous XBP-1 to activate the 
KSHV lytic cycle, define whether XBP-1 binds the ORF50 promoter directly and 
investigate the synergistic action of RTA and XBP-1.
203
Chapter 7
References
Abbas-Terki, T., Blanco-Bose, W., Deglon, N., Pralong, W., and Aebischer, P. (2002). 
Lentiviral-mediated RNA interference. Hum Gene Ther 13, 2197-2201.
Abbot, S. D., Rowe, M., Cadwallader, K., Ricksten, A., Gordon, J., Wang, F., Rymo, 
L., and Rickinson, A. B. (1990). Epstein-Barr vims nuclear antigen 2 induces 
expression of the vims-encoded latent membrane protein. J Virol 64, 2126-2134.
Ablashi, D. V., Chatlynne, L. G., Whitman, J. E., Jr., and Cesarman, E. (2002). 
Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. 
Clin Microbiol Rev 15, 439-464.
Adams, B., Dorfler, P., Aguzzi, A., Kozmik, Z., Urbanek, P., Maurer-Fogy, I., and 
Busslinger, M. (1992). Pax-5 encodes the transcription factor BSAP and is expressed in 
B lymphocytes, the developing CNS, and adult testis. Genes Dev 6, 1589-1607.
Akula, S. M., Naranatt, P. P., Walia, N. S., Wang, F. Z., Fegley, B., and Chandran, B.
(2003). Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of 
human fibroblast cells occurs through endocytosis. J Virol 77, 7978-7990.
Akula, S. M., Pramod, N. P., Wang, F. Z., and Chandran, B. (2002). Integrin 
alpha3betal (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated 
herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108, 407-419.
Akula, S. M., Wang, F. Z., Vieira, J., and Chandran, B. (2001). Human herpesvirus 8 
interaction with target cells involves heparan sulfate. Virology 282, 245-255.
Allman, D., Li, J., and Hardy, R. R. (1999). Commitment to the B lymphoid lineage 
occurs before DH-JH recombination. J Exp Med 189, 735-740.
Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350-355.
204
Ambroziak, J. A., Blackboum, D. J., Hemdier, B. G., Glogau, R. G., Gullett, J. H., 
McDonald, A. R., Lennette, E. T., and Levy, J. A. (1995). Herpes-like sequences in 
HIV-infected and uninfected Kaposi’s sarcoma patients. Science 268, 582-583.
An, J., Lichtenstein, A. K., Brent, G., and Rettig, M. B. (2002). The Kaposi sarcoma- 
associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the 
KSHV latency-associated nuclear antigen and the API response element. Blood 99, 
649-654.
Arguello, M., Sgarbanti, M., Hernandez, E., Mamane, Y., Sharma, S., Servant, M., Lin, 
R., and Hiscott, J. (2003). Disruption of the B-cell specific transcriptional program in 
HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22, 964-973.
Arpin, C., Banchereau, J., and Liu, Y. J. (1997). Memory B cells are biased towards 
terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med 186, 
931-940.
Arvanitakis, L., Mesri, E. A., Nador, R. G., Said, J. W., Asch, A. S., Knowles, D. M., 
and Cesarman, E. (1996). Establishment and characterization of a primary effusion 
(body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated 
herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88, 2648-2654.
Arvanitakis, L., Yaseen, N., and Sharma, S. (1995). Latent membrane protein-1 induces 
cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated 
growth inhibition in EBV-positive B cells. J Immunol 155, 1047-1056.
AuCoin, D. P., Colletti, K. S., Cei, S. A., Papouskova, I., Tarrant, M., and Pari, G. S.
(2004). Amplification of the Kaposi's sarcoma-associated herpesvirus/human 
herpesvirus 8 lytic origin of DNA replication is dependent upon a cis-acting AT-rich 
region and an ORF50 response element and the trans-acting factors ORF50 (K-Rta) and 
K8 (K-bZIP). Virology 318, 542-555.
205
AuCoin, D. P., Colletti, K. S., Xu, Y., Cei, S. A., and Pari, G. S. (2002). Kaposi's 
sarcoma-associated herpesvirus (human herpesvirus 8) contains two functional lytic 
origins of DNA replication. J Virol 76, 7890-7896.
Babcock, G. J., Decker, L. L., Freeman, R. B., and Thorley-Lawson, D. A. (1999). 
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, 
accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190, 567- 
576.
Babcock, G. J., Decker, L. L., Volk, M., and Thorley-Lawson, D. A. (1998). EBV 
persistence in memory B cells in vivo. Immunity 9, 395-404.
Baer, M., Nilsen, T. W., Costigan, C., and Altman, S. (1990). Structure and 
transcription of a human gene for HI RNA, the RNA component of human RNase P. 
Nucleic Acids Res 18, 97-103.
Baeten, J. M., Chohan, B. H., Lavreys, L., Rakwar, J. P., Ashley, R., Richardson, B. A., 
Mandaliya, K., Bwayo, J. J., and Kreiss, J. K. (2002). Correlates of human herpesvirus 8 
seropositivity among heterosexual men in Kenya. Aids 16, 2073-2078.
Ballestas, M. E., Chatis, P. A., and Kaye, K. M. (1999). Efficient persistence of 
extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. 
Science 284, 641-644.
Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J. P., van Kooten, C., Liu, 
Y. J., Rousset, F., and Saeland, S. (1994). The CD40 antigen and its ligand. Annu Rev 
Immunol 12, 881-922.
Bannister, A. J., and Kouzarides, T. (1996). The CBP co-activator is a histone 
acetyltransferase. Nature 384, 641-643.
Barat, C., Lullien, V., Schatz, O., Keith, G., Nugeyre, M. T., Gruninger-Leitch, F., 
Barre-Sinoussi, F., LeGrice, S. F., and Darlix, J. L. (1989). HIV-1 reverse transcriptase 
specifically interacts with the anticodon domain of its cognate primer tRNA. Embo J 8, 
3279-3285.
206
Barbey, S., Gogusev, J., Mouly, H., Le Pelletier, O., Smith, W., Richard, S., Soulie, J., 
and Nezelof, C. (1990). DEL cell line: a "malignant histiocytosis" CD30+ 
t(5;6)(q35;p21) cell line. Int J Cancer 45, 546-553.
Barozzi, P., Luppi, M., Facchetti, F., Mecucci, C., Alu, M., Sarid, R., Rasini, V., 
Ravazzini, L., Rossi, E., Festa, S., et al. (2003). Post-transplant Kaposi sarcoma 
originates from the seeding of donor-derived progenitors. Nat Med 9, 554-561.
Bastian, F. O., Rabson, A. S., Yee, C. L., and Tralka, T. S. (1972). Herpesvirus hominis: 
isolation from human trigeminal ganglion. Science 178, 306-307.
Batista, F. D., Iber, D., and Neuberger, M. S. (2001). B cells acquire antigen from target 
cells after synapse formation. Nature 411, 489-494.
Bechtel, J., Grundhoff, A., and Ganem, D. (2005a). RNAs in the virion of Kaposi’s 
sarcoma-associated herpesvirus. J Virol 79,10138-10146.
Bechtel, J. T., Liang, Y., Hvidding, J., and Ganem, D. (2003). Host range of Kaposi's 
sarcoma-associated herpesvirus in cultured cells. J Virol 77, 6474-6481.
Bechtel, J. T., Winant, R. C., and Ganem, D. (2005b). Host and viral proteins in the 
virion of Kaposi's sarcoma-associated herpesvirus. J Virol 79,4952-4964.
Benner, R., van Oudenaren, A., and de Ruiter, H. (1977). B memory cells in the thymus: 
part of the pool of potentially circulating memory cells. J Immunol 119, 1846-1848.
Beral, V., Peterman, T. A., Berkelman, R. L., and Jaffe, H. W. (1990). Kaposi's sarcoma 
among persons with AIDS: a sexually transmitted infection? Lancet 335, 123-128.
Berek, C., Berger, A., and Apel, M. (1991). Maturation of the immune response in 
germinal centers. Cell 67, 1121-1129.
Bereshchenko, O. R., Gu, W., and Dalla-Favera, R. (2002). Acetylation inactivates the 
transcriptional repressor BCL6. Nat Genet 32, 606-613.
207
Bemasconi, N. L., Onai, N., and Lanzavecchia, A. (2003). A role for Toll-like receptors 
in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and 
constitutive expression in memory B cells. Blood 101, 4500-4504.
Bemasconi, N. L., Traggiai, E., and Lanzavecchia, A. (2002). Maintenance of 
serological memory by polyclonal activation of human memory B cells. Science 298, 
2199-2202.
Bernstein, E., and Allis, C. D. (2005). RNA meets chromatin. Genes Dev 19, 1635- 
1655.
Bernstein, E., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001). Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366.
Bernstein, E., Kim, S. Y., Carmell, M. A., Murchison, E. P., Alcom, H., Li, M. Z., 
Mills, A. A., Elledge, S. J., Anderson, K. V., and Hannon, G. J. (2003). Dicer is 
essential for mouse development. Nat Genet 35, 215-217.
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., and Ron, D. (2000). 
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. 
Nat Cell Biol 2, 326-332.
Besnier, C., Takeuchi, Y., and Towers, G. (2002). Restriction of lentivirus in monkeys. 
Proc Natl Acad Sci U S A 99, 11920-11925.
Bevis, B. J., and Glick, B. S. (2002). Rapidly maturing variants of the Discosoma red 
fluorescent protein (DsRed). Nat Biotechnol 20, 83-87.
Bhat, N. M., Kantor, A. B., Bieber, M. M., Stall, A. M., Herzenberg, L. A., and Teng, 
N. N. (1992). The ontogeny and functional characteristics of human B-l (CD5+ B) 
cells. Int Immunol 4, 243-252.
208
Birkmann, A., Mahr, K., Ensser, A., Yaguboglu, S., Titgemeyer, F., Fleckenstein, B., 
and Neipel, F. (2001). Cell surface heparan sulfate is a receptor for human herpesvirus 8 
and interacts with envelope glycoprotein K8.1. J Virol 75,11583-11593.
Bishop, G. A., and Hostager, B. S. (2001). B lymphocyte activation by contact-mediated 
interactions with T lymphocytes. Curr Opin Immunol 13, 278-285.
Blackboum, D. J., Fujimura, S., Kutzkey, T., and Levy, J. A. (2000a). Induction of 
human herpesvirus-8 gene expression by recombinant interferon gamma. Aids 14, 98- 
99.
Blackboum, D. J., Lennette, E., Klencke, B., Moses, A., Chandran, B., Weinstein, M., 
Glogau, R. G., Witte, M. H., Way, D. L., Kutzkey, T., et al. (2000b). The restricted 
cellular host range of human herpesvirus 8. Aids 14, 1123-1133.
Blaheta, R. A., Michaelis, M., Driever, P. H., and Cinatl, J., Jr. (2005). Evolving 
anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res 
Rev 25, 383-397.
Blasig, C., Zietz, C., Haar, B., Neipel, F., Esser, S., Brockmeyer, N. H., Tschachler, E., 
Colombini, S., Ensoli, B., and Sturzl, M. (1997). Monocytes in Kaposi’s sarcoma lesions 
are productively infected by human herpesvirus 8. J Virol 71, 7963-7968.
Bleesing, J. J., and Fleisher, T. A. (2003). Human B cells express a CD45 isoform that 
is similar to murine B220 and is downregulated with acquisition of the memory B-cell 
marker CD27. Cytometry B Clin Cytom 51, 1-8.
Blink, E. J., Light, A., Kallies, A., Nutt, S. L., Hodgkin, P. D., and Tarlinton, D. M.
(2005). Early appearance of germinal center-derived memory B cells and plasma cells 
in blood after primary immunization. J Exp Med 201, 545-554.
Blond-Elguindi, S., Cwirla, S. E., Dower, W. J., Lipshutz, R. J., Sprang, S. R., 
Sambrook, J. F., and Gething, M. J. (1993). Affinity panning of a library of peptides 
displayed on bacteriophages reveals the binding specificity of BiP. Cell 75, 717-728.
209
Boehmer, P. E., and Lehman, I. R. (1997). Herpes simplex vims DNA replication. Annu 
Rev Biochem 66, 347-384.
Bogner, E., Radsak, K., and Stinski, M. F. (1998). The gene product of human 
cytomegalovirus open reading frame UL56 binds the pac motif and has specific 
nuclease activity. J Virol 72, 2259-2264.
Boshoff, C. (1998a). Kaposi's sarcoma. Coupling herpesvirus to angiogenesis. Nature 
391,24-25.
Boshoff, C., Gao, S. J., Healy, L. E., Matthews, S., Thomas, A. J., Coignet, L., Wamke, 
R. A., Strauchen, J. A., Matutes, E., Kamel, O. W., et al. (1998b). Establishing a 
KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in 
Nod/SCID mice. Blood 91, 1671-1679.
Boshoff, C., Schulz, T. F., Kennedy, M. M., Graham, A. K., Fisher, C., Thomas, A., 
McGee, J. O., Weiss, R. A., and O'Leary, J. J. (1995). Kaposi's sarcoma-associated 
herpesvirus infects endothelial and spindle cells. Nat Med 1, 1274-1278.
Boulanger, E., Gerard, L., Gabarre, J., Molina, J. M., Rapp, C., Abino, J. F., Cadranel, 
J., Chevret, S., and Oksenhendler, E. (2005). Prognostic factors and outcome of human 
herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin 
Oncol 23, 4372-4380.
Bourboulia, D., Aldam, D., Lagos, D., Allen, E., Williams, I., Comforth, D., Copas, A., 
and Boshoff, C. (2004). Short- and long-term effects of highly active antiretroviral 
therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. 
Aids 18, 485-493.
Bouyac-Bertoia, M., Dvorin, J. D., Fouchier, R. A., Jenkins, Y., Meyer, B. E., Wu, L. I., 
Emerman, M., and Malim, M. H. (2001). HIV-1 infection requires a functional integrase 
NLS. Mol Cell 7, 1025-1035.
Brack, C., Hirama, M., Lenhard-Schuller, R., and Tonegawa, S. (1978). A complete 
immunoglobulin gene is created by somatic recombination. Cell 15, 1-14.
210
Bridge, A. J., Pebemard, S., Ducraux, A., Nicoulaz, A. L., and Iggo, R. (2003). 
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34, 
263-264.
Brinkmann, M. M., Glenn, M., Rainbow, L., Kieser, A., Henke-Gendo, C., and Schulz, 
T. F. (2003). Activation of mitogen-activated protein kinase and NF-kappaB pathways 
by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol 77, 9346- 
9358.
Bronstein, J. C., Weller, S. K., and Weber, P. C. (1997). The product of the UL12.5 
gene of herpes simplex virus type 1 is a capsid-associated nuclease. J Virol 71, 3039- 
3047.
Bross, L., Fukita, Y., McBlane, F., Demolliere, C., Rajewsky, K., and Jacobs, H.
(2000). DNA double-strand breaks in immunoglobulin genes undergoing somatic 
hypermutation. Immunity 13, 589-597.
Brown, H. J., McBride, W. H., Zack, J. A., and Sun, R. (2005). Prostratin and 
bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. 
AntivirTher 10, 745-751.
Brown, H. J., Song, M. J., Deng, H., Wu, T. T., Cheng, G., and Sun, R. (2003). NF- 
kappaB inhibits gammaherpesvirus lytic replication. J Virol 77, 8532-8540.
Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable 
expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
Buchschacher, G. L., Jr., and Wong-Staal, F. (2000). Development of lentiviral vectors 
for gene therapy for human diseases. Blood 95, 2499-2504.
Bukovsky, A. A., Song, J. P., and Naldini, L. (1999). Interaction of human 
immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J 
Virol 73, 7087-7092.
211
Bukrinsky, M. I., Sharova, N., Dempsey, M. P., Stanwick, T. L., Bukrinskaya, A. G., 
Haggerty, S., and Stevenson, M. (1992). Active nuclear import of human 
immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A 89, 
6580-6584.
Burkhardt, A. L., Bolen, J. B., Kieff, E., and Longnecker, R. (1992). An Epstein-Barr 
virus transformation-associated membrane protein interacts with src family tyrosine 
kinases. J Virol 66, 5161-5167.
Burnet, F. M., and Fenner, F. (1949). The production of antibodies, 2d edn (Melbourne, 
Macmillan).
Burnet, F. M., and Williams, S. W. (1939). Herpes simplex: new point of view. Med J 
Aust 1, 637-640.
Burysek, L., and Pitha, P. M. (2001). Latently expressed human herpesvirus 8-encoded 
interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J 
Virol 75, 2345-2352.
Burysek, L., Yeow, W. S., and Pitha, P. M. (1999). Unique properties of a second 
human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J Hum Virol 2, 19- 
32.
Bushman, F. D. (2002). Integration site selection by lentiviruses: biology and possible 
control. Curr Top Microbiol Immunol 261, 165-177.
Butcher, S. E., and Brow, D. A. (2005). Towards understanding the catalytic core 
structure of the spliceosome. Biochem Soc Trans 33, 447-449.
Cai, X., Hagedom, C. H., and Cullen, B. R. (2004). Human microRNAs are processed 
from capped, polyadenylated transcripts that can also function as mRNAs. Rna 10, 
1957-1966.
212
Cai, X., Lu, S., Zhang, Z., Gonzalez, C. M., Damania, B., and Cullen, B. R. (2005). 
Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in 
latently infected cells. Proc Natl Acad Sci U S A 102, 5570-5575.
Calame, K. L., Lin, K. I., and Tunyaplin, C. (2003). Regulatory mechanisms that 
determine the development and function of plasma cells. Annu Rev Immunol 21, 205- 
230.
Caldwell, R. G., Wilson, J. B., Anderson, S. J., and Longnecker, R. (1998). Epstein- 
Barr virus LMP2A drives B cell development and survival in the absence of normal B 
cell receptor signals. Immunity 9, 405-411.
Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., 
and Ron, D. (2002). IRE1 couples endoplasmic reticulum load to secretory capacity by 
processing the XBP-1 mRNA. Nature 415, 92-96.
Caligaris-Cappio, F., Gobbi, M., Bofill, M., and Janossy, G. (1982). Infrequent normal 
B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 155, 
623-628.
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., 
Rattan, S., Keating, M., Rai, K., et al. (2002). Frequent deletions and down-regulation 
of micro- RNA genes miR15 and miR16 at 13ql4 in chronic lymphocytic leukemia. 
Proc Natl Acad Sci U S A 99, 15524-15529.
Campbell, M. E., Palfreyman, J. W., and Preston, C. M. (1984). Identification of herpes 
simplex virus DNA sequences which encode a trans-acting polypeptide responsible for 
stimulation of immediate early transcription. J Mol Biol 180, 1-19.
Campbell, T. B., Staskus, K. A., Folkvord, J., White, I. E., Neid, J., Zhang, X. Q., and 
Connick, E. (2005). Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)- 
infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases. J 
Infect Dis 191,367-371.
213
Cannon, J. S., Ciufo, D., Hawkins, A. L., Griffin, C. A., Borowitz, M. J., Hayward, G. 
S., and Ambinder, R. F. (2000). A new primary effusion lymphoma-derived cell line 
yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol 
74, 10187-10193.
Cannon, J. S., Hamzeh, F., Moore, S., Nicholas, J., and Ambinder, R. F. (1999). Human 
herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer 
sensitivity to ganciclovir. J Virol 73, 4786-4793.
Cannon, M. L., Cesarman, E., and Boshoff, C. (2005). The KSHV G protein-coupled 
receptor inhibits lytic gene transcription in primary effusion lymphoma cells via p21- 
mediated inhibition of Cdk2. Blood.
Cao, W., Hunter, R., Stmatka, D., McQueen, C. A., and Erickson, R. P. (2005). DNA 
constructs designed to produce short hairpin, interfering RNAs in transgenic mice 
sometimes show early lethality and an interferon response. J Appl Genet 46, 217-225.
Carbone, A., Gloghini, A., Vaccher, E., Zagonel, V., Pastore, C., Dalla Palma, P., 
Branz, F., Saglio, G., Volpe, R., Tirelli, U., and Gaidano, G. (1996). Kaposi's sarcoma- 
associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated 
lymphomatous effusions. Br J Haematol 94, 533-543.
Cariappa, A., Tang, M., Pamg, C., Nebelitskiy, E., Carroll, M., Georgopoulos, K , and 
Pillai, S. (2001). The follicular versus marginal zone B lymphocyte cell fate decision is 
regulated by Aiolos, Btk, and CD21. Immunity 14, 603-615.
Carroll, P. A., Brazeau, E., and Lagunoff, M. (2004). Kaposi's sarcoma-associated 
herpesvirus infection of blood endothelial cells induces lymphatic differentiation. 
Virology 328, 7-18.
Casali, P., Burastero, S. E., Nakamura, M., Inghirami, G., and Notkins, A. L. (1987). 
Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu- 
1+ B-cell subset. Science 236, 77-81.
214
Cascalho, M., Wong, J., Brown, J., Jack, H. M., Steinberg, C., and Wabl, M. (2000). A 
B220(-), CD19(-) population of B cells in the peripheral blood of quasimonoclonal 
mice. Int Immunol 12, 29-35.
Casola, S., Otipoby, K. L., Alimzhanov, M., Humme, S., Uyttersprot, N., Kutok, J. L., 
Carroll, M. C., and Rajewsky, K. (2004). B cell receptor signal strength determines B 
cell fate. Nat Immunol 5, 317-327.
Casper, C., Nichols, W. G., Huang, M. L., Corey, L., and Wald, A. (2004). Remission 
of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir 
treatment. Blood 103, 1632-1634.
Cathomas, G. (2003). Kaposi's sarcoma-associated herpesvirus (KSHV)/human 
herpesvirus 8 (HHV-8) as a tumour virus. Herpes 10, 72-77.
Cattani, P., Capuano, M., Graffeo, R., Ricci, R., Cerimele, F., Cerimele, D., Nanni, G., 
and Fadda, G. (2001). Kaposi's sarcoma associated with previous human herpesvirus 8 
infection in kidney transplant recipients. J Clin Microbiol 39, 506-508.
Cattoretti, G., Chang, C. C., Cechova, K., Zhang, J., Ye, B. H., Falini, B., Louie, D. C., 
Offit, K., Chaganti, R. S., and Dalla-Favera, R. (1995). BCL-6 protein is expressed in 
germinal-center B cells. Blood 86, 45-53.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., 
Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., et al. (2000). Gene therapy 
of human severe combined immunodeficiency (SCID)-Xl disease. Science 288, 669- 
672.
Cerutti, L., Mian, N., and Bateman, A. (2000). Domains in gene silencing and cell 
differentiation proteins: the novel PAZ domain and redefinition of the Piwi domain. 
Trends Biochem Sci 25, 481-482.
Cesarman, E., Chang, Y., Moore, P. S., Said, J. W., and Knowles, D. M. (1995a). 
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body- 
cavity-based lymphomas. N Engl J Med 332, 1186-1191.
215
Cesarman, E., Moore, P. S., Rao, P. H., Inghirami, G., Knowles, D. M., and Chang, Y. 
(1995b). In vitro establishment and characterization of two acquired immunodeficiency 
syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma- 
associated herpesvirus-like (KSHV) DNA sequences. Blood 86, 2708-2714.
Cesarman, E., Nador, R. G., Bai, F., Bohenzky, R. A., Russo, J. J., Moore, P. S., Chang, 
Y., and Knowles, D. M. (1996). Kaposi's sarcoma-associated herpesvirus contains G 
protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's 
sarcoma and malignant lymphoma. J Virol 70, 8218-8223.
Chan, S. R., Bloomer, C., and Chandran, B. (1998). Identification and characterization 
of human herpesvirus-8 lytic cycle-associated ORF 59 protein and the encoding cDNA 
by monoclonal antibody. Virology 240, 118-126.
Chan, S. R., and Chandran, B. (2000). Characterization of human herpesvirus 8 ORF59 
protein (PF-8) and mapping of the processivity and viral DNA polymerase-interacting 
domains. J Virol 74, 10920-10929.
Chang, C. C., Ye, B. H., Chaganti, R. S., and Dalla-Favera, R. (1996). BCL-6, a 
POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl 
Acad Sci U S A 93, 6947-6952.
Chang, H., Dittmer, D. P., Chul, S. Y., Hong, Y., and Jung, J. U. (2005a). Role of Notch 
signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 
79, 14371-14382.
Chang, J., Renne, R., Dittmer, D., and Ganem, D. (2000). Inflammatory cytokines and 
the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 
266, 17-25.
Chang, M., Brown, H. J., Collado-Hidalgo, A., Arevalo, J. M., Galic, Z., Symensma, T. 
L., Tanaka, L., Deng, H., Zack, J. A., Sun, R., and Cole, S. W. (2005b). beta- 
Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via 
PKA-dependent control of viral RTA. J Virol 79, 13538-13547.
216
Chang, P. J., Shedd, D., and Miller, G. (2005c). Two subclasses of Kaposi’s sarcoma- 
associated herpesvirus lytic cycle promoters distinguished by open reading frame 50 
mutant proteins that are deficient in binding to DNA. J Virol 79, 8750-8763.
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., and 
Moore, P. S. (1994). Identification of herpesvirus-like DNA sequences in AIDS- 
associated Kaposi's sarcoma. Science 266,1865-1869.
Chang, Y. E., Van Sant, C., Krug, P. W., Sears, A. E., and Roizman, B. (1997). The null 
mutant of the U(L)31 gene of herpes simplex virus 1: construction and phenotype in 
infected cells. J Virol 71, 8307-8315.
Chatterjee, M., Osborne, J., Bestetti, G., Chang, Y., and Moore, P. S. (2002). Viral IL- 
6-induced cell proliferation and immune evasion of interferon activity. Science 298, 
1432-1435.
Chee, M., and Barrell, B. (1990). Herpesviruses: a study of parts. Trends Genet 6, 86- 
91.
Chen, C. Z., Li, L., Lodish, H. F., and Bartel, D. P. (2004). MicroRNAs modulate 
hematopoietic lineage differentiation. Science 303, 83-86.
Chen, D. H., Jiang, H., Lee, M., Liu, F., and Zhou, Z. H. (1999). Three-dimensional 
visualization of tegument/capsid interactions in the intact human cytomegalovirus. 
Virology 260, 10-16.
Chen, J., Ueda, K., Sakakibara, S., Okuno, T., Parravicini, C., Corbellino, M., and 
Yamanishi, K. (2001). Activation of latent Kaposi's sarcoma-associated herpesvirus by 
demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A 98, 
4119-4124.
Chen, L., and Lagunoff, M. (2005). Establishment and Maintenance of Kaposi's 
Sarcoma-Associated Herpesvirus Latency in B Cells. J Virol 79,14383-14391.
217
Chendrimada, T. P., Gregory, R. I., Kumaraswamy, E., Norman, J., Cooch, N., 
Nishikura, K., and Shiekhattar, R. (2005). TRBP recruits the Dicer complex to Ago2 for 
microRNA processing and gene silencing. Nature 436, 740-744.
Cheng, Y. C., Huang, E. S., Lin, J. C., Mar, E. C., Pagano, J. S., Dutschman, G. E., and 
Grill, S. P. (1983). Unique spectrum of activity of 9-[(l,3-dihydroxy-2- 
propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against 
herpes simplex virus type 1. Proc Natl Acad Sci U S A 80, 2767-2770.
Cherayil, B. J., and Pillai, S. (1991). The omega/lambda 5 surrogate immunoglobulin 
light chain is expressed on the surface of transitional B lymphocytes in murine bone 
marrow. J Exp Med 173, 111-116.
Chi, J. T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., and Brown, P. O.
(2003). Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad 
Sci U S  A 100, 6343-6346.
Chiou, C. J., Poole, L. J., Kim, P. S., Ciufo, D. M., Cannon, J. S., ap Rhys, C. M., 
Alcendor, D. J., Zong, J. C., Ambinder, R. F., and Hayward, G. S. (2002). Patterns of 
gene expression and a transactivation function exhibited by the vGCR (ORF74) 
chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J Virol 76, 
3421-3439.
Choe, J., and Choi, Y. S. (1998). IL-10 interrupts memory B cell expansion in the 
germinal center by inducing differentiation into plasma cells. Eur J Immunol 28, 508- 
515.
Ciufo, D. M., Cannon, J. S., Poole, L. J., Wu, F. Y., Murray, P., Ambinder, R. F., and 
Hayward, G. S. (2001). Spindle cell conversion by Kaposi's sarcoma-associated 
herpesvirus: formation of colonies and plaques with mixed lytic and latent gene 
expression in infected primary dermal microvascular endothelial cell cultures. J Virol 
75, 5614-5626.
218
Clauss, I. M., Chu, M., Zhao, J. L., and Glimcher, L. H. (1996). The basic 
domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE- 
like sequences containing an ACGT core. Nucleic Acids Res 24,1855-1864.
Coffman, R. L., Lebman, D. A., and Shrader, B. (1989). Transforming growth factor 
beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B 
lymphocytes. J Exp Med 170, 1039-1044.
Coleman, H. M., de Lima, B., Morton, V., and Stevenson, P. G. (2003). Murine 
gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle 
replication in vivo but still establishes latency. J Virol 77,2410-2417.
Collins, A. M., Sewell, W. A., and Edwards, M. R. (2003). Immunoglobulin gene 
rearrangement, repertoire diversity, and the allergic response. Pharmacol Ther 100,157- 
170.
Cong, Y. Z., Rabin, E., and Wortis, H. H. (1991). Treatment of murine CD5- B cells 
with anti-Ig, but not LPS, induces surface CD5: two B-cell activation pathways. Int 
Immunol 3, 467-476.
Corey, L., Brodie, S., Huang, M. L., Koelle, D. M., and Wald, A. (2002). HHV-8 
infection: a model for reactivation and transmission. Rev Med Virol 12, 47-63.
Cortez, D., Guntuku, S., Qin, J., and Elledge, S. J. (2001). ATR and ATRIP: partners in 
checkpoint signaling. Science 294, 1713-1716.
Craig, I. W., and Carr, N. G. (1968). C-phycocyanin and allophycocyanin in two species 
of blue-green algae. Biochem J 106, 361-366.
Crandell, R. A., Fabricant, C. G., and Nelson-Rees, W. A. (1973). Development, 
characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). 
In Vitro 9, 176-185.
Crawford, D. H., and Ando, I. (1986). EB virus induction is associated with B-cell 
maturation. Immunology 59, 405-409.
219
Crump, C. M., Bruun, B., Bell, S., Pomeranz, L. E., Minson, T., and Browne, H. M.
(2004). Alphaherpesvirus glycoprotein M causes the relocalization of plasma membrane 
proteins. J Gen Virol 85, 3517-3527.
Cullinan, S. B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R. J., and Diehl, J. A.
(2003). Nr£2 is a direct PERK substrate and effector of PERK-dependent cell survival. 
Mol Cell Biol 23, 7198-7209.
Cyster, J. G., Hartley, S. B., and Goodnow, C. C. (1994). Competition for follicular 
niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371, 
389-395.
Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F., and 
Weiss, R. A. (1984). The CD4 (T4) antigen is an essential component of the receptor for 
the AIDS retrovirus. Nature 312, 763-767.
Daly, T. J., Cook, K. S., Gray, G. S., Maione, T. E., and Rusche, J. R. (1989). Specific 
binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. 
Nature 342, 816-819.
Damania, B., Jeong, J. H., Bowser, B. S., DeWire, S. M., Staudt, M. R., and Dittmer, D. 
P. (2004). Comparison of the Rta/Orf50 transactivator proteins of gamma-2- 
herpesviruses. J Virol 78, 5491-5499.
Darlington, R. W., and Moss, L. H., 3rd (1968). Herpesvirus envelopment. J Virol 2, 
48-55.
Dasgupta, A., and Wilson, D. W. (1999). ATP depletion blocks herpes simplex vims 
DNA packaging and capsid maturation. J Virol 73, 2006-2015.
Davis, D. A., Rinderknecht, A. S., Zoeteweij, J. P., Aoki, Y., Read-Connole, E. L., 
Tosato, G., Blauvelt, A., and Yarchoan, R. (2001). Hypoxia induces lytic replication of 
Kaposi sarcoma-associated herpesvirus. Blood 97, 3244-3250.
220
Davis, H. E., Morgan, J. R., and Yarmush, M. L. (2002). Polybrene increases retrovirus 
gene transfer efficiency by enhancing receptor-independent virus adsorption on target 
cell membranes. Biophys Chem 97,159-172.
Davis, H. E., Rosinski, M., Morgan, J. R., and Yarmush, M. L. (2004). Charged 
polymers modulate retrovirus transduction via membrane charge neutralization and 
virus aggregation. Biophys J 86, 1234-1242.
de Lange, P., van Blokland, R., Kooter, J. M., and Mol, J. N. (1995). Suppression of 
flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense 
and sense genes. Curr Top Microbiol Immunol 197, 57-75.
de Veer, M. J., Sledz, C. A., and Williams, B. R. (2005). Detection of foreign RNA: 
implications for RNAi. Immunol Cell Biol 83, 224-228.
de Vinuesa, C. G., Cook, M. C., Ball, J., Drew, M., Sunners, Y., Cascalho, M., Wabl, 
M., Klaus, G. G., and MacLennan, I. C. (2000). Germinal centers without T cells. J Exp 
Med 191,485-494.
Dedicoat, M., and Newton, R. (2003). Review of the distribution of Kaposi's sarcoma- 
associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's 
sarcoma. Br J Cancer 88, 1-3.
Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., 
and Thrasher, A. J. (2002). High-level transduction and gene expression in 
hematopoietic repopulating cells using a human immunodeficiency [correction of 
imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus 
forming virus promoter. Hum Gene Ther 13, 803-813.
Deng, H., Song, M. J., Chu, J. T., and Sun, R. (2002). Transcriptional regulation of the 
interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J 
Virol 76, 8252-8264.
Deng, H., Young, A., and Sim, R. (2000). Auto-activation of the rta gene of human 
herpesvirus-8/Kaposi's sarcoma-associated herpesvirus. J Gen Virol 81, 3043-3048.
221
Deng, J. H., Zhang, Y. J., Wang, X. P., and Gao, S. J. (2004). Lytic replication- 
defective Kaposi's sarcoma-associated herpesvirus: potential role in infection and 
malignant transformation. J Virol 78,11108-11120.
Dent, A. L., Shaffer, A. L., Yu, X., Allman, D., and Staudt, L. M. (1997). Control of 
inflammation, cytokine expression, and germinal center formation by BCL-6. Science 
276, 589-592.
Desrosiers, R. C., Sasseville, V. G., Czajak, S. C., Zhang, X., Mansfield, K. G., Kaur, 
A., Johnson, R. P., Lackner, A. A., and Jung, J. U. (1997). A herpesvirus of rhesus 
monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol 71, 
9764-9769.
Deutsch, E., Cohen, A., Kazimirsky, G., Dovrat, S., Rubinfeld, H., Brodie, C., and 
Sarid, R. (2004). Role of protein kinase C delta in reactivation of Kaposi's sarcoma- 
associated herpesvirus. J Virol 78, 10187-10192.
DeWire, S. M., and Damania, B. (2005). The latency-associated nuclear antigen of 
rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta 
transcriptional activation. J Virol 79, 3127-3138.
Dieu, M. C., Vanbervliet, B., Vicari, A., Bridon, J. M., Oldham, E., Ait-Yahia, S., 
Briere, F., Zlotnik, A., Lebecque, S., and Caux, C. (1998). Selective recruitment of 
immature and mature dendritic cells by distinct chemokines expressed in different 
anatomic sites. J Exp Med 188, 373-386.
Dittmer, D., Lagunoff, M., Renne, R., Staskus, K., Haase, A., and Ganem, D. (1998). A 
cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 
72, 8309-8315.
Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., and Grandien, A.
(1999). The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a 
new class of tumor progression factors. J Exp Med 190, 1025-1032.
222
Doench, J. G., Petersen, C. P., and Sharp, P. A. (2003). siRNAs can function as 
miRNAs. Genes Dev 17, 438-442.
Doi, N., Zenno, S., Ueda, R., Ohki-Hamazaki, H., Ui-Tei, K., and Saigo, K. (2003). 
Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and 
eIF2C translation initiation factors. Curr Biol 13, 41-46.
Dollard, S. C., Nelson, K. E., Ness, P. M., Stambolis, V., Kuehnert, M. J., Pellett, P. E., 
and Cannon, M. J. (2005). Possible transmission of human herpesvirus-8 by blood 
transfusion in a historical United States cohort. Transfusion 45, 500-503.
Dono, M., Burgio, V. L., Tacchetti, C., Favre, A., Augliera, A., Zupo, S., Taborelli, G., 
Chiorazzi, N., Grossi, C. E., and Ferrarini, M. (1996). Subepithelial B cells in the 
human palatine tonsil. I. Morphologic, cytochemical and phenotypic characterization. 
Eur J Immunol 26, 2035-2042.
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., 
Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. (1996). HIV- 
1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 
667-673.
Drexler, H. G., Meyer, C., Gaidano, G., and Carbone, A. (1999). Constitutive cytokine 
production by primary effusion (body cavity-based) lymphoma-derived cell lines. 
Leukemia 13, 634-640.
Driver, D. J., McHeyzer-Williams, L. J., Cool, M., Stetson, D. B., and McHeyzer- 
Williams, M. G. (2001). Development and maintenance of a B220- memory B cell 
compartment. J Immunol 167, 1393-1405.
Du, M. Q., Liu, H., Diss, T. C., Ye, H., Hamoudi, R. A., Dupin, N., Meignin, V., 
Oksenhendler, E., Boshoff, C., and Isaacson, P. G. (2001). Kaposi sarcoma-associated 
herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman 
disease and associated lymphoproliferative disorders. Blood 97, 2130-2136.
223
DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. 
(1987). Analysis of mutation in human cells by using an Epstein-Barr vims shuttle 
system. Mol Cell Biol 7, 379-387.
Dubrovsky, L., Ulrich, P., Nuovo, G. J., Manogue, K. R., Cerami, A., and Bukrinsky, 
M. (1995). Nuclear localization signal of HIV-1 as a novel target for therapeutic 
intervention. Mol Med 1, 217-230.
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L. 
(1998). A third-generation lentivims vector with a conditional packaging system. J 
Virol 72, 8463-8471.
Dupin, N., Diss, T. L., Kellam, P., Tulliez, M., Du, M. Q., Sicard, D., Weiss, R. A., 
Isaacson, P. G., and Boshoff, C. (2000). HHV-8 is associated with a plasmablastic 
variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. 
Blood 95, 1406-1412.
Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., 
Salmon, D., Gorin, I., Escande, J. P., et al. (1999). Distribution of human herpesvirus-8 
latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and 
primary effusion lymphoma. Proc Natl Acad Sci U S A 96, 4546-4551.
Duus, K. M., Lentchitsky, V., Wagenaar, T., Grose, C., and Webster-Cyriaque, J.
(2004). Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the 
oropharynx of immune-competent individuals has tropism for cultured oral epithelial 
cells. J Virol 78, 4074-4084.
Dyer, M. J., Fischer, P., Nacheva, E., Labastide, W., and Karpas, A. (1990). A new 
human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14; 18) 
and t(4; 11) chromosomal translocations. Blood 75, 709-714.
Efstathiou, S., and Preston, C. M. (2005). Towards an understanding of the molecular 
basis of herpes simplex vims latency. Vims Res 111, 108-119.
224
Ehlich, A., and Kuppers, R. (1995). Analysis of immunoglobulin gene rearrangements 
in single B cells. Curr Opin Immunol 7, 281-284.
Ehrenfeld, E., and Hunt, T. (1971). Double-stranded poliovirus RNA inhibits initiation 
of protein synthesis by reticulocyte lysates. Proc Natl Acad Sci U S A 68,1075-1078.
Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998). Cluster analysis 
and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95, 14863- 
14868.
Eisenbeis, C. F., Singh, H., and Storb, U. (1995). Pip, a novel IRF family member, is a 
lymphoid-specific, PU.l-dependent transcriptional activator. Genes Dev 9, 1377-1387.
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. 
(2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature 411, 494-498.
Elbashir, S. M., Lendeckel, W., and Tuschl, T. (2001b). RNA interference is mediated 
by 21- and 22-nucleotide RNAs. Genes Dev 15, 188-200.
Eltom, M. A., Mbulaiteye, S. M., Dada, A. J., Whitby, D., and Biggar, R. J. (2002). 
Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. 
Aids 16, 2473-2478.
Enbom, M., Urassa, W., Massambu, C., Thorstensson, R., Mhalu, F., and Linde, A.
(2002). Detection of human herpesvirus 8 DNA in serum from blood donors with HHV- 
8 antibodies indicates possible bloodbome virus transmission. J Med Virol 68, 264-267.
Enquist, L. W., Husak, P. J., Banfield, B. W., and Smith, G. A. (1998). Infection and 
spread of alphaherpesviruses in the nervous system. Adv Virus Res 51, 237-347.
Ensoli, B., Sgadari, C., Barillari, G., Sirianni, M. C., Sturzl, M., and Monini, P. (2001). 
Biology of Kaposi's sarcoma. Eur J Cancer 37, 1251-1269.
225
Ensser, A., and Fleckenstein, B. (2005). T-cell transformation and oncogenesis by 
gamma2-herpesviruses. Adv Cancer Res 93, 91-128.
Epstein, A. L., Levy, R., Kim, H., Henle, W., Henle, G., and Kaplan, H. S. (1978). 
Biology of the human malignant lymphomas. IV. Functional characterization of ten 
diffuse histiocytic lymphoma cell lines. Cancer 42, 2379-2391.
Esteban, M., Garcia, M. A., Domingo-Gil, E., Arroyo, J., Nombela, C., and Rivas, C.
(2003). The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus 
inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L 
activation. J Gen Virol 84, 1463-1470.
Eton, O., Scheinberg, D. A., and Houghton, A. N. (1989). Establishment and 
characterization of two human myeloma cell lines secreting kappa light chains. 
Leukemia 3, 729-735.
Fais, F., Gaidano, G., Capello, D., Gloghini, A., Ghiotto, F., Roncella, S., Carbone, A., 
Chiorazzi, N., and Ferrarini, M. (1999). Immunoglobulin V region gene use and 
structure suggest antigen selection in AIDS-related primary effusion lymphomas. 
Leukemia 13, 1093-1099.
Fan, W., Bubman, D., Chadbum, A., Harrington, W. J., Jr., Cesarman, E., and Knowles,
D. M. (2005). Distinct subsets of primary effusion lymphoma can be identified based on 
their cellular gene expression profile and viral association. J Virol 79, 1244-1251.
Farrell, P. J., Balkow, K., Hunt, T., Jackson, R. J., and Trachsel, H. (1977). 
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein 
synthesis. Cell 11, 187-200.
Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1 entry 
cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled 
receptor. Science 272, 872-877.
Ferguson, C., Larochelle, A., and Dunbar, C. E. (2005). Hematopoietic stem cell gene 
therapy : dead or alive? Trends Biotechnol.
226
Fernandez, L., Serraino, D., Rezza, G., Lence, J., Ortiz, R. M., Cruz, T., Vaccarella, S., 
Sarmati, L., Andreoni, M., and Franceschi, S. (2002). Infection with human herpesvirus 
type 8 and human T-cell leukaemia virus type 1 among individuals participating in a 
case-control study in Havana City, Cuba. Br J Cancer 87,1253-1256.
Fickenscher, H., and Fleckenstein, B. (2001). Herpesvirus saimiri. Philos Trans R Soc 
Lond B Biol Sci 356, 545-567.
Figdor, C. G., van Kooyk, Y., and Adema, G. J. (2002). C-type lectin receptors on 
dendritic cells and Langerhans cells. Nat Rev Immunol 2, 77-84.
Filipowicz, W. (2005). RNAi: the nuts and bolts of the RISC machine. Cell 122, 17-20.
Fire, A., Albertson, D., Harrison, S. W., and Moerman, D. G. (1991). Production of 
antisense RNA leads to effective and specific inhibition of gene expression in C. 
elegans muscle. Development 113, 503-514.
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. 
(1998). Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature 391, 806-811.
Fischer, U., Meyer, S., Teufel, M., Heckel, C., Luhrmann, R., and Rautmann, G. (1994). 
Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. Embo 
J 13,4105-4112.
Fish, R. J., and Kruithof, E. K. (2004). Short-term cytotoxic effects and long-term 
instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 5, 9.
Flore, O., Rafii, S., Ely, S., O’Leary, J. J., Hyjek, E. M., and Cesarman, E. (1998). 
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated 
herpesvirus. Nature 394, 588-592.
Flynn, G. C., Pohl, J., Flocco, M. T., and Rothman, J. E. (1991). Peptide-binding 
specificity of the molecular chaperone BiP. Nature 353, 726-730.
227
Forestell, S. P., Dando, J. S., Bohnlein, E., and Rigg, R. J. (1996). Improved detection 
of replication-competent retrovirus. J Virol Methods 60,171-178.
Forman, M. L., Inhom, S. L., Sheaff, E., and Cherry, J. D. (1969). Biological 
characteristics and viral spectrum of serially cultivated fetal rhesus monkey kidney 
cells. Proc Soc Exp Biol Med 131, 1060-1067.
Franklin, A., and Blanden, R. V. (2004). On the molecular mechanism of somatic 
hypermutation of rearranged immunoglobulin genes. Immunol Cell Biol 82, 557-567.
Friborg, J., Jr., Kong, W., Hottiger, M. O., and Nabel, G. J. (1999). p53 inhibition by 
the LANA protein of KSHV protects against cell death. Nature 402, 889-894.
Fujita, N., Jaye, D. L., Geigerman, C., Akyildiz, A., Mooney, M. R., Boss, J. M., and 
Wade, P. A. (2004). MTA3 and the Mi-2/NuRD complex regulate cell fate during B 
lymphocyte differentiation. Cell 119, 75-86.
Fukagawa, T., Nogami, M., Yoshikawa, M., Ikeno, M., Okazaki, T., Takami, Y., 
Nakayama, T., and Oshimura, M. (2004). Dicer is essential for formation of the 
heterochromatin structure in vertebrate cells. Nat Cell Biol 6, 784-791.
Furlong, D., Swift, H., and Roizman, B. (1972). Arrangement of herpesvirus 
deoxyribonucleic acid in the core. J Virol 10,1071-1074.
Gaidano, G., Capello, D., Cilia, A. M., Gloghini, A., Perin, T., Quattrone, S., Migliazza,
A., Lo Coco, F., Saglio, G., Ascoli, V., and Carbone, A. (1999). Genetic 
characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent 
mutations of BCL6: implications for disease pathogenesis and histogenesis. Genes 
Chromosomes Cancer 24, 16-23.
Gaidano, G., Cechova, K., Chang, Y., Moore, P. S., Knowles, D. M., and Dalla-Favera, 
R. (1996). Establishment of AIDS-related lymphoma cell lines from lymphomatous 
effusions. Leukemia 10, 1237-1240.
228
Gaidano, G., Gloghini, A., Gattei, V., Rossi, M. F., Cilia, A. M., Godeas, C., Degan, 
M., Perin, T., Canzonieri, V., Aldinucci, D., et al. (1997). Association of Kaposi's 
sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of 
the CD138/syndecan-l antigen. Blood 90, 4894-4900.
Gamer, J. A. (2003). Herpes simplex virion entry into and intracellular transport within 
mammalian cells. Adv Dmg Deliv Rev 55, 1497-1513.
Garrus, J. E., von Schwedler, U. K., Pomillos, O. W., Morham, S. G., Zavitz, K. H., 
Wang, H. E., Wettstein, D. A., Stray, K. M., Cote, M., Rich, R. L., et al. (2001). TsglOl 
and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107, 55- 
65.
Gasperini, P., Barbierato, M., Martinelli, C., Rigotti, P., Marchini, F., Masserizzi, G., 
Leoncini, F., Chieco-Bianchi, L., Schulz, T. F., and Calabro, M. L. (2005). Use of a 
BJAB-derived cell line for isolation of human herpesvirus 8. J Clin Microbiol 43, 2866- 
2875.
Gatignol, A., Buckler-White, A., Berkhout, B., and Jeang, K. T. (1991). 
Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. 
Science 251, 1597-1600.
Gazdar, A. F., Oie, H. K., Kirsch, I. R., and Hollis, G. F. (1986). Establishment and 
characterization of a human plasma cell myeloma culture having a rearranged cellular 
myc proto-oncogene. Blood 67, 1542-1549.
Gerster, T., and Roeder, R. G. (1988). A herpesvirus trans-activating protein interacts 
with transcription factor OTF-1 and other cellular proteins. Proc Natl Acad Sci U S A 
85, 6347-6351.
Gessain, A., Briere, J., Angelin-Duclos, C., Valensi, F., Beral, H. M., Davi, F., Nicola, 
M. A., Sudaka, A., Fouchard, N., Gabarre, J., et al. (1997). Human herpes vims 8 
(Kaposi’s sarcoma herpes vims) and malignant lymphoproliferations in France: a 
molecular study of 250 cases including two AIDS-associated body cavity based 
lymphomas. Leukemia 11, 266-272.
229
Gessain, A., and Duprez, R. (2005). Spindle cells and their role in Kaposi's sarcoma. Int 
J Biochem Cell Biol 37, 2457-2465.
Gessain, A., Sudaka, A., Briere, J., Fouchard, N., Nicola, M. A., Rio, B., Arborio, M., 
Troussard, X., Audouin, J., Diebold, J., and de The, G. (1996). Kaposi sarcoma- 
associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric 
Castleman's disease: is there any relevant association in non-human immunodeficiency 
virus-infected patients? Blood 87, 414-416.
Gill, P. S., Tsai, Y. C., Rao, A. P., Spruck, C. H., 3rd, Zheng, T., Harrington, W. A., Jr., 
Cheung, T., Nathwani, B., and Jones, P. A. (1998). Evidence for multiclonality in 
multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A 95, 8257-8261.
Giraldo, G., Beth, E., and Haguenau, F. (1972). Herpes-type virus particles in tissue 
culture of Kaposi's sarcoma from different geographic regions. J Natl Cancer Inst 49, 
1509-1526.
Giraldo, G., Beth, E., and Huang, E. S. (1980). Kaposi's sarcoma and its relationship to 
cytomegalovirus (CMV). III. CMV DNA and CMV early antigens in Kaposi's sarcoma. 
Int J Cancer 26, 23-29.
Glenn, M., Rainbow, L., Aurade, F., Davison, A., and Schulz, T. F. (1999). 
Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding 
a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J 
Virol 73, 6953-6963.
Godfrey, A., Laman, H., and Boshoff, C. (2003). RNA interference: a potential tool 
against Kaposi's sarcoma-associated herpesvirus. Curr Opin Infect Dis 16, 593-600.
Gonzalez, T. N., Sidrauski, C., Dorfler, S., and Walter, P. (1999). Mechanism of non- 
spliceosomal mRNA splicing in the unfolded protein response pathway. Embo J 18, 
3119-3132.
230
Good, P. D., Krikos, A. J., Li, S. X., Bertrand, E., Lee, N. S., Giver, L., Ellington, A., 
Zaia, J. A., Rossi, J. J., and Engelke, D. R. (1997). Expression of small, therapeutic 
RNAs in human cell nuclei. Gene Ther 4, 45-54.
Goodnow, C. C., Crosbie, J., Jorgensen, H., Brink, R. A., and Basten, A. (1989). 
Induction of self-tolerance in mature peripheral B lymphocytes. Nature 342, 385-391.
Goodwin, D. J., Walters, M. S., Smith, P. G., Thurau, M., Fickenscher, H., and 
Whitehouse, A. (2001). Herpesvirus saimiri open reading frame 50 (Rta) protein 
reactivates the lytic replication cycle in a persistently infected A549 cell line. J Virol 75, 
4008-4013.
Gotti, E., and Remuzzi, G. (1997). Post-transplant Kaposi’s sarcoma. J Am Soc Nephrol 
8, 130-137.
Goudsmit, J., Renwick, N., Dukers, N. H., Coutinho, R. A., Heisterkamp, S., Bakker, 
M., Schulz, T. F., Comelissen, M., and Weverling, G. J. (2000). Human herpesvirus 8 
infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to 
ORF65 and ORF73. Proc Natl Acad Sci U S A 97, 4838-4843.
Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., and 
Dustin, M. L. (1999). The immunological synapse: a molecular machine controlling T 
cell activation. Science 285, 221-227.
Granzow, H., Weiland, F., Jons, A., Klupp, B. G., Karger, A., and Mettenleiter, T. C.
(1997). Ultrastructural analysis of the replication cycle of pseudorabies virus in cell 
culture: a reassessment. J Virol 71, 2072-2082.
Grawunder, U., Leu, T. M., Schatz, D. G., Werner, A., Rolink, A. G., Melchers, F., and 
Winkler, T. H. (1995). Down-regulation of RAG1 and RAG2 gene expression in preB 
cells after functional immunoglobulin heavy chain rearrangement. Immunity 3, 601- 
608.
Gray, D., MacLennan, I. C., Bazin, H., and Khan, M. (1982). Migrant mu+ delta+ and 
static mu+ delta- B lymphocyte subsets. Eur J Immunol 12, 564-569.
231
Greber, U. F., and Fassati, A. (2003). Nuclear import of viral DNA genomes. Traffic 4, 
136-143.
Greensill, J., and Schulz, T. F. (2000a). Rhadinoviruses (gamma2-herpesviruses) of Old 
World primates: models for KSHV/HHV8-associated disease? Aids 14 Suppl 3, SI 1-19.
Greensill, J., Sheldon, J. A., Renwick, N. M., Beer, B. E., Norley, S., Goudsmit, J., and 
Schulz, T. F. (2000b). Two distinct gamma-2 herpesviruses in African green monkeys: a 
second gamma-2 herpesvirus lineage among old world primates? J Virol 74, 1572-1577.
Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., 
and Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of 
microRNAs. Nature 432, 235-240.
Griffiths-Jones, S. (2004). The microRNA Registry. Nucleic Acids Res 32, D109-111.
Grishok, A., Pasquinelli, A. E., Conte, D., Li, N., Parrish, S., Ha, I., Baillie, D. L., Fire,
A., Ruvkun, G., and Mello, C. C. (2001). Genes and mechanisms related to RNA 
interference regulate expression of the small temporal RNAs that control C. elegans 
developmental timing. Cell 106, 23-34.
Grundhoff, A., and Ganem, D. (2001). Mechanisms governing expression of the v-FLIP 
gene of Kaposi's sarcoma-associated herpesvirus. J Virol 75, 1857-1863.
Gruter, W. (1924). Das herpesvirus, seine atiologische und klinische bedeutung. Munch 
Med Wschr 71, 1058.
Guasparri, I., Keller, S. A., and Cesarman, E. (2004). KSHV vFLIP is essential for the 
survival of infected lymphoma cells. J Exp Med 199, 993-1003.
Gunn, M. D., Ngo, V. N., Ansel, K. M., Ekland, E. H., Cyster, J. G., and Williams, L. T.
(1998). A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's 
lymphoma receptor-1. Nature 391, 799-803.
232
Guo, S., and Kemphues, K. J. (1995). par-1, a gene required for establishing polarity in 
C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically 
distributed. Cell 81, 611-620.
Guzman-Rojas, L., Sims-Mourtada, J. C., Rangel, R., and Martinez-Valdez, H. (2002). 
Life and death within germinal centres: a double-edged sword. Immunology 107, 167- 
175.
Gwack, Y., Byun, H., Hwang, S., Lim, C., and Choe, J. (2001). CREB-binding protein 
and histone deacetylase regulate the transcriptional activity of Kaposi’s sarcoma- 
associated herpesvirus open reading frame 50. J Virol 75, 1909-1917.
Gyory, I., Wu, J., Fejer, G., Seto, E., and Wright, K. L. (2004). PRDI-BF1 recruits the 
histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5, 299-308.
Haas, I. G., and Wabl, M. (1983). Immunoglobulin heavy chain binding protein. Nature 
306, 387-389.
Hahn, G., Jores, R., and Mocarski, E. S. (1998). Cytomegalovirus remains latent in a 
common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A 95, 3937- 
3942.
Hammond, S. M., Bernstein, E., Beach, D., and Hannon, G. J. (2000). An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 
293-296.
Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R., and Hannon, G. J.
(2001). Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 
293, 1146-1150.
Hamoudi, R., Diss, T. C., Oksenhendler, E., Pan, L., Carbone, A., Ascoli, V., Boshoff,
C., Isaacson, P., and Du, M. Q. (2004). Distinct cellular origins of primary effusion 
lymphoma with and without EBV infection. Leuk Res 28, 333-338.
233
Hannum, L. G., Haberman, A. M., Anderson, S. M., and Shlomchik, M. J. (2000). 
Germinal center initiation, variable gene region hypermutation, and mutant B cell 
selection without detectable immune complexes on follicular dendritic cells. J Exp Med 
192, 931-942.
Haque, M., Davis, D. A., Wang, V., Widmer, I., and Yarchoan, R. (2003). Kaposi's 
sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response 
elements: relevance to lytic induction by hypoxia. J Virol 77, 6761-6768.
Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T., and Weber, K. (2001). 
Identification of essential genes in cultured mammalian cells using small interfering 
RNAs. J Cell Sci 114, 4557-4565.
Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, D.
(2000). Regulated translation initiation controls stress-induced gene expression in 
mammalian cells. Mol Cell 6, 1099-1108.
Harding, H. P., Zhang, Y., and Ron, D. (1999). Protein translation and folding are 
coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271-274.
Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D., and Hayakawa, K. (1991). 
Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse 
bone marrow. J Exp Med 173, 1213-1225.
Harless, S. M., Lentz, V. M., Sah, A. P., Hsu, B. L., Clise-Dwyer, K., Hilbert, D. M., 
Hayes, C. E., and Cancro, M. P. (2001). Competition for BLyS-mediated signaling 
through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 11, 1986- 
1989.
Harrington, W., Jr., Sieczkowski, L., Sosa, C., Chan-a-Sue, S., Cai, J. P., Cabral, L., and 
Wood, C. (1997). Activation of HHV-8 by HIV-1 tat. Lancet 349, 774-775.
Harrington, W. J., Jr., Bagasra, O., Sosa, C. E., Bobroski, L. E., Baum, M., Wen, X. L., 
Cabral, L., Byrne, G. E., Pomerantz, R. J., and Wood, C. (1996). Human herpesvirus
234
type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi’s sarcoma 
patients. J Infect Dis 174, 1101-1105.
Harwood, A. R., Osoba, D., Hofstader, S. L., Goldstein, M. B., Cardella, C. J., Holecek, 
M. J., Kunynetz, R., and Giammarco, R. A. (1979). Kaposi's sarcoma in recipients of 
renal transplants. Am J Med 67, 759-765.
Hasbold, J., Corcoran, L. M., Tarlinton, D. M., Tangye, S. G., and Hodgkin, P. D.
(2004). Evidence from the generation of immunoglobulin G-secreting cells that 
stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol 5, 55-63.
Hatfield, S. D., Shcherbata, H. R., Fischer, K. A., Nakahara, K., Carthew, R. W., and 
Ruohola-Baker, H. (2005). Stem cell division is regulated by the microRNA pathway. 
Nature 435, 974-978.
Hayakawa, K., Shinton, S. A., Asano, M., and Hardy, R. R. (2000). B-l cell definition. 
Curr Top Microbiol Immunol 252, 15-22.
Hayward, G. S. (1999). KSHV strains: the origins and global spread of the virus. Semin 
Cancer Biol 9, 187-199.
Hayward, G. S. (2003). Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 
3, 1-3.
He, B., Raab-Traub, N., Casali, P., and Cerutti, A. (2003). EBV-encoded latent 
membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell- 
independent Ig heavy chain class switching. J Immunol 171, 5215-5224.
He, L., Thomson, J. M., Hemann, M. T., Hemando-Monge, E., Mu, D., Goodson, S., 
Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and Hammond, S. M.
(2005). A microRNA polycistron as a potential human oncogene. Nature 435, 828-833.
Hemesath, T. J., Steingrimsson, E., McGill, G., Hansen, M. J., Vaught, J., Hodgkinson,
C. A., Amheiter, H., Copeland, N. G., Jenkins, N. A., and Fisher, D. E. (1994).
235
microphthalmia, a critical factor in melanocyte development, defines a discrete 
transcription factor family. Genes Dev 8, 2770-2780.
Henke-Gendo, C., and Schulz, T. F. (2004). Transmission and disease association of 
Kaposi’s sarcoma-associated herpesvirus: recent developments. Curr Opin Infect Dis 17, 
53-57.
Hemdier, B. G., Werner, A., Amstein, P., Abbey, N. W., Demartis, F., Cohen, R. L., 
Shuman, M. A., and Levy, J. A. (1994). Characterization of a human Kaposi's sarcoma 
cell line that induces angiogenic tumors in animals. Aids 8, 575-581.
Hidvegi, N. C., Sales, K. M., Izadi, D., Ong, J., Kellam, P., Eastwood, D., and Butler, P.
E. (2005). A low temperature method of isolating normal human articular chondrocytes. 
Osteoarthritis Cartilage.
Ho, F., Lortan, J. E., MacLennan, I. C., and Khan, M. (1986). Distinct short-lived and 
long-lived antibody-producing cell populations. Eur J Immunol 16, 1297-1301.
Hong, M., Luo, S., Baumeister, P., Huang, J. M., Gogia, R. K., Li, M., and Lee, A. S. 
(2004a). Underglycosylation of ATF6 as a novel sensing mechanism for activation of 
the unfolded protein response. J Biol Chem 279, 11354-11363.
Hong, Y. K., Foreman, K., Shin, J. W., Hirakawa, S., Curry, C. L., Sage, D. R., 
Libermann, T., Dezube, B. J., Fingeroth, J. D., and Detmar, M. (2004b). Lymphatic 
reprogramming of blood vascular endothelium by Kaposi sarcoma-associated 
herpesvirus. Nat Genet 36, 683-685.
Honjo, T., Nagaoka, H., Shinkura, R., and Muramatsu, M. (2005). AID to overcome the 
limitations of genomic information. Nat Immunol 6, 655-661.
Hozumi, N., and Tonegawa, S. (1976). Evidence for somatic rearrangement of 
immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U 
S A 73, 3628-3632.
236
Hu, Z. B., Ma, W., Zaborski, M., MacLeod, R., Quentmeier, H., and Drexler, H. G. 
(1996). Establishment and characterization of two novel cytokine-responsive acute 
myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3. Leukemia 10, 
1025-1040.
Hudnall, S. D., Rady, P. L., Tyring, S. K., and Fish, J. C. (1999). Hydrocortisone 
activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. 
Transplantation 67, 648-652.
Hutvagner, G., and Zamore, P. D. (2002). A microRNA in a multiple-tumover RNAi 
enzyme complex. Science 297, 2056-2060.
Hwang, S., Gwack, Y., Byun, H., Lim, C., and Choe, J. (2001). The Kaposi's sarcoma- 
associated herpesvirus K8 protein interacts with CREB-binding protein (CBP) and 
represses CBP-mediated transcription. J Virol 75, 9509-9516.
Hymes, K. B., Cheung, T., Greene, J. B., Prose, N. S., Marcus, A., Ballard, H., William,
D. C., and Laubenstein, L. J. (1981). Kaposi's sarcoma in homosexual men-a report of 
eight cases. Lancet 2, 598-600.
Imren, S., Fabry, M. E., Westerman, K. A., Pawliuk, R., Tang, P., Rosten, P. M., Nagel, 
R. L., Leboulch, P., Eaves, C. J., and Humphries, R. K. (2004). High-level beta-globin 
expression and preferred intragenic integration after lentiviral transduction of human 
cord blood stem cells. J Clin Invest 114, 953-962.
Inoue, N., Winter, J., Lai, R. B., Offermann, M. K., and Koyano, S. (2003). 
Characterization of entry mechanisms of human herpesvirus 8 by using an Rta- 
dependent reporter cell line. J Virol 77, 8147-8152.
Iscovich, J., Boffetta, P., Franceschi, S., Azizi, E., and Sarid, R. (2000). Classic kaposi 
sarcoma: epidemiology and risk factors. Cancer 88, 500-517.
Iwakoshi, N. N., Lee, A. H., Vallabhajosyula, P., Otipoby, K. L., Rajewsky, K., and 
Glimcher, L. H. (2003). Plasma cell differentiation and the unfolded protein response 
intersect at the transcription factor XBP-1. Nat Immunol 4, 321-329.
237
Izuchukwu, I. S., Tourbaf, K., and Mahoney, M. C. (2003). An unusual presentation of 
Castleman's disease:a case report. BMC Infect Dis 3, 20.
Izumiya, Y., Lin, S. F., Ellison, T., Chen, L. Y., Izumiya, C., Luciw, P., and Kung, H. J.
(2003). Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: 
physical association and promoter-dependent transcriptional repression. J Virol 77, 
1441-1451.
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li,
B., Cavet, G., and Linsley, P. S. (2003). Expression profiling reveals off-target gene 
regulation by RNAi. Nat Biotechnol 21, 635-637.
Jackson, A. L., and Linsley, P. S. (2004). Noise amidst the silence: off-target effects of 
siRNAs? Trends Genet 20, 521-524.
Jacob, J., Kassir, R., and Kelsoe, G. (1991a). In situ studies of the primary immune 
response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of 
responding cell populations. J Exp Med 173, 1165-1175.
Jacob, J., and Kelsoe, G. (1992). In situ studies of the primary immune response to (4- 
hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid 
sheath-associated foci and germinal centers. J Exp Med 176, 679-687.
Jacob, J., Kelsoe, G., Rajewsky, K., and Weiss, U. (1991b). Intraclonal generation of 
antibody mutants in germinal centres. Nature 354, 389-392.
Jacquot, S., Kobata, T., Iwata, S., Morimoto, C., and Schlossman, S. F. (1997). 
CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T 
cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 
signaling. J Immunol 159, 2652-2657.
Jenner, R. G., Alba, M. M., Boshoff, C., and Kellam, P. (2001). Kaposi's sarcoma- 
associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J 
Virol 75, 891-902.
238
Jenner, R. G., Maillard, K., Cattini, N., Weiss, R. A., Boshoff, C., Wooster, R., and 
Kellam, P. (2003). Kaposi's sarcoma-associated herpesvirus-infected primary effusion 
lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100, 
10399-10404.
Jensen, F. C., Girardi, A. J., Gilden, R. V., and Koprowski, H. (1964). Infection of 
Human and Simian Tissue Cultures with Rous Sarcoma Virus. Proc Natl Acad Sci U S 
A 52, 53-59.
Jeong, J. H., Hines-Boykin, R., Ash, J. D., and Dittmer, D. P. (2002). Tissue specificity 
of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) 
promoter in transgenic mice. J Virol 76, 11024-11032.
Johnson, A. S., Maronian, N., and Vieira, J. (2005). Activation of Kaposi's sarcoma- 
associated herpesvirus lytic gene expression during epithelial differentiation. J Virol 79, 
13769-13777.
Jones, K. A., and Peterlin, B. M. (1994). Control of RNA initiation and elongation at the 
HIV-1 promoter. Annu Rev Biochem 63, 717-743.
Joseph, A. M., Babcock, G. J., and Thorley-Lawson, D. A. (2000). Cells expressing the 
Epstein-Barr virus growth program are present in and restricted to the naive B-cell 
subset of healthy tonsils. J Virol 74, 9964-9971.
Judde, J. G., Lacoste, V., Briere, J., Kassa-Kelembho, E., Clyti, E., Couppie, P., 
Buchrieser, C., Tulliez, M., Morvan, J., and Gessain, A. (2000). Monoclonality or 
oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma 
and other diseases. J Natl Cancer Inst 92, 729-736.
Kadonaga, J. T. (2004). Regulation of RNA polymerase II transcription by sequence- 
specific DNA binding factors. Cell 116, 247-257.
Kang, D. C., Gopalkrishnan, R. V., Wu, Q., Jankowsky, E., Pyle, A. M., and Fisher, P.
B. (2002). mda-5: An interferon-inducible putative RNA helicase with double-stranded
239
RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc 
Natl Acad Sci U S A 99, 637-642.
Kantor, A. B., Stall, A. M., Adams, S., and Herzenberg, L. A. (1992). Differential 
development of progenitor activity for three B-cell lineages. Proc Natl Acad Sci U S A 
89, 3320-3324.
Kaplan, A. H. (2002). Assembly of the HIV-1 core particle. AIDS Rev 4, 104-111.
Kaposi, M. (1872). Idiopathic multiple pigmented sarcoma of the skin. Arch Dermatol 
Syphil 4, 256-273.
Karasuyama, H., Kudo, A., and Melchers, F. (1990). The proteins encoded by the 
VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with 
mu heavy chain. J Exp Med 172, 969-972.
Karcher, D. S., and Alkan, S. (1995). Herpes-like DNA sequences, AIDS-related 
tumors, and Castleman's disease. N Engl J Med 333, 797-798; author reply 798-799.
Kariko, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., and Weissman,
D. (2004a). Exogenous siRNA mediates sequence-independent gene suppression by 
signaling through toll-like receptor 3. Cells Tissues Organs 177, 132-138.
Kariko, K., Bhuyan, P., Capodici, J., and Weissman, D. (2004b). Small interfering 
RNAs mediate sequence-independent gene suppression and induce immune activation 
by signaling through toll-like receptor 3. J Immunol 172, 6545-6549.
Kasolo, F. C., Mpabalwani, E., and Gompels, U. A. (1997). Infection with AIDS-related 
herpesviruses in human immunodeficiency virus-negative infants and endemic 
childhood Kaposi's sarcoma in Africa. J Gen Virol 78 ( Pt 4), 847-855.
Kasschau, K. D., and Carrington, J. C. (1998). A counterdefensive strategy of plant 
viruses: suppression of posttranscriptional gene silencing. Cell 95, 461-470.
240
Katano, H., Sato, Y., Kurata, T., Mori, S., and Sata, T. (2000). Expression and 
localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, 
Kaposi’s sarcoma, and multicentric Castleman's disease. Virology 269, 335-344.
Kawai, T., and Akira, S. (2005). Pathogen recognition with Toll-like receptors. Curr 
Opin Immunol 17, 338-344.
Kawasaki, H., and Taira, K. (2004). Induction of DNA methylation and gene silencing 
by short interfering RNAs in human cells. Nature 431, 211-217.
Kedes, D. H., Lagunoff, M., Renne, R., and Ganem, D. (1997). Identification of the 
gene encoding the major latency-associated nuclear antigen of the Kaposi’s sarcoma- 
associated herpesvirus. J Clin Invest 100, 2606-2610.
Kellam, P., Boshoff, C., Whitby, D., Matthews, S., Weiss, R. A., and Talbot, S. J.
(1997). Identification of a major latent nuclear antigen, LNA-1, in the human 
herpesvirus 8 genome. J Hum Virol 1, 19-29.
Keller, A. D., and Maniatis, T. (1991). Identification and characterization of a novel 
repressor of beta-interferon gene expression. Genes Dev 5, 868-879.
Keller, A. D., and Maniatis, T. (1992). Only two of the five zinc fingers of the 
eukaryotic transcriptional repressor PRDI-BF1 are required for sequence-specific DNA 
binding. Mol Cell Biol 12, 1940-1949.
Kennedy, P. G. (2002). Varicella-zoster virus latency in human ganglia. Rev Med Virol 
12, 327-334.
Ketting, R. F., Fischer, S. E., Bernstein, E., Sijen, T., Hannon, G. J., and Plasterk, R. H.
(2001). Dicer functions in RNA interference and in synthesis of small RNA involved in 
developmental timing in C. elegans. Genes Dev 15, 2654-2659.
Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003). Functional siRNAs and 
miRNAs exhibit strand bias. Cell 115, 209-216.
241
Kieff, E., and Rickinson, A. B. (2001). Epstein-Barr virus. In Fields virology 
(Philadelphia ;London, Lippincott Williams & Wilkins), pp. Chapters 74 and 75.
Kieff, E., and Rickinson, A. B. (2001). Epstein-Barr virus and its replication. In Fields 
virology (Philadelphia; Londdon, Lippincott Williams & Wilkins).
Kilger, E., Kieser, A., Baumann, M., and Hammerschmidt, W. (1998). Epstein-Barr 
virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which 
simulates an activated CD40 receptor. Embo J 17, 1700-1709.
Kim, C. H., Rott, L. S., Clark-Lewis, I., Campbell, D. J., Wu, L., and Butcher, E. C.
(2001). Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal 
center-localized subset of CXCR5+ T cells. J Exp Med 193, 1373-1381.
Kim, D. H., Behlke, M. A., Rose, S. D., Chang, M. S., Choi, S., and Rossi, J. J. (2005). 
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 
23, 222-226.
Kim, D. H., Longo, M., Han, Y., Lundberg, P., Cantin, E., and Rossi, J. J. (2004). 
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat 
Biotechnol 22, 321-325.
Kitamura, D., Kudo, A., Schaal, S., Muller, W., Melchers, F., and Rajewsky, K. (1992). 
A critical role of lambda 5 protein in B cell development. Cell 69, 823-831.
Klass, C. M., Krug, L. T., Pozharskaya, V. P., and Offermann, M. K. (2005). The 
targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication 
of human herpesvirus 8 while blocking virus production. Blood 105, 4028-4034.
Klein, U., Gloghini, A., Gaidano, G., Chadbum, A., Cesarman, E., Dalla-Favera, R., and 
Carbone, A. (2003). Gene expression profile analysis of AIDS-related primary effusion 
lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific 
transcripts. Blood 101, 4115-4121.
242
Klein, U., Rajewsky, K., and Kuppers, R. (1998). Human immunoglobulin (Ig)M+IgD+ 
peripheral blood B cells expressing the CD27 cell surface antigen carry somatically 
mutated variable region genes: CD27 as a general marker for somatically mutated 
(memory) B cells. J Exp Med 188, 1679-1689.
Kleizen, B., and Braakman, I. (2004). Protein folding and quality control in the 
endoplasmic reticulum. Curr Opin Cell Biol 16, 343-349.
Kliche, S., Kremmer, E., Hammerschmidt, W., Koszinowski, U., and Haas, J. (1998). 
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 
8. J Virol 72,8143-8149.
Kluin-Nelemans, J. C., Wientjens, G. J., and Jansen, J. H. (1992). Establishment of a 
new human B-cell line (BONNA-12) with trisomy 9 and trisomy 12 chromosomal 
abnormality. Leukemia 6, 158.
Knowles, D. M. (2003). Etiology and pathogenesis of AIDS-related non-Hodgkin's 
lymphoma. Hematol Oncol Clin North Am 17, 785-820.
Knowles, D. M., Inghirami, G., Ubriaco, A., and Dalla-Favera, R. (1989). Molecular 
genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates 
their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. 
Blood 73, 792-799.
Koelle, D. M., Huang, M. L., Chandran, B., Vieira, J., Piepkom, M., and Corey, L.
(1997). Frequent detection of Kaposi's sarcoma-associated herpesvirus (human 
herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical 
and immunologic correlates. J Infect Dis 176, 94-102.
Kojima, H., Sitkovsky, M. V., and Cascalho, M. (2003). HIF-1 alpha deficiency 
perturbs T and B cell functions. Curr Pharm Des 9, 1827-1832.
Komanduri, K. V., Luce, J. A., McGrath, M. S., Hemdier, B. G., and Ng, V. L. (1996). 
The natural history and molecular heterogeneity of HIV-associated primary malignant 
lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol 13, 215-226.
243
Komori, T., Okada, A., Stewart, V., and Alt, F. W. (1993). Lack of N regions in antigen 
receptor variable region genes of TdT-deficient lymphocytes. Science 261, 1171-1175.
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., 
Zinkemagel, R., Bluethmann, H., and Kohler, G. (1994). Impaired immune and acute- 
phase responses in interleukin-6-deficient mice. Nature 368, 339-342.
Kosco-Vilbois, M. H. (2003). Are follicular dendritic cells really good for nothing? Nat 
Rev Immunol 3, 764-769.
Kozmik, Z., Wang, S., Dorfler, P., Adams, B., and Busslinger, M. (1992). The promoter 
of the CD 19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell 
Biol 12, 2662-2672.
Kozutsumi, Y., Segal, M., Normington, K., Gething, M. J., and Sambrook, J. (1988). 
The presence of malfolded proteins in the endoplasmic reticulum signals the induction 
of glucose-regulated proteins. Nature 332, 462-464.
Kreidberg, J. A. (2000). Functions of alpha3betal integrin. Curr Opin Cell Biol 12, 548- 
553.
Krishnan, H. H., Naranatt, P. P., Smith, M. S., Zeng, L., Bloomer, C., and Chandran, B. 
(2004). Concurrent expression of latent and a limited number of lytic genes with 
immune modulation and antiapoptotic function by Kaposi's sarcoma-associated 
herpesvirus early during infection of primary endothelial and fibroblast cells and 
subsequent decline of lytic gene expression. J Virol 78, 3601-3620.
Kristie, T. M., Vogel, J. L., and Sears, A. E. (1999). Nuclear localization of the Cl 
factor (host cell factor) in sensory neurons correlates with reactivation of herpes simplex 
virus from latency. Proc Natl Acad Sci U S A  96, 1229-1233.
Kuhn, R., Rajewsky, K., and Muller, W. (1991). Generation and analysis of interleukin- 
4 deficient mice. Science 254, 707-710.
244
Kunkel, G. R., and Pederson, T. (1988). Upstream elements required for efficient 
transcription of a human U6 RNA gene resemble those of U1 and U2 genes even though 
a different polymerase is used. Genes Dev 2, 196-204.
Kuppers, R., Zhao, M., Hansmann, M. L., and Rajewsky, K. (1993). Tracing B cell 
development in human germinal centres by molecular analysis of single cells picked 
from histological sections. Embo J 12, 4955-4967.
La Boissiere, S., Hughes, T., and O'Hare, P. (1999). HCF-dependent nuclear import of 
VP 16. Embo J 18, 480-489.
Lacoste, V., Mauclere, P., Dubreuil, G., Lewis, J., Georges-Courbot, M. C., and 
Gessain, A. (2000). KSHV-like herpesviruses in chimps and gorillas. Nature 407, 151- 
152.
Laichalk, L. L., Hochberg, D., Babcock, G. J., Freeman, R. B., and Thorley-Lawson, D. 
A. (2002). The dispersal of mucosal memory B cells: evidence from persistent EBV 
infection. Immunity 16, 745-754.
Laichalk, L. L., and Thorley-Lawson, D. A. (2005). Terminal differentiation into 
plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79, 
1296-1307.
Lan, K., Kuppers, D. A., and Robertson, E. S. (2005a). Kaposi's sarcoma-associated 
herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen 
with recombination signal sequence-binding protein Jkappa, the major downstream 
effector of the Notch signaling pathway. J Virol 79, 3468-3478.
Lan, K., Kuppers, D. A., Verma, S. C., and Robertson, E. S. (2004). Kaposi's sarcoma- 
associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic 
replication by targeting Rta: a potential mechanism for virus-mediated control of 
latency. J Virol 78, 6585-6594.
Lan, K., Kuppers, D. A., Verma, S. C., Sharma, N., Murakami, M., and Robertson, E. S. 
(2005b). Induction of Kaposi's sarcoma-associated herpesvirus latency-associated
245
nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of 
latency. J Virol 79, 7453-7465.
Lang, J., Jackson, M., Teyton, L., Brunmark, A., Kane, K., and Nemazee, D. (1996). B 
cells are exquisitely sensitive to central tolerance and receptor editing induced by 
ultralow affinity, membrane-bound antigen. J Exp Med 184, 1685-1697.
Lanzavecchia, A. (1985). Antigen-specific interaction between T and B cells. Nature 
314, 537-539.
Lee, A. H., Iwakoshi, N. N., Anderson, K. C., and Glimcher, L. H. (2003a). Proteasome 
inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U 
S A 100, 9946-9951.
Lee, A. H., Iwakoshi, N. N., and Glimcher, L. H. (2003b). XBP-1 regulates a subset of 
endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol 
Cell Biol 23, 7448-7459.
Lee, G., Namen, A. E., Gillis, S., and Kincade, P. W. (1988). Recombinant interleukin-7 
supports the growth of normal B lymphocyte precursors. Curr Top Microbiol Immunol 
141, 16-18.
Lee, K., Tirasophon, W., Shen, X., Michalak, M., Prywes, R., Okada, T., Yoshida, H., 
Mori, K., and Kaufman, R. J. (2002a). IRE 1-mediated unconventional mRNA splicing 
and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded 
protein response. Genes Dev 16, 452-466.
Lee, K. H., Holdorf, A. D., Dustin, M. L., Chan, A. C., Allen, P. M., and Shaw, A. S. 
(2002b). T cell receptor signaling precedes immunological synapse formation. Science 
295, 1539-1542.
Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854.
246
Lee, Y., Jeon, K., Lee, J. T., Kim, S., and Kim, V. N. (2002c). MicroRNA maturation: 
stepwise processing and subcellular localization. Embo J 21, 4663-4670.
Lee, Y. S., Nakahara, K., Pham, J. W., Kim, K , He, Z., Sontheimer, E. J., and Carthew, 
R. W. (2004). Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA 
silencing pathways. Cell 117, 69-81.
Lehman, I. R., and Boehmer, P. E. (1999). Replication of herpes simplex virus DNA. J 
Biol Chem 274, 28059-28062.
Lennette, E. T., Blackboum, D. J., and Levy, J. A. (1996). Antibodies to human 
herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 
348, 858-861.
Lever, A., Gottlinger, H., Haseltine, W., and Sodroski, J. (1989). Identification of a 
sequence required for efficient packaging of human immunodeficiency virus type 1 
RNA into virions. J Virol 63, 4085-4087.
Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C. C., and Kain, S. R.
(1998). Generation of destabilized green fluorescent protein as a transcription reporter. J 
Biol Chem 273, 34970-34975.
Liang, Y., Chang, J., Lynch, S. J., Lukac, D. M., and Ganem, D. (2002). The lytic 
switch protein of KSHV activates gene expression via functional interaction with RBP- 
Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev 16, 1977-1989.
Liang, Y., and Ganem, D. (2003). Lytic but not latent infection by Kaposi's sarcoma- 
associated herpesvirus requires host CSL protein, the mediator of Notch signaling. Proc 
Natl Acad Sci U S A 100, 8490-8495.
Liao, W., Tang, Y., Lin, S. F., Kung, H. J., and Giam, C. Z. (2003). K-bZIP of Kaposi's 
sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds 
KSHV/HHV-8 Rta and represses Rta-mediated transactivation. J Virol 77, 3809-3815.
247
Lim, C., Gwack, Y., Hwang, S., Kim, S., and Choe, J. (2001). The transcriptional 
activity of cAMP response element-binding protein-binding protein is modulated by the 
latency associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Biol 
Chem 276,31016-31022.
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., 
Bartel, D. P., Linsley, P. S., and Johnson, J. M. (2005). Microarray analysis shows that 
some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769-773.
Lin, C. L., Li, H., Wang, Y., Zhu, F. X., Kudchodkar, S., and Yuan, Y. (2003a). 
Kaposi's sarcoma-associated herpesvirus lytic origin (ori-Lyt)-dependent DNA 
replication: identification of the ori-Lyt and association of K8 bZip protein with the 
origin. J Virol 77, 5578-5588.
Lin, H., and Spradling, A. C. (1997). A novel group of pumilio mutations affects the 
asymmetric division of germline stem cells in the Drosophila ovary. Development 124, 
2463-2476.
Lin, K. I., Angelin-Duclos, C., Kuo, T. C., and Calame, K. (2002). Blimp-1-dependent 
repression of Pax-5 is required for differentiation of B cells to immunoglobulin M- 
secreting plasma cells. Mol Cell Biol 22, 4771-4780.
Lin, K. I., Tunyaplin, C., and Calame, K. (2003b). Transcriptional regulatory cascades 
controlling plasma cell differentiation. Immunol Rev 194, 19-28.
Lin, L., Gerth, A. J., and Peng, S. L. (2004). Active inhibition of plasma cell 
development in resting B cells by microphthalmia-associated transcription factor. J Exp 
Med 200, 115-122.
Lin, S. F., Robinson, D. R., Miller, G., and Kung, H. J. (1999). Kaposi’s sarcoma- 
associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein- 
Barr virus. J Virol 73, 1909-1917.
248
Lin, X., Ruan, X., Anderson, M. G., McDowell, J. A., Kroeger, P. E., Fesik, S. W., and 
Shen, Y. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt 
complementation. Nucleic Acids Res 33, 4527-4535.
Lingel, A., Simon, B., Izaurralde, E., and Sattler, M. (2004). Nucleic acid 3'-end 
recognition by the Argonaute2 PAZ domain. Nat Struct Mol Biol 11, 576-577.
Liou, H. C., Boothby, M. R., Finn, P. W., Davidon, R., Nabavi, N., Zeleznik-Le, N. J., 
Ting, J. P., and Glimcher, L. H. (1990). A new member of the leucine zipper class of 
proteins that binds to the HLA DR alpha promoter. Science 247, 1581-1584.
Lisitsyn, N., and Wigler, M. (1993). Cloning the differences between two complex 
genomes. Science 259, 946-951.
Litinskiy, M. B., Nardelli, B., Hilbert, D. M., He, B., Schaffer, A., Casali, P., and 
Cerutti, A. (2002). DCs induce CD40-independent immunoglobulin class switching 
through BLyS and APRIL. Nat Immunol 3, 822-829.
Liu, C. Y., Schroder, M., and Kaufman, R. J. (2000). Ligand-independent dimerization 
activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic 
reticulum. J Biol Chem 275, 24881-24885.
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., 
Hammond, S. M., Joshua-Tor, L., and Hannon, G. J. (2004). Argonaute2 is the catalytic 
engine of mammalian RNAi. Science 305, 1437-1441.
Liu, J., Valencia-Sanchez, M. A., Hannon, G. J., and Parker, R. (2005). MicroRNA- 
dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7, 
719-723.
Liu, L., Eby, M. T., Rathore, N., Sinha, S. K., Kumar, A., and Chaudhary, P. M. (2002). 
The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates 
with and persistently activates the Ikappa B kinase complex. J Biol Chem 277, 13745- 
13751.
249
Liu, Q., Rand, T. A., Kalidas, S., Du, F., Kim, H. E., Smith, D. P., and Wang, X.
(2003). R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi 
pathway. Science 301, 1921-1925.
Liu, Y. J., Joshua, D. E., Williams, G. T., Smith, C. A., Gordon, J., and MacLennan, I. 
C. (1989). Mechanism of antigen-driven selection in germinal centres. Nature 342, 929- 
931.
Liu, Y. J., Oldfield, S., and MacLennan, I. C. (1988). Memory B cells in T cell- 
dependent antibody responses colonize the splenic marginal zones. Eur J Immunol 18, 
355-362.
Llave, C., Xie, Z., Kasschau, K. D., and Carrington, J. C. (2002). Cleavage of 
Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 297, 
2053-2056.
Logan, A. C., Haas, D. L., Kafri, T., and Kohn, D. B. (2004). Integrated self- 
inactivating lentiviral vectors produce full-length genomic transcripts competent for 
encapsidation and integration. J Virol 78, 8421-8436.
Low, W., Harries, M., Ye, H., Du, M. Q., Boshoff, C., and Collins, M. (2001). Internal 
ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus 
FLICE inhibitory protein. J Virol 75, 2938-2945.
Lu, C., Zeng, Y., Huang, Z., Huang, L., Qian, C., Tang, G., and Qin, D. (2005a). 
Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated 
herpesvirus. Am J Pathol 166, 173-183.
Lu, F., Day, L., and Lieberman, P. M. (2005b). Kaposi's sarcoma-associated herpesvirus 
virion-induced transcription activation of the ORF50 immediate-early promoter. J Virol 
79, 13180-13185.
Lu, F., Zhou, J., Wiedmer, A., Madden, K., Yuan, Y., and Lieberman, P. M. (2003). 
Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter 
correlates with reactivation from latency. J Virol 77, 11425-11435.
250
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, 
A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005c). MicroRNA expression 
profiles classify human cancers. Nature 435, 834-838.
Lu, M., Suen, J., Frias, C., Pfeiffer, R., Tsai, M. H., Chuang, E., and Zeichner, S. L.
(2004). Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression 
program by using the viral DNA replication inhibitor cidofovir. J Virol 78, 13637- 
13652.
Lukac, D. M., Kirshner, J. R., and Ganem, D. (1999). Transcriptional activation by the 
product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is 
required for lytic viral reactivation in B cells. J Virol 73, 9348-9361.
Lukac, D. M., Renne, R., Kirshner, J. R., and Ganem, D. (1998). Reactivation of 
Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the 
ORF 50 transactivator, a homolog of the EBV R protein. Virology 252, 304-312.
Luna, R. E., Zhou, F., Baghian, A., Chouljenko, V., Forghani, B., Gao, S. J., and 
Kousoulas, K. G. (2004). Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is 
dispensable for virus entry. J Virol 78, 6389-6398.
Luppi, M., Barozzi, P., Maiorana, A., Artusi, T., Trovato, R., Marasca, R., Savarino, 
M., Ceccherini-Nelli, L., and Torelli, G. (1996). Human herpesvirus-8 DNA sequences 
in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and 
benign lymphadenopathy with giant germinal center hyperplasia and increased 
vascularity. Blood 87, 3903-3909.
Malik, P., Blackboum, D. J., Cheng, M. F., Hayward, G. S., and Clements, J. B. (2004). 
Functional co-operation between the Kaposi's sarcoma-associated herpesvirus ORF57 
and ORF50 regulatory proteins. J Gen Virol 85, 2155-2166.
Manche, L., Green, S. R., Schmedt, C., and Mathews, M. B. (1992). Interactions 
between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 12, 
5238-5248.
251
Marcelin, A. G., Grandadam, M., Flandre, P., Nicand, E., Milliancourt, C., Koeck, J. L., 
Philippon, M., Teyssou, R., Agut, H., Dupin, N., and Calvez, V. (2002). Kaposi's 
sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti. J Med Virol 
68, 164-167.
Marshall, K. R., Lachmann, R. H., Efstathiou, S., Rinaldi, A., and Preston, C. M. 
(2000). Long-term transgene expression in mice infected with a herpes simplex virus 
type 1 mutant severely impaired for immediate-early gene expression. J Virol 74, 956- 
964.
Martin, D. F., Kuppermann, B. D., Wolitz, R. A., Palestine, A. G., Li, H., and Robinson,
C. A. (1999). Oral ganciclovir for patients with cytomegalovirus retinitis treated with a 
ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340, 1063-1070.
Martin, F., and Kearney, J. F. (2000). B-cell subsets and the mature preimmune 
repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". 
Immunol Rev 175, 70-79.
Martin, F., Oliver, A. M., and Kearney, J. F. (2001). Marginal zone and B1 B cells unite 
in the early response against T-independent blood-bome particulate antigens. Immunity 
14, 617-629.
Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., and Tuschl, T. (2002). 
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563- 
574.
Martinez, J., and Tuschl, T. (2004). RISC is a 5' phosphomonoester-producing RNA 
endonuclease. Genes Dev 18, 975-980.
Maruyama, M., Lam, K. P., and Rajewsky, K. (2000). Memory B-cell persistence is 
independent of persisting immunizing antigen. Nature 407, 636-642.
252
Matolcsy, A. (1999). Primary effusional lymphoma: A new non-Hodgkin s lymphoma 
entity. Pathol Oncol Res 5, 87-89.
Matolcsy, A., Nador, R. G., Cesarman, E., and Knowles, D. M. (1998). 
Immunoglobulin VH gene mutational analysis suggests that primary effusion 
lymphomas derive from different stages of B cell maturation. Am J Pathol 153, 1609- 
1614.
Matsumura, S., Fujita, Y., Gomez, E., Tanese, N., and Wilson, A. C. (2005). Activation 
of the Kaposi’s sarcoma-associated herpesvirus major latency locus by the lytic switch 
protein RTA (ORF50). J Virol 79, 8493-8505.
Mbulaiteye, S. M., Pfeiffer, R. M., Whitby, D., Brubaker, G. R., Shao, J., and Biggar, R. 
J. (2003). Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis 
187, 1780-1785.
McAllister, R. M., Isaacs, H., Rongey, R., Peer, M., Au, W., Soukup, S. W., and 
Gardner, M. B. (1977). Establishment of a human medulloblastoma cell line. Int J 
Cancer 20, 206-212.
McAllister, S. C., Hansen, S. G., Messaoudi, I., Nikolich-Zugich, J., and Moses, A. V.
(2005). Increased efficiency of phorbol ester-induced lytic reactivation of Kaposi's 
sarcoma-associated herpesvirus during S phase. J Virol 79, 2626-2630.
McCormick, C., and Ganem, D. (2005). The kaposin B protein of KSHV activates the 
p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307, 739-741.
McHeyzer-Williams, L. J., Cool, M., and McHeyzer-Williams, M. G. (2000). Antigen- 
specific B cell memory: expression and replenishment of a novel b220(-) memory b cell 
compartment. J Exp Med 191,1149-1166.
McHeyzer-Williams, L. J., and McHeyzer-Williams, M. G. (2005). Antigen-specific 
memory B cell development. Annu Rev Immunol 23, 487-513.
253
McHeyzer-Williams, M. G. (2003). B cells as effectors. Curr Opin Immunol 15, 354- 
361.
McKean, D., Huppi, K., Bell, M., Staudt, L., Gerhard, W., and Weigert, M. (1984). 
Generation of antibody diversity in the immune response of BALB/c mice to influenza 
virus hemagglutinin. Proc Natl Acad Sci U S A 81, 3180-3184.
McKnight, A., Griffiths, D. J., Dittmar, M., Clapham, P., and Thomas, E. (2001). 
Characterization of a late entry event in the replication cycle of human 
immunodeficiency virus type 2. J Virol 75, 6914-6922.
McNiece, I. K., Langley, K. E., and Zsebo, K. M. (1991). Recombinant human stem cell 
factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor 
cells of the myeloid and erythroid lineages. Exp Hematol 19, 226-231.
Mehr, R., Shannon, M., and Litwin, S. (1999). Models for antigen receptor gene 
rearrangement. I. Biased receptor editing in B cells: implications for allelic exclusion. J 
Immunol 163, 1793-1798.
Meier, J. L., and Stinski, M. F. (1996). Regulation of human cytomegalovirus 
immediate-early gene expression. Intervirology 39, 331-342.
Meister, G., and Tuschl, T. (2004). Mechanisms of gene silencing by double-stranded 
RNA. Nature 431, 343-349.
Menezes, J., Leibold, W., Klein, G., and Clements, G. (1975). Establishment and 
characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line 
(BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. 
Biomedicine 22, 276-284.
Mentzer, S. J., Fingeroth, J., Reilly, J. J., Perrine, S. P., and Faller, D. V. (1998). 
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus- 
associated lymphoma. Blood Cells Mol Dis 24, 114-123.
254
Merat, R., Amara, A., Lebbe, C., de The, H., Morel, P., and Saib, A. (2002). HIV-1 
infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated 
herpesvirus (KSHV) reactivation. Int J Cancer 97, 791-795.
Mercader, M., Taddeo, B., Panella, J. R., Chandran, B., Nickoloff, B. J., and Foreman, 
K. E. (2000). Induction of HHV-8 lytic cycle replication by inflammatory cytokines 
produced by HIV-1-infected T cells. Am J Pathol 156, 1961-1971.
Mesri, E. A., Cesarman, E., Arvanitakis, L., Rafii, S., Moore, M. A., Posnett, D. N., 
Knowles, D. M., and Asch, A. S. (1996). Human herpesvirus-8/Kaposi's sarcoma- 
associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med 183, 
2385-2390.
Mettenleiter, T. C. (2004). Budding events in herpesvirus morphogenesis. Virus Res 
106, 167-180.
Miller, G., Heston, L., Grogan, E., Gradoville, L., Rigsby, M., Sun, R., Shedd, D., 
Kushnaryov, V. M., Grossberg, S., and Chang, Y. (1997). Selective switch between 
latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in 
dually infected body cavity lymphoma cells. J Virol 71, 314-324.
Miller, G., Rigsby, M. O., Heston, L., Grogan, E., Sun, R., Metroka, C., Levy, J. A., 
Gao, S. J., Chang, Y., and Moore, P. (1996). Antibodies to butyrate-inducible antigens 
of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J 
Med 334, 1292-1297.
Minks, M. A., West, D. K., Benvin, S., and Baglioni, C. (1979). Structural requirements 
of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein 
kinase of interferon-treated HeLa cells. J Biol Chem 254, 10180-10183.
Mitchell, G. F., Chan, E. L., Noble, M. S., Weissman, I. L., Mishell, R. I., and 
Herzenberg, L. A. (1972). Immunological memory in mice. 3. Memory to heterologous 
erythrocytes in both T cell and B cell populations and requirement for T cells in 
expression of B cell memory. Evidence using immunoglobulin allotype and mouse 
alloantigen theta markers with congenic mice. J Exp Med 135, 165-184.
255
Mittrucker, H. W., Matsuyama, T., Grossman, A., Kundig, T. M., Potter, J., Shahinian, 
A., Wakeham, A., Patterson, B., Ohashi, P. S., and Mak, T. W. (1997). Requirement for 
the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 
275, 540-543.
Miyagishi, M., and Taira, K. (2002). U6 promoter-driven siRNAs with four uridine 3' 
overhangs efficiently suppress targeted gene expression in mammalian cells. Nat 
Biotechnol 20, 497-500.
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). 
Development of a self-inactivating lentivirus vector. J Virol 72, 8150-8157.
Mocarski, J., Edward S., and Courcelle, C. T. (2001). Cytomegaloviruses and their 
replication. In Fields virology (Philadelphia ;London, Lippincott Williams & Wilkins), 
pp. Chapter 76.
Monini, P., Colombini, S., Sturzl, M., Goletti, D., Cafaro, A., Sgadari, C., Butto, S., 
Franco, M., Leone, P., Fais, S., et al. (1999). Reactivation and persistence of human 
herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in 
Kaposi’s sarcoma. Blood 93, 4044-4058.
Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N., and Kupfer, A. (1998). Three- 
dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 
82-86.
Montaner, S., Sodhi, A., Molinolo, A., Bugge, T. H., Sawai, E. T., He, Y., Li, Y., Ray, 
P. E., and Gutkind, J. S. (2003). Endothelial infection with KSHV genes in vivo reveals 
that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic 
potential of viral latent genes. Cancer Cell 3, 23-36.
Moore, P. S. (2003). Transplanting cancer: donor-cell transmission of Kaposi sarcoma. 
Nat Med 9, 506-508.
256
Moore, P. S., Boshoff, C., Weiss, R. A., and Chang, Y. (1996a). Molecular mimicry of 
human cytokine and cytokine response pathway genes by KSHV. Science 274, 1739- 
1744.
Moore, P. S., Gao, S. J., Dominguez, G., Cesarman, E., Lungu, O., Knowles, D. M., 
Garber, R., Pellett, P. E., McGeoch, D. J., and Chang, Y. (1996b). Primary 
characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 70, 
549-558.
Morris, K. V., Chan, S. W., Jacobsen, S. E., and Looney, D. J. (2004). Small interfering 
RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292.
Moses, A. V., Fish, K. N., Ruhl, R., Smith, P. P., Strussenberg, J. G., Zhu, L., 
Chandran, B., and Nelson, J. A. (1999). Long-term infection and transformation of 
dermal microvascular endothelial cells by human herpesvirus 8. J Virol 73, 6892-6902.
Mumm, J. S., and Kopan, R. (2000). Notch signaling: from the outside in. Dev Biol 
228, 151-165.
Muralidhar, S., Veytsmann, G., Chandran, B., Ablashi, D., Doniger, J., and Rosenthal, 
L. J. (2000). Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated 
herpesvirus) oncogene, kaposin (ORF K12). J Clin Virol 16, 203-213.
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and Honjo, T. 
(2000). Class switch recombination and hypermutation require activation-induced 
cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563.
Muranyi, W., Haas, J., Wagner, M., Krohne, G., and Koszinowski, U. H. (2002). 
Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 
297,854-857.
Murata, K., Ishii, N., Takano, H., Miura, S., Ndhlovu, L. C., Nose, M., Noda, T., and 
Sugamura, K. (2000). Impairment of antigen-presenting cell function in mice lacking 
expression of 0X40 ligand. J Exp Med 191, 365-374.
257
Nador, R. G., Cesarman, E., Chadbum, A., Dawson, D. B., Ansari, M. Q., Said, J., and 
Knowles, D. M. (1996). Primary effusion lymphoma: a distinct clinicopathologic entity 
associated with the Kaposi's sarcoma-associated herpes virus. Blood 88, 645-656.
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., 
Yoshida, N., Kikutani, H., and Kishimoto, T. (1996). Defects of B-cell lymphopoiesis 
and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. 
Nature 382, 635-638.
Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996). Efficient 
transfer, integration, and sustained long-term expression of the transgene in adult rat 
brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93, 11382-11388.
Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and 
Bird, A. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 
involves a histone deacetylase complex. Nature 393, 386-389.
Napoli, C., Lemieux, C., and Jorgensen, R. (1990). Introduction of a Chimeric Chalcone 
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous 
Genes in trans. Plant Cell 2, 279-289.
Naranatt, P. P., Krishnan, H. H., Smith, M. S., and Chandran, B. (2005). Kaposi's 
sarcoma-associated herpesvirus modulates microtubule dynamics via RhoA-GTP- 
diaphanous 2 signaling and utilizes the dynein motors to deliver its DNA to the nucleus. 
J Virol 79, 1191-1206.
Naranatt, P. P., Krishnan, H. H., Svojanovsky, S. R., Bloomer, C., Mathur, S., and 
Chandran, B. (2004). Host gene induction and transcriptional reprogramming in 
Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, 
fibroblast, and B cells: insights into modulation events early during infection. Cancer 
Res 64, 72-84.
Nemazee, D. A., and Burki, K. (1989). Clonal deletion of B lymphocytes in a transgenic 
mouse bearing anti-MHC class I antibody genes. Nature 337, 562-566.
258
Newcomb, W. W., Homa, F. L., Thomsen, D. R., Trus, B. L., Cheng, N., Steven, A., 
Booy, F., and Brown, J. C. (1999). Assembly of the herpes simplex virus procapsid 
from purified components and identification of small complexes containing the major 
capsid and scaffolding proteins. J Virol 73, 4239-4250.
Newcomb, W. W., Homa, F. L., Thomsen, D. R., Ye, Z., and Brown, J. C. (1994). Cell- 
free assembly of the herpes simplex virus capsid. J Virol 68, 6059-6063.
Newman, J. R., and Keating, A. E. (2003). Comprehensive identification of human bZIP 
interactions with coiled-coil arrays. Science 300, 2097-2101.
Nicholas, J., Zong, J. C., Alcendor, D. J., Ciufo, D. M., Poole, L. J., Sarisky, R. T., 
Chiou, C. J., Zhang, X., Wan, X., Guo, H. G., et al. (1998). Novel organizational 
features, captured cellular genes, and strain variability within the genome of 
KSHV/HHV8. J Natl Cancer Inst Monogr, 79-88.
Niu, H., Ye, B. H., and Dalla-Favera, R. (1998). Antigen receptor signaling induces 
MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription 
factor. Genes Dev 12, 1953-1961.
Novoa, I., Zhang, Y., Zeng, H., Jungreis, R., Harding, H. P., and Ron, D. (2003). Stress- 
induced gene expression requires programmed recovery from translational repression. 
Embo J22, 1180-1187.
Nutt, S. L., Heavey, B., Rolink, A. G., and Busslinger, M. (1999). Commitment to the 
B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562.
Nykanen, A., Haley, B., and Zamore, P. D. (2001). ATP requirements and small 
interfering RNA structure in the RNA interference pathway. Cell 107, 309-321.
O'Doherty, U., Swiggard, W. J., and Malim, M. H. (2000). Human immunodeficiency 
virus type 1 spinoculation enhances infection through virus binding. J Virol 74, 10074- 
10080.
259
Oettinger, M. A., Schatz, D. G., Gorka, C., and Baltimore, D. (1990). RAG-1 and RAG- 
2, adjacent genes that synergistically activate V(D)J recombination. Science 248, 1517- 
1523.
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996). 
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 
953-959.
Okabe, M., Matsushima, S., Morioka, M., Kobayashi, M., Abe, S., Sakurada, K., 
Kakinuma, M., and Miyazaki, T. (1987). Establishment and characterization of a cell 
line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute 
lymphocytic leukemia. Blood 69, 990-998.
Okazaki, I. M., Kinoshita, K., Muramatsu, M., Yoshikawa, K., and Honjo, T. (2002). 
The AID enzyme induces class switch recombination in fibroblasts. Nature 416, 340- 
345.
Oksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J. P., 
and Agbalika, F. (2000). High levels of human herpesvirus 8 viral load, human 
interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of 
multicentric castleman disease in HIV-infected patients. Blood 96, 2069-2073.
Okuno, T., Jiang, Y. B., Ueda, K., Nishimura, K., Tamura, T., and Yamanishi, K. 
(2002). Activation of human herpesvirus 8 open reading frame K5 independent of 
ORF50 expression. Virus Res 90, 77-89.
Ollila, J., and Vihinen, M. (2005). B cells. Int J Biochem Cell Biol 37, 518-523.
Olsen, P. H., and Ambros, V. (1999). The lin-4 regulatory RNA controls developmental 
timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the 
initiation of translation. Dev Biol 216, 671-680.
Operskalski, E. A., Busch, M. P., Mosley, J. W., and Kedes, D. H. (1997). Blood 
donations and viruses. Lancet 349, 1327.
260
Orban, T. I., and Izaurralde, E. (2005). Decay of mRNAs targeted by RISC requires 
XRN1, the Ski complex, and the exosome. Rna 11, 459-469.
Otsuki, T., Kumar, S., Ensoli, B., Kingma, D. W., Yano, T., Stetler-Stevenson, M., 
Jaffe, E. S., and Raffeld, M. (1996). Detection of HHV-8/KSHV DNA sequences in 
AIDS-associated extranodal lymphoid malignancies. Leukemia 10, 1358-1362.
Ozaki, K., Spolski, R., Ettinger, R., Kim, H. P., Wang, G., Qi, C. F., Hwu, P., Shaffer,
D. J., Akilesh, S., Roopenian, D. C., et al. (2004). Regulation of B cell differentiation 
and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 
173, 5361-5371.
Ozaki, K., Spolski, R., Feng, C. G., Qi, C. F., Cheng, J., Sher, A., Morse, H. C., 3rd, 
Liu, C., Schwartzberg, P. L., and Leonard, W. J. (2002). A critical role for IL-21 in 
regulating immunoglobulin production. Science 298, 1630-1634.
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., and Conklin, D. S. (2002). 
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. 
Genes Dev 16, 948-958.
Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S., Balija, 
V., O'Shaughnessy, A., Gnoj, L., Scobie, K., et al. (2004). A resource for large-scale 
RNA-interference-based screens in mammals. Nature 428, 427-431.
Page, C. P. (1997). Proteoglycans: the "Teflon" of the airways? Thorax 52, 924-925.
Page, K. A., Landau, N. R., and Littman, D. R. (1990). Construction and use of a human 
immunodeficiency virus vector for analysis of virus infectivity. J Virol 64, 5270-5276.
Panagopoulos, D., Victoratos, P., Alexiou, M., Kollias, G., and Mosialos, G. (2004). 
Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus 
oncoprotein LMP1 in vivo. J Virol 78, 13253-13261.
Park, H., Davies, M. V., Langland, J. O., Chang, H. W., Nam, Y. S., Tartaglia, J., 
Paoletti, E., Jacobs, B. L., Kaufman, R. J., and Venkatesan, S. (1994). TAR RNA-
261
binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl 
Acad Sci U S A 91, 4713-4717.
Parker, J. S., Roe, S. M., and Barford, D. (2004). Crystal structure of a PIWI protein 
suggests mechanisms for siRNA recognition and slicer activity. Embo J 23, 4727-4737.
Parravicini, C., Chandran, B., Corbellino, M., Berti, E., Paulli, M., Moore, P. S., and 
Chang, Y. (2000). Differential viral protein expression in Kaposi's sarcoma-associated 
herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and 
multicentric Castleman's disease. Am J Pathol 156, 743-749.
Parravicini, C., Olsen, S. J., Capra, M., Poli, F., Sirchia, G., Gao, S. J., Berti, E., 
Nocera, A., Rossi, E., Bestetti, G., et al. (1997a). Risk of Kaposi's sarcoma-associated 
herpes virus transmission from donor allografts among Italian posttransplant Kaposi's 
sarcoma patients. Blood 90, 2826-2829.
Parravinci, C., Corbellino, M., Paulli, M., Magrini, U., Lazzarino, M., Moore, P. S., and 
Chang, Y. (1997!). Expression of a virus-derived cytokine, KSHV vIL-6, in HIV- 
seronegative Castleman's disease. Am J Pathol 151, 1517-1522.
Pasquinelli, A. E., Hunter, S., and Bracht, J. (2005). MicroRNAs: a developing story. 
Curr Opin Genet Dev 15, 200-205.
Pastore, C., Gloghini, A., Volpe, G., Nomdedeu, J., Leonardo, E., Mazza, U., Saglio, 
G., Carbone, A., and Gaidano, G. (1995). Distribution of Kaposi's sarcoma herpesvirus 
sequences among lymphoid malignancies in Italy and Spain. Br J Haematol 91, 918- 
920.
Pauk, J., Huang, M. L., Brodie, S. J., Wald, A., Koelle, D. M., Schacker, T., Celum, C., 
Selke, S., and Corey, L. (2000). Mucosal shedding of human herpesvirus 8 in men. N 
Engl J Med 343, 1369-1377.
Paul, C. P., Good, P. D., Winer, I., and Engelke, D. R. (2002). Effective expression of 
small interfering RNA in human cells. Nat Biotechnol 20, 505-508.
262
Pearce, M., Matsumura, S., and Wilson, A. C. (2005). Transcripts encoding K12, v- 
FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus 
originate from a common promoter. J Virol 79, 14457-14464.
Pebemard, S., and Iggo, R. D. (2004). Determinants of interferon-stimulated gene 
induction by RNAi vectors. Differentiation 72, 103-111.
Persengiev, S. P., Zhu, X., and Green, M. R. (2004). Nonspecific, concentration- 
dependent stimulation and repression of mammalian gene expression by small 
interfering RNAs (siRNAs). Rna 10, 12-18.
Pertel, P. E. (2002). Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate 
cell fusion. J Virol 76, 4390-4400.
Pfeffer, S., Sewer, A., Lagos-Quintana, M., Sheridan, R., Sander, C., Grasser, F. A., van 
Dyk, L. F., Ho, C. K., Shuman, S., Chien, M., et al. (2005). Identification of 
microRNAs of the herpesvirus family. Nat Methods 2, 269-276.
Pfeffer, S., Zavolan, M., Grasser, F. A., Chien, M., Russo, J. J., Ju, J., John, B., Enright, 
A. J., Marks, D., Sander, C., and Tuschl, T. (2004). Identification of virus-encoded 
microRNAs. Science 304, 734-736.
Pham, J. W., Pellino, J. L., Lee, Y. S., Carthew, R. W., and Sontheimer, E. J. (2004). A 
Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila. 
Cell 117, 83-94.
Pillai, R. S., Artus, C. G., and Filipowicz, W. (2004). Tethering of human Ago proteins 
to mRNA mimics the miRNA-mediated repression of protein synthesis. Rna 10, 1518- 
1525.
Pillai, R. S., Bhattacharyya, S. N., Artus, C. G., Zoller, T., Cougot, N., Basyuk, E., 
Bertrand, E., and Filipowicz, W. (2005a). Inhibition of translational initiation by Let-7 
MicroRNA in human cells. Science 309, 1573-1576.
263
Pillai, S., Cariappa, A., and Moran, S. T. (2005b). Marginal zone B cells. Annu Rev 
Immunol 23, 161-196.
Piskurich, J. F., Lin, K. I., Lin, Y., Wang, Y., Ting, J. P., and Calame, K. (2000). 
BLIMP-I mediates extinction of major histocompatibility class II transactivator 
expression in plasma cells. Nat Immunol 1, 526-532.
Plancoulaine, S., Abel, L., van Beveren, M., Tregouet, D. A., Joubert, M., Tortevoye, 
P., de The, G., and Gessain, A. (2000). Human herpesvirus 8 transmission from mother 
to child and between siblings in an endemic population. Lancet 356, 1062-1065.
Platt, G. M., Cannell, E., Cuomo, M. E., Singh, S., and Mittnacht, S. (2000). Detection 
of the human herpesvirus 8-encoded cyclin protein in primary effusion lymphoma- 
derived cell lines. Virology 272, 257-266.
Popov, S., Rexach, M., Ratner, L., Blobel, G., and Bukrinsky, M. (1998). Viral protein 
R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J 
Biol Chem 273, 13347-13352.
Post, L. E., Mackem, S., and Roizman, B. (1981). Regulation of alpha genes of herpes 
simplex virus: expression of chimeric genes produced by fusion of thymidine kinase 
with alpha gene promoters. Cell 24, 555-565.
Pulvertaft, J. V. (1964). Cytology of Burkitt's Tumour (African Lymphoma). Lancet 39, 
238-240.
Qin, X. F., Schwers, S., Yu, W., Papavasiliou, F., Suh, H., Nussenzweig, A., Rajewsky, 
K., and Nussenzweig, M. C. (1999). Secondary V(D)J recombination in B-l cells. 
Nature 397, 355-359.
Qiu, G., and Stavnezer, J. (1998). Overexpression of BSAP/Pax-5 inhibits switching to 
IgA and enhances switching to IgE in the 1.29 mu B cell line. J Immunol 161, 2906- 
2918.
264
Quah, B. J., and O'Neill, H. C. (2005). Maturation of function in dendritic cells for 
tolerance and immunity. J Cell Mol Med 9, 643-654.
Quinonez, R., and Sutton, R. E. (2002). Lentiviral vectors for gene delivery into cells. 
DNA Cell Biol 21, 937-951.
Raab-Traub, N., and Flynn, K. (1986). The structure of the termini of the Epstein-Barr 
virus as a marker of clonal cellular proliferation. Cell 47, 883-889.
Rada, C., Williams, G. T., Nilsen, H., Barnes, D. E., Lindahl, T., and Neuberger, M. S.
(2002). Immunoglobulin isotype switching is inhibited and somatic hypermutation 
perturbed in UNG-deficient mice. Curr Biol 12, 1748-1755.
Radkov, S. A., Kellam, P., and Boshoff, C. (2000). The latent nuclear antigen of Kaposi 
sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the 
oncogene Hras transforms primary rat cells. Nat Med 6, 1121-1127.
Rainbow, L., Platt, G. M., Simpson, G. R., Sarid, R., Gao, S. J., Stoiber, H., Herrington,
C. S., Moore, P. S., and Schulz, T. F. (1997). The 222- to 234-kilodalton latent nuclear 
protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is 
encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 
71,5915-5921.
Ramezani, A., Hawley, T. S., and Hawley, R. G. (2000). Lentiviral vectors for enhanced 
gene expression in human hematopoietic cells. Mol Ther 2, 458-469.
Rand, T. A., Ginalski, K., Grishin, N. V., and Wang, X. (2004). Biochemical 
identification of Argonaute 2 as the sole protein required for RNA-induced silencing 
complex activity. Proc Natl Acad Sci U S A  101, 14385-14389.
Reed, J. A., Nador, R. G., Spaulding, D., Tani, Y., Cesarman, E., and Knowles, D. M.
(1998). Demonstration of Kaposi's sarcoma-associated herpes virus cyclin D homolog 
in cutaneous Kaposi's sarcoma by colorimetric in situ hybridization using a catalyzed 
signal amplification system. Blood 91, 3825-3832.
265
Reimold, A. M., Iwakoshi, N. N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., 
Gravallese, E. M., Friend, D., Grusby, M. J., Alt, F., and Glimcher, L. H. (2001). 
Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300- 
307.
Reimold, A. M., Ponath, P. D., Li, Y. S., Hardy, R. R., David, C. S., Strominger, J. L., 
and Glimcher, L. H. (1996). Transcription factor B cell lineage-specific activator 
protein regulates the gene for human X-box binding protein 1. J Exp Med 183, 393-401.
Reljic, R., Wagner, S. D., Peakman, L. J., and Fearon, D. T. (2000). Suppression of 
signal transducer and activator of transcription 3-dependent B lymphocyte terminal 
differentiation by BCL-6. J Exp Med 192, 1841-1848.
Renne, R., Barry, C., Dittmer, D., Compitello, N., Brown, P. O., and Ganem, D. (2001). 
Modulation of cellular and viral gene expression by the latency-associated nuclear 
antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 75, 458-468.
Renne, R., Blackboum, D., Whitby, D., Levy, J., and Ganem, D. (1998). Limited 
transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol 72, 
5182-5188.
Renne, R., Lagunoff, M., Zhong, W., and Ganem, D. (1996a). The size and 
conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA 
in infected cells and virions. J Virol 70, 8151-8154.
Renne, R., Zhong, W., Hemdier, B., McGrath, M., Abbey, N., Kedes, D., and Ganem,
D. (1996b). Lytic growth of Kaposi's sarcoma-associated herpesvirus (human 
herpesvirus 8) in culture. Nat Med 2, 342-346.
Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O., Catalan, N., 
Forveille, M., Dufourcq-Labelouse, R., Gennery, A., et al. (2000). Activation-induced 
cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper- 
IgM syndrome (HIGM2). Cell 102, 565-575.
266
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., and Khvorova, A.
(2004). Rational siRNA design for RNA interference. Nat Biotechnol 22, 326-330.
Rhoades, M. W., Reinhart, B. J., Lim, L. P., Burge, C. B., Bartel, B., and Bartel, D. P.
(2002). Prediction of plant microRNA targets. Cell 110, 513-520.
Rinkenberger, J. L., Wallin, J. J., Johnson, K. W., and Koshland, M. E. (1996). An 
interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J 
chain gene. Immunity 5, 377-386.
Rivas, C., Thlick, A. E., Parravicini, C., Moore, P. S., and Chang, Y. (2001). Kaposi's 
sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that 
inhibits p53. J Virol 75, 429-438.
Rivas, F. V., Tolia, N. H., Song, J. J., Aragon, J. P., Liu, J., Hannon, G. J., and Joshua- 
Tor, L. (2005). Purified Argonaute2 and an siRNA form recombinant human RISC. Nat 
Struct Mol Biol 12, 340-349.
Robles, R., Lugo, D., Gee, L., and Jacobson, M. A. (1999). Effect of antiviral drugs 
used to treat cytomegalovirus end-organ disease on subsequent course of previously 
diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum 
Retrovirol 20, 34-38.
Roizman, B., Carmichael, L. E., Deinhardt, F., de-The, G., Nahmias, A. J., Plowright, 
W., Rapp, F., Sheldrick, P., Takahashi, M., and Wolf, K. (1981). Herpesviridae. 
Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the 
International Committee on Taxonomy of Viruses. Intervirology 16, 201-217.
Roizman, B., and Knipe, D. M. (2001). Herpes simplex viruses and their replication. In 
Fields virology (Philadelphia ;London, Lippincott Williams & Wilkins), pp. Chapter 72.
Roller, R. J., Zhou, Y., Schnetzer, R., Ferguson, J., and DeSalvo, D. (2000). Herpes 
simplex virus type 1 U(L)34 gene product is required for viral envelopment. J Virol 74, 
117-129.
267
Rose, T. M., Strand, K. B., Schultz, E. R., Schaefer, G., Rankin, G. W., Jr., Thouless, 
M. E., Tsai, C. C., and Bosch, M. L. (1997). Identification of two homologs of the 
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal 
fibromatosis of different macaque species. J Virol 71, 4138-4144.
Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., 
Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B., et al. (2003). A lentivirus- 
based system to functionally silence genes in primary mammalian cells, stem cells and 
transgenic mice by RNA interference. Nat Genet 33, 401-406.
Russell, D. M., Dembic, Z., Morahan, G., Miller, J. F., Burki, K., and Nemazee, D. 
(1991). Peripheral deletion of self-reactive B cells. Nature 354, 308-311.
Russo, J. J., Bohenzky, R. A., Chien, M. C., Chen, J., Yan, M., Maddalena, D., Parry, J. 
P., Peruzzi, D., Edelman, I. S., Chang, Y., and Moore, P. S. (1996). Nucleotide 
sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U 
S A 93, 14862-14867.
Rywlin, A. M., Rosen, L., and Cabello, B. (1983). Coexistence of Castleman's disease 
and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 5, 277- 
281.
Sadler, R., Wu, L., Forghani, B., Renne, R., Zhong, W., Hemdier, B., and Ganem, D.
(1999). A complex translational program generates multiple novel proteins from the 
latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J 
Virol 73, 5722-5730.
Sakakibara, S., Ueda, K., Chen, J., Okuno, T., and Yamanishi, K. (2001). Octamer- 
binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated 
herpesvirus ORF50/Lyta gene expression. J Virol 75, 6894-6900.
Samaniego, L. A., Neiderhiser, L., and DeLuca, N. A. (1998). Persistence and 
expression of the herpes simplex virus genome in the absence of immediate-early 
proteins. J Virol 72, 3307-3320.
268
Samols, M. A., Hu, J., Skalsky, R. L., and Renne, R. (2005). Cloning and identification 
of a microRNA cluster within the latency-associated region of Kaposi’s sarcoma- 
associated herpesvirus. J Virol 79, 9301-9305.
Sarid, R., Wiezorek, J. S., Moore, P. S., and Chang, Y. (1999). Characterization and cell 
cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human 
herpesvirus 8) latent genes and their promoter. J Virol 73, 1438-1446.
Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N. J., Wolfsberg, T. G., Umayam, L., 
Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattachaijee, A., Meyerson, M., and 
Collins, F. S. (2004). Short interfering RNAs can induce unexpected and divergent 
changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S 
A 101, 1892-1897.
Scanlan, P. M., Tiwari, V., Bommireddy, S., and Shukla, D. (2005). Spinoculation of 
heparan sulfate deficient cells enhances HSV-1 entry, but does not abolish the need for 
essential glycoproteins in viral fusion. J Virol Methods 128, 104-112.
Schaadt, M., Fonatsch, C., Kirchner, H., and Diehl, V. (1979). Establishment of a 
malignant, Epstein-Barr-virus (EBV)-negative cell-line from the pleura effusion of a 
patient with Hodgkin's disease. Blut 38, 185-190.
Schafer, A., Lengenfelder, D., Grillhosl, C., Wieser, C., Fleckenstein, B., and Ensser, A.
(2003). The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits 
lytic virus replication. J Virol 77, 5911-5925.
Scherer, W. F., Syverton, J. T., and Gey, G. O. (1953). Studies on the propagation in 
vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human 
malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the 
cervix. J Exp Med 97, 695-710.
Schliephake, D. E., and Schimpl, A. (1996). Blimp-1 overcomes the block in IgM 
secretion in lipopolysaccharide/anti-mu F(ab’)2-co-stimulated B lymphocytes. Eur J 
Immunol 26, 268-271.
269
Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., and Bushman, F. (2002). 
HIV-1 integration in the human genome favors active genes and local hotspots. Cell 
110, 521-529.
Schroder, M., and Kaufman, R. J. (2005). The mammalian unfolded protein response. 
Annu Rev Biochem 74, 739-789.
Schulz, T. F. (1998). Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). J 
Gen Virol 79 ( Pt 7), 1573-1591.
Schulz, T. F. (1999). Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human 
herpesvirus 8. Adv Cancer Res 76, 121-160.
Schulz, T. F. (2000). Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): 
epidemiology and pathogenesis. J Antimicrob Chemother 45 Suppl T3, 15-27.
Schulz, T. F. (2006). The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 
208, 187-198.
Schwartz, R. A. (2004). Kaposi's sarcoma: an update. J Surg Oncol 87, 146-151.
Schwartz, S., Felber, B. K., Benko, D. M., Fenyo, E. M., and Pavlakis, G. N. (1990). 
Cloning and functional analysis of multiply spliced mRNA species of human 
immunodeficiency virus type 1. J Virol 64, 2519-2529.
Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P. D. (2003). 
Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208.
Semizarov, D., Kroeger, P., and Fesik, S. (2004). siRNA-mediated gene silencing: a 
global genome view. Nucleic Acids Res 32, 3836-3845.
Sen, G. C., and Sarkar, S. N. (2005). Transcriptional signaling by double-stranded 
RNA: role of TLR3. Cytokine Growth Factor Rev 16, 1-14.
270
Sen, G. L., and Blau, H. M. (2005). Argonaute 2/RISC resides in sites of mammalian 
mRNA decay known as cytoplasmic bodies. Nat Cell Biol 7, 633-636.
Shaffer, A. L., Lin, K. I., Kuo, T. C., Yu, X., Hurt, E. M., Rosenwald, A., Giltnane, J. 
M., Yang, L., Zhao, H., Calame, K., and Staudt, L. M. (2002). Blimp-1 orchestrates 
plasma cell differentiation by extinguishing the mature B cell gene expression program. 
Immunity 17, 51-62.
Shaffer, A. L., Peng, A., and Schlissel, M. S. (1997). In vivo occupancy of the kappa 
light chain enhancers in primary pro- and pre-B cells: a model for kappa locus 
activation. Immunity 6, 131-143.
Shaffer, A. L., Shapiro-Shelef, M., Iwakoshi, N. N., Lee, A. H., Qian, S. B., Zhao, H., 
Yu, X., Yang, L., Tan, B. K., Rosenwald, A., et al. (2004). XBP1, downstream of 
Blimp-1, expands the secretory apparatus and other organelles, and increases protein 
synthesis in plasma cell differentiation. Immunity 21, 81-93.
Shaffer, A. L., Yu, X., He, Y., Boldrick, J., Chan, E. P., and Staudt, L. M. (2000). BCL- 
6 represses genes that function in lymphocyte differentiation, inflammation, and cell 
cycle control. Immunity 13, 199-212.
Shamu, C. E., and Walter, P. (1996). Oligomerization and phosphorylation of the Irelp 
kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. 
Embo J 15, 3028-3039.
Shapiro-Shelef, M., and Calame, K. (2004). Plasma cell differentiation and multiple 
myeloma. Curr Opin Immunol 16, 226-234.
Shapiro-Shelef, M., and Calame, K. (2005). Regulation of plasma-cell development. 
Nat Rev Immunol 5, 230-242.
Shapiro-Shelef, M., Lin, K. I., McHeyzer-Williams, L. J., Liao, J., McHeyzer-Williams, 
M. G., and Calame, K. (2003). Blimp-1 is required for the formation of immunoglobulin 
secreting plasma cells and pre-plasma memory B cells. Immunity 19, 607-620.
271
Sharma-Walia, N., Krishnan, H. H., Naranatt, P. P., Zeng, L., Smith, M. S., and 
Chandran, B. (2005). ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated 
herpesvirus (human herpesvirus 8) early during infection of target cells are essential for 
expression of viral genes and for establishment of infection. J Virol 79, 10308-10329.
Sharma-Walia, N., Naranatt, P. P., Krishnan, H. H., Zeng, L., and Chandran, B. (2004). 
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein 
gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3- 
kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 78, 4207- 
4223.
Sharp, T. V., Wang, H. W., Koumi, A., Hollyman, D., Endo, Y., Ye, H., Du, M. Q., and 
Boshoff, C. (2002). K15 protein of Kaposi's sarcoma-associated herpesvirus is latently 
expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol 76, 802- 
816.
Shaw, R. N., Arbiser, J. L., and Offermann, M. K. (2000). Valproic acid induces human 
herpesvirus 8 lytic gene expression in BCBL-1 cells. Aids 14, 899-902.
Shen, J., Chen, X., Hendershot, L., and Prywes, R. (2002). ER stress regulation of 
ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi 
localization signals. Dev Cell 3, 99-111.
Shih, T. A., Meffre, E., Roederer, M., and Nussenzweig, M. C. (2002). Role of BCR 
affinity in T cell dependent antibody responses in vivo. Nat Immunol 3, 570-575.
Silva, J. M., Sachidanandam, R., and Hannon, G. J. (2003). Free energy lights the path 
toward more effective RNAi. Nat Genet 35, 303-305.
Siminoff, P., and Menefee, M. G. (1966). Normal and 5-bromodeoxyuridine-inhibited 
development of herpes simplex virus. An electron microscope study. Exp Cell Res 44, 
241-255.
272
Sinclair, J. (2000). Cellular sites and mechanisms of human cytomegalovirus 
replication. In DNA virus replication, A. Cann, ed. (Oxford, Oxford University Press), 
pp. xvi, 232.
Singh, M., and Birshtein, B. K. (1993). NF-HB (BSAP) is a repressor of the murine 
immunoglobulin heavy-chain 3’ alpha enhancer at early stages of B-cell differentiation. 
Mol Cell Biol 13, 3611-3622.
Singh, M., and Birshtein, B. K. (1996). Concerted repression of an immunoglobulin 
heavy-chain enhancer, 3' alpha E(hsl,2). Proc Natl Acad Sci U S A 93, 4392-4397.
Singh, R., Gupta, S., and Reddy, R. (1990). Capping of mammalian U6 small nuclear 
RNA in vitro is directed by a conserved stem-loop and AUAUAC sequence: conversion 
of a noncapped RNA into a capped RNA. Mol Cell Biol 10, 939-946.
Siolas, D., Lemer, C., Burchard, J., Ge, W., Linsley, P. S., Paddison, P. J., Hannon, G. 
J., and Cleary, M. A. (2005). Synthetic shRNAs as potent RNAi triggers. Nat 
Biotechnol 23, 227-231.
Sirven, A., Pflumio, F., Zennou, V., Titeux, M., Vainchenker, W., Coulombel, L., 
Dubart-Kupperschmitt, A., and Chameau, P. (2000). The human immunodeficiency 
virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear 
import and gene transduction of human hematopoietic stem cells. Blood 96, 4103-4110.
Sitas, F., Newton, R., and Boshoff, C. (1999). Increasing probability of mother-to-child 
transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J 
Med 340, 1923.
Skepper, J. N., Whiteley, A., Browne, H., and Minson, A. (2001). Herpes simplex virus 
nucleocapsids mature to progeny virions by an envelopment ~> deenvelopment --> 
reenvelopment pathway. J Virol 75, 5697-5702.
Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., and Williams, B. R. (2003). 
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5, 834- 
839.
273
Sledz, C. A., and Williams, B. R. (2004). RNA interference and double-stranded-RNA- 
activated pathways. Biochem Soc Trans 32, 952-956.
Snapper, C. M., and Paul, W. E. (1987). Interferon-gamma and B cell stimulatory 
factor-1 reciprocally regulate Ig isotype production. Science 236, 944-947.
Song, J., Ohkura, T., Sugimoto, M., Mori, Y., Inagi, R., Yamanishi, K., Yoshizaki, K., 
and Nishimoto, N. (2002). Human interleukin-6 induces human herpesvirus-8 
replication in a body cavity-based lymphoma cell line. J Med Virol 68, 404-411.
Sontheimer, E. J., and Carthew, R. W. (2005). Silence from within: endogenous siRNAs 
andmiRNAs. Cell 122, 9-12.
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., 
d'Agay, M. F., Clauvel, J. P., Raphael, M., Degos, L., and et al. (1995). Kaposi's 
sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's 
disease. Blood 86, 1276-1280.
Souza, T. A., Stollar, B. D., Sullivan, J. L., Luzuriaga, K., and Thorley-Lawson, D. A. 
(2005). Peripheral B cells latently infected with Epstein-Barr virus display molecular 
hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A 102, 
18093-18098.
Spear, P. G., and Longnecker, R. (2003). Herpesvirus entry: an update. J Virol 77, 
10179-10185.
Spencer, J., Perry, M. E., and Dunn-Walters, D. K. (1998). Human marginal-zone B 
cells. Immunol Today 19, 421-426.
Staskus, K. A., Sun, R., Miller, G., Racz, P., Jaslowski, A., Metroka, C., Brett-Smith, 
H., and Haase, A. T. (1999). Cellular tropism and viral interleukin-6 expression 
distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion 
lymphoma, and multicentric Castleman's disease. J Virol 73, 4181-4187.
274
Staskus, K. A., Zhong, W., Gebhard, K., Hemdier, B., Wang, H., Renne, R., Beneke, J., 
Pudney, J., Anderson, D. J., Ganem, D., and Haase, A. T. (1997). Kaposi’s sarcoma- 
associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71, 
715-719.
Stavnezer, J., and Schrader, C. E. (2006). Mismatch repair converts AID-instigated 
nicks to double-strand breaks for antibody class-switch recombination. Trends Genet 
22, 23-28.
Stem, S., Tanaka, M., and Herr, W. (1989). The Oct-1 homoeodomain directs formation 
of a multiprotein-DNA complex with the HSV transactivator VP 16. Nature 341, 624- 
630.
Stevenson, P. G. (2004). Immune evasion by gamma-herpesviruses. Curr Opin Immunol 
16, 456-462.
Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P., and Sodroski, J. 
(2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old 
World monkeys. Nature 427, 848-853.
Sturzl, M., Hohenadl, C., Zietz, C., Castanos-Velez, E., Wunderlich, A., Ascherl, G., 
Biberfeld, P., Monini, P., Browning, P. J., and Ensoli, B. (1999). Expression of K13/v- 
FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J 
Natl Cancer Inst 91, 1725-1733.
Sugiyama, T., Cam, H., Verdel, A., Moazed, D., and Grewal, S. I. (2005). RNA- 
dependent RNA polymerase is an essential component of a self-enforcing loop coupling 
heterochromatin assembly to siRNA production. Proc Natl Acad Sci U S A 102, 152- 
157.
Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., and Forrester, W. C. (2002). A DNA 
vector-based RNAi technology to suppress gene expression in mammalian cells. Proc 
Natl Acad Sci U S A 99, 5515-5520.
275
Sun, R., Lin, S. F., Staskus, K., Gradoville, L., Grogan, E., Haase, A., and Miller, G.
(1999). Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 
73, 2232-2242.
Svoboda, P., Stein, P., and Schultz, R. M. (2001). RNAi in mouse oocytes and 
preimplantation embryos: effectiveness of hairpin dsRNA. Biochem Biophys Res 
Commun 287, 1099-1104.
Swanton, C., Mann, D. J., Fleckenstein, B., Neipel, F., Peters, G., and Jones, N. (1997). 
Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 
390, 184-187.
Ta, V. T., Nagaoka, H., Catalan, N., Durandy, A., Fischer, A., Imai, K , Nonoyama, S., 
Tashiro, J., Ikegawa, M., Ito, S., et al. (2003). AID mutant analyses indicate requirement 
for class-switch-specific cofactors. Nat Immunol 4, 843-848.
Tabara, H., Sarkissian, M., Kelly, W. G., Fleenor, J., Grishok, A., Timmons, L., Fire, 
A., and Mello, C. C. (1999). The rde-1 gene, RNA interference, and transposon 
silencing in C. elegans. Cell 99, 123-132.
Tabara, H., Yigit, E., Siomi, H., and Mello, C. C. (2002). The dsRNA binding protein 
RDE-4 interacts with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. 
elegans. Cell 109, 861-871.
Tahbaz, N., Kolb, F. A., Zhang, H., Jaronczyk, K , Filipowicz, W., and Hobman, T. C. 
(2004). Characterization of the interactions between mammalian PAZ PIWI domain 
proteins and Dicer. EMBO Rep 5, 189-194.
Takahashi, Y., Cerasoli, D. M., Dal Porto, J. M., Shimoda, M., Freund, R., Fang, W., 
Telander, D. G., Malvey, E. N., Mueller, D. L., Behrens, T. W., and Kelsoe, G. (1999). 
Relaxed negative selection in germinal centers and impaired affinity maturation in bcl- 
xL transgenic mice. J Exp Med 190, 399-410.
276
Talbot, S. J., Weiss, R. A., Kellam, P., and Boshoff, C. (1999). Transcriptional analysis 
of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary 
effusion lymphoma cell line. Virology 257, 84-94.
Tangye, S. G., and Hodgkin, P. D. (2004). Divide and conquer: the importance of cell 
division in regulating B-cell responses. Immunology 112, 509-520.
Tanigaki, K., Han, H., Yamamoto, N., Tashiro, K., Ikegawa, M., Kuroda, K., Suzuki, 
A., Nakano, T., and Honjo, T. (2002). Notch-RBP-J signaling is involved in cell fate 
determination of marginal zone B cells. Nat Immunol 3, 443-450.
Thorley-Lawson, D. A. (2001). Epstein-Barr virus: exploiting the immune system. Nat 
Rev Immunol 1, 75-82.
Thorley-Lawson, D. A. (2005). EBV the prototypical human tumor virus—just how bad 
is it? J Allergy Clin Immunol 116, 251-261; quiz 262.
Thorley-Lawson, D. A., and Babcock, G. J. (1999). A model for persistent infection 
with Epstein-Barr virus: the stealth virus of human B cells. Life Sci 65, 1433-1453.
Thorley-Lawson, D. A., and Gross, A. (2004). Persistence of the Epstein-Barr virus and 
the origins of associated lymphomas. N Engl J Med 350, 1328-1337.
Thuerauf, D. J., Morrison, L., and Glembotski, C. C. (2004). Opposing roles for 
ATF6alpha and ATF6beta in endoplasmic reticulum stress response gene induction. J 
Biol Chem 279, 21078-21084.
Tiegs, S. L., Russell, D. M., and Nemazee, D. (1993). Receptor editing in self-reactive 
bone marrow B cells. J Exp Med 177, 1009-1020.
Tierney, R., Kirby, H., Nagra, J., Rickinson, A., and Bell, A. (2000). The Epstein-Barr 
virus promoter initiating B-cell transformation is activated by RFX proteins and the B- 
cell-specific activator protein BSAP/Pax5. J Virol 74, 10458-10467.
277
Tirosh, B., Iwakoshi, N. N., Glimcher, L. H., and Ploegh, H. L. (2005a). XBP-1 
specifically promotes IgM synthesis and secretion, but is dispensable for degradation of 
glycoproteins in primary B cells. J Exp Med 202, 505-516.
Tirosh, B., Iwakoshi, N. N., Glimcher, L. H., and Ploegh, H. L. (2005b). Rapid turnover 
of unspliced XBP-1 as a factor that modulates the unfolded protein response. J Biol 
Chem.
Tomari, Y., Matranga, C., Haley, B., Martinez, N., and Zamore, P. D. (2004). A protein 
sensor for siRNA asymmetry. Science 306, 1377-1380.
Tomida, A., Suzuki, H., Kim, H. D., and Tsuruo, T. (1996). Glucose-regulated stresses 
cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma 
protein in human cancer cells. Oncogene 13, 2699-2705.
Towers, G. J. (2005). Control of viral infectivity by tripartite motif proteins. Hum Gene 
Ther 16, 1125-1132.
Trus, B. L., Booy, F. P., Newcomb, W. W., Brown, J. C., Homa, F. L., Thomsen, D. R., 
and Steven, A. C. (1996). The herpes simplex virus procapsid: structure, conformational 
changes upon maturation, and roles of the triplex proteins VP 19c and VP23 in 
assembly. J Mol Biol 263, 447-462.
Tumang, J. R., Frances, R., Yeo, S. G., and Rothstein, T. L. (2005). Spontaneously Ig- 
secreting B-l cells violate the accepted paradigm for expression of differentiation- 
associated transcription factors. J Immunol 174, 3173-3177.
Tunyaplin, C., Shaffer, A. L., Angelin-Duclos, C. D., Yu, X., Staudt, L. M., and 
Calame, K. L. (2004). Direct repression of prdml by Bcl-6 inhibits plasmacytic 
differentiation. J Immunol 173, 1158-1165.
Turner, C. A., Jr., Mack, D. H., and Davis, M. M. (1994). Blimp-1, a novel zinc finger- 
containing protein that can drive the maturation of B lymphocytes into 
immunoglobulin-secreting cells. Cell 77, 297-306.
278
Turner, M., Gulbranson-Judge, A., Quinn, M. E., Walters, A. E., MacLennan, I. C., and 
Tybulewicz, V. L. (1997). Syk tyrosine kinase is required for the positive selection of 
immature B cells into the recirculating B cell pool. J Exp Med 186, 2013-2021.
Tusher, V. G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays 
applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98, 5116-5121.
van Anken, E., Romijn, E. P., Maggioni, C., Mezghrani, A., Sitia, R., Braakman, I., and 
Heck, A. J. (2003). Sequential waves of functionally related proteins are expressed 
when B cells prepare for antibody secretion. Immunity 18, 243-253.
van der Krol, A. R., Mur, L. A., Beld, M., Mol, J. N., and Stuitje, A. R. (1990). 
Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a 
suppression of gene expression. Plant Cell 2, 291-299.
van Huizen, R., Martindale, J. L., Gorospe, M., and Holbrook, N. J. (2003). P58IPK, a 
novel endoplasmic reticulum stress-inducible protein and potential negative regulator of 
eIF2alpha signaling. J Biol Chem 278, 15558-15564.
Vara, J. A., Portela, A., Ortin, J., and Jimenez, A. (1986). Expression in mammalian 
cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic 
Acids Res 14, 4617-4624.
Venugopal, R., and Jaiswal, A. K. (1998). Nrf2 and Nrfl in association with Jun 
proteins regulate antioxidant response element-mediated expression and coordinated 
induction of genes encoding detoxifying enzymes. Oncogene 17, 3145-3156.
Verdel, A., Jia, S., Gerber, S., Sugiyama, T., Gygi, S., Grewal, S. I., and Moazed, D.
(2004). RNAi-mediated targeting of heterochromatin by the RITS complex. Science 
303, 672-676.
Vermeulen, A., Behlen, L., Reynolds, A., Wolfson, A., Marshall, W. S., Karpilow, J., 
and Khvorova, A. (2005). The contributions of dsRNA structure to Dicer specificity and 
efficiency. Rna 11, 674-682.
279
Vieira, J., Huang, M. L., Koelle, D. M., and Corey, L. (1997). Transmissible Kaposi's 
sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of 
Kaposi's sarcoma. J Virol 71, 7083-7087.
Vieira, J., O'Heam, P., Kimball, L., Chandran, B., and Corey, L. (2001). Activation of 
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by 
human cytomegalovirus. J Virol 75, 1378-1386.
Vieira, J., and O'Heam, P. M. (2004). Use of the red fluorescent protein as a marker of 
Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325, 225-240.
Volpe, T. A., Kidner, C., Hall, I. M., Teng, G., Grewal, S. I., and Martienssen, R. A. 
(2002). Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by 
RNAi. Science 297, 1833-1837.
Waddick, K. G., and Uckun, F. M. (1993). CD5 antigen-positive B lymphocytes in 
human B cell ontogeny during fetal development and after autologous bone marrow 
transplantation. Exp Hematol 21, 791-798.
Wang, F., Gregory, C. D., Rowe, M., Rickinson, A. B., Wang, D., Birkenbach, M., 
Kikutani, H., Kishimoto, T., and Kieff, E. (1987). Epstein-Barr virus nuclear antigen 2 
specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad 
Sci U S A 84, 3452-3456.
Wang, H. W., Trotter, M. W., Lagos, D., Bourboulia, D., Henderson, S., Makinen, T., 
Elliman, S., Flanagan, A. M., Alitalo, K., and Boshoff, C. (2004a). Kaposi sarcoma 
herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial 
gene expression in Kaposi sarcoma. Nat Genet 36, 687-693.
Wang, Q. J., Jenkins, F. J., Jacobson, L. P., Kingsley, L. A., Day, R. D., Zhang, Z. W., 
Meng, Y. X., Pellett, P. E., Kousoulas, K. G., Baghian, A., and Rinaldo, C. R., Jr. 
(2001a). Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T- 
cell response to viral lytic cycle proteins. Blood 97, 2366-2373.
280
Wang, S., Liu, S., Wu, M. H., Geng, Y., and Wood, C. (2001b). Identification of a 
cellular protein that interacts and synergizes with the RTA (ORF50) protein of Kaposi's 
sarcoma-associated herpesvirus in transcriptional activation. J Virol 75, 11961-11973.
Wang, S. E., Wu, F. Y., Chen, H., Shamay, M., Zheng, Q., and Hayward, G. S. (2004b). 
Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA 
promoters by the tetradecanoyl phorbol acetate-induced API pathway. J Virol 78, 4248- 
4267.
Wang, S. E., Wu, F. Y., Yu, Y., and Hayward, G. S. (2003). CCAAT/enhancer-binding 
protein-alpha is induced during the early stages of Kaposi's sarcoma-associated 
herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication 
and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and 
PAN promoters. J Virol 77, 9590-9612.
Wang, Y., Li, H., Chan, M. Y., Zhu, F. X., Lukac, D. M., and Yuan, Y. (2004c). 
Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: cis-acting 
requirements for replication and ori-Lyt-associated RNA transcription. J Virol 78, 8615- 
8629.
Wang, Y. C., Zhang, Q., and Montalvo, E. A. (1998). Purification of Kaposi's sarcoma- 
associated herpesvirus (human herpesvirus 8) and analyses of the structural proteins. J 
Virol Methods 73, 219-228.
Waterston, A., and Bower, M. (2004). Fifty years of multicentric Castleman's disease. 
Acta Oncol 43, 698-704.
Weinberg, J. B., Matthews, T. J., Cullen, B. R., and Malim, M. H. (1991). Productive 
human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human 
monocytes. J Exp Med 174, 1477-1482.
Weinberg, R. A., and Penman, S. (1968). Small molecular weight monodisperse nuclear 
RNA. J Mol Biol 38, 289-304.
281
Weiss, J. M., Renkl, A. C., Maier, C. S., Kimmig, M., Liaw, L., Ahrens, T., Kon, S., 
Maeda, M., Hotta, H., Uede, T., and Simon, J. C. (2001). Osteopontin is involved in the 
initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic 
cell migration to lymph nodes. J Exp Med 194, 1219-1229.
Weiss, S. H., and Biggar, R. J. (1986). The epidemiology of human retrovirus-
associated illnesses. Mt Sinai J Med 53, 579-591.
Welihinda, A. A., and Kaufman, R. J. (1996). The unfolded protein response pathway in 
Saccharomyces cerevisiae. Oligomerization and trans-phosphorylation of Irelp (Emlp) 
are required for kinase activation. J Biol Chem 271, 18181-18187.
Weller, S., Braun, M. C., Tan, B. K., Rosenwald, A., Cordier, C., Conley, M. E., 
Plebani, A., Kumararatne, D. S., Bonnet, D., Toumilhac, O., et al. (2004). Human blood 
IgM "memory" B cells are circulating splenic marginal zone B cells harboring a 
prediversified immunoglobulin repertoire. Blood 104, 3647-3654.
Weller, S., Faili, A., Garcia, C., Braun, M. C., Le Deist, F. F., de Saint Basile, G. G.,
Hermine, O., Fischer, A., Reynaud, C. A., and Weill, J. C. (2001). CD40-CD40L
independent Ig gene hypermutation suggests a second B cell diversification pathway in 
humans. Proc Natl Acad Sci U S A  98, 1166-1170.
West, J. T., and Wood, C. (2003). The role of Kaposi’s sarcoma-associated 
herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control 
of gene expression. Oncogene 22, 5150-5163.
Whitby, D., Howard, M. R., Tenant-Flowers, M., Brink, N. S., Copas, A., Boshoff, C., 
Hatzioannou, T., Suggett, F. E., Aldam, D. M., Denton, A. S., and et al. (1995). 
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected 
individuals and progression to Kaposi’s sarcoma. Lancet 346, 799-802.
Williams, B. R. (2001). Signal integration via PKR. Sci STKE 2001, RE2.
Willis, I. M. (1993). RNA polymerase III. Genes, factors and transcriptional specificity. 
Eur J Biochem 212, 1-11.
282
Wilson, K. S., McKenna, R. W., Kroft, S. H., Dawson, D. B., Ansari, Q., and Schneider, 
N. R. (2002). Primary effusion lymphomas exhibit complex and recurrent cytogenetic 
abnormalities. Br J Haematol 116, 113-121.
Wiznerowicz, M., and Trono, D. (2005). Harnessing HIV for therapy, basic research 
and biotechnology. Trends Biotechnol 23, 42-47.
Wohrl, B. M., and Moelling, K. (1990). Interaction of HIV-1 ribonuclease H with 
polypurine tract containing RNA-DNA hybrids. Biochemistry 29, 10141-10147.
Wolniak, K. L., Shinall, S. M., and Waldschmidt, T. J. (2004). The germinal center 
response. Crit Rev Immunol 24, 39-65.
Wood, L. J., Baxter, M. K., Plafker, S. M., and Gibson, W. (1997). Human 
cytomegalovirus capsid assembly protein precursor (pUL80.5) interacts with itself and 
with the major capsid protein (pUL86) through two different domains. J Virol 71, 179- 
190.
Wu, F. Y., Ahn, J. H., Alcendor, D. J., Jang, W. J., Xiao, J., Hayward, S. D., and 
Hayward, G. S. (2001). Origin-independent assembly of Kaposi's sarcoma-associated 
herpesvirus DNA replication compartments in transient cotransfection assays and 
association with the ORF-K8 protein and cellular PML. J Virol 75, 1487-1506.
Wu, L., Lo, P., Yu, X., Stoops, J. K., Forghani, B., and Zhou, Z. H. (2000). Three- 
dimensional structure of the human herpesvirus 8 capsid. J Virol 74, 9646-9654.
Wysocka, J., and Herr, W. (2003). The herpes simplex virus VP16-induced complex: 
the makings of a regulatory switch. Trends Biochem Sci 28, 294-304.
Xu, Y., AuCoin, D. P., Huete, A. R., Cei, S. A., Hanson, L. J., and Pari, G. S. (2005). A 
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant 
is defective for reactivation of latent virus and DNA replication. J Virol 79, 3479-3487.
283
Yan, W., Frank, C. L., Korth, M. J., Sopher, B. L., Novoa, I., Ron, D., and Katze, M. G. 
(2002). Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress- 
induced molecular chaperone P58IPK. Proc Natl Acad Sci U S A 99, 15920-15925.
Yao, Q. Y., Ogan, P., Rowe, M., Wood, M., and Rickinson, A. B. (1989). Epstein-Barr 
virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J 
Cancer 43, 67-71.
Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S., 
and Goldstein, J. L. (2000). ER stress induces cleavage of membrane-bound ATF6 by 
the same proteases that process SREBPs. Mol Cell 6, 1355-1364.
Ye, J., Shedd, D., and Miller, G. (2005). An Spl response element in the Kaposi's 
sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle 
induction by butyrate. J Virol 79, 1397-1408.
Yi, R., Qin, Y., Macara, I. G., and Cullen, B. R. (2003). Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev 17, 3011-3016.
Yi, Y., Hahm, S. H., and Lee, K. H. (2005). Retroviral gene therapy: safety issues and 
possible solutions. Curr Gene Ther 5, 25-35.
Ylinen, L. M., Keckesova, Z., Wilson, S. J., Ranasinghe, S., and Towers, G. J. (2005). 
Differential restriction of human immunodeficiency virus type 2 and simian 
immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol 79, 11580-11587.
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., 
Taira, K., Akira, S., and Fujita, T. (2004). The RNA helicase RIG-I has an essential 
function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5, 
730-737.
Yoshida, H., Okada, T., Haze, K., Yanagi, H., Yura, T., Negishi, M., and Mori, K. 
(2000). ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to 
the cis-acting element responsible for the mammalian unfolded protein response. Mol 
Cell Biol 20, 6755-6767.
284
Yu, J., Angelin-Duclos, C., Greenwood, J., Liao, J., and Calame, K. (2000). 
Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone 
deacetylase. Mol Cell Biol 20, 2592-2603.
Yu, S. F., von Ruden, T., Kantoff, P. W., Garber, C., Seiberg, M., Ruther, U., Anderson, 
W. F., Wagner, E. F., and Gilboa, E. (1986). Self-inactivating retroviral vectors 
designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 
83,3194-3198.
Yue, W., Davenport, M. G., Shackelford, J., and Pagano, J. S. (2004). Mitosis-specific 
hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function. J 
Virol 78, 3542-3552.
Zamore, P. D., and Haley, B. (2005). Ribo-gnome: the big world of small RNAs. 
Science 309, 1519-1524.
Zamore, P. D., Tuschl, T., Sharp, P. A., and Bartel, D. P. (2000). RNAi: double­
stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide 
intervals. Cell 101, 25-33.
Zan, H., Komori, A., Li, Z., Cerutti, A., Schaffer, A., Flajnik, M. F., Diaz, M., and 
Casali, P. (2001). The translesion DNA polymerase zeta plays a major role in Ig and 
bcl-6 somatic hypermutation. Immunity 14, 643-653.
Zandvoort, A., and Timens, W. (2002). The dual function of the splenic marginal zone: 
essential for initiation of anti-TI-2 responses but also vital in the general first-line 
defense against blood-borne antigens. Clin Exp Immunol 130, 4-11.
Zeng, Y., and Cullen, B. R. (2004). Structural requirements for pre-microRNA binding 
and nuclear export by Exportin 5. Nucleic Acids Res 32, 4776-4785.
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., and Chameau, P.
(2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 
173-185.
285
Zhang, F., Romano, P. R., Nagamura-Inoue, T., Tian, B., Dever, T. E., Mathews, M. B., 
Ozato, K., and Hinnebusch, A. G. (2001). Binding of double-stranded RNA to protein 
kinase PKR is required for dimerization and promotes critical autophosphorylation 
events in the activation loop. J Biol Chem 276, 24946-24958.
Zhang, H., Kolb, F. A., Brondani, V., Billy, E., and Filipowicz, W. (2002). Human 
Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. 
Embo J21, 5875-5885.
Zheng, Z. M. (2003). Split genes and their expression in Kaposi's sarcoma-associated 
herpesvirus. Rev Med Virol 13, 173-184.
Zhong, W., and Ganem, D. (1997). Characterization of ribonucleoprotein complexes 
containing an abundant polyadenylated nuclear RNA encoded by Kaposi's sarcoma- 
associated herpesvirus (human herpesvirus 8). J Virol 71, 1207-1212.
Zhong, W., Wang, H., Hemdier, B., and Ganem, D. (1996). Restricted expression of 
Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. 
Proc Natl Acad Sci U S A 93, 6641-6646.
Zhou, F. C., Zhang, Y. J., Deng, J. H., Wang, X. P., Pan, H. Y., Hettler, E., and Gao, S. 
J. (2002). Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus 
cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 76, 
6185-6196.
Zhou, Z. H., Chen, D. H., Jakana, J., Rixon, F. J., and Chiu, W. (1999). Visualization of 
tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. J 
Virol 73, 3210-3218.
Zhu, F. X., Chong, J. M., Wu, L., and Yuan, Y. (2005). Virion proteins of Kaposi's 
sarcoma-associated herpesvirus. J Virol 79, 800-811.
Zhu, F. X., Cusano, T., and Yuan, Y. (1999). Identification of the immediate-early 
transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol 73, 5556-5567.
286
Ziegler, J., Newton, R., Bourboulia, D., Casabonne, D., Beral, V., Mbidde, E., 
Carpenter, L., Reeves, G., Parkin, D. M., Wabinga, H., et al. (2003). Risk factors for 
Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J 
Cancer 103, 233-240.
Ziegler, J. L., and Katongole-Mbidde, E. (1996). Kaposi's sarcoma in childhood: an 
analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 65, 
200-203.
Zimber-Strobl, U., Kempkes, B., Marschall, G., Zeidler, R., Van Kooten, C., 
Banchereau, J., Bomkamm, G. W., and Hammerschmidt, W. (1996). Epstein-Barr virus 
latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but 
both it and activated CD40 can prolong their survival. Embo J 15, 7070-7078.
Zoeteweij, J. P., Moses, A. V., Rinderknecht, A. S., Davis, D. A., Overwijk, W. W., 
Yarchoan, R., Orenstein, J. M., and Blauvelt, A. (2001). Targeted inhibition of 
calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma- 
associated herpesvirus. Blood 97, 2374-2380.
Zoeteweij, J. P., Rinderknecht, A. S., Davis, D. A., Yarchoan, R., and Blauvelt, A. 
(2002). Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by 
corticosteroids in latently infected B cell lines. J Med Virol 66, 378-383.
Zong, J., Ciufo, D. M., Viscidi, R., Alagiozoglou, L., Tyring, S., Rady, P., Orenstein, J., 
Boto, W., Kalumbuja, H., Romano, N., et al. (2002). Genotypic analysis at multiple loci 
across Kaposi's sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, 
novel variants and chimerism. J Clin Virol 23, 119-148.
Zong, J. C., Ciufo, D. M., Alcendor, D. J., Wan, X., Nicholas, J., Browning, P. J., Rady, 
P. L., Tyring, S. K., Orenstein, J. M., Rabkin, C. S., et al. (1999). High-level variability 
in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma- 
associated herpesvirus genome defines four major virus subtypes and multiple variants 
or clades in different human populations. J Virol 73, 4156-4170.
287
Zong, J. C., Metroka, C., Reitz, M. S., Nicholas, J., and Hayward, G. S. (1997). Strain 
variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) 
genomes: evidence that a large cohort of United States AIDS patients may have been 
infected by a single common isolate. J Virol 71, 2505-2511.
Zufferey, R., Donello, J. E., Trono, D., and Hope, T. J. (1999). Woodchuck hepatitis 
virus posttranscriptional regulatory element enhances expression of transgenes delivered 
by retroviral vectors. J Virol 73, 2886-2892.
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, 
D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. 
J Virol 72, 9873-9880.
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997). Multiply 
attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 
871-875.
288
Appendix
XBP1 S
N=155
H= 48 
V= 107
XBP1_US
N=147
H= 63 /
V= 8 4 / All host
H= 17 
V= 1All host
H= 10 
V= 83
All host
H= 9 
V= 20H= 6
y =  1All host
N= 26
H= 25 
V= 1
All host
TPA
N=169
H= 65 
V= 104
Figure 1.5. KSHV and host core and diverging transcriptional upregulation in JSC-1, in 
response to TPA, IE, XBP-1 s and XBP-1 us.
Venn diagram showing numbers of significantly up regulated KSHV and host genes, as 
compared to in normal JSC-1 s, in JSC-1 s stimulated with TPA, IE, XBP-1 s and XBP-1 us.
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Figure 1.5. Host core and diverging transcriptional downregulation in JSC-1, in response 
to TPA, IE, XBP-1 s and XBP-1 us.
Venn diagram showing numbers of significantly down regulated genes, as compared to normal 
JSC-1 s, in JSC-1 s stimulated with TPA, IE, XBP-1 s and XBP-1 us. Only host genes are down- 
regulated.
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Figure 4.9 Evaluation of variation in gene expression data across all experimental 
conditions.
(A) Graph represents the distribution of mean log(2) ratios for each array element (after filtering) 
for JSC-1 cells stimulated with TPA, XBP-1s, XBP-1us, IE and unstimulated JSC-1s. For the 
latter two experimental conditions the distribution is slightly skewed to the left, as in comparison 
to the other three experimental conditions these samples possessed significantly fewer 
upregulated host and viral genes. The other three distributions are comparable. This is 
important to establish as large variations in sample distribution and variance can affect the way 
that SAM computes significantly regulated genes: all response variables must be comparable.
(B) Table of general statistics derived from the log(2) expression data for each array element 
(after filtering) for JSC-1 cells stimulated with TPA, XBP-1 s, XBP-1 us, IE and unstimulated 
JSC-1 s. The sample distribution (standard deviation) and variance are higher for the two 
experimental control conditions (JSC-1 neg and IE), compared to the most highly 
transcriptionally activated samples (TPA and XBP1s), as a result of convergent and focussed 
gene expression occurring during activation of KSHV lytic replication. XB PIus is intermediary 
between the two.
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